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Abstract 
Conventional cancer chemotherapy often lacks specificity and is consequently associated with 
significant normal tissue toxicities. Molecular chemotherapy offers the potential to target the 
activation of inert prodrugs by utilising tumour-specific catalytic enzymes to restrict 
cytotoxicity to neoplastic tissues. Appropriate expression of therapeutic enzymes can be 
achieved by exploiting the genetic distinctions that exist between tumour and normal tissues 
through the use of tissue- or disease-specific promoters. Alternatively, the unique 
physiological differences that arise in solid tumour masses as a consequence of the abnormal 
vascular architecture might also be exploited to achieve therapeutic selectivity. The most 
conspicuous of these differences is the presence of areas of low oxygen tension (hypoxia) 
arising through both diffusion and perfusion-limited oxygen availability. Hypoxia is an 
important cause of radioresistance and is a independent prognostic indicator for local 
recurrence, metastatic spread and overall survival. Evidence also implicates hypoxia in 
chemotherapeutic resistance and genetic instability, as well as the progression of and selection 
for an aggressive neoplastic phenotype. 
Attempts to eliminate tumour hypoxia have met with some success, but the opportunity 
to utilise thisphenomenonfor therapeutic gain, through the exploitation of the unique reductive 
tissue environment have lead to the development of hypoxic-specific cytotoxins. These 
bioreductive prodrugs rely. on the natural complement of tumour enzymes to catalyse their 
activation under low tissue oxygen tensions. Levels of these reductases are potentially 
heterogeneous and are often down-regulated in the neoplastic state. The artificial 
reintroduction of high levels of reductive enzyme expression may be of significant therapeutic 
value, particularly if expression is restricted to the hypoxic tissue enviroment in which the 
prodrugs will be activated. This might be achieved through the utilisation of the specific cis-
acting sequences that are responsive to hypoxia-regulated transcription factors. 
A diverse spectrum of genes are known to be induced as a consequence of oxygen 
deprivation, being involved in systemic oxygen supply, vascular tone, neovascularisation, 
iron homeostasis, glucose metabolism, drug detoxification and protein chaperoning. The 
details of the cis-acting sequences and transcription factors that mediate this oxygen-sensitive 
gene control are beginning to emerge. This provides the opportunity to exploit these defined 
sequences to regulate therapeutic genes in a hypoxia-responsive manner. 
This thesis describes the evaluation of three potential prodruglenzyme paradigms that 
may have application in this context. Further, the potential of hypoxia-response-elements to 
specifically regulate heterologous genes in response to low oxygen tension is described. The 
application of such an oxygen-regulated gene-directed enzyme/prodrug therapy to solid 
tumours may provide chemotherapeutic specificity aimed at a clinically important tumour 
subpopulation. 
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Chapter 1 Tumour hypoxia 
Chapter 1 
1. Hypoxia in solid tumours. 
1.1 Tumour vascularisation 
Human tumours are not highly angiogenic when they initially develop and can remain 
without vascularisation for months to years (Review: Folkman, 1990; 1995). The progression 
, of a solid malignant growth is only possible if it can recruit a vascular network from the host, 
providing a blood supply to allow the exchange of nutrients and waste products. This requires 
the attenuation or loss of certain angiogenic suppressors ego angiostatin, endostatin and 
thrombospondin 1 with the concurrent induction of a variety of angiogenic stimuli (Rastinejad et 
al., 1989; Taraboletti et al., 1990; Folkman, 1995). Establishing of a net balance of pro-
angiogenic factors is critical to the provision of the angiogenic phenotype, and is essential for the 
progression of both primary and metastatic neoplastic tissues (Folkman, 1995). Critically, the 
degree of tumour angiogenesis is inversely related to patient survival (Review: Fox, 1997). 
Multiple cell types that have been implicated in the primary and secondary roles of 
tumour angiogenesis including tumour cells (epithelial and endothelial origins), macrophages, 
mast cells, leucocytes, lymphocytes and platelets. These cells produce a variety of factors that 
are implicated as components of the angiogenesis process, including; vascular endothelial 
growth factor (VEGF) (Kech et al., 1989), acidic I basic fibroblast growth factor (FGF) 
(Klagsbrun et al., 1986; Kandel et ai., 1991; Slavin, 1995), platelet-derived growth factors-A 
, and -B (PDGF) (Risau et al., 1992), placental growth factor (PLGF) (Maglione et ai., 1993) 
platelet-derived endothelial cell growth factor (PD-ECGF) (Moghaddam et ai., 1995) and type II 
nitric oxide synthase (iNOS, NOS2) (Jenkins et al., 1995). The appeat."B:I:~~. of microregional 
hypoxia (low oxygen tension) is thought to be a key stimulus in the initiation of 
neovascularisation, since it can induce cell-type dependent elevations of the above mentioned 
angiogenic factors; VEGF (Shweiki et ai., 1992; Plate et al., 1992; Goldberg and Schneider, 
1994; Levy et al., 1995; Ikeda et ai., 1995), acidiclbasic FGF (Kuwabara et al., 1995), PDGF-
A and -B (Kourembanas et al., 1990; Plate et al., 1992b; Kuwabara et al., 1995; Gleadle et al., 
1995), PLGF (Gleadle et al., 1995), endothelin (Kourembanas et ai., 1991; U et al., 1994), 
PD-ECGF (Griffith et al., 1997) and iNOS genes (Pohl and Busse, 1989; Hwang et al., 1994; 
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Xue et aZ., 1994; Melillo et aZ., 1995). Cytokines such as tumour necrosis factor a (TNFa) 
(Ghezzi et aZ., 1991; Lim et aZ., 1996), transforming growth factor ~1 (TGF-~I) (Bicknell and 
Harris, 1991; Klempt et aZ., 1992), interleukin-la (IL-la) (Shreeniwas et al., 1992; Ghezzi et 
aZ., 1991), interleukin-6 (IL-6) (Yan et aZ., 1995) and interleukin-8 (IL-8) (Karakuram et aZ., 
1994) are also known to be induced by low oxygen tension, and can work cooperatively with 
these angiogenic factors. Another potential source of oxygen-dependent cytokine production in 
tumours can occur through various infiltrating lymphocyte populations (Sunderkotter et aZ., 
1994; Scannell et aZ., 1993). For example, TNFa is secreted by tumour-infiltrating mononuclear 
cells in a hypoxia-dependent manner (Scannell et aZ., 1993) which can in tum induce endothelial 
cells to produce bFGF. Mild hypoxia can marginally increase the expression of VEGF in 
vascular smooth muscle cells, but the co-treatment of mild hypoxia and either bFGF or TGF-J31 
elicits a marked synergistic effect on VEGF production (Shweiki et aZ., 1995). VEGF and bFGF 
in turn can synergise in the induction of angiogenesis (Pepper et al., 1992). TGF-~1 stimulates 
angiogenesis in vivo, probably through induction of an inflammatory angiogenic infIltrate 
(Sunderkotter et aZ., 1994), though it can also enhance angiogenesis by modulating the cellular 
production of extracellular matrix proteins (Kuzuya and Kinsella, 1994). IL-6 can promote 
vasorelaxation and the induction of proliferation of smooth muscle cells (Ohkawa et aZ., 1994). 
The cytokines TNFa, IL-la, bFGF, IFN-a, IFN-yand perhaps TGF-~ can each induce PD-
ECGF and/or iNOS expression (Fox et aZ., 1996; de Vera et aZ., 1996). A number of angiogenic 
factors such as VEGF, iNOS, PD-ECGF are regulated by hypoxia in epithelium and other tissue 
types (Claffey et aZ., 1992; Pohl and Busse, 1989; Hwang et aZ., 1994; Fox et aZ., 1996a; 
GriffIth et aZ., 1997), while tissue oxygenation affects the regulation of some cytokine growth 
factors specifIcally in endothelial cells, including PDGF-B, IL-la, IL-8 and endothelin. The 
expression of cognate receptors for endothelin-l and VEGF (Flt-llFlk-l) (Shweiki et aZ., 1992; 
Plate et al., 1992a, 1993; Sandner et al., 1997; Kourembanas et aZ., 1991; Li et al., 1994) are 
also upregulated on endothelial cells in response to oxygen deprivation, suggesting that tumour 
angiogenesis is regulated in a paracrine fashion (Plate et al., 1992a). VEGF shares primary 
sequence homologies with other hypoxia-inducible cytokines; PLGF, PDGF-A and -B, of 
which PLGF has been shown to form functional heterodimers with VEGF (Disalvo et aZ., 
1995). A number of important adhesion molecules such as vascular cell adhesion molecule-l 
(VCAM-l), intercellular adhesion molecule-l (ICAM-l), endothelial leucocyte adhesion 
molecule-l (ELAM-l) and P-selectin are also upregulated on endothelium in response to oxygen 
deprivation (Goebeler et al., 1993; Closse et al., 1996). Of note, P-selectin is important in the 
initial step of neutrophil recruitment. Hypoxia dependent increases in protein expression can 
result from several mechanisms including; enhanced transcription, improved mRNA stability 
and extended protein half-life (Review: Bunn and Poyton, 1996). The molecular mechanisms 
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underlying the nature of these and other oxygen-responsive genes are discussed in detail in 
section 1.6. 
As a malignant growth progresses, the preexisting host vessels can be incorporated into 
the tumour from which neovascularisation arises, fulfilling the microcirculatory needs within 
some areas of the expanding tissue mass. The influence of tumour angiogenesis factors will also 
promote neovascularisation from venules of the host tissue adjacent to the invasion front. Newly 
formed vascular sprouts grow out of the venular sites, fusing randomly to generate loops and 
ultimately anastomosing with arteriolar vessels. The static columns of red cells are then free to 
flow, and a microcirculatory network begins to establish. Yet, despite the aggressive process of 
neovascularisation, a Malthusian principle can operate, characterised by a more rapid increase of 
oxygen-consuming tumour cell populations than expansion of the oxygen-supplying functional 
microvasculature (Vaupel et ai., 1989a). Consequently a tumour mass will frequently outstrip 
the growth of the supporting vascular supply. This deficiency can be accentuated by the highly 
disorganised vascular architecture (Folkman, 1990), often with limited development of 
supporting collateral vessels bearing hastily formed micro vessel structures; many of which show 
severe structural and functional abnormalities. Typically. vessel walls are characterised by 
interrupted or absent endothelial linings and basement membranes (Cater and Silver, 1960), as 
well as a lack of pericytes, contractile wall components and physiological receptors. Venules can 
develop marked contour irregularities, becoming tortuous and sinusoidal, with both exaggerated 
elongation and dilation, and display a significant loss of morphological heirarchy (Warren, 
1979). Venular sprouts can fuse with other venules so that the newly formed vascular network 
is both supplied and drained by venules. This chaotic and spatially inadequate vascular 
architecture gives rise to large and variable intercapillary distances, which severely limits oxygen 
availability (Kolstad, 1968; Awwad et aI., 1986). The resulting oxygen tension (p02) gradients 
give rise to areas of chronic diffusion-limited hypoxia (Denger and Sutherland, 1988; Vaupel et 
al., 1989a; Vaupel, 1990; 1993). Moreover, as a consequence of altered vascular morphology, 
tumour vessels are not only prone to spontaneous hemorrage andlor thrombosis (Gatenby et ai., 
1988) but also to the invasion andlor compression of the vessel lumen by surrounding neoplastic 
tissues (Jain, 1988), As a result vessel integrity can be compromised and the blood supply can 
be temporarily slowed or halted, reducing oxygen availability even to the most favourably 
located tumour cell populations. Thus two forms of hypoxia are thought to exist in solid 
tumours: chronic hypoxia caused by limitations of oxygen diffusion, and acute hypoxia resulting 
from relatively rapid changes in tumour tissue perfusion. 
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1.2 Chronic hypoxia 
It was first suggested by Thomlinson and Gray (1955), following a histological study of 
necrosis in bronchial carcinomas, that hypoxic cells exist beyond the diffusion distance of 
oxygen in solid tumours. They observed that all tumour cords of greater than 200 JlIll had a 
necrotic centre, while those tumour cords less than 160 JlIll showed no such evidence of 
necrosis. These histological observations in conjunction with some simplified oxygen diffusion 
calculations led Thomlinson and Gray to propose that tissue p02 would be effectively zero 150 -
200 Jlm from a functional capillary. It was suggested that along this limited diffusion distance 
would exist gradients of oxygen concentration, where cells could remain viable. Later studies 
modelling the oxygen supply and tissue oxygenation in tumours (Denger and Sutherland, 1988), 
as well as evaluation of oxygen diffusion distances in human xenograft models (Groebe and 
Vaupel, 1988) provided further evidence in support:rthe existence of chronic diffusion-limited 
hypoxia. For example, Groebe and Vaupel provided evidence that radiosensitivity might be less 
than 10% of maximum at intercapillary distances above 100 Jlm, and if intercapillary distances 
exceeded 140 Jlm, areas of radiobiological hypoxia extended right up to the arterial end of the 
microvessel. Direct inter-capillary distance measurements in cervix uterus carcinomas have also 
been shown to predict for the presence of tissue hypoxia (Awwad et al., 1986; Kolstad, 1968). 
More recently, using videomicroscopic analysis of tumours transplanted into rat dorsal-flap 
window chambers, Dewhirst et al. (1996) have identified the presence of some vessel segments 
(9%) with detectable plasma flow but low or absent erythrocyte flux. They have suggested that 
such vessels might occur in human tumour tissues and would constitute an additional source of 
chronic hypoxia. Further, some cell subpopulations might also experience chronic hypoxia if 
disadvantageously located in situations of high oxygen consumption, where local tissue demand 
exceeded supply (Vaupel et al., 1987). 
1.3 Acute hypoxia. 
Transient perfusion-limited hypoxia is thought to arise from the circulatory "chaos" that 
is generated as a consequence of abnormal vascular morphology, geometric resistance (governed 
by the vessel diameter), and viscous resistance which is determined predominantly by the 
rheological properties of the blood (Review: Jain, 1988). As a result of the altered morphology. 
serious functional disturbances of the microflow are inevitably manifest including; arteriovenous 
shunt perfusion, regurgitation and intermittent blood flow, and unstable speed and direction of 
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flux. Geometric resistance to blood flow (Sevick and Jain, 1989a; 1989b; Boucher and Jain, 
1992) may occur as a result of mechanical obstruction by micro- and macro-thrombosis, 
erythrocyte sludging, transient plugging of microvessels by white blood cells (WBC) (Honess et 
at., 1996), platelet aggregation or the invasion and/or compression of the vessel lumen by 
surrounding neoplastic tissues (Jain, 1988). Viscous resistance is influenced by many factors 
including; haemoconcentration, aggregation of red blood cells (RBC), cell deformability, plasma 
viscosity and plasma protein concentration. Decrease in the systemic haematocrit with tumour 
growth has been reported for both humans and animals, and is associated with the onset of 
anaemia (Dintenfass, 1982; Vaupel et al., 1987). This can influence the fraction of hypoxic cells 
within a tumour mass (Hill et at., 1971). 
Significant increases in RBC aggregation and rigidity have been reported in melanoma 
patients (Dintenfass, 1982), lung and bowel cancers (Dintenfass and Forbes, 1973; Dintenfass, 
1975), breast cancer (Riley, 1976) and in various carcinomas (Tietjen et al., 1977). At low flow 
rates RBC will tend to form large aggregates (rouleaux) which raise blood viscosity and can 
potentially block flow through tumour microvessels. The bridging of adjacent RBC by 
fibrinogen, globulins and other macromolecules (eg. dextrans) also causes these cells to 
aggregate and form rouleaux. Increasedfibrinogenand albumin concentrations may also explain 
the elevated plasma viscosity. The increased viscosity will also reduce flow, markedly 
suppressing the shear rates in the blood. For example, in normal blood (45% RBC @ 37°C) a 
10 -fold increase in viscosity can equate to a 1000 -fold drop in shear rate (Chein et al., 1984a). 
The reasons for increases in RBC rigidity are less clear, although low pH and changes in plasma 
tonicity (hypo- or hypertonic) make RBC less deformable (Dintenfass, 1982; Chein et al., 
1984a). WBC rigidity can be three to five orders of magnitude higher than RBC rigidity (Chein 
et at., 1984b), and circulating cancer cells even more so (Jain and Ward-Hartley, 1987). Thus a 
component of the increased viscous resistance in tumours might be attributed to increased WBC 
flux and the presence of intravascular tumour cells. Furthermore, in the presence of large RBC 
aggregates, WBC are forced towards the vessel wall, raising their local concentrations. This 
lateral displacement of WBC by RBC also occurs in vessels with increasing diameter. 
Additionally, in convergent flows, WBC entering from one capillary tend to be pushed to the 
wall by RBC entering from another. All these characteristics can be found in tumour 
postcapillary venules, since they are formed by converging capillaries which are gradually 
increasing in size, and can have the lowest shear rates in the circulation, thus favouring 
rouleaux formation. Consequently all these conditions collectively promote WBC migration to 
the vessel wall, so that - 95% of WBC roll slowly along the wall in postcapillary venules, 
greatly increasing opportunities for adhesion and abnormal platelet aggregation. 
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Tumour vasculature is also characterised by hyper-permeability and high hydraulic 
conductivity (Gerlowski and Jain, 1986; Sevick and Jain, 1991), which raises the microvascular 
hydrostatic pressure, and increases interstitial fluid pressure (IFP). IFP has been shown to be 
higher in tumours than in most normal tissues (Jain, 1987) and some evidence from 
experimental tumour models suggests that IFP may be inversely related to perfusion rates and 
oxygen tensions (Lee et al., 1992; Roh et al., 1991a). Data from clinical studies of patients with 
squamous cell carcinoma of the uterine cervix is consistent with these experimental studies (Roh 
et al., 1991b; Milosevic et al., 1995). This might be anticipated, since the actual blood flow rate 
through the tumour vasculature will depend to some extent upon the perfusion pressure and the 
vascular and interstitial resistances to that pressure. Sevick and Jain (1989a, 1989b) studied 
flow resistance under a variety of perfusion conditions using an isolated perfused tumour model, 
and demonstrated that flow resistance increased disproportionatly with reduced perfusion 
pressure. Both geometrical and viscous resistances contributed independently to the increase in 
flow resistance, with the increase in geometric resistance being indirectly related to collapse of 
vessels at low perfusion pressures as a result of elevated IFP. This hypothesis has been 
confirmed in both murine and human tumours (Boucher et al., 1990, 1991; Roh et al., 1991b). 
However there is no direct reason to believe that IFP of tumours should be closely 
correlated to perfusion rate or p02' since each depends upon several biological, physiological 
and biophysical properties which are not all inter-dependent (Jain, 1987, 1988; Vaupel, 1990). 
Consistent with this, some studies have failed to find correlations between IFP and tumour p02 
microelectrode determinations (Tufto et al., 1996). However the pronounced bulk transfer of 
fluid in the interstitial space that accompanies the high interstitial fluid pressure can almost 
certainly cause progressive vascular compression. Moreover, venous pressures in tumours are 
significantly lower than in normal tissues (Peters et al., 1980), and this poor vascular tone along 
with the relative fragility of tumour vessels will confer sensitivity to these external fluid and 
tissue pressures, resulting in periods of flow stasis and vascular collapse. These interruptions in 
blood flow generate transient foci of acute hypoxia in tumour tissues normally proximal to well 
established microvascular networks (Reinhold et al., 1977; Brown, 1979). 
Fluctuating blood flow in tumour microvessels has been recognised since the invention 
of the window chamber model (Algire, 1943; Algire and Chalkley, 1945; Endrich et al., 1977, 
1982; Intaglietta et al., 1977). The therapeutic relevance of such intermittent perfusion has been 
demonstrated in transplantable murine tumours (Chaplin et al., 1986) through its relationship 
with the induction of transient radiobiological hypoxia. Using cell sorting techniques in 
7 
Chapter 1 Tumour hypoxia 
conjunction with the fluorescent perfusion marker, Hoechst 33342, Chaplin et al. (1986) 
showed that if the DNA-binding dye was injected into mice 20 minutes before irradiation, there 
was no link between staining intensity of tumour cells and radioresistance. However when the 
dye and radiation were administered simultaneously, there was a direct relationship between 
stain intensity and radiosensitivity. Further work combining the Hoechst dye technique with 
fluorescent cadmium disulphide microparticle injection in the SCCVII murine carcinoma model, 
given together, or with a 20 minute time interval (Chaplin et al., 1987; Trotter et al., 1989), 
corroborated these initial observations. Comparable results have been reported in other murine 
tumour models (Jirtle, 1988; Minchinton et ai., 1990) and some human tumour xenografts 
(Chaplin and Trotter, 1990) indicating that perfusion-limited hypoxia is a common experimental 
phenomenon. Image analysis of SCCVII tumours following simultaneous or sequential 
fluorescent dye administration (Trotter et al., 1991) identified regions of decreased staining 
intensity, as well as areas completely devoid of staining of one dye vs. the other. This incidence 
of total dye mismatch was 8%, which was similar to the levels of complete vascular stasis or 
intermittent blood flow subsequently reported by Dewhirst et al. (1992) in a transplantable 
mammary tumour model growing in a dorsal flap window chamber. Further, Trotter et al. 
(1991) found evidence of coordinated fluctuations in the staining intensity of contiguous vessel 
segments, and speculated that such vessels never reached total vascular stasis, but experienced 
periods of reduced flow in the time between administration of the first and second dye markers. 
They suggested that induction of hypoxia does not require total cessation of tumour blood flow. 
In agreement, Dewhirst et al. (1996) found direct evidence correlating temporal changes 
in microvessel erythrocyte flux (but not necessarily total vascular stasis) with changes in the 
oxygen content of the same vessel. Utilising videomicroscopy, R3230AC tumours were 
transplanted into Fischer-344 rat dorsal-flap window chambers, and erythrocyte and plasma flux 
were visualised using 1 % carbocyanine-IabeUed peripheral red cells and liposomes respectively, 
while perivascular oxygen concentration was monitored using recessed tip microelectrodes. In 
the unperturbed conditions of this model no evidence was seen for total vascular collapse, 
followed by reopening or reperfusion. Two main types of aberrant flow were observed. Firstly, 
marked instability of flow magnitude and direction occurred,as well as total vascular stasis. This 
was usually confined to a single vessel (4% incidence) and persisted for a few seconds at a time. 
Secondly, groups of vessels underwent coordinated cycles of fluctuations in flow, ranging from 
20 - 60 minutes. Other microvessel segments were identified (9% of total) where plasma flow 
was evident, but very low or absent red cell flux was seen over many minutes. These complex 
patterns of restricted blood flow were associated with reductions in oxygen microelectrode 
readings. The pattern of tumour arteriolar vasomotion was also assessed, and coordinated 
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reductions in diameter could be seen between large arterioles and several daughter vessels. 
Dewhirst et ai. (1996) speculated that the temporal characteristics of the oscillations were similar 
to the fluctuations in red cell flux (20 - 60 min) suggesting a cause and effect relationship. 
Theoretically the degree to which vasoconstriction affects the oxygenation of nearby tissues will 
depend upon the frequency of the oscillations (Secomb et aI., 1989). High frequency changes (~ 
1 Hz) are likely to influence the oxygen status of proximal cells, while the lower fequency 
oscillations will affect a greater tissue volume, with the rate of local oxygen consumption 
partially dictating the extent of the latter phenomenon. 
Since the techniques employed in these experimental tumour systems are not directly 
applicable to the clinic, multichannel laser Doppler microprobes have been developed to directly 
monitor changes in microregional blood flow in both experimental tumour xenografts (Chaplin 
and Hill, 1995; Hill and Chaplin, 1995; Hill et ai., 1996) and human tumours in the clinic (Hill 
et ai. 1996; Powell et ai., 1997). Using 300 J..lm diameter probes, fluctuations in erythrocyte flux 
can be recorded in tumour microregions with an estimated volume of 0.01 mm3• Inital studies in 
an undifferentiated murine sarcoma SaF xenograft model (Chaplin and Hill, 1995) recorded 
changes of 2-fold or greater in 48% of microregions examined over a 60 minute period. Similar 
results (37%) were seen in the human colon adenocarcinoma HT-29 xenograft model (Hill et ai., 
1996), and in both systems over 50% of the changes in blood flow occurred within 20 minutes. 
Clinical analysis of both primary and recurrent breast carcinomas, as well as metastases to 
regional lymph nodes and skin from a variety of tumours of different histologies, revealed 
similar results (Hill et ai., 1996). Of 66 human tumour microregions sampled, 26% showed a 
change in red cell flux by at least a factor of 2, while 58% of the samples demonstrated ~ 1.5 -
fold change. The frequency of slower, more persistent fluctuations was greater than that seen in 
the earlier experimental systems. However a high proportion of the changes measured still 
occurred within 20 minutes and in at least 30% of cases the change was reversed within the 60 
minute observation period. A factor of 2 reduction in perfusion could correspond to a 50% 
reduction in blood flow in all the vessels contained in the probes' sampling volume, or at the 
other extreme, the complete closure of 50% of the vessels contained within the microregion. 
Likewise, a 1.5 -fold decrease would result if flow ceased in 30% of the sampled vessels. The 
development of laser Doppler microprobes has been crucial in the demonstration of the temporal 
nature of microregional fluctuations in tumour perfusion. While no system presently exists to 
measure temporal changes in tissue oxygenation directly, the observation that radiobiologically 
hypoxic cells can result from dynamic perfusion changes (Chaplin et ai., 1987) supports the 
inference that acute hypoxia, arising from changes in vascular flux, which can occur spatially 
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and temporally on both a micro- and macroscopic scale, is a major contributing factor to the 
presence of low p02 in human solid tumours. 
However caution is required in interpreting the relation between changes in microscopic, 
macroscopic or global tumour perfusion and tissue p02 status, since tissue oxygenation is the 
resultant of both oxygen availability (Le. blood flow x arterial 02 concentration) and the actual 
respiration rate of the cells. Arterial 02 concentration is mainly determined by the p02 of the 
arterial blood, the shape of the 02 dissociation curve, and hemoglobin concentration (Thews and 
Vaupel, 1985). Release of O2 from the RBC into tissues is largely dependent on the shape of the 
dissociation curve (which can be shifted through changes of 2,3-DPG, pH, pC02 etc.), the 
fluidity of RBC, and the p02 gradient between the blood and the surrounding tissue. Oxygen 
consumption rates of tumours in vivo are generally intermediate (2 - 35 J.1l 02 g-! min-i) between 
normal tissues with low metabolic rates (eg. resting skeletal muscle - 3 J.1l 02 g-! minot) and 
normal tissues with high activities (eg. active skeletal muscle - 150 J.1l 02 g-t minot) (Fleckenstein 
et al., 1984; Lund, 1985; Vaupel, 1989a), although oxygen consumption will adapt to changes 
in availability. 
Measurements of the Hb02 saturation of individual RBC in experimental tumour 
microvessels have heen achieved using cryospectrophotometric ex vivo techniques (Vaupel et 
al., 1978). Characterisation of the oxyhemoglobin saturation status of murine tumours and 
xenografted human tumours (Rofstad et aI., 1988; Fenton et al., 1988) demonstrates that Hb02 
saturations are significantly lower in tumours than in normal tissues. These Hb02 values were 
gradually shifted downwards as the tumour volume increased. Furthermore, different tumour 
cell lines revealed different oxygenation patterns, and substantial intratumour heterogeneity and 
tumour-to-tumour variability was found (Vaupel and Mueller-Klieser, 1986; Vaupel, 1991). The 
in situ assessment of some human tumours has also been conducted, and the mean Hb02 values 
observed in the tumours were markedly lower than those found in the surrounding normal 
tissues. For example, in differentiated adenocarcinomas of the rectum 72% of measurements 
showed Hb02 saturation to be 60% or less, while in normal rectal mucosa only 7% of 
measurements were 60% or less, with no values below 45% (Figure 1) (Wendling et ai., 1984). 
Similar results were found between squamous cell carcinomas of the oral cavity and normal oral 
mucosa, with median of the Hb02 frequency distributions of the normal oral mucosa being 80% 
compared to tumour medians of 49% saturation (Figure 2). Variations were shown to correlate 
with changes in vascular density (Mueller-Klieser et al., 1981). 
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Figures 1 and 2. Frequency distributions of measured oxyhemoglobin 
(Hb02) saturation values of individual red blood cells within microvessels 
of (1) normal rectal mucosa vs. differentiated rectal adenocarcinoma of the 
rectum, and normal oral mucosa and of poorly vascularised cancers of the 
oral cavity. Adapted from Wendling et al. (1984); Mueller-Klieser et al. 
(1981 ). 
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Considerable intra- and inter-tumoural differences were observed, even when tumours of 
the same clinical stage and histological grade were compared. Similar intra-individual variability 
was also found in a metastatic lesion of a lung cancer (Vaupel et ai., 1989a). Consideration 
should also be given to the fact that a proportion of global tumour perfusion does not result in 
the significant exchange of nutrients due to arteriovenous shunt flow. This arises from aberrant 
arterial-venous connections, where intermediate microcapillary structures are minimal or absent. 
Estimates of arteriovenous shunt perfusion in experimental tumours showed that at least 30% of 
the arterial blood can pass through the malignant tissue without taking part in the 
microcirculatory exchange process (Endrich et al., 1982; Vaupel et al., 1978; Weiss et al., 
1979). Shunt flow was reported to account for 8-43% (mean ± S.E. = 23±13) of total blood 
flow in patients receiving intraarterial chemotherapy for head and neck cancer (Wheeler et al., 
1986). 
1.4 Direct determinations of tumour hypoxia 
With the advent of the Eppendorf polarographic electrode system, direct measurements 
of tumour tissue oxygenation became possible, and the existence of regions of low p02 was 
demonstrated clinically (Kallinowski et al., 1990; Vaupel et ai., 1991; Hockel et al., 1993). 
While this technique provides a global picture of p02 distribution throughout a tumour, it does 
not reflect the dynamic changes in oxygen tension which may occur transiently in different 
regions of the tumour due to impaired perfusion or vessel closure. Furthermore, a major 
limitation of this electrochemical method of measuring oxygen in biological systems is that the 
measurement itself consumes oxygen, thereby perturbing the enviroment under study. In a 
heterologous enviroment and particularly at low oxygen levels, the measurement can be difficult 
to obtain and may not reflect the actual oxygenation state. However recent improvements in 
microelectrodes, including miniaturization and the addition of a recessed tip, have reduced both 
oxygen consumption rates and tissue volumes sampled (-12 f.lJll diameter). In 1989 a 
computerised histography system was introduced, allowing rapid and reliable polarographic 
tissue p02 readings in the clinical setting (Kallinowski et al., 1990; Vaupel et al., 1991; Hockel 
etal., 1991; Nordsmark et al., 1994). These improved oxygen microelectrodes have also been 
used to demonstrate correlations between radiobiological hypoxia and direct estimates of tumour 
oxygenation both experimentally and clinically (Vaupel, 1977; 1979; Vaupel et al., 1989a; 
Moulder and Rockwell, 1984; Kallinowski et al., 1989; Gatenby et al., 1985; 1988; Okunieff et 
al., 1993; Horseman et al., 1993, 1994), and has lead to a resurgence in their clinical 
application, leading to their designation as "gold standard" for measuring tumour oxygenation 
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(Stone et al., 1993). Thus, despite the disadvantages, the Eppendorf oxygen probe is currently 
the system of choice in the clinical assessment of tumour hypoxia. 
In studies, direct measurement of p02 in human tumours shows a wide variation in 
median oxygen concentrations, ranging from 1.1 to 3.9 %, (Vaupel et al., 1989a, Vaupel, 1993; 
Gatenbyetal., 1985; 1988; Kallinowski etat., 1990; Vaupel etaZ., 1991; Hockel etat., 1993; 
Rampling et al., 1994; Nordsmark et at., 1994; Brizel et at., 1995). In contrast, the median p02 
values of normal tissues range from 3.1 to 8.7 %, (Vaupel et al., 1977; Cater and Silver, 1960; 
Ernst et al., 1976; Gatenby et al., 1985, 1988; Jamieson et al., 1965; Wiess and Fleckenstein, 
1986; Kolstad, 1968; Fleckenstein etal., 1984; Lund, 1986; Wiener et al., 1982; Cooper et al., 
1966; Roberts and Owens, 1972; Silver, 1979). Furthermore, readings of less than 0.3 % 02 
(2.5 mm Hg) are common, being found in up to 82 % of samples taken (Review: Vaupel, 
1993). When the mean p02 values found in human malignancies are compared against their 
respective normal tissues, differences can be consistently demonstrated. These and other data are 
summarised in table 1 and are expressed as a ratio of mean p02 for normal vs. tumour tissue. 
Comparative examples for colon adenocarcinomas, glioblastomas, breast and cervix cancers and 
their respective normal tissue p02 distributions are shown in figures 3-6 respectively. 
The phenomenon is independent of either staging and/or grading of individual tumours, 
as well as the tissue type (Figure 7-8). Such lack of predictability arises as a consequence of 
pronounced tumour-to-tumour variability, even amongst tumours of the same pathological stage 
and histological grade (Figure 9). Marked intratumour heterogeneity can also be seen, and 
examples of different oxygen partial pressure histographs being derived from consecutive needle 
tracks have been reported (Figure 10) (Vaupel, 1993). 
However, Hockel et al. (1996) demonstrated that a minimal two track procedure was 
adequately representative of the median tumour p02 distribution, negating the requirement for 
multiple invasive determinations. Further, using the standard two track procedure,the inter-
observer variation of the median p02' with respect to histograph, operator and time of 
measurement was of the magnitude 2-3 mm Hg. Notably, intratumour variation was similar 
irrespective of whether measuring positions were within a few millimeters of each other or 
spanned several centimeters. The observed tumour-to-tumour heterogeneity was significantly 
greater than that of the intratumoural variation, enabling this standardised procedure .. to 
categorise individual cervical cancers. Importantly, use of the needle oxygen probe was well 
tolerated (with only minor discomfort reported in a few cases). This direct approach to the 
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measurement of oxygen concentration adds convIncmg support for the presence of large 
differences in p02 between tumour and normal tissues. 
Table 1: Ratio of mean p02 values found in human malignancies are compared against their 
respective normal tissues. 
Tumour type 
Cervix cancer 
Stage 0 
Stage 1 
Stage 2 
Stage 2 
Undefined 
Squamous cell 
cancers 
Breast cancer 
Melanomas 
Soft tissue sarcomas 
Malignant lymphomas 
Adenocarcinomas 
Basal cell epitheliomas 
Glioblastomas 
Ratio tissue mean pOz 
Normal : Tumour 
1 : 0.63 
1 : 0.42 
1 : 0.31 
1 : 0.56 
1 : 0.29 
1 : 0.42 
1 : 0.40 
1 : 0.23 
1 : 0.16 
1 : 0.50 
1 : 0.43 
1 : 0.42 
1 : 0.23 
1 : 0.16 
1 : 0.15 
1 : 0.16 
1 : 0.36 
1 : 0.16 
1 : 0.67 
1 : 0.45 
1: 0.14 
1 : 0.18 
1 : 0.31 
References. 
Kolstad (1968) 
Kolstad (1968) 
Kolstad (1968) 
Bergsjo & Evans (1971) 
Brizel et al. (1995) 
Urbach and Noell (1958) 
Cater and Silver (1960) 
Gatenby et ai. (1985) 
Urbach (1956) 
Badib & Webster (1969) 
Vaupel (1994) 
Cater and Silver (1960) 
Urbach (1956) 
Gatenby et al. (1985) 
Urbach & Noell (1958) 
Urbach (1956) 
Urbach (1956) 
Gatenby et ai. (1985) 
Badib & Webster (1969) 
Urbach & Noell (1958) 
Gatenby et al. (1985) 
Urbach (1956) 
Rampling et ai. (1994). 
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Figures 3 and 4. Frequency distributions of measured oxygen partial 
pressures (p02 histograms) for normal vs. malignant tissues of the colon 
and brain respectively. Pooled data from various sources: Normal gastric 
mucosa, Endrich (1988); Colon adenocarcinoma, Gatenby et al. (1985) 
and Endrich (1988); Normal brain , Cooper et al. (1966), Roberts and 
Owens (1972) and Silver (1979); Glioblastoma, Rampling et al. (1994). 
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Figures 5 and 6. Frequency distributions of measured oxygen partial 
pressures (p02 histograms) for normal vs. malignant tissues of the breast 
and cervix respectively. Pooled data from various sources: Breast, 
Hoeckel et al. (1992); cervix, Schlenger et al. (1991). 
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Figures 7 and 8. Frequency distributions of measured oxygen partial 
pressures (p02 histograms) for malignant tissues of the breast and cervix 
respectively, at either stage 1-2 or 3-4. Dataadapted from various sources: 
Breast, Hoeckel et al. (1992) ; cervix, Schlenger et al. (1991). 
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Figures 9 and 10. Frequency distributions of measured oxygen partial 
pressures (p02 histograms), exemplifying marked tumour heterogeneity 
between (Fig.9) and within breast tumour tissues. Data from Vaupel et al. 
(1991); Vaupel (1990) . 
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1.5 Alternative techniques for measu~ents of tumour oxygen status 
A 
Many other techniques, both direct and indirect, have been and are being developed to 
measure tumour tissue oxygenation status. (Reviews: Raleigh et at., 1996; Stone et ai., 1993). 
The wealth of new and emerging imaging agents and techniques reflects the growing awareness 
of the importance of hypoxia in the etiology and management of human neoplasia. 
Direct determination of radiobiological hypoxia can be achieved on an individual cell 
basis using the alkaline comet assay (Review: Fairbairn et ai., 1995; Olive and Durand, 1992; 
Olive et ai., 1990; 1993; 1994; Hu et ai., 1995). This assay relies on the 3-fold reduction in the 
number of radiation-induced DNA single strand breaks under radiobiologically hypoxic 
conditions (Olive et at., 1993; Zhang et al., 1995), the presence of which can be visualised 
. following single cell gel electrophoresis of tumour fine needle aspirates. The cells are irradiated 
prior to being embedded and lysed in agarose gel. Since broken cellular DNA migrates more 
readily in an electric field than undamaged DNA, the greater the radiation damage the more the 
DNA will migrate out of the nucleus (Olive et al., 1990). While it is the most direct measure of 
the radiation damage believed to underlie radiation response in tumour cells, estimations of 
experimental tumour hypoxic fraction do not consistently agree with other established 
techniques. For example, while Olive and Durand (1992) found good agreement between 
techniques, Hu et ai. (1995) found that the hypoxic fractions detected using the comet assay 
were lower (by a factor of 3 to 6) than those measured by the paired survival method, an 
established radiobiological techinque to calculate the actual fraction of radiobiologically hypoxic 
cells. In the conventional paired survival method the hypoxic fraction is calculated by comparing 
the surviving fraction of tumour cells from air-breathing mice with those obtained from mice 
killed by carbon monoxide inhalation 5 min before irradiation. Thus the paired survival assay 
measures the hypoxic fractions of the clonogenically viable tumour cells, whereas the comet 
assay measures the hypoxic fraction of all cells in the tumour. Other confounding factors may 
arise from the forces involved in aspiration (Le. background DNA damage) and sample 
contamination by unirradiated white blood cells (Hu et ai., 1995). The invasive nature of this 
technique is a disadvantage, and moreover sampling is subject to errors, and necessitates a 
relatively large single dose of radiation (minimum of 3.5 Gy). Also the repair half-time for the 
DNA single-strand breaks is very short (t~ 0= 3 min), requiring very rapid sample collection and 
processing (Wheeler et ai., 1992). 
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Chemical hypoxia markers are dominated by the 2-nitroimidazole (2-NI) compounds 
which are activated and bound to macromolecules within hypoxic cells with a dependence 
fortuitously' close to that required for the radiobiological oxygen effect (Chapman et al., 1981; 
1983; Review: Chapman, 1991). Methods to visualise tissue-bound nitroimidazoles differ by 
nature of the detectable label and include; 19p-hexafluoromisonidazole magnetic resonance 
spectroscopy and imaging (MRS and MRI) (Li et al., 1991; Kwock et al., 1992), 18p_ 
fluoromisonidazole positron emission tomography (PET) (Koh et al., 1995), 99mTc_ 
nitroimidazole scintigraphy (Under et al., 1994), 123I-nitroimidazole single photon emission 
computed tomography (SPECT) (Groshar et al., 1993), 3H and 14C-misonidazole 
autoradiography (Urtasun et al., 1986; Chapman et al., 1989) or immunohistochemistry 
(formalin-fixed tissue sections, FACS, ELISA) (Cline etal., 1994; Lord et al., 1993; Raleigh et 
al., 1996). However limited concentrations of bound adducts and the relatively low detection 
sensitivity of 19F MR can restrict clinical application (Workman et al., 1992). Further, 
bioactivation of these agents to selectively bind in hypoxic tissues is dependent upon the 
complement of cellular reductases, which are known to vary across tumours (Chapman et ai., 
1983; Workman et al., 1992; Joseph et al., 1994; Workman and Stratford, 1993). Joseph et al. 
(1994) demonstrated that both DT-diaphorase and xanthine oxidase were inefficent enzymes for 
reducing the 2-NIs, misonidazole and desmethylmisonidazole, while NADPH:cytochrome P450 
reductase initiated metabolism was the major pathway for determining the 2-NI adduction to 
both aerobic and hypoxic COS-l cells. Over 90% of the hypoxic binding reaction was inhibited 
by oxygen, suggesting that the one-electron reduction produces radical anions that are efficiently 
back-oxidised in the presence of molecular oxygen. The kinetics of binding to cells under 
hypoxic conditions was - ~ order with respect to P450 reductase, indicating the involvement of 
other enzymes in the further reduction of 2-NI to the nitroso and hydroxylamine derivatives. 
This is consistent with studies on the rat liver microsomal metabolism of benznidazole, a readily 
monitored model drug (Walton and Workman, 1987), where P450 reductase was shown to 
dominate the early stages of metabolism, particularly the one-electron reduction to the nitro 
radical. The cytochrome P450 isozymes were found to be more actively involved at the terminal 
phase of amine formation. The levels of P450 reductase and cytochrome P450 isoforms have 
been shown to be heterogenous in tumours (Stout and Becker, 1986; Hall et al., 1989; Forrester 
et al., 1990; de Waziers et al., 1991; Shepard et at., 1992; Philip et al., 1994; Patterson et al., 
1997), with examples of tumour activities both higher and lower than that found in normal 
tissues. 
Raleigh et al. (1996) demonstrated the discrepancies that can arise between 2-NI labeling 
techniques and direct Eppendorf oxygen electrode measurements. Using an in vivo rat mammary 
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carcinoma model they directly compared the 02 tension variations along single tracks through the 
solid tumour with the observed radiobiological hypoxia, as defmed by immunohistochemical 
analysis of the pimonidazoie-iabelled photomicrographs of the corresponding tissue sections. 
Clear examples of microregional zones of pimonidazole binding could be seen at points adjacent 
to the electrode track where p02 values (12 mm Hg) were apparently well above the ~ for both 
radiobiological hypoxia and pimonidazole binding. Raleigh et al. (1996) reported the presence of 
similar microscopic regions of pimonidazole binding in human cervical tumours, suggesting that 
hypoxic cells might exist in cells that are not accurately detected by oxygen microelectrodes. 
Kavanagh et al. (1996) have extended these studies in five transplantable murine tumours, 
comparing Eppendorf p02 histographs and [3H]-misonidazole binding profiles with the paired 
survival assay to calculate the actual fraction of radiobiologically hypoxic cells. A correlation 
was observed between the mean values of the hypoxic proportion as measured by the paired 
survival assay and the mean binding of [3H]-misonidazole (r=O.94; P=O.02), However no 
biologically significant correlation was seen between the mean values of the hypoxic cell fraction 
(paired survival assay) and the pooled Eppendorf p02 histograph measurements. Furthermore, 
when these two techiques were applied on the same individual KHT -C tumours, there was again 
no correlation between the two measurements of hypoxia. 
Alternative approaches to 19F imaging of tumour oxygenation have been developed 
including the use of perfluorocarbon probes (Rockwell, 1985), which are lipid emulsions of 
19p-substituted hydrocarbon molecules that can themselves carry high levels of dissolved 
oxygen. These suspended micelles are smaller than erythrocytes and when administered 
intravenously can not only enhance tumour oxygenation to assist radiotherapy (Teicher, 1992), 
but can also be employed to image vessels in a tumour mass (Sotak et al., 1993). Since the MR 
signal characteristics are modified by 02 concentration, image projections through tumours can 
be used to profile the tissue p02 distribution (Dardzinski and Sotak, 1994). 
Non-invasive nuclear magnetic resonance techniques, relying on the abundance of 
natural endogenous NMR nuclides such a~ the proton eH) nucleus and phosphorous elp), can 
also be used to indirectly measure tissue oxygenation. 31p MRS can monitor tissue bioenergetic 
parameters such as ATP, inorganic phosphate (Pi),phosphocreatine(PCr) and pH, all of which 
depend upon tissue oxygenation. The PilPCr ratio is considered useful in that it reflects changes 
in cellular [ADP] which are inversely dependent upon the tissue p02 requirements for ATP 
production via oxidative phosphorylation. Determinations of these parameters have been shown 
to correlate with 02 electrode measurements (Vaupel et al., 1989b; 1994), intracapillary 
oxyhaemoglobin saturation (Rofstad et al., 1988a), 150 2 perfusion measurements (Evelhoch et 
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at., 1986) and tumour fraction of radiobiological hypoxic cells (Rofstad et ai., 1988b; Sostman 
et at., 1991). IH MRS can detect elevated lactate levels, which are associated with highly 
glycolytic tissues such as tumours, although the correlation between tissue lactate and p02 is 
questionable since many other factors such as glucose availability will be involved (Howe et at., 
1993; Vaupal et ai., 1994; Helmlinger et ai., 1997). However, of clinical relevance, high lactate 
levels in human cervical cancer have been shown to correlate with incidence of metastasis 
(Schwickert et at., 1995). IH MRS can also be used to determine the tissue equilibrium of 
oxymyoglogin and deoxymyoglobin, although this technique is limited by low concentrations of 
myglobin in tumours (Shungu et at., 1992). In contrast the application of IH nuclear magnetic 
resonance to direct tumour imaging, rather than spectroscopic analysis, has proved more useful. 
IH MRI can visualise changes in blood flow and oxygenation in some detail, since haemoglobin 
(like myoglobin) is paramagnetic, and hence the magnetic field around blood vessels is 
perturbed. Some MRI methods can exploit this characteristic (eg. gradient recalled echo 
sequences) and are very sensitive to the blood oxygen level dependent effect (Haase et at., 
1986). As a result this technique is sensitive to local variations in blood vessels, such as changes 
in haemoglogin concentration or the degree of 02 saturation in the blood (Kwock et ai., 1992; 
Howe et at., 1996). These methods are summarised in table 2. 
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Table 2: Summary of physical and chemical techniques for monitoring tissue hypoxia. 
Technique Invasive Parameter measured Reference 
Polographic electrode - needle I Yes extracellular p02 Kallinowski (1990) 
fibre Stohrer (1992) 
Polograph electrode - surface Yes extracellular p02 Kessler (1981) 
Fleckenstein (1984) 
Oxygen-quenched Yes extracellular p02 Peterson (1984) 
luminescence Young (1996) 
Phosphorescence No extracellular p02 Wilson (1996) 
Bioreductive hypoxic markers Yes nitroimidazole binding Hodgkiss (1991) 
Evans (1995) 
Intrinsic markers Yes ego LDH, VEGF Murphy (1991) 
31p MRS No phosphate metabolites Chance (1986) 
Vaupel (1989) 
1H MRS (lactate) No water protons Stone (1993) 
1HGREMRI No water protons - Robinson (1995) 
influenced by HbO, 
19pMRI No fluorinated bioreductives, Rockwell (1991) 
perfluorocarbon Mason (1994) 
emulsions 
19F PET No fluorinated bioreductives Koh (1992) 
Groshar (1993) 
Near-infrared spectroscopy No deoxyhaemoglobin, Delpy (1987) 
oxyhaemoglobin, Wahr(1996) 
cytochrome aa3 
[1231] IAZA No misonidazole analogue Parliment (1992) 
binding 
ESR No p02 -paramagnetic probe Swartz (1992) 
molecules Halpern (1996) 
Cryospectrophotometry Yes oxyhaemoglobin Rofstad (1989) 
saturation ~ueller-Klieser (1990) 
Bioluminescence imaging Yes ATP Mueller-Klieser (1990) 
HPLC of reductive metabolites Yes nitroaryl fluorescence Stratford (1984) 
Comet assay Yes DNA strand breaks- Olive and Durand 
radiosensitivity (1992) 
Alkaline elution assay Yes DNA strand breaks - Zhang and Wheeler 
radiosensitivity (1993) 
Tumour vascularity Yes vascular density Awwad (1988) 
Lactate Yes lactate production Vaupel (1994) 
Tumour interstitial pressure Yes interstitial pressure Roh (1991) 
Blood flow - laser Doppler Yes red cell flux Chaplin and Hill 
flowmetry (1995); Hill (1996) 
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1.6 Oxygen sensing and the cellular response to hypoxia 
Molecular oxygen is a chemically versatile, abundant, and permeating molecule. Its 
capacity to accept electrons allows dioxygen to participate efficiently in oxidation-reduction 
reactions necessary to release the metabolic energy of reduced organic chemicals. Eucaryotes (in 
contrast to procaryotes) have one major type of energy-conserving respiratory chain, located in 
mitochondria, and use oxygen as the terminal oxidant. Thus oxygen tension influences whether 
A TP will be produced primarily by aerobic respiration linked phosphorylation, or by catabolic 
reactions that generate ATP at the substrate level (Harold, 1986). Oxidative phosphorylation is 
far more efficient than substrate level phosphorylation in capturing the redox energy of reduced 
substrates (Krebs and Kornberg, 1957), with the oxygen-dependent tricarboxcylic (Krebs) cycle 
generating an I8-fold greater equivalent yield of ATP than the anaerobic glycolytic (Embden-
Meyerhof) pathway. Utilisation of the primary cellular nutrients, glucose and fatty acids, to 
provide pyruvate for subsequent processing by oxidative phosphorylation, is far more 
energetically favourable than the generation of lactate by anaerobic glycolysis. Thus oxygen 
deprivation in solid tumour tissues impacts upon the pathways of glucose utilisation and so will 
elicit an adaptive physiological response at the cellular level. 
A rapid increase in glucose utilisation occurs upon inhibition of mitochondrial function 
(Pasteur effect), the rate of which is determined by the transport of glucose into cells, and the 
activities of the three rate-limiting glycolytic enzymes; hexokinase, phosphofructokinase and 
pyruvate kinase. These enzymes are normally far from eqUilibrium and present in low 
abundance and their immediate regulation depends upon allosteric alterations of catalytic activity 
by substrate, product, nucleotides and redox state (Bunn and Poyton, 1996). More long term 
adaption also occurs with increases in biosynthetic rate of the genes encoding enzymes 
responsible for both high-capacity facilitated glucose transport, (primarily Glut-l and -3) 
(Mueckler, 1994; Pessin and Bell, 1992), and glycolytic metabolism including; 
phosphofructokinase-L and -M (PFK-L and -M), pyruvate kinase-M (PK-M), aldolase-A and -
C (ADL-A and -C), phosphoglycerate kinase-l (pGK-l), enolase-l (END-I), and lactate 
dehydrogenase A (LDH-A) (Firth et ai., 1994; Semenza et ai., 1994; Ebert et ai., 1995a, 1995b; 
Semenza et ai., 1996). The induction of glycolytic enzymes in response to oxygen deprivation is 
isozyme specific, reflecting the specific catalytic funtions of various isoforms (Ebert et al., 
1995b). 
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Yet a striking feature of cancer cells is their ability to generate large amounts of lactic acid 
through enhanced glycolysis, despite the presence of sufficent oxygen (Warberg effect) 
(Warberg, 1956). Evidence points to a role for certain key oncogenic transcription factors, 
particularly c-Myc, as well as activated oncogene tyrosine kinases (ras, src, bcr-abl) in the 
constitutive upregulation of glycolytic flux (Dang et al., 1997). This increase in aerobic 
glycolysis is not necessarily a reflection of an elevated demand for metabolic energy via glucose 
catabolism, but is perhaps anabolic, in that glycolytic enzymes themselves or by-products of 
glycolysis, perform multiple functions that help promote and sustain unregulated proliferation. 
This is suggested by several observations; in cells transformed by Rous sarcoma virus, ENO-l, 
PGM and LDH-A are found to be tyrosine phosphorylated (Cooper et al., 1983). Enolase has 
apparent plasmin-binding functions, while PGM can function as a neuropeptide growth factor. 
Also, in its phosphorylated form LDH-A localises to the cell nucleus, and has been found to be a 
single-stranded DNA binding protein with DNA helix-destabilising activity (Zhong and 
Howard, 1990). Further, pyruvate kinase has beeen shown to be identical to the cell division 
cycle protein, cdc 19, implying a direct link between glycolysis and cell cycle control (Aon et 
al., 1995). 
1.6.1 Studies of cis-acting elements 
The DNA regulatory elements controlling the expression of oxygen-responsive genes 
have been implicated or defined in most cases, and involve the specific binding and 
transactivation by various inducible, phosphorylation-dependent and/or redox sensitive 
transcription factors including; Hypoxia Inducible Factor-l aJ~ (HIP-I) (Wang and Semenza, 
1993a; 1993b), fos/jun Activator Protein-l (AP-I) (Goldberg and Schneider, 1994; Yao et al., 
1994a; 1994b; Norris and Millhom, 1992), Nuclear Factor 1C~ (NF-1C~) (Koong et al., 1994a; 
1994b; Yao and O'Dwyer, 1995; Lavrovsky et al., 1994), p53 (Graeber et al., 1994), the 
CCAAT-enhancer binding protein ~ (CIEBP-~) from the NF-IL6 family.(Ohkawa et al., 1994; 
Estes et al., 1995), the Heat Shock Transcription Factor (HSTF) (Benjamin et al., 1990; Giaccia 
et al., 1992) and perhaps the ubiquitous SP-l transcription factor (Kobayashi et al., 1996; 
Schafer et al., 1996). Published evidence indicates that only HIP-l is specifically oxygen-
responsive, while the other transcriptional systems appear to contribute to the response to 
hypoxia via its related redox and metabolic changes. Indeed it is not uncommon to find multiple 
regulatory elements within the same promoter, not all of which are necessarily functional. 
Evidence also exists for cooperative interactions between some of these transcription factors, 
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suggesting that the functional induction of gene expression relies, at least in part, on the 
assembly of a critical concentration of trans-acting factors. 
Figure 12: Simplified representation of the complex integration of multiple trans-acting factors in 
the response of mammalian cellular systems to changes in oxygen concentration. 
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1.6.1.1 Hypoxia Inducible Factor-l (HIF-l) 
Hypoxia-inducible factor-l is a heterodimer (HIF-la/~) that has been shown to 
transcriptionally regulate oxygen-responsive genes that contain hypoxia response elements 
(HREs) (Reviews: Dachs and Stratford, 1996; Bunn and Poyton, 1996; O'Rourke et al., 1997). 
Oxygen-dependent control of HIF-l is predominantly achieved by changes in the proteolytic 
stability and trans-activation capacity of the HIF-la subunit, while HIF-l~ is constitutively 
expressed (O'Rourke et al., 1997). As implied the HIF-la subunit is regulated at the post-
mRNA level, being continuously synthesised and degraded under normoxic conditions (Wenger 
et al., 1997; Salceda and Caro, 1997). Degr~dation is mediated, at least in part, by the ubiquitin-
proteasome system that is regulated through a defined regulatory domain (Pugh et al., 1997). 
Stabilisation is dependent upon redox-induced changes (Wang et al., 1995; Huang et al., 1996; 
Pugh et al., 1997) which is complemented and amplified by post-translational changes in 
transactivation capacity probably involving other redox and protein phosphorylation events 
(Wang et al., 1995c; Salceda et al., 1997; Pugh et al., 1997; Jiang et al., 1997). Ultimately, 
transcriptional activation will depend upon an interrelated series of events which includes 
nuclear accumulation, dimerisation, DNA binding, co-factor recruitment and trans activation. 
The oxygen sensing mechanism is thought to involve a heme-sensor protein (Goldberg 
et al., 1988; Ehleben et al., 1997), which perhaps functions downstream from a flavoprotein 
oxidoreductase (Gleadle et al., 1995a). This sensor appears to function universally in all 
malignant cells studied to date (Maxwell et al., 1993; Firth et al., 1994; Ratcliffe et al., 1997). 
Functional IDF-l has been shown to be essential for tumour neovascularisation and growth in 
vivo (Maxwell et al., 1997). HREs are found within a range of genes including growth factors 
and glycolytic enzymes (Maxwell et al., 1993; Firth et al., 1994; Semenza et ai., 1994; Gleadle 
et al., 1995b; Woods et al., 1997), and has been shown to specifically regulate the transcription 
of HIF-l regulated genes in response to hypoxia. Recently several closely related transcription 
factors to HIF-la have been described. A molecule with 48% homology, first termed 
endothelial PAS protein-l (EPAS-l) has been shown to be induced by hypoxia, and can 
dimerise with ARNT and activate transcription from similar DNA recognition sequences (Tian et 
ai., 1997). EPAS-l was also independently identified and reported as HIF-related factor (HRF), 
being found in murine brain capillary endothelial cells, and bronchial epithelium (Flamme et al., 
1997). A further identification of EPAS-l, termed HIF-la-like factor (HLF) has also been 
observed in mouse lung, heart and hepatic tissues, although constitutive expression was greater 
than seen for HIF-la itself (Ema et al., 1997). 
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A trimer of the minimal HRE from the mouse phosphogylcerate kinase-l promoter (Firth 
et al., 1994) has been utilised in a heterologous promoter context to demonstrate the potential for 
regulating both marker and therapeutic genes in response to low oxygen conditions « 2% 02) 
(Chapter 5; Dachs et al., 1997). In vitro, transcriptional response was shown to be time and 
oxygen concentration dependent, and no HRE-dependent activity was seen at normal tissue p02 
(5% 02)' In vivo, marker gene expression was restricted to tumour tissues adjacent to areas of 
necrosis, and single cell electrophoresis of irradiated xenografts demonstrated that only hypoxic 
tumour cells expressed the marker gene. 
1.6.1.2 Activator Protein-l (AP-I) 
A number of oxygen-responsive genes (eg. VEGF, TH, Glut-I, DT-diaphorase, y-
glutamylcysteine synthetase) contain API or API-like elements which are binding sites for 
members of the Fos family (c-Fos, Fos-B, Fra-l, Fra-2) and Jun family (c-Jun, Jun-B, Jun-D) 
of transcription factors (Herschman 1991; Nakabeppu and Nathans 1991). All the Jun family are 
capable of binding to API sites as hetero- or homo-dimers, while Fos members can only bind in 
association with a Jun family member. Fos and Jun can also form selective cross-family 
heterodimers with ATF/CREB family members (Hai and Curran, 1991). 
Hypoxia induces the expression of a number of phase II "detoxifying" enzymes which 
are coordinately regulated via conserved antioxidant response elements (AREs) (Jaiswal, 1994). 
These cis-acting regulatory sequences contain two or more copies of the API or API-like 
elements in a short stretch (40-45 bp) of DNA, and have been reported to confer the coordinated 
induction of mRNAs for both the obligate two-electron reductase DT -diaphorase, and the rate 
limiting enzyme in glutathione synthesis, y-glutamylcysteine synthetase (>lO-fold @ 24h post) 
in response to hypoxia (O'Dwyer et al., 1994). The elevations in gene expression were thought 
to be associated with the hypoxic induction of both c-jun and junD by -30-fold (max. @ 8h) and 
c-fos by -17-fold (max. @ 24h post) in the human adenocarcinoma cell line HT-29 (Yao et al., 
1 994a, 1994b; Yao and O'Dwyer, 1995). However, the time course of induction of these 
factors was not identical, in that the Jun proteins were strongly and rapidly induced without the 
requirement for reoxygenation, while Fos protein was induced more slowely and appeared to 
require reoxygenation for maximal expression. Furthermore, although association of fos, jun-
andjun-D with the DT-diaphorase ARE was demonstrated by EMSA and supershift assays and 
this binding could be outcompeted by an AP-l (but not a mutant) oligonucleotide, the AP-l 
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binding did not follow the time course of DT -diaphorase induction. Several other genes that 
contain AREs have also been shown to bind c-fos, junO and junB in supershift assays (Li and 
Jaiswal, 1992a; 1992b; Favreau and Pickett, 1993; Friling et ai., 1993), including both rat and 
murine glutathione-S-transferase Ya and 1t genes (Li and Jaiswal, 1992b; Friling et ai., 1992; 
Diccianni et ai., 1992; Nguyen and Pickett, 1992; Bergelson et ai., 1994). 
Chronic hypoxia « 0.01% 02) has been shown to induce enhanced DNA-binding 
activity of an AP-l transcriptional complex (perhaps ATF-2/c-Jun) in SiHa cells, which was 
correlated with a large depletion (80%) in total intracellular glutathione (Laderoute et at., 1996). 
The response potentially involved an inducible ATF-2 kinase, and earlier work had identified 
substantial inductions of the c-jun proto-oncogene in SiHa cells (Ausserer et al., 1994), 
although these studies failed to demonstrate changes in nuclear protein binding to AP-l sites of 
the MT-llA promoter and a reporter construct containing multimerised AP-l binding sites was 
not responsive to chronic hypoxia (12h) (Ausserer et ai., 1994). However, AP-l activation in 
response to hypoxia has been reported for rat PC-12 cells (Norris and Millhom, 1995; Mishra et 
al., 1997) and neonatal rat cardiac myocytes (Webster et al., 1993), although there is suggestion 
for the obligatory involvement of c-fos (Mishra et ai., 1997). Increased transcription of the 
tyrosine hydroxylase (TH) gene in response to hypoxia is mediated through several regulatory 
elements in the proximal promoter including an AP-l and a HIP-l binding site. A specific c-
fos/junB complex binds to this AP-l element, and mutation of the AP-l element ablates 
responsiveness of the TH promoter to hypoxia (Norris and Millhom, 1995). The available 
evidence would suggest that the involvement of AP-l in the hypoxic-responsiveness of genes is 
not only cell line dependent, but also heterodimer and promoter context-specific. 
1.6.1.3 Nuclear factor-K~ (NF-K~) 
NF-K~ complexes are activated by a wide variety of stimuli including cytokines (TNFu, IL-l), 
lipopolysaccharide,phorbol ester, calciumionoph?re,lectins and UV light (Thanos and Maniatis, 
1995). Induction of NF-K~ DNA-binding activity appears to occur over a relatively narrow 
range of oxygen tensions in some cell lines (0.1 - 0.01 % p02) (Laderoute et al., 1996). The 
response to hypoxia does not require de novo protein synthesis, but rather, occurs as a 
consequence of the reversible tyrosine phosphorylation and dissociation of an inhibitory 
subunit, IK-Ba, allowing the NF-K~ dimer to translocate to the nuclear compartment (Koong et 
al., 1994a). The hypoxia signal is thought to be mediated via a RaslRaf signal transduction 
pathway, possibly downstream from c-Src tyrosine kinase, and independent of MAP kinase 
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(Koong et al., 1994b). The agonists of NF-lC~ increase levels of reactive oxygen species (ROS) 
and deplete cells of reduced glutathione, triggering a common redox signalling pathway. The 
well documented induction of NF-lC~ by oxidants, which stimulates tyrosine phosphorylation 
of IlC-B would appear to be in conflict with the limited reports that NF-lC~ can be activated by 
hypoxia. 
Nevertheless, NF-lC~ activation by hypoxia has been demonstrated in Jurkat leukemia 
cells, NIH 3T3 fibroblasts, HT-29 adenocarcinoma cells and SiHa squamous carcinoma cells 
(Koong et al., 1994a; 1994b; Yao and O'Dwyer, 1995; Laderoute et al., 1996). NF-lC~ -driven 
reporter constructs have been shown to respond to p02 < 0.1 % over relatively short periods of 
time (4h) (Koong et al., 1994a; Laderoute et al., 1996). The hypoxic induction of both DT-
diaphorase and heme oxygenase-l may be mediated, in part, by NF-lC~ binding (Lavrosky et 
al., 1994; Yao and O'Dwyer, 1995), although HIF-l is also involved in the activation of heme 
oxygenase-l (Lee et al., 1997a). 
1.6.1.4 Other hypoxia-sensitive transcriptional factors 
The glucose responsive proteins (GRPs) are endoplasmic reticulum-localised proteins that 
function as molecular chaperones and calcium binding proteins, responding to a plethora of 
other stresses including; malfolded proteins, glycosylation block, sulfhydryl reducing agents, 
oxidative stress, amino acid analogues, viral infection and calcium ionophores (Wooden et al., 
1991; Little et al., 1994). These stimuli act through the same cis-acting regulatory elements, 
implying that common signalling mechanisms are involved in the transcriptional induction of 
GRPs. The proximal grp78 promoter (-599/+33) has been studied in the context of marker 
gene expression in vitro (Gazit et al., 1995) and shown to be responsive to glucose stavation, 
hypoxia and acidity (Tannock and Rotin, 1989; Sciandra et al., 1984; Roll et al., 1991; 
Attenello and Lee, 1984). GRP78 is a major protein induced in solid tumours (Sciandra et al., 
1984), and grp78 mRNA levels have been correlated with tumour size (Cai et al., 1993). A 
large number of CCAAT-like motifs are found in the proximal region of the grp78 promoter 
and are important for both basal and inducible activity (Little et al., 1994). The nuclear factor 
CTFINF-l can trans activate the promoter through the CCAAT element located closest to the 
transcription start site. A cyclic-AMP reponsive element (CRE) has also been identified 
(Alexandra et al., 1991), suggesting that cAMP, phorbol esters, steroids and other cAMP-
inducers may be involved in the regulation of the grp78 promoter (Koong et al., 1994d). 
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Heat shock proteins (HSPs) are also induced by multiple stresses, including; thennal 
injury, ROIs, sulphydryl reagents, oxidising agents, heavy metals and uncouplers of 
oxidative phosphorylation. HSPs appear to serve as molecular chaperones, protecting stressed 
proteins from denaturation. HSP genes are regulated by the redox-sensitive heat-shock 
transcription factor(s) (Huang et ai., 1994), and have been found to be induced by transient 
hypoxia, although evidence suggests that HSP expression may be more accurately defined as 
a response to reoxygenation injury (Benjamin et ai., 1990; Sciandra et al., 1992). 
1.6.1.5 Redox regulation of transcription factors 
Hypoxia has been demonstrated to induce expression of the multifunctional redox I DNA repair 
enzyme HAPI (also known as Ref-I, APE or APEX) (Walker et ai., 1994; Yao et ai., 1994b) 
which possesses both apurinic I apyrimidinic (AP) endonuclease activity and 3' 
phosphodiesterase activity as well as cellular redox functions (Abate et ai., 1990; Xanthoudakis 
et ai., 1992). Consistent with its redox role, HAPI can substitute for DTI and reductively 
activate the DNA-binding of oxidised c-Fos and c-Jun (Xanthoudakis et ai., 1992). These two 
properties of HAP 1 are located in structurally and functionally distinct domains (Review: 
Barzilay et al., 1996). It role as a redox regulator of the DNA binding activity of transcription 
factors can be narrowed to the N-terminal domain from residue 36-62, which is sufficient to 
reactivate oxidised c-Jun protein (Walker et ai., 1993; 1994). Two of the seven cysteine residues 
in HAPI (Cys-65 and Cys-95) are also necessary for full activity, and can be targets for 
thioredoxin (TDX)-mediated reduction (Hirota et ai., 1997). TDX is an endogenous redox 
molecule that can directly associate with HAPI and consequently reduce it (Quin et ai., 1996). 
Cys-32 and Cys-35 of TDX, which constitute its catalytic centre, are involved in this association 
(Hirota et al., 1997). 
While AP-l is not a direct substrate of TDX (Xanthoudakis et ai., 1992), nuclear 
translocation ofTDX is indispensible for potentiating the AP-l transcriptional activity, through 
its association with HAP1 (Hirota et at., 1997). Redox regulation of AP-l involves a conserved 
cysteine residue in the DNA binding domain (Abate et ai., 1990). Substitution of the cysteine 
with a serine results in a gain-of-function, which is one of the changes seen in the transforming 
oncogene v-Jun compared with the non-transforming c-Jun protein (Okuno et ai., 1993). This 
relationship between TDX, HAPI and AP-l transcriptional activation suggests a cascade of 
cellular redox couples that leads to coordinate gene regulation. In support of its wider role, a 
direct physical interaction between TDX and the DNA-binding loop of NF-K~ p50 subunit has 
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been demonstrated, suggesting that NF-K~ ia a target for redox regulation by TDX (Qin et al., 
1995). Additionally, intracellular expression of both TDX and HAPI can markedly potentiate 
the HIF-l -dependent hypoxic induction of a reporter gene in a cooperative fashion (Huang et 
al., 1996). In agreement, oxidation or alkylation of the cystine residues in HIF-l completely 
eliminated its ability to bind a HRE probe (Wang et ai., 1995c). Together this suggests a central 
role for HAP1, TDX, and by implication TDX reductase, in the regulation of multiple 
transcription factors via a redox-sensitive signal cascade. 
1.6.1.6 Signal transduction - protein phosphorylation 
. 
Protein phosphorylation is a- _ widely used mechanism of cellular signal transduction, involving 
the interplay of a broad repertoire of kinases and phosphatases. Tyrosine phosphorylation, 
involving c-Src, Ras, Raf and the MAP kinase pathway has been implicated in the hypoxic 
activation of DNA-binding activity (Koong et ai., 1994a; 1994b). Utilising a range of inhibitors, 
both serine/threonine and tyrosine phosphorylation has been shown to contribute to HIF-l 
induction under hypoxic conditions. Genistein, which has an inhibitory effect on many protein 
kinases including the non-receptor tyrosine kinase c-Src, completely blocks the hypoxic 
induction of HIF-l DNA-binding activity (Wang et al., 1995d). V-Src expression has been 
linked to HIF-l activation (Jiang et ai., 1997a). A selective MEK inhibitor that can prevent 
phosphorylation of ERK, the terminal kinases of the MAP kinase cascade, also suppressess the 
hypoxia-induced trans-activation function (but not DNA-binding) of HIF-l (Salceda et ai., 
1997). Together these observations suggest an important role for protein phosphorylation in 
cellular signalling in response to oxygen deprivation. 
1.6.1. 7 Regulation of messenger RNA stability 
mRNA stability is an important site at which gene expression is regulated. Elements critical for 
stability have been found throughout the mRNA molecule, from the 5' cap structure, which is 
resistant to RNases, to the 3' poly(A)tail, which must be deadenylated before the mRNA can be 
degraded. Message degradation is closely associated with translation, such that a minimal level 
of translation is necessary for mRNA degredation. Thus sequences in the 5' UTR that inhibit 
translation also inhibit mRNA decay, while sequences in the open reading frame can influence 
co-translational degredation. The AUUUA-destabilising sequences in the 3' UTR of many 
unstable mRNAs are the best characterised elements (Sachs, 1993). Evidence suggests that 
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multiple AUUUA and polypyrimidine sequence motifs in the VEGF mRNA 3' UTR (also 
present in Epo. GM-CSF. TNFa. HIF-la. GLUT-l and tyrosine hydroxylase mRNAs) confer 
increased stability under hypoxic conditions (Glodberg et ai .• 1991; Stein et al .• 1995; Ikeda et 
ai .• 1995; Wang et al .• 1997; Levy et al .• 1995; Darnert et al .• 1997; Shaw and Kamen. 1986; 
Czyzyk-Krzeska et ai .• 1994). The mechanisms governing rnRNA stabilisation are poorly 
defined but may involve the induction of various molecular chaperones during and following 
hypoxic stress (Giaccia et ai .• 1992). A region of the VEGF 3'-UTR forms a hypoxia-inducible 
RNA-protein complex. which is believed to participate in the post-transcriptional mechanism of 
mRNA stabilisation (Levy et al .• 1997). Negative regulation of rnRNA stability has been found 
to involve the von Hippel-Lindau protein (Gnarra et ai .• 1996; Iliopoulos et al.. 1996). 
1.7 Hypoxia and its therapeutic consequences 
Multiple factors are involved in the relative resistance of many malignancies to radiotherapy and 
chemotherapy. including an intrinsic genetically determined resistance and other physiological 
extrinsic factors. primarily created by inadequate and heterogeneous vascular networks. Thus 
properties such as blood flow. tissue oxygenation. nutrient supply. pH distribution and 
bioenergetic status. factors which are usually interrelated. can markedly influence therapeutic 
response. The presence of regions of low oxygen tension in a variety of human solid tumours is 
now well established (Dishe. 1985; Gatenby et ai .• 1988; Vaupel et ai., 1991; Nordsmark et al .• 
1994) and this hypoxia can predispose to failure of treatments with radiotherapy and probably 
many chemotherapeutic drugs (Hall. 1994; Gatenby et al., 1988; Overgaard, 1992; Hockel et 
ai .• 1993a; 1993b; 1996; Okunieff et al., 1993; 1996; Moulder and Rockwell, 1987; Wilson, 
1992; Teicher, 1994). 
1.7.1 Cytokinetic and apoptotic effects of hypoxia. 
Under severe hypoxia no cells enter S-phase and most cells within S-phase remain stationary 
except in late S-phase, where they are able to complete DNA synthesis (Amellem and Petterson, 
1991). The progression from Gz through to G. is slowed, but cell division is successful 
irrespective of oxygenation status (Petterson et ai., 1986; Amellem and Petterson, 1993). The 
transit time from the completion of mitosis to late G 1 is also unaffected by pOz status, and cells 
eventually accumulate at an oxygen-sensitive restriction point at the G/S border (Amellem and 
Petterson, 1993). Although hypoxia perturbs the energy status of a cell, it appears that lack of 
energy is not directly responsible for the G. arrest observed under such conditions (Loffler, 
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1985). Cells in S-phase are the most sensitive to a hypoxic insult, and the G 1 arrest under 
hypoxia plays a fundamental role in protecting cells from its lethal effects (Spiro et ai., 1984; 
Amellem and Petterson, 1991). This was illustrated in studies where hypoxic cells were 
stimulated to proliferate by treatment with mitogen stimulating factors, such as phorbol esters 
(Koong et ai., 1994c). Phorbol esters that activated the family of mitogen activated protein 
kinases (MAP kinases) or extracellular signal regulated protein kinases (ERKs) increased cell 
proliferation and consequently rendered cells highly sensitive to prolonged chronic hypoxia. 
At least two pathways appear to participate in hypoxia-induced cell-cycle arrest; the 
pyrimidine de novo synthesis pathway (LOffler, 1987; Amellem et at., 1994) and the 
phosphorylation status of the Retinoblastoma gene product, pRB (Amellem et at., 1996). Cell-
cycle inhibition due to the depletion of intracellular pyrimi. dine precursor pools, dCTP and 
dTTP, (Loffler et at., 1983) may occur through inhibition of the respiratory chain-dependent 
UMP synthesis at the stage of dihydroorotate dehydrogenase, an enzyme dependent on 
molecular oxygen for its activation. Ribonucleotide reductase activity is also be influenced by 
low oxygen tension, but this appears not to be limiting even at p02 < 0.01 % (Probst et at., 
1989; Amellem et at., 1994). Under p02 ranging from 0.13 to 0.01 %, salvagable deoxycytidine 
or uridine can significantly counteract cell-cycle arrest, almost completely abolishing the 
hypoxia-induced inhibition of DNA synthesis. The dCTP pool is partially restored (75%) by the 
addition of deoxycytidine under hypoxic conditions (Loffler et at., 1983). Under severe hypoxia 
( < 4 ppm 02) deoxycytidine has no effect on the arrest maintained in G 1 or on the inhibition of 
cell proliferation in S-phase, but it completely abolishes the delay in initiation of DNA synthesis 
following reoxygenation (Amellem et al., 1994). This effect is not seen when deoxycytidine is 
only present upon reoxygenation suggesting that the dCTP pool is an important G2-phase signal 
in the preparation for DNA synthesis upon reoxygenation. The dCTP pool has been implicated 
in the regulation of the rate of DNA synthesis (Bjursell and Reichard, 1973), and other results 
also point to the size of the dCTP pool rather than that of the purine deoxynucleotide pools as 
critical in the regulation of cell proliferation under hypoxia (Probst et at., 1989; Loffler, 1992). 
The role of pRB is less clear, since hypophosphorylation and nuclear binding of pRB 
initiates - 4 h after the onset of hypoxia, whereas progression through S-phase is blocked 
immediately (Amellem et al., 1996). While the immediate arrest appears to be a consequence of 
blOCking de novo synthesis of pyrimidine deoxynucleotides, reentry of G.-arrested cells into S-
phase after reoxygenation, only takes place after pRB deactivation by hyperphosphorylation. It 
has been proposed that pRB phosphorylation status serves as a stress indicator and can take over 
as the main negative regulator of cell-cycle progression during prolonged hypoxia. This 
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hypoxia-induced dephosphorylation of pRB appears to be independent of p53, and may be due 
to activation of a specific pRB-phosphatase, although p21WAFIICIPI or other cdk inhibitors can not 
be excluded from contributing to this pS3-independent growth arrest mechanism (Amellem et 
al., 1996). 
Hypoxia can also induce the hyperphosphorylation of the p34 subunit of replication 
protein A (RPA) , a single-stranded DNA binding protein that plays a central role in DNA 
replication. RPA hyperphosphorylation inhibits replicon initiation and may be the signal for 
early S-phase arrest under hypoxic conditions (Giaccia, 1996). Alternatively the hypoxia-
inducible protein GADD4S, (Price and Calderwood, 1992), is known to bind proliferating cell 
nuclear antigen (PCNA) and inhibit PCNA's association with replication factor C, an association 
necessary for recruitment of DNA polymerase a (Tsurimoto et al., 1990). This would in 
principle prevent the complete assembly of the initiation complex necessary for DNA elongation, 
thereby inhibiting DNA synthesis (Graeber et al., 1996; Giaccia, 1996). 
While cell-cycle arrest is independent of the activity of p53 tumour suppressor gene, 
hypoxia stimulates the nuclear accumulation of p53 protein, increased p53 DNA binding and 
transactivation function in cells that do not possess mutant pS3 (p53mt) (Graeber et al., 1994; 
Giaccia, 1996). This has recently been demonstrated to involve the direct interaction between 
p53wt and HIP-I, resulting in pS3wt protein stabilisation (An et al., 1998). PS3, but not pS3mt, 
is also activated by the hypoxia-inducible redox/repair enzyme HAPl, through a noncovalent 
interaction that involves both redox-dependent and -independent mechanisms (Jayaraman et al., 
1997). Hypoxia induces apoptosis in a pS3-dependent manner, and thus it can select for 
individual clonogens that harbour disfunctional pS3mt, such that they will eventually become the 
dominant genotype. This hypoxia-mediated selection of cells with diminished apoptotic potential 
has important implications for the response of solid tumours to therapy (Graeber et al., 1996; 
Giaccia, 1996). Graeber et al. (1996) demonstrated that apoptosis in wild-type p53 tumours was 
distal to blood vessels and correlated with binding of the hypoxia-specific marker EFS. In 
contrast pS3mt tumours showed a lower frequency of apoptosis (3.4-fold) in EFS-positive 
regions, and no relationship was seen with blood vessel density. Consequently hypoxia was 
acting as a physiological selective agent against apoptosis-competent cells, thereby promoting 
the expansion of cells defective in apoptosis. Since these same pathways govern the apoptotic 
response of cells to radiation and chemotherapeutic agents (Lowe et al., 1993; Lotem and Sachs, 
1993), hypoxia may drive theacquisitionof apoptosis-incompetent solid tumours, resulting in the 
poor response of solid tumours to multiple therapies (Lowe et al., 1994). 
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1.7.2 Radiotherapy. 
The importance of tumour oxygenation in radiocurability was first proposed by Gray in 1953, 
and its role in radiotherapy has since been recognised both in experimental systems (Brown, 
1979; Moulder and Rockwell, 1984, 1987; Rockwell and Moulder, 1990; Horsman et aI., 1993; 
Norclsmark et ai., 1995) and clinically (Gatenby et ai., 1988; Overgaard, 1992; Okunieff et ai., 
1993; Hockel et ai., 1993a; 1993b; 1996; Brizel et ai., 1996). Anoxic cells « 10 ppm. 02) are 
approximately 2.5 to 3-fold more radioresistant than normoxic cells; that is, a 2.5 to 3 times 
larger radiation dose is required to achieve the same reduction in clonogenicity or· effective 
tumour control (Figure 11-12). Half-maximal sensitivity (K value) is seen at about 0.3 % 02 
(3000 p.p.m. °2, 2.1 mm Hg) (Review: Hall, 1994). This phenomenon, known as the oxygen 
enhancement ratio (Tubiana et ai., 1990), is thought primarily to result from oxygen's ability to 
react with and chemically modify the initial radiation-induced DNA radical (Zhang et ai., 1995). 
If oxygen is present it reacts with the ionised target molecules generating organic peroxide 
lesions, which are thought to be significantly less repairable forms of damage. For the "oxygen 
fixation" effect to be observed, oxygen must be present during, or within a millisecond after, the 
radiation exposure (Michael et aI., 1973) . 
The recent development of methodologies incorporating the technique of gas 
chromatography-mass spectrometry (GC-MS) has facilitated the detailed analysis of free radical 
induced DNA damage (Dizdaroglu, 1985; 1991). This technique permits measurement of a large 
number of products in the same sample of DNA or chromatin in a single analysis, and allows the 
chemical characterisation and quantification of base-derived and sugar-derived products as well 
as DNA-protein cross-links. GC-MS analysis of chromatonised DNA following exposure to 
ionising irradiation, has demonstrated the formation of various pyrimidine-derived and purine-
derived modified bases, the yields and characteristics of which have been shown to be 
dependent upon factors such as the type of irradiation, DNA conformation and the direct radical 
environm~~!,(Fuciarelli et al., 1990; Gajewski et ai., 1989; 1990). The modifications of DNA 
bases through addition or abstraction by ionising radiation-generated free radicals (eg. OH-, e'aq , 
H atom) is strongly influenced by the presence of an oxic vs. an anoxic enviroment. Different 
radical enviroments can be provided by saturating an aqueous suspension of chromatin with 
various gases (argon, air, N20, N20 & 02) and has profound effects on the types of DNA base 
products formed and their quantitative yields. The presence of oxygen increases the yields of 
most products with the exception of formamidopyrimidines. Some products (eg. 8-
hydroxyguanine) are produced almost exclusively in the presence of oxygen, while others are 
produced under bQth conditions. When oxygen is present, peroxyl radicals are formed by 
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addition of molecular oxygen to sugar or base radicals of DNA. Further short chain reactions of 
DNA radicals may occur but these will depend upon the types of radicals, their reaction partners 
and the reaction environment. This results in the formation of a wide variety of final products 
through a spectrum of different mechanisms. Many of these modified bases have been shown to 
be produced in 'Y-irradiated cultured mammalian cells (Dizdaroglu etai., 1987; Nackerdien et ai., 
1992). DNA-protein cross-links are also formed through radical-radical and radical addition 
reactions, examples of which, involving thymine and tyrosine, have been identified in the 
chromatin of 'Y-irradiated mammalian cells in vitro (Olinski et ai., 1992). 
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Figure 11. Relative radiosensitivity as a function of oxygen partial 
pressure (p02). The range in values usually found in blood, normal tissues, 
and malignant tissues is iltistrated. The p02 at which the sensitizing effect 
is half-maximal is indicated. (Adapted from Vaupel, 1989a). 
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Figure 12. Differential cell kill under aerated or hypoxic ratio, resulting 
in an oxygen enhancement ratio of 2.5 - 3.5. (Adapted from Hall, 1994). 
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The large body of experimental evidence defming a role for molecular oxygen in the 
radioresponse of mammalian cells would strongly suggest that the low oxygen tensions found in 
many human tumours will alter response to radiation therapy. However the in vivo situation is 
more complex and a number of clinical parameters are known to influence the probability of 
tumour control, including; tumour size, histological grade, clinical stage, patient performance 
status and the skill of the physician providing the radiation treatment. Other metabolic and 
physiological variables, which like p02 distribution may be intrinsically heterogeneous, are 
believed to impact on treatment response. These include glucose delivery and utilisation rates, 
glutathione content, intracellular pH, and blood flow. Also cell cycle alterations and the rate of 
clonal repopulation following a radiation dose, along with the potential for intrinsic and acquired 
radioresistance, will all impact on the final treatment outcome. Thus it has been argued that the 
intrinsic heterogeneity of both intra- and inter-tumour response will dominate as a cause of 
failure (Hendry and Thames, 1992), and the impact of hypoxia will effectively be negligible. 
Considering the wide range in intrinsic radiation sensitivity that is suggested from in vitro 
studies, governed by multiple biological factors such as repair capacity, altered apoptotic 
potential, modified proliferation and cell cycle effects as well as changes in expression of 
oncogenes, such a contention seems feasible. Furthermore, it is anticipated that the impact of 
hypoxia might be decreased in a fractionated radiation regimen, where reoxygenation can occur 
between doses, and other biological responses between fractions such as redistribution of the 
cell cycle, repopulation and radiation damage repair might play a dominant role in overall 
response (Suit et al., 1988). However, despite all these considerations, attempts to use intrinsic 
radiation sensitivity to predict radiation treatment response have been of limited value (Muller et 
al., 1985; Peters et ai., 1985; 1986; West et ai., 1989), and the clinical application of hyper-
fractionated regimens, while providing a survival benefit, have not met with the success that 
optimistic rationalisations might suggest. It is argued that complete reoxygenation between 
fractions is rare (Finkelstein and Glatstein, 1988), and the marked radiation protection afforded 
by a hypoxic enviroment, will be a key determinant of many, if not most, treatment failures. 
The accumulating clinical evidence of the actual relationship between tumour oxygen 
status and outcome of treatment overwhelmingly points to tumour oxygenation as an extremely 
important modifier of the slope of the dose-response curve in some tumour types. Gatenby et al. 
(1988) measured the oxygenation of cervical lymph nodes metastasis in patients with squamous 
cell carcinoma of the head and neck and showed a significant relationship between low mean 
intratumoural p02 values and failure to respond to fractionated radiotherapy. Furthermore, the 
proportion of tumour tissue readings with a p02 of < 8 mm Hg (1 % p02 == 7.6 mm Hg) was 
related to the probability of achieving a clinically complete response after radiotherapy. In 
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support of these observations, Okunieff et al. (1993) showed that low-p02 distribution in breast 
tumours was a significant independent prognosticator, and alone was sufficient to explain the 
incidence of local recurrence following radiotherapy. Hoeckel et al. (1993; 1996) found that 
patients with advanced-stage cervical carcinoma, who had tumours with a median p02 of less 
than 10 mm Hg had significantly worse overall survival (P= 0.0039) and relapse-free survival 
(P= 0.0085) than those individuals whose tumours were relatively well oxygenated (> 10 mm 
Hg). Remarkably, the disadvantage in outcome for low-p02 tumours was substantial 
irrespective of whether the primary treatment was fractionated radiotherapy or radical surgery. 
For example the 27-month disease-free survival after radical surgery was 82% in "non-hypoxic" 
tumours VS. 27% in those with "hypoxic" tumours (P= 0.01). This suggests that hypoxia may 
identify tumours with an aggressive phenotype, independent of the therapy received. Indeed, 
multivariate Cox regression analysis confirmed tumour oxygenation status as the most powerful 
pretreatment prognostic indicator and demonstrated the strong predictive value of tumour 
oxygenation measurements on recurrence-free and overall survival. In contrast, p02 status was 
independent of clinical tumour grade (P= 1.0), tumour size (P= 1.0), histological type (P= 
0.416) and differentiation (P= 0.296). Neither did pretreatment p02 status relate to any patient 
demographics including; age, menopausal status, or hemoglobin levels. A suggestive 
observation from the histopathological examination of the subset of surgically resected 
specimens (n=47), was that low-p02 tumours exhibited larger tumour extensions (P= 0.036) 
and more frequent occult parametrial spread (P= 0.026), as well as greater probability of 
pronounced lymph-vascular space involvement (P= 0.036) relative to their non-hypoxic 
counterparts. Although locoregional failure was the dominant source of recurrence in this study, 
it was noted that in the surgically treated subpopulation, 8 of 13 recurrences of the hypoxic 
tumours had a metastatic component, as compared to only 2 of 7 recurrences in the non-hypoxic 
tumours. This is interesting in view of the report by Brizel et al. (1996) where pretreatment 
tumour p02 measurements in soft tissue sarcoma predicted the likelihood of distant relapse, but 
not local failure. The actuarial 18-month disease free survival in the nonhypoxic vs. the hypoxic 
tumours was 70% vs. 35% respectively. 
1.7.3 Chemotherapy 
Less clinical evidence is available regarding the impact of hypoxia in the failure of 
chemotherapy. However there are compelling reasons (Moulder and Rockwell, 1987; Wilson, 
1992; Teicher, 1994; 1995) and considerable experimental suggestion (Smith et al., 1979; 
Teicheret al., 1981; Tannock and Guttman, 1981; Kennedy, 1987; Sartorelli, 1988; Grau and 
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Overgaard, 1988; Hockel et ai., 1993) to anticipate that hypoxic cells are resistant to some types 
of cytotoxic drugs, not least because a high proportion of hypoxic cells are non-cycling and 
many chemotherapeutic agents are preferential mitotic poisons. An exposure period of 16h 
hypoxia can reduce DNA synthesis by 80-90% in vitro (Krtolica and Ludlow, 1996; Graeber et 
ai., 1994), irrespective of cell cycle, providing marked protection from many commonly 
employed anti-metabolites. This is evidenced by reports showing that exponentially growing 
cells in vitro, when rendered chronically hypoxic during drug exposure, are more resistant to 
many chemotherapeutic agents, particularly anti-metabolites and DNA-interchelators. These 
include actinomycin D, doxorubicin, etoposide, mitoxantrone, vincristine, m-AMSA, taxol, 5-
fluorouracil, arabinoside, procarbazine, streptonigrin, and bleomycin (Roizin-Towle and Hall, 
1978; Smith et ai., 1979; Adams et al., 1980; Teicher et ai., 1981; Teicher et ai., 1985; Shen et 
al., 1987; Hughes et al., 1989; Hennan et al., 1992; Bisset and Kaye, 1993; Teicher, 1994). 
With redox active agents such as bleomycin, streptonigrin (and perhaps etoposide), oxygen 
itself is directly involved in the mechanism of toxicity (Teicher et al., 1981; 1985), but for the 
majority of chemotherapeutics, resistance is not strictly related to the absence of molecular 
oxygen during drug exposure per se, and may involve the induction of multiple early stress 
response proteins, complex modulations of cell cycle progression and changes in recognition 
and/or response to DNA damage. This capacity for rapid adaptation also exte~ to the 
acquisition of temporary drug resistance as a post-hypoxic characteristic. This transient 
phenomenQphas been reported for doxorubicin, methotrexate, 5-Fluorouracil, actinomycin-D, 
etoposide, BCNU, and cisplatin, in various murine and human cell lines models (Smith et al., 
1980; Wilson et at., 1989; Luk et at., 1990; Sakata et al., 1991; Kalra et at., 1993; Sanna and 
Rofstad, 1994; Liang, 1996). 
The biological mechanisms underlying these changes in drug sensitivity are not well 
understood but evidence suggests such hypoxia-induced resistance may reflect changes in 
metabolic and/or repair processes, particularly as a number of stress related proteins are known 
to be expressed in response to hypoxic stress (Heacock and Sutherland, 1986; Dachs and 
Stratford, 1996). As discussed earlier, hypoxia induces the expression of a number of 
detoxifying enzymes, the transcription of which are coordinately regulated via AREs (J aiswal, 
1994), including; 'Y-g1utamylcysteine synthetase, glutathione-S-transferase Ya and 1t genes (U 
and Jaiswal, 1992b; Friling et al., 1992; Diccianni et ai., 1992; Nguyen and Pickett, 1992; 
Bergelson et ai., 1994; O'Dwyer et al., 1994). These enzymes are known to be involved in the 
glutathione-mediated inactivation of many chemotherapeutic agents (Hodgkiss and Middleton, 
1985; Wang and Tew, 1985; Miyazaki et ai., 1990; Nakagawa et ai., 1990; Schecter et al., 
1993; Tew, 1994; Chen and Waxman, 1995; Dirven et al., 1995). Metallothionein ITA (MT-
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TIA), a stress-inducible protein known to be involved in resistance to cisplatin (Kelley et al., 
1988; Satoh et at., 1993), doxorubicin (Naganuma et at., 1988) and mitomycin C (Lohrer and 
Robson, 1989) is also up-regulated by chronic hypoxia (Murphy et al., 1994). A proximal 
fragment of the human MT-TIA promoter (0.2 kb) was demonstrated to confer hypoxia 
responsiveness to a reporter gene in A431 human squamous carcinoma cells (Murphy et al., 
1994). These responses may involve the sensing of perturbations in cellular redox state, that 
ultimately result in the phosphorylation of specific AP-l transcriptional complexes (Bergelson et 
al., 1994; Laderoute et al., 1996). Other known targets of Fos/Jun action include dTMP 
synthase and topoisomerase I which are implicated in resistance to 5-Fluorouracil and 
camptothecin respectively. The fact that both the GST gene and the MDR gene contain AP-l 
binding sites, perhaps suggest that Fos/Jun may contribute towards a coordinated acquisition of 
drug resistance (Dietel, 1993). 
Hypoxia has also been demonstrated to induce expression of the cellular redox and AP 
endonuclease repair enzyme, HAPI (section 1.6.1.5) (Walker et al., 1994; Yao et al., 1994b; 
Abate et al., 1990; Xanthoudakis et al., 1992). Depletion of HAPI protein via expression of 
antisense HAPI RNA renders HeLa cells hypersensitive to killing by a wide range of cytotoxic 
agents including simple alkylating agents, peroxides, bleomycin, the redox cycling drug 
menadione and X-rays (Walker et al., 1994; Chen and Olkowski, 1994). HAPI has an 
important functional role in vivo modification of the apurinic I apyrimidinic (AP) sites generated 
by the action of DNA glycosylases in the DNA base excision repair pathway (Review: Barzilay 
and Hickson, 1995). DNA glycosylases recognise and remove a wide range of small DNA 
adducts (eg. alkylation) which are generally associated with a single base residue, as well as 
oxidative damage involving base modification andlor disruption of the sugarphosphate backbone 
(Review: Demple and Harrison, 1994). The AP-sites resulting from this base excision prompt 
the 5' hydrolytic cleavage of the sugar-phosphate backbone by HAP1, generating both a 3' OH 
site for subsequent priming of a DNA repair polymerase and also a 5' deoxyribose phosphate 
group, which then requires further modification by a deoxyribose phosphodiesterase. Of note, 
DNA polymerase ~ which is thought to perform most of the DNA synthesis associated with 
base excision repair also possesses efficient deoxyribose phosphodiesterase activity (Matsumoto 
and Kim, 1995). 
Interestingly, the HAPI-depleted HeLa cells not only demonstrate sensitivity to 
hyperoxia (95% O2) but are also hypersensitive to hypoxic exposure (1% O2), The functional 
involvement of HAP 1 in protection from hypoxia-induced cell death is less obviously explained. 
It is possible that hypoxia produces as yet unidentified DNA lesion(s) that require the action of 
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HAPI as a DNA repair enzyme (Russo et al., 1995). More likely, its partially defined redox 
regulatory role in transcriptional activation (see section 1.6) may be an essential component for 
the coordinated response of a large number of other oxygen responsive proteins that serve to 
protect cells under redox-stress. As a whole, experimental observations point to the cellular 
redox functions of HAP 1 as being critical in the coordinate redox-regulation of several oxygen-
responsive transcription factor families, including; fos/jun, NF-1C~, and HIF-l (Abate et al., 
1990; Xanthoudakis and Curran, 1992; Hirota et al., 1997; Xanthoudakis et al., 1992; Huang et 
al., 1996) These trans-acting factors represent a major collection of redox-sensitive nuclear 
proteins that govern the transcriptional response of a plethora of genes to oxygen deprivation, 
some of which are known to contribute to multidrug resistance. 
Other in vivo pharmacokinetic considerations may also contribute to the protection of 
hypoxic cells during systemically delivered chemotherapy. Hypoxic tumour cells are more likely 
to be distal to functionalvasculattgeat the time of drug administration and gradients of drug 
penetration can arise (Kennedy, 1987). It has been demonstrated that cells distal from functional 
blood vessels (as determined by the limit of Hoechst 33342 penetration) are spared by many 
antitumour agents in vivo (Teicher et al., 1990). Since many chemotherapy agents have a 
narrow therapeutic index, even modest heterogeneity in tumour drug exposure may have 
important implications for clinical drug resistance. Further, the possible relationship between 
interstitial fluid pressure (Jain, 1987) and reduced perfusion rates and tissue p02 (Lee et al., 
1992; Roh et al., 1991a) suggests that hypoxic tumours are more likely to resist the influx of 
systemically administered agents. 
1.8 Hypoxia-induced genetic instability and tumour progression. 
Experimental and clinical evidence points to hypoxia as a critical component, not only in the 
resistance of solid tumours to conventional therapies, but as a potent physiological stimuli that 
promotes tumour progression, both driving genetic diversity and selecting for aggressive 
neoplastic phenotypes (Hill, 1990; Graeber et al., 1994; Hockel et al., 1996). Hypoxia appears 
not only to provide an environment directly facilitating drug resistance as well as temporarily 
inducing a spectrum of drug resistance-associated genes, but can also encourage the evolution of 
stable phenotypic change characteristic of permanent chemotherapeutic drug resistance. Anoxia 
has been shown to enhance DNA strand breaks, leading to increased genomic instability (Russo 
et al., 1995). A marked enhancement in the frequency of methotrexate resistance and 
dihydrofolate reductase (DHFR) gene amplification has been observed in vitro, with acquisition 
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of resistance being related to the duration of both hypoxia and re-oxygenation (Rice et al., 
1986). In further studies, hypoxia was shown to markedly enhance the frequencies of 
simultaneous resistanatto methotrexate and doxorubicin, and was related to both DHFR and p-
glycoprotein gene amplification (Rice et al., 1987). 
Loss of p53 also appears to enhance certain types of genetic instability and has been 
linked to enhanced aneuploidy, gene amplification and recombination events, all of which may 
then contribute to further tumour progression (Review: Hartwell and Kastan, 1994). Loss of 
functional p53 has been demonstrated to occur following cycles of hypoxia and reoxygenation in 
vitro (Graeber et al., 1996). In addition, the mutation of p53 during tumour progression results 
in the elimination of certain signals which usually promote apoptotic cell death and consequently 
some tumours can become inherently resistant to chemotherapy or radiation therapy-induced 
apoptosis. 
Cell cycle perturbations and DNA overreplication arise as a consequence of hypoxia, and 
have been related to enhanced metastatic potential of fibrosarcoma and melanoma cells (Young et 
al., 1988). Metastatic potential may also be promoted through the hypoxia-induced hyperploidy 
(Rofstad et al., 1996) and other genotypic changes, phenomena which are also associated with 
the evolution of acquired multidrug resistance. Hypoxia might also potentiate the capacity for 
metastatic spread from local disease sites, through the induction of vascular permeabilising 
factors such as VEGF or proteolytic enzymes, including the cathepsins (Liotta and Stetler-
Stevenson, 1991; Mareel et al., 1993). Indeed, transient hypoxia increased the total cathepsin B 
+ L levels in murine KHT cells, which was correlated with invasive capacity (Cuvier et al., 
1997). Glucose starvation and acidosis have also been found to enhance the metastatic potential 
of KHT cells in vivo (Schappack et al., 1991). The relationship between proteolysis and 
invasion has been firmly established for many tumour types (Mignatti and Rifkin, 1993). 
Clinical evidence in support of a role for hypoxia in promoting metastatic spread is now just 
beginning to emerge. It was recently reported that the pretreatment oxygenation status of soft 
tissue sarcomas predicted the probability of distant relapse, but not local failure (Brizel et al., 
1996). The probability of distant metastasis was twice as high for tumours with median p02 of < 
10 mm Hg relative to those with median p02 > 10 mm Hg. The average median p02 of 7.5 mm 
Hg for those patients that relapsed was significantly lower than the average median of 20 mm 
Hg for those that did not (P= 0.03). All treatment failures were distant lung metastases, with 
only one patient subsequently developing local recurrence. Since all the tumours studied were 
high grade it was suggested that hypoxia may be a valid independent prognostic indicator. In 
agreement Hackel et al. (1996) observed that low-p0 2 cervical tumours exhibited larger tumour 
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extensions and more frequent parametrial spread and lymph-vascular space involvement, 
compared to well-oxygenated tumours of similar clinical grade and size. Interestingly, high 
lactate levels in cervical cancer have also been correlated with the incidence of metastatic disease 
(Schwickert et ai., 1995). 
1.9 Reversing the clinical radioresistance of solid tumours 
Methods designed to overcome hypoxia-dependent radioresistance have included the use of 
hyperbaric oxygen, the development of oxygen mimetic radio sensitizers (Adams, 1976; 
Stratford, 1992) and more recently, the combination of nicotinamide (vitamin B derivative) and 
carbogen (95% O2 and 5% CO2) in an attempt to improve tumour oxygenation during 
radiotherapy (Chaplin et ai., 1991). 
A meta-analysis of 50 clinical trials using nitroimidazoles as hypoxic cell radiosensitisers 
has demonstrated a modest survival benefit in head and neck and bladder, but not in cervical, 
lung, oesophagal or CNS tumours (Overgaard, 1994). For all disease sites there was an overall 
survival benefit of 2.8 % (P = 0.02). This was closely correlated to the probability of local 
control, where hypoxic cell sensitisers provided an overall improvement of 3.9 % (P = 0.005), 
giving benefit in head and neck and bladder tumours, but not in cervix, lung or oesophagus. 
Meta-analysis of 17 randomised trials comparing hyperbaric oxygen with conventional 
radiotherapy revealed a similar influence of tumour oxygenation on the probability of local 
control (Overgaard, 1995). Overall a 6.6 % (P = 0.003) improvement in local disease control 
was seen. 
Putting all the radiosensitisation trials together, there is a clear improvement in both local 
tumour control and survival of 4.6 % (P = 0.00001) and 2.8 % (P= 0.005), respectively 
(Review: Saunders and Dishe, 1996). While this is a modest gain in treatment outcome, it 
nonetheless confirms that hypoxia is a contributory factor in the failure of radiotherapy. It must 
be considered that patient selection was not carried out for these trials, such that a proportion of 
the treated tumours would not have harboured a therapeutically relevent concentration of 
radioresistant hypoxic cells, and thus recieved no benefit from the improvement in tumour 
oxygenation or the application of oxygen mimetics. 
An appreciation of the contributions of both chronic (diffusion-limited) and acute 
(perfusion-limited) hypoxia in solid tumours has lead to the application of combinatorial 
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treatments to cooperatively overcome both mechanisms of radioresistance. Nicotinamide is 
thought to maintain vascular tone, and thus reduces the incidence of temporary vascular 
shutdown (Horsman et ai., 1989). The plugging of microvessels by relatively rigid leucocytes 
which may also contribute to the proportion of non-perfused vessels, is also partially overcome 
by nicotinamide (Honess et ai., 1996). In animal studies, nicotinamide enhanced local tumour 
control with radiotherapy (enhancement ratio -1.2), and was particularly effective when 
carbogen breathing was included in the treatment (enhancement ratio -1.6 - 1.8) (Kjellen et ai., 
1991). The combination of nicotinamide and carbogen has recently been demonstrated to 
improve tumour perfusion in human subjects, relative to each treatment alone, or no treatment 
(Powell et al., 1997). Accelerated radiotherapy, when utilised in combination with carbogen and 
nicotinamide (ARCON), has demonstrated an enhancement ratio of 2.8 in animal tumour models 
(Rojas et ai., 1993), which is better than any other achieved using multi-fraction regimes in 
similar models (Rojas, 1992). ARCON is currently in European wide clinical trials (Saunders 
and Dishe, 1996). 
1.10 Bioreductive drugs as hypoxia selective cytotoxins. 
Since severe hypoxia is largely restricted to solid tumours, its exploitation is an attractive basis 
for therapeutic selectivity in cancer treatment. As an alternative strategy to using 
radiosensitisers or improving tumour oxygenation, strategies which by their nature will only 
restore cellular radiosensitivity to that of the oxygenated popUlation, has been to develop 
agents that exhibit selective toxicity towards hypoxic cells (Adams and Stratford, 1986; 1994; 
Stratford et ai., 1986; Brown and Siim, 1996; Denny et ai., 1996) through the exploitation of 
enzyme-mediated reductive activation of drugs at low oxygen tensions (Kennedy. 1987; 
Workman, 1992; Workman and Stratford, 1993). 
Five types of metabolic biotransformation are currently known to be inhibited by 
molecular oxygen, and form the basis for the design of hypoxia-selective cytotoxins (HSCs) 
(Review: Denny et ai., 1996). This includes reduction of nitro(hetero)aromatics, aliphatic and 
aromatic N-oxides, quinones and transition metal complexes. The hypoxic selectivity of these 
agents relies upon the inactivation of a one-electron reduction intermediate through the 
reoxidation by molecular oxygen. Thus the "futile cycling" that occurs in the presence of 
oxygen inhibits the net reduction of the parent compound in aerobic cells. Selectivity arises 
because the reduction products of these prodrugs are significantly more cytotoxic than the 
reactive oxygen species generated as a consequence of rapid back-oxidation. The tertiary 
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amine (aliphatic) N-oxides, including AQ4N and nitracine N-oxide are notable exceptions to 
this mechanism since they require concerted two-electron reduction in order to become 
activated, but the biotransformation is still sensitive to oxygen (Patterson, 1993; Patterson et 
al., 1994; Wilson et al., 1996). Quinones can be activated by either one- or two-electron 
reductions to the semiquinone or hydroquinone respectively. Direct two-electron reduction of 
this class of compounds is not inhibited by oxygen, which reflects a distinction in the 
enzymology of aliphatic N-oxide vs. quinone metabolism. The contribution of the 
hydroquinone to cytotoxicity is unclear, and the semiquinone is generally considered the 
proximal cytotoxin (Pan et al., 1984; Powis, 1989; Butler et al., 1996). 
Classes of compound that are in, have or are being considered for entry into clinical trial 
as bioreductive HSCs include; (I) CI-lOlO, the R enantiomer of RB6145, the lead compound 
from a series of dual-fu~ction, alkylating 2-nitroimidazoles (Adams et al., 1984; Jenkins et al., 
1990; Cole et al., 1990; 1992); (ll) quinones such as the mitomycin C analogue porftromycin 
(Rockwell et al., 1988) and the indoloquinone E09 (Hendriks et al., 1993; Smitskamp-Wilms et 
al., 1996); (III) the lead compound in a series of benzotriazene-di-N-oxide analogues, 
tirapazamine (TPZ, SR4233, WIN 59075) (Brown and Lemmon, 1991; Brown, 1993); and 
(N) an aliphatic N-oxide analogue of mitoxantrone, AQ4N (Patterson et al., 1994). For these 
agents to be effective within hypoxic cells they require metabolic activation, catalysed by the 
cellular complement of reductase enzymes. These may include isozymes of the cytochrome P450 
system, NADPH:cytochrome P450 reductase, NADH:cytochrome Bs reductase, xanthine 
oxidase, aldehyde oxidase, glutathione reductase, succinic dehydrogenase, 
NADH:dehydrogenase, xanthine dehydrogenase and DT-diaphorase (Brown, 1993; Workman, 
1992; Walton et al., 1989; Hodnick and Sartorelli, 1993; Gustafson and Pritsos, 1993; 
Robertson et al., 1994; Bailey et ai., 1992; 1994; Patterson et ai., 1995b; Fitzsimmons et al., 
1996; Patterson et ai., 1997). 
Hypoxic cells constitute only a minor proportion of the total mass of a tumour, so the 
selective elimination of this subpopulation with a bioreductive agent would not be expected to 
result in significant single-agent efficacy. Yet, the experimental observations that vascular 
shunting and fluctuating blood flow (Chaplin et al., 1987; 1995; Hill et al., 1996; Dewhirst et 
al., 1992; 1996) causes cell populations to rapidly cycle between the hypoxic and oxygenated 
tumour compartments, suggests that the clinical opportunities for utilising bioreductive drugs are 
broader than might have been initially anticipated. It has been suggested that this phenomenon of 
relatively rapid changes in tumour oxygenation status, underlies the impressive activity of 
tirapazamine (TPZ) when repeatedly co-administered in a factionation radiation schedule (Brown 
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and Koong, 1991; Brown and Giaccia, 1994). In marked contrast to HSCs, the use of 
radiosensitisers in fractionation radiation schedules is associated with loss of activity (Hill, 
1986). 
1.11 Modifying tumour vasculature to enhance bioreductive drug activation 
The combination of HSCs with other treatment modalities that target the aerobic compartment of 
solid tumours is necessary to adequately treat the whole tumour mass. Alternatively vascular 
modifiers can be employed, in order to actively render all cells in a tumour mass hypoxic. This 
can be achieved by selectively inhibiting tumour blood flow through the exploitation of the 
differences in vascular physiology between normal and neoplastic tissues. For example, the anti-
hypertensive agent hydralazine induces selective dilation of normal vasculature, thereby 
increasing normal tissue blood flow at the expense of the tumour (Chaplin, 1989). Its 
effectiveness in combination with RSU 1069, E09 or TPZ has been demonstrated in 
transplantable tumour models (Chaplin and Acker, 1987; Stratford et al., 1989; Adams et al., 
1992; Bibby et aZ., 1993), but some evidence has suggested that induction of hypoxia is less 
effective in human xenografts (Rowell et al., 1990). Recent studies have shown that the 
induction of tumour hypoxia is also seen in spontaneous murine tumours, ruling out the 
suggestion that reduced tumour blood flow is an artifact of transplantable tumour models 
(Nordsmark et aZ., 1996). 
The synthetic flavonoid, flavone acetic acid (FAA) induces a profound reduction in 
blood flow in murine tumours (Hill et al., 1989), which is known to involve the induction of 
tumour necrosis factor a (TNFa) (Mace et al., 1990) and activation of coagulation (Murray et 
aI., 1989). Clinical trials with FAA alone or in combination with interlukin-2 were disappointing 
(Olver et al., 1991; Holmlund et al., 1995). A related compound, 5,6-dimethyl xanthenone-4-
acetic acid (MeXAA) was found to be 10-15 times more effective than FAA in murine tumours, 
and is currently in phase I clinical trials (Rewcastle et aZ., 1991; Cliffe et al., 1994; Wilson and 
Pruijn, 1995). MeXAA has both vascular and immunological mechanisms of action similar to 
FAA and causes rapid haemorrhagic necrosis (Zwi et aZ., 1994; Ching et al., 1994; Laws et al., 
1995). MeXAA provides significant enhancement of anti-tumour activity in combination with 
several bioreductive agents, including TPZ, CI-101O, and SN 23862 (Cliffe et al., 1994; Wilson 
and Pruijn, 1995; Vincent et aZ., 1997). In combination with serotonin (5-HT), MeXAA has 
enhanced antitumour activity (Baguley et al., 1993; Pedley et al., 1996), and the addition of 5-
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HT to MeXAAlbioreductive drug combinations can be particularly effective, although 
therapeutic gain can be dependent upon the class of bioreductive agent used (Simm et ai., 1997). 
Other strategies such as inhibition of nitric oxide synthase (NOS) to reduce production of 
the endogenous vasodilator nitric oxide (NO), have also been shown to lower tumour blood 
flow (Andrade et al., 1992). Nitro-L-arginine, one such NOS inhibitor, can increase 
radiobiological hypoxia and decrease energy metabolism in certain tumours (Wood et ai., 1994a; 
1994b), and has been shown to enhance the anti-tumour effects of the 2-nitroimidazole, RB 
6145 (Wood et al., 1994b). Alternative approaches to selectively lowering tumour tissue 
oxygenation include the use of left-shift agents to modify the haemoglobin saturation curve and 
impede oxygen delivery (Adams et al., 1986). 
Novel anti-vascular therapies, such as gene therapy-directed TNFa production, might 
also be utilised in combination with HSCs (Mauceri et al., 1996). TNFa expression has be 
specifically localised to the tumour endothelium, and this approach is attractive since 
endothelium provides a readily accessible target cell population for viral transduction (Jaggar et 
al., 1997). In principle, selective damage to tumour vasculature through novel endothelial cell-
targeted virus-directed cytokine or enzyme/prodrug therapy, may render solid tumours very 
responsive to secondary treatment with HSCs. 
1.12 Bioreductive drugs as hypoxia-activated diffusible cytotoxins 
An extension of the idea of targeting hypoxic tumour cells with HSCs, is to exploit the reductive 
enviroment of a solid tumour to activate HSCs that release oxygen-insensitive diffusible 
cytotoxins (Wilson, 1992; Denny and Wilson, 1993). Thus tumour hypoxia may provide a 
unique approach to selectively eliminate a much larger proportion of a tumour mass. Rather than 
just killing the hypoxic compartment of the tumour, the activated cytotoxin can extend its effects 
to surrounding tumour tissues of intermediate or normal p02 levels. The extent of this 
"bystander" killing effect can be governed by the reactivity and half-life of the diffusible 
cytotoxins (Friedlos et ai., 1997.) By extending the spatial range of the hypoxia-activated 
prodrugs, the heterogeneity of cell killing that can arise at intermediate p02 levels when 
conventional HSCs are combined with irradiation, or alternatively through clonogenic loss of 
bioactivating enzymes, may be effectively overcome (Denny and Wilson, 1993). 
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Of the five redox centres that have been exploited as bioreducible triggers, only 
nitro(hetero )aromatics and colbalt(1II) complexes have been developed in the context of 
reductive triggers for diffusible cytotoxins (Denny et al., 1996; Siim et al., 1997). A number of 
the nitro-triggered bioreductive prodrugs show good efficacy in vivo, particularly in 
combination with anti-vascular strategies (Cliffe et al., 1994; Wilson and Pruijin, 1995; Siim et 
al., 1997). This class of diffusible nitro-prodrugs also lend themselves to exploitation in 
combination with gene-directed enzyme/prodrug therapies (GDEPT). Currently E.coli 
nitroreductase (NR) is being developed as an activating enzyme for many of the nitro-prodrugs, 
but metabolism is not restricted to hypoxic tissues, since it is an oxygen-independent obligate 
two-electron reductase (Anlezark et al., 1995). Therefore the tissue-specificity of prodrug 
activation must, like conventional GDEPT, rely upon selective therapeutic gene delivery and/or 
tissue-specific NR expression. An alternative approach might be to utilise an oxygen-sensitive 
reductase, perhaps transcriptionally regulated by hypoxia-responsive enhancers/promoters, to 
effectively exploit the hypoxic compartment of a solid tumour through redox-sensitive, gene-
directed enzyme/prodrug therapy. Any inappropriate therapeutic gene delivery to and/or 
.~ .----~ --- .. ~ 
expression would not confer prodrug sensitivity to normoxic tissues. This additional selectivity, 
ensured by both hypoxia-selective therapeutic gene expression and oxygen-sensitive prodrug 
activation, could be targeted at the majority of a tumour mass if combined with anti-vascular 
strategies. 
50 
Chapter 2 Tirapazamine activation 
Chapter 2 
2. Enzymology of Trrapazamine Metabolism 
2.1 Introduction 
A clearer understanding of the key enzymes involved in the metabolism of tirapazamine 
(TPZ) is of great importance if this hypoxic cytotoxin is ultimately to be applied to a rationally 
selected patient population. Its impressive hypoxic selectivity at radiobiologically relevant oxygen 
tensions and its synergistic interaction with radiation and some chemotherapeutic agents have 
made it a lead second generation bioreductive compound in the treatment of solid tumours 
(Workman and Stratford, 1992; Brown, 1993; Koch, 1993; Dorie and Brown, 1993, 1997; 
Langmuir et at., 1994; Lartigau and Guichard, 1995). 
The enzymology of Tirapazamine (TPZ, SR 4233, WIN 59075, 3-amino-l,2,4-
benzotriazene l,4-dioxide, Tirazone™) has been extensively studied in rodents and to a lesser 
extent in human systems. While it is clear that the initial reductive step in TPZ activation is 
enzyme-mediated, there is limited consensus in the published literature as to the relative 
contributions of the cellular reductases involved. Moreover, not only is the importance of sub-
'cellular localisation for these putative activating reductase(s) far from clear, but their activity 
profiles, in vivo are poorly defined. The same might also be said of the potential detoxifying 
enzymes. 
In the presence of certain cellular reductases, TPZ will be subject to one-electron 
reduction to give the radical anion, which in its protonated form has been identified as a 
nitroxide radical (Lloyd et al., 1991). This species is unstable in the presence of oxygen and is 
rapidly back-oxidised to the parent compound with the concomitant production of significantly 
less cytotoxic superoxide radical species (Lloyd et al., 1991). This "futile cycling" in the 
presence of oxygen may account for the less severe oxic cellular toxicity of TPZ, probably due 
to the abundance of cellular reactive oxygen detoxifying mechanisms, most notably the 
superoxide dismutase(s) and catalase combination. In contrast, the absence of oxygen facilitates 
a TPZ radical mediated oxidising reaction with bio-molecules e.g. hydrogen abstraction from 
DNA (Laderoute et al., 1988; Baker et al., 1988) resulting in the formation of the non-toxic two-
electron reduction product, SR 4317. An oxidative mechanism of free radical attack, rather than 
51 
Chapter 2 Tirapazamine activation 
TPZ-nucleic acid base adducts, is most likely, since TPZ exposure results in DNA double strand 
breaks, whilst virtually no covalent binding of this drug to DNA or other cellular 
macromolecules occurs. 
Figure 1: Proposed mechanism of hypoxia selectivity of tirapazamine. 
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Consistently, electron spin resonance spectrometry (esr) evidence has clearly shown that a 
TPZ nitroxide radical anion can be formed, although the authors did not speculate as to the 
oxidising capability of this radical (Lloyd et al., 1991). The protonated neutral form of a TPZ 
nitroxide radical is presumed to be the reactive species, although there is no direct evidence for 
this. It has been further demonstrated that TPZ interaction with DNA results in formation of 
phosphoglycolates; fragments of damaged deoxyribose moieties (Jones & Weinfield, 1996). 
Since this requires the addition of oxygen it is concluded that TPZ acts in a dual fashion, firstly by 
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a TPZ free radical mediated attack on ribose to generate a C-4' free radical, following which 
unmetabolised TPZ then donates oxygen to this sugar radical by an oxygen atom transfer process. 
This produces an oxy-radical that decomposes to the phosphoglycolates observed. A further 
complication to this mechanism is evidence that the protonated neutral TPZ radical may also 
decompose by liberating a hydroxyl radical in keeping with direct formation of the mono-N-oxide 
metabolite (Daniels & Gates, 1996). These authors also showed that TPZ-mediated strand 
breakage is DNA non-sequence specific consistent with involvement of a highly reactive, non-
selective cleaving agent such as the hydroxyl radical. Using esr spectrometry in combination with 
DMPO as a spin trapping agent we have shown formation of a hydroxyl radical following 
anaerobic incubation of TPZ in several different human tumour xenograft microsomes (Patterson 
et al., 1998). Whatever the precise nature of the TPZ free radical it is the primary reactive species 
responsible for the cytotoxicity of this agent. 
The stoichiometry observed in mouse liver microsomes and human cell lines is reported to 
be 1.7 - 2.5 moles TPZ consumed for each mole of SR4317 formed, leaving 30 to 60% of 
starting material apparently unaccounted for (Walton and Workman, 1990; Walton et al., 1992; 
Siim et al., 1996). Very little, if any, four-electron reduction product, SR4330, is generated by 
rodent liver microsomal metabolism (Walton et ai., 1992) although rat DT-diaphorase appears 
particularly efficient at generating this product, and perhaps even a six-electron reduction product 
(Riley and Workman, 1992). Although some material can be accounted for in an unidentified 
HPLC peak (Baker et al., 1988; Laderoute et al., 1988; Walton and Workman, 1990) the 
observed stoichiometry is largely unexplained. Very little 14C_ TPZ (~0.1 %) is found associated 
with DNA (Laderoute et at., 1988), and plasma protein binding in mouse and human 
pharmacokinetic studies is only:::: 10 and 19% of total TPZ, respectively (Robin et al., 1995). 
Despite this gap in our understanding, the rate of SR 4317 formation has been related to 
cytotoxicty in a number of studies (Biedermann et al., 1988; Costa et al. 1989) but not in others 
(Siim et al., 1996). The high proportion of unrecoverable TPZ during reductive metabolism 
studies suggest that other highly reactive TPZ species are generated. These are most likely due to 
fragmentation of the chromophore producing (probably small) reactive metabolites that hitherto 
have evaded detection. The possible contribution of unknown reactive species to TPZ cytotoxicity 
should not be underestimated since a mechanism of action based on the nitroxide free radical is far 
from certain. Alternative possibilities have been suggested; for example, in principle TPZ could 
be enzymatically activated through a ring opening mechanism producing an unstable intermediate 
that can fragment, with the theoretical formation of a cytotoxic phenyldiazonium ion or an 
oxygen-inhibited phenyl radical (Laderoute et at., 1988; Ara et at., 1994). Whatever the 
underlying mechanism for DNA damage, there is a clear relationship between the rate of 
53 
Chapter 2 Tirapazamine activation 
formation of single-strand breaks (Siim et al., 1996), the final extent of unrepaired chromosome 
aberrations (Wang et al., 1992) and hypoxic cytotoxicity. Thus, the level of hypoxia (Koch, 
1993; Lartigau and Guichard, 1995), the ability of cells to repair DNA damage (Keohane et al., 
1990; Biedermann et al., 1991; Olive, 1995), and the expression of cellular reductases, will all 
influence the therapeutic selectivity of TPZ. 
In order to assess the role of the various reductase enzymes in a physiologically relevant 
context, activities of four major reductase enzymes were determined for a panel of human lung 
and breast cancer cell lines in vitro, and related to their hypoxic and aerobic sensitivity to TPZ, 
and the ability of celllysates to metabolise TPZ to its stable 2-electron reduced product SR4317. 
The panel of breast and lung cancer cell lines were chosen to represent the range of 
biological characteristics found clinically. The breast cell lines expressed a variable spectrum of 
growth factor and hormone receptors. SKBr3 (Trempe and Fogh, 1973) over-expresses c-erbB2 
and topoisomerase ITa., MDA-468 (Cailleau et al. 1974) and MDA-231 (Cailleau et al. 1978) are 
oestrogen receptor negative (ER -ve) and epidermal growth factor receptor positive (EGFR +ve), 
while T47D (Freake et al. 1981), MCF-7 (Soule et al. 1973) and ZR-75 (Engel et al. 1978) are 
ER +ve and EGFR -ve. ZR-75 is also progesterone receptor positive (POR +ve), while MDA-
231 is positive for c-erbB3. HBL-l00 is a non-tumourogenic, SV40 large T-antigen transformed 
cell line that is ER -ve (Polanowski et al. 1976) The lung cancer cell lines were representative of 
the major histological SUbtypes and include four small cell lung cancer (SCLC) cell lines, two 
bronchioloalveolar cell lines and two adenocarcinoma cell lines (Carmichael et al. 1988). 
Where possible, cell lines were established as xenografts in athymic nude mice and 
allowed to grow to - 300mm3 before being surgically removed and snap frozen in liquid N 2 for 
further analysis. Identical analyses of reductive enzyme activities were performed as for the in 
vitro lysates. 
2.2 Methods 
Chemicals. Tirapazamine, SR4317 and SR4330 were obtained from Sterling Winthrop or 
synthesised in house (Dr. M. Jaffar) using previously described methods (Seng and Ley, 1972). 
NADPH was purchased from Boehringer Mannheim (Lewes, UK). HPLC grade methanol was 
purchased from Merck (Lutterworth, UK). AlI other reagents were of analytical grade and were 
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purchased from Sigma (Poole, UK) or Aldrich. Tissue culture medium was obtained from ICRF 
(Clare Hall Labs., UK.) and Fetal calf serum from Sigma. 
Cells and culture. Table 1 lists the 22 cell lines used in this work. All cell lines were 
maintained in exponential growth phase by routine passaging. Most cell lines were grown in 
RPMI-1640, except for SKBr3 and SK-MES which were maintained in DMEM, and CALU-3 
and LDAN which were maintained in a 1: 1 mixture of DMEM:Hams F-12. (All media were 
prepared at ICRF, Clare Hall.) Media was supplemented with 10% (v/v) fetal calf serum and 
2mM glutamine. No antibiotic supplements were used. Cells were grown at 37°C in 100% 
humidified incubator with a gas phase of 5% CO2, 21 % 02' Cultures were routinely screened and 
found free of mycoplasma. 
In vitro quantification of TPZ sensitivity. A panel of seven breast and fifteen lung cell 
lines were assessed for their sensitivity to TPZ in two sets of experiments. Cells were either 
exposed to drug for 3h under aerobic or hypoxic conditions and allowed to grow in 0.4 ml fresh 
media for a total of 96h, or grown in air (final volume 0.2 ml) for 96h in the constant presence of 
TPZ. Dose response curves were determined using the MTI proliferation assay which is based 
on the ability of viable cells to convert a soluble tetrazolium salt, MTT, into purple formazan 
crystals (Mossman 1983). The optical density is proportional to the number of viable cells, 
although the absolute metabolism varies slightly between cell lines, as the conversion of MTI to 
formazan depends on the level of mitochondrial dehydrogenase activity in each cell line 
(Carmichael et al. 1987). Previous experiments have demonstrated that cellular sensitivity to 
bioreductive agents, whether assessed by clonogenic survival or the MIT assay, is similar and the 
two assay methods correlate well (Stratford and Stephens 1989). Cells are seeded at 103 to 104 
cells per well (depending on the doubling time of the cell line in question) in either 24- or 96-well 
format and allowed to attach for 3h prior to drug exposure. After 4 days, M1T (0.2 mglml) was 
added to a fmal concentration of 40 Jlglml and cells were incubated for a further 4h. Culture 
medium and unconverted MIT were removed and the fonnazan crystals dissolved in 200 Jll 
DMSO, 25 JlI glycine buffer, pH 10.5 (Plumb et al., 1989). Following 5 min vigorous shaking, 
optical density at 540 nm was measured on a multi-well spectrophotometer (Titretek Multiscan 
Plus MKII, Flow laboratories). Values of ICso (the concentration of drug required to reduce 
optical density by 50% compared to untreated controls) were determined from the individual 
survival curves of independent experiments (Deltasoft software; Biometallics Inc., Princeton, 
USA). Mean IC,o values (± s.d.) were derived from at least 6 independent experiments conducted 
on different days. 
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Preparation of in vitro cell Iysates. Cells in exponential growth phase were washed twice 
in ice cold PBS and harvested using a sterile cell scraper. Cells were resuspended in 1.5m1 ice 
cold hypotonic nuclear buffer A (l0mM HEPESIKOH, 1.5mM MgCI2, 10mM KCI, 0.05mM 
DIT, pH 7.4) and allowed to stand for 10 min at 4°C. Suspensions were sonicated using a MSE 
Soniprep 150 for 3 x 5 sec. at a nominal frequency of 23kHz and an oscillation amplitude 
between 5 and 10 flm. Samples were placed on ice between each sonication. The suspensions 
were allowed to stand on ice a further 10 min. and then were centrifuged at 7800g for 15 min at 
4°C. Protein content of the celilysates was detennined using the Bio-Rad protein dye binding 
assay (Bradford 1976) and quantified against high grade BSA protein standard. All samples were 
stored in liquid N2 until required « 6 weeks). 
Preparation of human cell line xenografts. All of the cell lines that would form viable 
xenografts when inocculated subcutaneously in nude mice were profiled. In some cases (e.g. 
MCF-7, ZR-75) it was necessary to support xenograft growth with a subcutaneous 90 day release 
oestrogen (1.7mg) implant. Cells were harvested in exponential growth phase, washed twice in 
cold PBS and resuspended at 2x107 cellslml in cold serum free RPMI. Using pre-cooled glass 
pipettes, the cell suspension was mixed with an equal volume of pre-cooled matrigel and lOOfll 
aliquotes (106 cells) were inoculated subcutaneously into the hind leg of female nude mice. 
Growth was monitored weekly, and xenograft tissues were removed at == 400mm3 and snap 
frozen in liquid N2. Samples were homogenised and excess debris was removed with an initial 
3OO0g spin (4°C). S-9 fractions were prepared, assayed and stored in an identical manner to the 
in vitro lysates. 
NADPH:cytochrome P450 reductase activity. P450 reductase activity was determined 
spectrophotometrically by monitoring the ability of the cell lysates to catalyse the NADPH-
dependent reduction of cytochrome c. (Patterson et ale 1995b). Each incubation comprised 400 f..Ll 
cytochrome c (final concentration 50flM), 100 f..Ll 10mM KCN (final concentration 1 rnM) and 
100-300 flg lysate protein (50-100 fll) made upto 0.98ml with lOOmM potassium phosphate 
buffer, pH 7.4. The reaction was equilibrated to 37°C and initiated by addition of 20 fll 10mM 
NADPH to the test cuvette (final concentration 200flM) and the rate of reduction of cytochrome c 
was monitored at 550nm for 3 min against a blank without NADPH. Initial rates of reaction were 
based upon an extinction coefficient of 21.0 mM-I em-I. P450 reductase activity was determined 
for at least 5 independent lysates, harvested on different days and the results were expressed as 
nmol cyt.c reduced per minute per mg of lysate (S-9) protein. 
56 
Chapter 2 Tirapazamine activation 
NADH:cytochrome hs reductase activity. Bs reductase activity was determined 
spectroscopically as the para -hydromecuricbenzamide (p-HMB) -inhibitable component of the 
NADH supported reduction of cytochrome c (37°C) (Barham et al., 1996). 
NAD(P)H: DT.diaphorase activity. DT-diaphorase activity of the cell lysates was 
determined spectrophotometrically as the dicumoral-: inhibited· component of NADH-dependent 
reduction of cytochrome c when supported by menadione (Patterson et ai., 1994; Robertson et 
ai., 1994). 
Cytochrome P450 isozyme activity. Cytochrome P450 (CYP P450) activity 
determinations were carried out by Prof. Laurence Patterson (Dept. Pharmaceutical Sciences, IX 
Montford University, Leicester).The assay is based upon the ability of specific CYP P4S0 
isozymes to catalyse the O-dealkylation of specific alkyloxyresorufin analogues to produce the 
highly fluorescent compound resorufin (Burke et ai., 1994). Methoxyresorufin O-demethylation 
(MROD) and ethoxyresorufin O-deethylation (BROD) are probes for two closely related forms of 
human and rat CYPIAI and CYPIA2 respectively. Pentoxyresorufin O-depentylation (PROD) is 
a probe for CYP2B activity, whilst benzyloxyresorufin O-debenzylation is specific to the CYP3A 
family. The assay used is a modification of the method used by Burke and Mayer (1975). The 
reaction was carried out under yellow light to prevent photo-decomposition of the 
alkylquinolinol.The reaction mixture contained 5J..lM alkoxyresorufin substrate (5JlI of a lrnM 
solution in DMSO), lOOJlM sodium phosphate buffer (pH 7.6), 1OJ..lM dicoumarol (5Jll of a 2rnM 
solution in DMSO) and 2S0J.lM NADPH (5J.1l of a 50mM solution in sodium phosphate buffer). 
This was pre-incubated for 2 minutes at 37°C in the housing unit of a Perkin-Elmer Model LS-SB 
luminescence spectrophotometer. The reaction was initiated by adding 50J.1l of S-9 (prepared from 
cell line or xenograft). The total reaction volume was Iml. The excitation wavelength was 530nm 
and emission was monitored at 58Snm (slit width Snm). Rate of formation of resorufin was 
calculated from an authentic resorufin standard. Positive control reactions were carried out as 
above but with the S-9 proteins replaced with liver microsomes prepared from untreated rat (50JlI 
of 8.9 mglml microsomal protein) for MROD, EROD and BROD. Microsomal proteins from the 
liver of PB-treated rat (501l1 of 1.65 mg/ml micrsomal protein) were used to assay for PROD. 
Analysis of total intracellular glutathione. Total glutathione (GSH) was determined as 
the NADPH dependent reduction of 5,5' -dithiobis (2-nitrobenzoic acid) (DTNB) when supported 
by excess exogenous glutathione reductase (30°C) (Griffith, 1980). DTNB is converted to a 
yellow compound, 2-nitro-5-thiobenzoic acid (DTTB), the formation rate of which can be 
monitored spectroscopically at 412nm. The formation rate of DTTB is proportional to the 
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concentration of (GSH) in the sample, and values can be interpolated via an authentic GSH 
standard of known concentration. Values were expressed as nmol GSH 1106 cells. 
Western immunoblot analysis. Samples of cells harvested for enzyme assays were washed 
in cold PBS buffer containing ImM phenlymethylsulphonyl fluoride, ImM benzamide, 50 Jlg/ml 
leupeptin and 50 Ilg/ml soyabean trypsin inhibitor. Cells were lysed in 1 ml 2% SDS, plus 
inhibitors in PBS at 65°C for 5 min. DNA was broken up by passing up and down a fine gauge 
needle. Samples were stored at -20°C. Proteins were subsequently resolved by 10% SDS-
polyacrylamide gel electrophoresis, and proteins on the gel were transferred overnight to a 
nitrocellulose hybridization transfer membrane. The membrane was washed 3 x 15 min with 
blocking buffer (20mM Tris-HCII pH7.5, 0.9% NaCI, 0.5% Tween 20, 1 % low fat Marvel), 
and incubated for 60 min with specific anti-human P450 reductase rabbit antibody (dilution 
1:500). After washing, horseradish peroxidase-conjugated goat anti-rabbit antibody (dilution 
1 :5000) was added and incubated for 30 min. All antibodies were diluted in blocking buffer. The 
membrane was developed using an enhanced chemo-Iuminescence western blotting detection kit 
(Amersham, U.K.). 
Metabolism of tirapazamine by in vitro cell lysates. Incubations were carried out under 
nitrogen at 37°C. The final incubation volume of 500J.11 comprised 100JlI cell lysate (max. final 
concentration 1.5 mg/ml) , l00Jll NADPH (final concentration ImM), 20J..lI TPZ (final 
concentration 2mM) and 280Jll of200mM potassium phosphate buffer, pH 7.4. The reaction was 
initiated by addition of substrate and stopped after 40 min by transferring 2 x 200J..lI aliquots into 
400JlI methanol and 50111 internal standard (0.4 mglml 4-nitroquinoline N-oxide in 20% (v/v) 
ethanol). Supernatants were prepared and injected onto the HPLC for analysis. Three lysate 
preparations for each cell line were incubated, each in duplicate, with duplicate analyses. 
Formation of SR4317 was linear for at least 40 min and up to a protein concentration of 1.5 
mg/mI, determined using SKBr3 lysates, which have the highest endogenous P450 reductase 
activity amongst the panel of cell lines. 
HPLC. Concentrations of SR4317 and SR4330 in incubation samples were determined by 
isocratic reverse phase HPLC (Walton and Workman 1990). Chromatography was performed 
using a waters IlBondpak phenyl41l radial compression cartridge in a Waters Radial Compression 
Module, and protected with a phenyl guard column. The mobile phase consisted of 32% methanol 
in water delivered at a flow rate of 3 mlImin. Detection was at 267 nm. Approximate retention 
times were 2.7, 4.6, 5.2 and 8.4 min for tirapazamine, SR4330, SR4317 and 4-nitroquinoline N-
oxide respectively. Concentrations of metabolites were calculated from peak height ratios and 
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compared with calibration curves (O-500J..LM) prepared by spiking lysate preparations with known 
amounts of metabolite. 
Data analysis. P450 reductase activity measurements were determined for each of the cell 
lysates and compared with the ICso values derived for each cell line under hypoxic and aerobic 
conditions. The abilities of the different cell line lysates to metabolise TPZ to its reduced product 
SR4317 under hypoxic conditions were determined. The relationship between TPZ sensitivity, 
P450 reductase, Bs reductase, DT-diaphorase activities and SR4317 formation velocity was 
assessed. The datawereanalysed using the standard model for a linear functional relationship with 
sampling errors in both variables. Briefly, the data were logarithmically transformed and the 
pooled variance of each data set was calculated. For statistical analysis of any two data sets, the 
model is fitted to the observations by the method of weighted least squares, each sample mean 
being weighted in direct proportion to the sample size. The statistical goodness-of-fit for any two 
data sets was tested by calculating the weighted mean-square deviation of the observations for 
mean xn and mean yn from the fitted model, and comparing this mean-square with the pooled 
variance within samples by a variance-ratio test. The statistical significance of the estimate of the 
slope of the straight line of best fit was tested by a' students t-test. 
2.3 Results 
Analysis of the inter-relationships between hypoxic and aerobic TPZ sensitivity, a complement of 
cellular reductase activities, intracellular glutathione and SR4317 formation velocity for the in 
vitro human lung and breast cell lines was conducted. The characterisation of endogenous 
reductase activities found in the in vitro cell line panel is summarised in table 1. No statistically 
significant relationship was found for TPZ sensitivity and any of the parameters in the lung cell 
lines. In contrast, there was a clear relationship between NADPH:P450 reductase activity, 
sensitivity to TPZ exposure and SR4317 formation velocity in this panel of breast cell lines (table 
2) (Patterson et al. 1995b). 
59 
Table 1. In vitro determinations of key enzymes in a panel of human breast and lung cell lines. 
Cell line Tissue Characteristics NADPH: NADH: NAD(P)H: Cytochrome 
type P4S0 reductase B 5 reductase DT -diaphorase P450 3A 
nmol cyt. c nmol cyt. c nmol cyt. c BROD oxidation 
reducedlminlmg reduced /minImg reducedlminlmg pmollminlmg 
SKBr3 adenocarcinoma ~ c-erbB2,top ITa 39.8 ± 3.2 59.7 ± 7.3 1870 +480 1.89 
MDA-468 adenocarcinoma EGFR+ve 20.9 ± 1.8 38.9 ± 8.3 13 ±2 1.71 
T47D adenocarcinoma ER+ve 17.2 ± 3.3 50.4 ± 6.5 46 ± 15 n.d. 
MCF-7 adenocarcinoma ER+ve 18.7 ± 3.4 61.3 ± 3.6 709 ±442 < 0.1 
ZR-75-1 adenocarcinoma ER&PGR+ve 11.2 ± 2.3 109 ± 11 2290 ±650 < 0.1 
MDA-231 adenocarcinoma EGFR+ve 6.7 ± 2.0 49.8 ± 3.0 12 ±6 < 0.1 
HBL-l00 non-tumourigenic ~V40 transfonned 8.8 ± 0.1 102 ±9 <1 n.d. 
A549 NSCLC adenocarcinoma 22.0 ± 2.7 51.6 ± 3.4 5930 ± 1500 1.38 
CALU-3 NSCLC 21.5 ± 0.8 83.0 ±7.6 10 ±4 < 0.1 
SK-MES NSCLC 19.2 ± 1.5 37.1 ± 12 362 ± 88 < 0.1 
NCI-H 322 NSCLC bronchio-alveolar 18.4 ± 3.2 60.7 ±24 5030 ± 1632 0.99 
NCI-H 358 NSCLC bronchio-alveolar 17.7 ± 1.0 39.0 ± 7.2 3290 ± 196 < 0.1 
NCI-H460 NSCLC large cell 17.6 ± 2.3 38.7 ±4.7 5340 ±989 <0.1 
NCI-H 522 NSCLC adenocarcinoma 15.4 ± 1.9 78.4 ± 1.6 240 ±79 <0.1 
LDAN NSCLC 9.2 ±0.4 35.9 ± 4.6 403 ±97 < 0.1 
NCI-H 647 NSCLC adenosquamous 9.1 ± 1.0 49.7 ±5.0 5140 ±781 0.94 
NCI-H 226 NSCLC squamous carcin. 7.3 ± 1.0 81.5 ± 4.8 1040 ±291 n.d. 
NCI-H 841 SCLC variant 31.6 ± 5.0 71.3 ± 2.6 450 ±81 n.d. 
NCI-H249 SCLC 27.1 ± 4.5 92.2 ± 16 5 ±3 < 0.1 
NCI-H 69 SCLC 16.6 ± 3.4 61.0 ± 10 403 ±47 n.d. 
gj NCI-H417 SCLC variant 13.1 ± 1.7 - 120 ±48 n.d. 
NCI-H526 SCLC variant 8.1 ±0.7 - 19 ± 10 n.d. 
Glutathione 
nmolGSH 
/106 cells 
12.2 
16.4 
13.0 
30.5 
11.8 
9.0 
-
40.8 
-
-
41.2 
14.1 
33.0 
4.6 
-
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Table 2: Sensitivity of a panel of human cancer cell lines to aerobic and hypoxic TPZ exposure, 
and the rates of hypoxic TPZ metabolism to the two-electron reduction product, SR 4317. 
Tirapazamine SR4317 
Cell line ICso (IlM ) formation 
± s.d. velocity 
96h 3h 3h Ol:N1 nmolformed 
aerobic aerobic hypoxic differential min·l mg·l 
SKBr3 10.4 ±0.3 161 ±48 5.1 ±2.0 29.8 22.4 ±3.4 
MDA-468 20.1 ±4.1 181 ±76 7.3 ±2.1 23.4 11.0 ± 1.9 
T47D 20.9 ±5.2 294 ±68 12.7 ± 2.0 23.3 13.2 ±2.7 
MCF-7 23.1 ±2.9 546 ±61 15.0 ± 3.9 37.1 10.2 ±0.9 
ZR-75-1 26.6 ± 1.6 1235 ±502 18.9 ±2.4 65.8 9.1 ±1.4 
MDA-231 35.4 ±4.1 302 ±65 22.8 ±4.0 15.0 3.7 ±0.7 
HBL-100 24.0 ±2.0 550 ±56 11.7 ±2.2 46.9 4.1 ±0.4 
A549 21.5 ±5.4 247 ±44 7.4 ± 0.5 33.2 15.1 ±2.4 
CALU-3 5.2 ± 0.7 
SK-MES 396 ±84 18.4 ±4.2 21.5 16.1 ±2.4 
NCI-H 322 62.4 ±7.2 980 ±24 54.3 ± 1.7 18.0 13.6 ± 1.6 
NCI-H 358 120 ±32 1231 ± 62 48.1 ± 5.6 25.6 7.3 ±0.7 
NCI-H 460 13.5 ± 1.3 110 ± 10 4.2 ± 2.0 26.2 11.8 ±2.3 
NCI-H 522 32.3 ± 1.3 141 ± 12 8.9 ± 0.6 15.8 9.3 ±3.0 
WAN 14.5 ±2.9 
NCI-H 647 16.7 ± 1.3 135 ±22 6.3 ±2.0 21.3 8.8 ±2.5 
NCI-H 226 56.4 ±1O 941 ± 189 22.8 ±4.6 41.4 5.5 ± 2.1 
NCI-H 841 10.2 ± 1.0 9.3 ±0.1 
NCI-H 249 14.9 ± 1.3 7.7 ±1.4 
NCI-H 69 9.3 ±0.8 
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Intrinsic sensitivities of human cell lines to the cytotoxic effects of aerobic and 
hypoxic tirapazamine exposure. The toxic effects of TPZ on the panel of cell lines was 
determined in two sets of experiments. Firstly, by exposing cells to drug for 3h under aerobic or 
hypoxic conditions, and secondly by growing cells in air for 96h in the continual presence of 
TPZ. Cytotoxicty was assessed by the MIT proliferation assay and typical survival curves, 
derived from individual experiments as given in figure 2. 
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Figure 2: Representative dose-response curves for the P450R-rich SKBr3 cell line (open 
symbols) and P450R-poor ZR-75 cell line (closed symbols) for 3h aerobic (circular symbols) or 
3h hypoxic (square symbols) exposure to tirapazamine. 
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From these dose-response curves, values of ICso (concentration of drug that will inhibit growth 
by 50%) can be derived. The data demonstrates the large increase in toxicity that results from TPZ 
exposure under hypoxic conditions, and also shows the variation in the absolute potency of the 
drug in air and hypoxia. The spectrum of sensitivity to TPZ is exemplified by the 12-fold range in 
aerobic and hypoxic ICsos seen across the cell line panel (table 2). 
P450 reductase activity correlates with sensitivity to TPZ in the human breast but 
not lung cell line panels. A 6-fold range in endogenous P450 reductase activity was found 
across the panel of 22 cell lines. This variation was narrower (3-fold) in the lung cell lines. The 
collective data were in broad agreement with the spectrum of expression observed for the NCI 
panel of 69 cell lines, which includes a range of tissue types (Fitzsimmons et al., 1996). 
Statistical analysis of the data revealed that the ICso values derived from acute 3h exposures to 
TPZ under hypoxic conditions correlated strongly with the independently determined P450 
reductase activities for the breast adenocarcinoma cell lines (slope value = -1.1 iO.17; P > 10-1°). 
The SV40 T antigen immortalised cell line, HBL-lOO, was atypically sensitive to TPZ and was 
excluded from the fmal breast adenocarcinoma cell line analysis. In contrast, aerobic toxicity 
following a 3h exposure does not show such a statistical dependency (slope value = -1.34 ±0.84; 
P=O.19) (figure 3). However the relationship under aerobic conditions was apparent following 
chronic (96h) exposure (slope value = - 1.6 iO.3; P=O.OO57) (figure 4). 
Eight of the NSCLC cell lines (A549, SK-MES, H322, H358, H460, H522, H647, 
H226) were also evaluated for acute TPZ sensitivity. No correlation was found with intracellular 
P450 reductase activity under either 3h hypoxic (P=0.34) or 3h aerobic (P=O.71) exposure 
conditions (figure 5). Consistently, no relationship was seen for 96h aerobic exposure to TPZ 
(P=0.81) (figure 6). 
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Figure 3 & 4: Human breast cell lines. Relationships between P450 reductase activity and 3h or 
96h tirapazamine exposure under either aerobic Ce ) or hypoxic (0) conditions. 
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Figure 5 & 6: Human lun& cell lines. Relationships between P450 reductase activity and 3h or 
96h tirapazamine exposure under either aerobic (e) or hypoxic (0) conditions. 
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P450 reductase activity correlates with SR4317 formation velocity in the human 
breast but not lung cellUne panels. In order to confirm whether P450 reductase is a major 
factor contributing to the metabolism of TPZ in the breast cell lines, the rate at which cell lysates 
reduce TPZ to its 2-electron reduced product SR4317, was measured under hypoxic conditions. 
The structures of these compounds are given in figure 1. No formation of the deoxygenated 4-
electron reduced product, SR4330, was detected in these experiments. The rates of formation are 
given in table 2 and a plot of P450 reductase activity in the breast cell lines versus the rate of 
SR4317 formation velocity cataysed by lysates of each cell line, with NADPH provided as the 
electron source. is given in figure 7. With respect to the breast celllysates. it is clear that a strong 
correlation exists between P450 reductase activity and SR4317 formation. with higher values of 
enzyme activity resulting in greater rates of metabolism (slope = 1.10 ±O.23; P=0.009). 
Interestingly in the HBL-lOO immortalised cell line. reduction of TPZ to SR4317 was consistent 
with the levels of P450 reductase expression. indicating that the hypersensitivity of this cell line 
was not a consequence of elevated reductive metabolism of the drug. This suggests that HBL-l00 
differs from the six adenocarcinoma cell lines in its ability to respond to the TPZ induced DNA 
damage. 
The relationship found in the 7 breast cell lines is not apparent in the panel of 13 lung cell line 
lysates (P=0.94). with up to 5-fold differences in SR4317 formation velocities for cell lines of 
similar P450 reductase activities (figure 8). This suggests that other enzymes besides P450 
reductase are contributing to the overall reductive metabolism of TPZ in this in vitro model. 
However. although conversion ofTPZ to its one-electron reduced product is an enzyme mediated 
process under hypoxic conditions. subsequent conversion to SR4317 is a chemical process. Thus 
measurement of formation of SR4317 is an indirect measure of "toxic" radical formation. 
Therefore. in the breast cell lines (but not the lung), one would anticipate that the formation of 
SR4317 by celllysates should correlate with the IC.50 for TPZ under hypoxic conditions, which is 
indeed the case (slope = -0.93 ±o.30; P=O.036) (figure 9). No such correlation is seen in the 
NSCLC and SCLC panel (P=0.87) (figure 10). When similar metabolism experiments were 
carried out in air, no SR4317 formation was detected, indicating that the obligate two-electron 
reductase, NAD(P)H dependent DT-diaphorase. is not measurably contributing to drug 
metabolism. 
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Figures 7 & 8: Human breast & lun~ cell lines. Relationships between endogenous P450 
reductase activity and the rate of hypoxic metabolism of TPZ to its two-electron reduction product 
SR 4317. 
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Figure 9 & 10: Human breast & NSCLC ce1llines. Relationships between the rate of metabolism 
of TPZ to its two-electron reduction product, SR 4317, and 3h hypoxic of sensitivity to TPZ. 
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No correlation between NADH:Bs reductase and TPZ sensitivity in the cell line 
panel. A 3-fold range in bs reductase activity is seen across the cell line panel. No correlation 
was found between bs reductase activity and hypoxic TPZ sensitivity in either the breast (P=O.81) 
(figure 11) or lung (P=O.85) (figure 12) cell lines. 
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Figure 11 & 12: Human breast & NSCLC cell lines. Relationships between the 
endogenous bs reductase activity and 3h hypoxic sensitivity to TPZ. 
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In support of this no relationship was seen between bs reductase activity and SR 4317 formation 
activity in either the breast (P=O.88) (figure 13) or lung cell lines (P=O.11) (figure 14). 
25 
Q) -... 0> e E 20 -c .f: 
.2 E ... -CIS"'C 
E Q) 15 .... E .E .... 0 
",- 10 ...- -
('I) 0 
"it E a: c en- 5 
0 
25 
Q) -... 0> e E - 20 c .f: 
.2 E -;-
E-g 15 ... E o .... 
- 0 
",- 10 ...-
('1)-
"it 0 a: E 
en-=- 5 
0 
0 
0 
Human breast cell lines 
+ 
1-0-4 
HBL·100 
20 40 60 80 100 120 
B5 reductase activity (pHMB-inhibitable) 
(nmol cyt.c reduced/min/mg) 
Human Lung cell lines 
• NSCLC 
[J SCLC 
~+.g..Ci 
20 40 60 80 100 120 
B5 reductase activity (pHMB-inhibitable) 
(nmol cyt.c reduced/min/mg) 
Figures 13 & 14: Human breast & IUDi cell lines. Relationships between endogenous bs reductase 
activity and the rate of hypoxic metabolism of TPZ to its two-electron reduction product SR 4317. 
70 
Chapter 2 Tirapazarnine activation 
No relationship between DT -diaphorase expression and protection from TPZ 
toxicity in the cell line panel. A 50oo-fold range in DT-diaphorase activity was found 
across the panel of 22 cell lines. Despite these large differences, no correlation was found 
between DT -diaphorase activity and resistance to chronic TPZ exposure under aerobic conditions 
(P=0.96) (figure 15) (Patterson et ai. 1994). 
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Figure 15: Human breast & NSCLC cell lines. Relationship between the endogenous DT-
diaphorase activity and 96h aerobic sensitivity to TPZ. 
It has been reported that rat Walker cell DT -diaphorase can efficiently reduce TPZ to its 2-
electron reduction product SR4317 (Riley and Workman 1992). Since this reduction is a direct 2-
e' transfer (which operates irrespective of tissue oxygenation status), reduction of TPZ would 
bypass the postulated cytotoxic nitroxide radical intermediate, providing an effective cellular 
detoxification mechanism. However it would appear that in contrast to rat, the human DT-
diaphorase does not efficiently catalyse this direct two-electron detoxification pathway. and thus is 
not an important determinant of the aerobic or hypoxic toxicity of TPZ. This is consistent with the 
observation that when celllysates were incubated with TPZ and NAD(P)H in air, no SR4317 
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formation could be detected, despite the presence of very high DT -diaphorase activities in some 
cell line extracts (eg. ZR-75 and A549). Significant differences in the substrate specificities of rat 
and human DT-diaphorases have been reported (Walton and Workman, 1990; Beall et al., 1994), 
and if also true of TPZ, would explain the observations in the panel of cell lines. 
Intracellular glutathione levels are not an important determinant of resistance to 
aerobic TPZ exposure. Glutathione (GSH) is known to be important in the scavenging of 
superoxide and hydroxyl radical species, and it is the most abundant intracellular source of 
reduced sulfhydryl groups (Kappus, 1986). OSH can be conjugated to many potentially cytotoxic 
species through the catalytic activity of cellular glutathione transferases. Although the panel of 
breast and lung cell lines exhibited a lO-fold range in total intracellular OSH, this did not show 
any relationship with the 96h aerobic sensitivity to TPZ (P=0.93) (figure 16). This indicates that 
GSH levels are not the determining factor in the response of these cell lines to chronic aerobic 
TPZ exposure in vitro. 
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Figure 16: Human breast & NSCLC cell lines. Relationship between the total intracellular 
glutathione levels and 96h aerobic sensitivity to TPZ. 
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Western immunoblot of breast cell line SDS extracts. Further evidence to qualify the 
relationship between P450 reductase expression and catalytic activity was provided by SDS-
polyacrylamide gel electrophoresis experiments in which the levels of P450 reductase protein in the 
breast cell lines was measured using a specific polyc1onal antibody for P450 reductase. An 
equivalent quantity of protein (60J,.lg) from each cell line was loaded onto the gel lanes in rank 
order of their sensitivity to TPZ (Fig. 17) and a band corresponding to P450 reductase was 
visualised at 78 Kda. It is apparent that the levels of P450 reductase protein decrease from left to 
right, i.e. the lowest level of protein occuring in the cell line with the greatest resistance to 
tirapazamine. When compared with the values determined for catalytic activity in each cell line 
there is a strong correlation (slope = 2.43 ±o.32; P<lO,5) (fig. 18). 
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Figure 17: Representative western immunoblot of the relative NADPH: cytochrome P450 
reductase expression in the six breast adenocarcinoma cell lines, ranked in order of in vitro 
sensitivity to TPZ. Gels were loaded with equal total lysate protein for each ceU line (67 J,.lg). 
Microsomes prepared from liver samples of phenobarbital treated mice were u ed a a po itive 
control (10 J,.lg). 
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Figure 18: Human breast adenocarcinoma cell lines: Relationship between functional NADPH: 
cytochrome P450 reductase enzyme activity and total intracellular P450 reductase protein, as 
determined by densitometric analysis of western immunoblots. Data is mean ± s.d. (n=3). 
Compare analysis of the intrinsic sensitivities of the breast and lung cell line 
panel to a range of unrelated chemotherapeutic agents. This panel of cell lines had 
previously been adopted to study the mechanisms of multidrug resistance (Houlbrook et al. 1994) 
using a range of commonly used but mechanistically unrelated chemotherapeutic agents 
(alkylating agents and intercalators). As with TPZ, sensitivities were determined using the MIT 
proliferation assay (96 h growth) and results were expressed as IC50 ± s.d .. This allowed the 
comparative analysis of the TPZ sensitivities against each of the other chemotherapeutic agent 
data, for both the breast and lung cell line panels. It was anticipated that this might provide 
suggestive patterns of sensitivity and resistance amongst the cell lines. 
The results were very striking. In the breast cell lines (n=6) the pattern of hypoxic 
sensitivity to TPZ did not correlate with that seen for any of the diverse chemotherapy agents 
(table 3). In marked contrast, an identical analysis in the panel of NSCLC cell lines (n=7) revealed 
a statistically significant correlation (Le. P < 0.05) with 1Ul the other agents tested in the lung cell 
line panel (table 4). Further analysis of the 3h & 96h aerobic TPZ sensitivities of the cell lines, 
revealed an identical pattern.These data strongly suggests that in the lung cell line panel the 
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intrinsic sensitivity of each cell line is strongly governed by its capacity to prevent and/or 
efficiently recognise and repair a diverse set of potentially lethal DNA lesions. Resistance to such 
a broad spectrum of chemotherapy agents is almost certainly multi-factorial and these 
characteristics may explain why no relationships were seen between the expression of reductive 
enzymes necessary to activate TPZ, and the consequential sensitivity to this agent. 
Table 3. Human Breast cell lines. Correlations between sensitivity to tirapazamine and other 
unrelated chemotherapeutic agents. 
Agent Tirapazamine sensitivity 
96h aerobic 3h aerobic 3h hypoxic 
Adriamycin t4 = 0.728 (p= 0.51) t4 = ·1.23 (p= 0.29) t4 = 0.524 (p= 0.63) 
m-AMSA t4 = 0.230 (p= 0.23) tA = -0.47 (p= 0.67) t4 = 0.152 (p= 0.89) 
Chlorambucil t4 = -0.35 (p= 0.74) t4 = 0.083 (P= 0.94) t4 = 0.311 (P= 0.77) 
VP-16 t4 = 0.825 (p= 0.46) t4 = 0.328 (p= 0.76) t4 = 0.454 (P= 0.67) 
Melphalan tA = 0.868 (p= 0.43) t4 = 1.110 (P= 0.33) t4 = 1.050 (p= 0.35) 
BCNU t4 = 0.624 (p= 0.57) t4 = 3.35 (p= 0.028 t4 = 1.520 (p= 0.20) 
Cis-platin t4 = 0.361 (p= 0.74) t4 = 1.420 (p= 0.23) t4 = 1.660 (p= 0.17) 
Mitoxantrone t4 = 0.723 (p= 0.76) td = 0.929 (p= 0.41) t4 = 0.245 (p= 0.82) 
Table 4: Human NSCLC cell lines. Correlations between sensitivity to tirapazamine and other 
unrelated chemotherapeutic agents. 
A2ent Tirapazamine sensitivity 
96b aerobic 3b aerobic 3h hypoxic 
Adriamycin t9 = 2.96 (p= 0.061) t, = 13.0 (P= 0.000048) t, = 7.60 (P= 0.00063) 
m-AMSA t9 = 4.45 (P= 0.0016) ts = 2.44 (P= 0.059) ts = 3.42 (P= 0.019) 
Chlorambucil t9 = 4.01 (P= 0.031) ts = 8.69 (P= 0.00033) ts = 13.7 (P= 0.000038) 
VP-16 t9 = 2.88 (P= 0.018) t, = 3.50 (P= 0.017) t, = 4.68 (P= 0.0054) 
Melphalan t9 = 2.44 (P= 0.038) ts = 6.62 (P= 0.0012) ts = 5.68 (P= 0.0024) 
BCND t9 = 3.34 (P= 0.0087) t, = 2.62 (P= 0.047) t~ = 3.17 (P= 0.025) 
Cis-platin t9 = 2.56 (P= 0.031) t, = 4.55 (P= 0.0061) t, = 4.99 (P= 0.0041) 
Mitoxantrone t9 = 2.02 (P= 0.034) t., = 3.01 (P= 0.031) t, = 3.95 (P= 0.011) 
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Tables 3 & 4: Tests for correlation are conducted by fitting a linear functional relationship on a 
log-log plot, and testing significance of the slope using a student's t-test. The p-values are 2-
tailed. Bold indicates significance at 5% level or higher (on 9df, t ~ 2.26 for 5%, ~ 3.25 for 1%; 
on 5df, t ~ 2.57 for 5%, ~ 4.03 for 1 %; on 4df, t ~ 2.94 for 5% significance). 
Profiling of reductive enzymology of in vivo xenografts. The comparative activities 
of the key reductive enzymesweredetermined in a panel of breast and lung cen1ine xenografts. 
Table 5: In vitro & in vivo determinations of metabolic enzymes in a panel of human cell lines. 
Tissue NADPH: NAD(P)H: Cytochrome P450 3A 
Cell lines type P450 reductase DT .diaphorase BROD O-debenzylation 
nmol cyt.c/minlmg nmol cyt.clminlmg pmoloxidised/minlmg 
In Vitro In Vivo In Vitro In Vivo In Vitro· In Vivo 
SKBr3 Breast 39.8 nld 1870 nld 1.89 nld 
MDA-468 Breast 20.9 3.0 13 6.5 1.71 6.1 
T47D Breast 17.2 nld 46 nld nld nld 
MCF-7 Breast 18.7 3.5 709 nld < 0.1 6.7 
ZR-75-1 Breast 11.2 2.5 2290 nld < 0.1 6.6 
MDA-231 Breast 6.7 3.3 12 23.2 < 0.1 5.5 
A549 NSCLC 22.0 4.4 5930 5537 1.38 12.6 
CALU-3 NSCLC 21.5 nld 10 nld < 0.1 nld 
SK-MES NSCLC 19.2 nld 362 nld < 0.1 nld 
NCI-H 322 NSCLC 18.4 nld 5030 nld 0.99 nld 
NCI-H 358 NSCLC 17.7 nld 3290 nld < 0.1 nld 
NCI-H 647 NSCLC 9.1 4.5 5140 1960 0.94 12.5 
NCI-H 249 SCLC 27.1 7.5 5 nld < 0.1 6.4 
HT-29 Colon 16.3 6.5 2760 1544 < 0.1 8.3 
* Limit of detection for BROD metabolism = 0.1 pmoVminlmg. 
(N.B. Human liver BROD activity varies between 4-130 pmoVmg microsomal proteinlmin). nld 
= not determined 
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Similar in vivo and in vitro activities were seen within the subset of cell lines with respect 
to DT -diaphorase and Bs reductase. Generally the expression of these enzymes was ranked in the 
same order for both in vitro and in vivo detenninations. In contrast, P450 reductase activity was 
consistently and markedly down-regulated, such that only a modest 2 -fold difference in activity 
was found across the xenograft panel (2.5 - 6.4 nmol cyt.c reduced min-I mg- I ). This was the 
opposite pattern to that seen for cytochrome P450 3A activity (BROD oxidation), which was 2- to 
lO-fold higher than that found in the in vitro lysates. In vitro and in vivo no CYP P450 IAI, 
lA2 or 2B activities were detected in any of the cell line or xenograft samples. CYP2C was not 
assayed due to the lack of anappropriatelyspecific substrate. 
2.4 Discussion 
Through the application of "enzyme profiling" in a panel of 22 human cell lines it was 
demonstrated that within the subset of 6 breast adenocarcinoma lines, P450 reductase plays a 
major role in the metabolic reduction of the TPZ and thus in determining the toxicity of the drug in 
vitro. 
The observations in the breast cell line panel that the formation of SR 4317 correlates with 
P450 reductase activity (figure 7) and that this production of SR 4317 also correlates with the 
hypoxic toxicity of TPZ (figure 9), implicates the P450 reductase-driven activation of TPZ to its 
one-electron reduced radical as an important contributory factor in the hypoxic toxicity of this 
drug. In the application of these observations it is useful to note that the expression of P450 
reductase protein (measured by western blotting) correlates well with the activity of P450 
reductase (figures 17 & 18), indicating that in each case all the enzyme detected is catalytically 
active. Thus, enzyme proftling of cells and tissues, together with a measure of tumour hypoxia, 
may provide a useful screen for predicting the activity ofTPZ in vivo (Olive et al. 1993; Philip et 
al. 1994; Rampling et al. 1994; Raleigh et al. 1996). 
In marked contrast to the breast adenocarcinoma cell lines, no relationships were seen in 
the panel of 15 NSCLC and SCLC cell lines; with neither the metabolic reduction of TPZ (n=13) 
nor the sensitivity to the drug (n=7) being apparently dependent upon the cellular complement of 
P450 reductase. The SR4317 formation data strongly suggests that cellular reductase(s) other than 
P450 reductase are involved in the metabolism of TPZ. However, since the monitoring of 
SR4317 formation rate does not differentiate between the relative contributions of either one- or 
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two-electron reduction pathways, the differences in SR4317 formation will not necessarily relate 
to toxicity. This is consistent with the lack of correlation between hypoxic ICso values and the 
velocity of SR 4317 formation, but it also suggests that factor(s) other than drug activation may 
also contribute to the sensitivity of these cell lines. 
This possibility is supported by the statistical analysis of the relative sensitivity of each of 
the cell lines to a spectrum of unrelated chemotherapeutic agents (table 4), and suggests that 
intrinsic sensitivity is a distinct characteristic of each cell type irrespective of the chemotherapeutic 
agent employed. Since most of the agents tested do not depend upon specific cellular metabolism 
to manifest their cytotoxic effects, and are known to have distinct modes of action, the 
correlations found between TPZ and these unrelated compounds suggests that the diverse 
histological subtypes represented in the lung cell line panel dominate the pattern of response to 
drug induced growth inhibition. Indeed, Houlbrook et al. (1994) demonstrated that this lung cell 
line panel showed significant inter-drug correlations, with the calculation of Kendall's coefficient 
of concordance giving a value of 0.69 (P= 0.0001), indicating that if a cell line is resistant to one 
drug it is likely to be resistant to many others. This is arguably consistent with the patterns of 
response seen clinically; where SCLC is usually highly responsive to first line chemotherapy, 
while NSCLC is generally multidrug resistant at presentation and consequently refractory to 
treatment. 
However, it is far from clear which other reductase(s) are involved in the metabolism of 
TPZ in these cell lines in vitro. The majority of published studies have focused upon microsomal 
metabolism of TPZ, since by far the greatest proportion of enzyme activity resides in this 
subcellular fraction. Walton and Workman (1990) have shown that anaerobic TPZ metabolism by 
mouse liver microsomes was some 40-fold higher than equivalent cytosolic-dependent reduction, 
with this microsomal reduction displaying a strong preference for NADPH over NADH as a 
source of reducing equivalents. Cytosolic reduction in contrast was found to be equally dependent 
on NADH and NADPH. Although a considerable number of publications have implicated or 
defined the contributions of a number of reductive enzymes in TPZ metabolism, for the majority, 
the relevence to TPZ cytotoxicity is not particularly clear. A critical analysis of the published 
literature serves to illustrate this uncertainty. 
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2.4.1 Microsomal metabolism 
2.4.1.1 NADPH: cytochrome P450 reductase. 
EPR spectroscopic studies (Lloyd et al., 1991) utilising rat liver microsomes identified 
NADPH: cytochrome c (P450) reductase (EC 1.6.2.4, P450 reductase) as the major hepatic 
microsomal enzyme responsible for the reduction of TPZ to a one-electron nitroxide radical 
intermediate, which in its protonated form, is thought to be the cytotoxic species (Costa et al., 
1989; Wang et al., 1992; Brown, 1993). In agreement with Lloyd et al. (1991), incubation of 
TPZ with purified rat liver P450 reductase under nitrogen has been shown to lead to the 
production of strand breaks in co-incubated plasmid DNA (Fitzsimmons et al., 1994). Other 
studies have shown that TPZ is reductively metabolised to SR4317 by purified rat liver P450 
reductase (Cahill and White, 1990; Fitzsimmons et al., 1994). The rate of SR4317 formation by 
in vitro celllysates has been linked to cytotoxicity under anaerobic conditions (Biedermann et al., 
1988; Costa et al., 1989; Wang et al., 1993). Further, Silva and O'Brien (1993) demonstrated 
that freshly harvested rat hepatocytes were highly sensitive to TPZ under hypoxia, but if 
preincubated with the flavoprotein (Le. P450 reductase) inhibitor, diphenylene iodonium (DPr+) 
(Doussiere and Vignais, 1992), both cytotoxicity and TPZ metabolism were prevented. In 
agreement, in this chapter it was showed that the formation velocity of SR 4317 correlated with 
P450 reductase activity, and that the rate of SR 4317 formation in turn correlated with the hypoxic 
toxicity of TPZ. These observations implicated the P450 reductase-driven activation of TPZ as a 
major contributory factor in the hypoxic toxicity of this drug in vitro. 
However contradictary evidence has recently been published, questioning the role of P450 
reductase in the bioactivation of TPZ in vitro (Elwell et al., 1997). Elwell and colleagues adapted 
the A549 human lung adenocarcinoma cell line to chronic aerobic TPZ exposure in incremental 
steps over a period of six months. In the cell lines adapted to 25-100 J.LM TPZ, P450 reductase 
activity was reduced to only 1-3% of the parental value, yet total cellular bioreductive capacity, 
determined as production of SR 4317 under hypoxic conditions, was only reduced 2-fold. In 
turn, only a 1.5-fold decrease in hypoxic TPZ sensitivity was seen. This contrasted with the 1.8 
to 9.2 -fold range in increased resistance to cell killing by TPZ under aerobic conditions. An 
alternative example of P450 reductase down-regulation following chronic exposure to a 
reductively-activated cytotoxin (mitomycin C) has been reported in a Chinese hamster ovary cell 
line, MMCR (Hoban et al., 1990), but in this case cross-resistance to TPZ was found under hmh 
aerobic and hypoxic conditions (Keohane et al., 1990). 
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Interestingly, these incremental adaptions in aerobic resistance observed by Elwell et al. 
(1997) were mirrored by similar magnitudes of elevation in mitochondrial manganese superoxide 
dismutase activity (MnSOD), with the most resistant population (100 J.lMR) being 9.2-fold more 
resistant to TPZ under normoxia, and having a 9.4-fold elevation in MnSOD activity. The data 
thus provided good statistical evidence to suggest a role for MnSOD in the acquisition of aerobic 
TPZ tolerance (r = 0.966), and agrees with Silva and O'Brien (1993) in implicating the 
mitochondrial compartment as playing an important role in aerobic detoxification of TPZ 
metabolites. Multiple changes in cellular biochemistry often occur following chronic exposure of a 
mixed population of cells to an escalating negative selection (in this case, increasing doses of . 
TPZ). The changes in P450 reductase, MnSOD and glutathione reductase are only three changes 
reported by Elwell et al. (1997) that appear to relate to aerobic TPZ tolerence. Unexpectedly, it 
was also discovered that DT -diaphorase was markedly down-regulated in the adapted populations 
-- despite its proposed obligate two-electron detoxifying role in TPZ metabolism (Walton and 
Workman, 1990). In the course of any such long term adaptions, other metabolic enzymes(s) 
might also become dis-regulated, to compensate for loss of function and so maintain metabolic 
viability. If true, one would anticipate that other putative one-electron reductase(s) may be up-
regulated, which would not significantly metabolise TPZ under aerobic conditions, but could 
contribute to the hypoxic metabolism of TPZ in the adapted cells. Indeed, Wang and colleagues 
(1993) identified 30-40% of the reductive TPZ metabolism as belonging to as yet unidentified 
enzymes. If some other reductase(s) could compensate for P450 reductase in its critical NADPH-
dependent flavoprotein functions, including the reduction of TPZ, the contradiction might be 
resolved. Perhaps approaches such as differential display PCR could aid in the identification of 
the other putative reductase(s) that contribute to TPZ metabolism. 
2.4.1.2 Cytochrome P450 (CYP450). 
In vitro studies with mouse liver microsomes and human tumour lysates have 
demonstrated that a large proportion (58-86%) of all TPZ reductive metabolism is catalysed by 
CYP450 (Walton and Workman, 1990; Walton et al., 1992; Riley and Workman, 1992; Riley et 
al., 1993; Wang et al., 1993). While the oxidative metabolism of organic substrates by CYP450 
isozymes is well recognised, far fewer studies have explored their role as a reducing catalyst. For 
a better understanding of the relationship of CYP450 reductive activity to the metabolism of TPZ, 
it is pertinent to review the role and functions of CYP450 in the reductive metabolism of other 
model substrates. 
80 
Chapter 2 Tirapazamine activation 
The CYP450 hemoproteins exhibit four different types of activity. They can act as a 
monooxygenases, reductases, peroxidases and oxidases. In its capacity as a reductase, the 
metabolism of carbon tetrachloride and halothane has been studied most extensively (Johansson 
and Ingelman-Sundberg, 1985; de Groot and Noll, 1986; Reinke et al., 1988; Van Dyke et al., 
1988). Following the interaction and binding of a polyhalogenated alkane substrate with the 
CYP450, the fIrst one-electron transfer occurs, usually provided by NADPH via the flavoprotein 
P450 reductase. The CYP450 heme Fe(III) is reduced to Fe(IJ) while P450 reductase is 
concurrently oxidised to the stable semiquinone radical. After the release of a halide ion, a 
haloalkane radical is fonned which can either leave the active site or undergo a second one-
electron reduction. Thus CYP450 isozymes are essentially two-electron reductases, although they 
receive their electrons from P450 reductase as two sequential one-electron transfers (and in some 
cases from cytochrome bs via cytochrome bs reductase) (Peterson and Prough, 1986). In the 
absence of competition with oxygen, substrates can dissociate after the transfer of only a single 
electron, or the reduced CYP450 is able to donate its one-electron to an alternate electron acceptor. 
Therefore in some cases, the availability of a second electron in the catalytic cycle of CYP450 via 
P450 reductase or cytochrome bs may influence the extent of radical generation (Pompon and 
Coon, 1984; Peterson and Prough, 1986; Guengerich, 1991). 
Because of the low reduction potential of CYP450, a variety of compounds are reducible 
including; aliphatic N-oxides, azo-dyes and epoxides, which undergo apparent stepwise 2-
electron reductions (Levine and Raza, 1988; Koop, 1992). Other substrates are reductively 
activated by CYP450 in a similar way to the polyhalogenated alkanes (Levine and Raza, 1988; 
Docampo and Moreno, 1990; de Groot and Sies, 1989; de Groot and Noll, 1986; van de Straat 
et al., 1987; Vromans et al .• 1990; Goeptar et al .• 1993). Direct electron spin resonance 
techniques have been employed to show that gentian violet undergoes a CYP450 dependent one-
electron reduction. with fonnation of the free radical species being strongly inhibited by O2, 
carbon monoxide (CO) and metyrapone (Harrelson and Mason, 1982; Docampo and Moreno, 
1990). Comparable inhibitable properties have been observed for 3,3'-dichlorobenzidine (lba 
and Lang. 1988) and benidazole (Masana et al .• 1984). Similarly. the one-electron reduction of 
the model quinone 2,3.5,6-tetramethylbenzoquinone, or the anticancer agents mitomycin C and 
doxorubicin to semiquinone free radicals, is strongly suppressed by the well known type I 
inhibitor of cytochrome P450, SKF 525A (Vromans et al .• 1990; Goeptar et al .• 1992; 1993). 
Thus, as a consequence of the potential contributions from either or both 1 and 2-electron 
transfers arising from the CYP450-dependent reductive metabolism. the possible outcomes are 
not necessarily predictable; being dependent not only upon substrate specificities and the degree 
of hypoxia, but also upon the composition of the experimental CYP450 system in both 
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microsomal and intact cell systems. Yet, while the above examples serve to illustrate the 
metabolic flexibility of CYP450 reduction, caution is indicated in the interpretation of the 
mechanisms, since direct parallels between nitrogen, oxygen and carbon centred reductions by 
CYP450 should not be made. 
The contribution of the CYP450 isozymes in the hypoxia-dependent cytotoxicity of TPZ is 
uncertain, particularly since cultured cells widely used to study drug activation and toxicty, 
rapidly lose their ability to express the P450 gene family (Paine, 1990). Published studies on the 
metabolism of TPZ using mouse liver microsomes (Walton and Workman, 1990; Walton et al., 
1992; Riley and Workman, 1992; Riley et al., 1993), tumour celllysates (Wang et al., 1993) and 
purified enzymes (Walton et al., 1989; Walton and Workman, 1990), have shown that both 
CYP450 isozymes and P450 reductase contribute to the overall two-electron reduction of TPZ to 
its non-toxic mono-N-oxide, SR4317, while studies with rat liver microsomes attribute all 
reductive activity exclusively to P450 reductase (Cahill and White, 1990; Lloyd et al., 1991). 
Dexamethasone induced and uninduced mouse liver microsomes, in combination with 
both chemical- (CO, metyrapone, SKF-525A, tolbutamide, p-nitrophenol) and immuno-
inhibitors, have been employed to identify the metabolic contribution of the cyp450 isozymes 
(Riley et al. 1993). Riley and colleagues confirmed earlier observations (Walton and Workman 
1990; Walton et al., 1992) that these cyp450 isozymes contributed at least 70% of the total 
SR4317 formation, with P450 reductase apparently accounting for the remaining 30%. Detailed 
CYP450-specific inhibitor studies resulted in the identification of the cyp450 2B (53%) and 2C 
(26%) families as contributing significantly to SR4317 formation under hypoxic conditions. 
However, the potential contributions of the one and two electron reduction pathways were not 
discussed. Some corroborative evidence in human tissues (Lewis et al., 1996) has also been 
demonstrated. Immuno-profiling of CYP450 isozymes in a panel of human liver microsomes 
(western blotting) and the relationship to hypoxia-dependent SR4317 formation rates has proved 
significant for CYP450 2B6 (r = 0.883, P = 0.002) but not CYP450 2C8 or 2C9. Lewis et al. 
also showed that celllysates from a human lymphoblastoid cell line (Crespi, 1991; Crespi et ai., 
1993) transfected with a mammalian expression vector to stably express the CYP450 2B6, 
demonstrated a 1.9-fold increase in TPZ metabolism relative to control lysates, as determined by 
the measurement of SR4317 formation velocity. However, the relative sensitivities to in vitro TPZ 
exposure under oxic and hypoxic conditions of the parental and the CYP450 2B6-expressing cell 
line have not been published. 
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Wang and colleagues (1993) reported that CYF450 apparently contributed> 60% of the 
metabolism of TPZ under hypoxic conditions in a mouse (SCCVII) and a human sarcoma 
(HTI080) cell line lysates; as implied by the observation that CO inhibited the NADPH-dependent 
reduction of TPZ. Such a result is surprising in view of the low levels of CYF450 activity in most 
in vitro cultured cell lines (Paine, 1990). Indeed, utilising celllysates from the in vitro HT1080 
cell line, to catalyse the O-dealkylation of specific alkyloxyresorufin analogues (Burke et al., 
1975; 1994), we were unable to detect CYF450 1AI, 1A2, 2B or 3A activities in vitro (Table I). 
Experiments in our laboratory using in vitro HT1080 lysates have shown that metyrapone did not 
inhibit the NADPH-dependent reduction of TPZ to SR 4317, while the flavoprotein inhibitor DPI+ 
effectively reduced SR 4317 formation velocity by over 90%. These observations raise the 
intriguing'possibility that in vitro, TPZ is reductively metabolised by a non-CYP450 hemoprotein 
that is not down-regulated by long-term CUlturing, but is (by its heme-containing nature) inhibited 
by CO. In support of this possibility, it has been shown that the tertiary aliphatic di-N-oxide 
AQ4N, a bioreductive antitumour agent, is reduced by recombinant nitric oxide synthase 
(EC.1.14.13.39) (LH Patterson & SM Raleigh, unpublished observations), P450 reductase and 
free haem (Raleigh et al., 1995). Both reactions are dependent on NADPH and inhibited by CO. 
As discussed earlier, Lloyd et al. (1991) concluded that all of the rat hepatic microsomal 
TPZ reduction could be attributed to P450 reductase, finding no observable contribution from the 
cyp450 isozymes, with neither CO nor metyrapone having any impact upon the EPR signal. 
Cahill and White (1990) also demonstrated that SR4317 formation was not influenced by CO in 
rat hepatocytes, and again suggested a dominant role for P450 reductase. It is unlikely that the 
disagreement over the involvement of the cyp450 system has arisen through a technical problem 
with the carbon monoxide inhibition, since metyrapone-based inhibition produces the same 
observed contradiction. One possibility is that these observations could reflect differences 
between mouse and human on the one hand and rat on the other. Although tertiary amine N-
oxides have been shown to undergo reduction by cyp450 in rat liver microsomes, formation 
velocities and cofactor requirements imply a distinctly more complex mechanism of NADPH-
dependent metabolism (Bickel, 1969; Sugiura et al., 1974, 1976, 1977; Kato et al., 1978). Of 
those studies which have implied a dominant role for murine cyp450 and human CYF450 (Walton 
and Workman, 1990; Walton et al., 1992; Riley et al., 1993; Wang et al., 1993), all have 
monitored the formation velocity of the two-electron reduction product SR4317 by HPLC. Since 
the measurement of SR4317 production under hypoxic conditions is only a surrogate measure for 
the formation of the nitroxide radical, it makes no discrimination between the enzyme-mediated 
conversion of TPZ to its one-electron reduced product (with its subsequent chemical conversion 
to the mono-N-oxide, SR4317), and any direct two-electron reduction events which would 
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bypass the cytotoxic radical intermediate. Lloyd and colleagues directly monitored the steady-state 
generation of the nitroxide radical by EPR spectroscopy, unambiguously ruling out a role for the 
rat cyp450 system in the reductive activation of TPZ. Neglecting the possible differences in the 
orthology of rodent cyp450, it might be argued that the results of rat versus mouse liver 
micro somes are consistent if one postulates of that the murine P450 isozyme-dependent reduction 
of TPZ is not proceeding via the nitroxide radical, but instead represents a potent two-electron 
detoxification pathway (i.e. 58-86% of total metabolism). TPZ could interact with the 
ferrohaemoprotein form of CYP450, generated following NADPH:cytochrome P450 reductase 
mediated reduction. The interaction with TPZ would be followed by a direct two-electron 
oxidative cleavage of the [Fe-O-N] complex to generate FeN=O and mono-N-oxide, and is 
effectively a ''TPZ-detoxifying'' oxygen atom transfer process. A further one-electron transfer by 
P450 reductase would generate the ferric form of CYP450 ready for the next catalytic cycle. A 
similar mechanism has been proposed for aliphatic N-oxide reduction (Suguira, 1976; 1977). 
Only EPR spectroscopic analysis of the effects of CYP450 inhibitors on anoxia-dependent 
nitroxide radical formation by mouse and human microsomes or reconstituted systems will 
resolve this uncertainty. 
Other factors must question the apparent dominance of CYP450 in the reductive 
metabolism of TPZ. The reduction rate of TPZ to SR4317 by both uninduced and induced mouse 
liver is extremely rapid, having reported values of 182 to 372 nmollminlmg microsomal protein 
(Riley et al., 1993). Similar values have been reported for human liver microsomes, with values 
ranging from 88 to 197 nmollminlmg microsomal protein (Lewis et ai., 1996). The spectrally 
determined cyp450 content of mouse liver microsomes used by Riley et al. was 0.65 to 1.83 nmol 
cytochrome P450 I mg microsomal protein, for control and dexamethasone treated animals 
respectively. Since most CYP450 reactions are relatively slow, with rates of = 1 nmol of product 
formed I nmol of cytochrome P450 I min being typical for many substrates (Guengerich, 1991), 
this apparent cyp450-dependent metabolism is proceeding 200 - 280 times more rapidly than 
might be predicted. Of note, Lloyd and colleagues (1991) pointed out that their V rrmx (900 
nmollminlmg protein) and ~ (1.4mM) values detennined for futile cycling of TPZ were in 
exellent agreement with the values determined for the anaerobic metabolism of TPZ by mouse 
liver micro somes (Walton and Workman, 1990). It was concluded that such a large cyp450-
dependent V max value was hard to understand, although these catalytic rates were typical of P450 
reductase (Fitzsimmons et al., 1994). 
Consistent with the literature on rat liver metabolism, Silva and O'Brien (1993) found that 
the inhibition of cyp450 by metyrapone or SKF-525A in intact rat hepatocytes. did not affect the 
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reduction of TPZ under hypoxic conditions « 0.1 % O2), Subsequently. Khan and O'Brien 
(1995) extended the work in this freshly harvested rat hepatocyte model to demonstrate that under 
1 % O2 , metyrapone and SKF-525A, (as well as cimetidine and erythromycin), could not protect 
against TPZ cytotoxicty as defined by trypan blue exclusion. However they found that the cyp450 
2EI-specific inhibitors (substrates), ethanol, isopropanol, phenylimidazole and isoniazid afforded 
significant cytoprotection, and suggested that TPZ was activated by rat cyp450 2E 1 as a result of 
a redox cycling-mediated oxygen activation. The data extensively implicates reactive oxygen 
species (ROS) in the TPZ dependent cytotoxicity at 1 % 02' since glutathione-depleted as well as 
catalase or glutathione reductase-inactivated hepatocytes were more sensitive to cell killing by 
TPZ. The disulphide reductant DIT (5mM) also prevented TPZ cytotoxicity, although at this 
concentration it is an effective inhibitor of cyp450 2EI activity (Yoo et al., 1987). 
In support of the dominant involvement of ROS, polyphenolic antioxidants quercetin, 
purpurogallin and caffeic acid, which scavange superoxide radicals, effectively prevented both 
cytotoxicity and GSH oxidation, although the lack of protection afforded by phenolic antioxidants 
implied that lipid peroxidation was not an important determinant of the TPZ cytotoxic mechanism. 
Further, the radical trap and superoxide dismutase mimic, Tempol, or the ferric chelator 
desferrioxamine (DFX) , prevented hepatocyte toxicity, perhaps implicating the generation of 
hydroxyl radicals by the Haber-Weiss reaction. The role of the nitroxide radical itself was not 
discussed in detail, although the authors concluded that" under 1% °2 , reduced cytochrome 2E1 
is more effective than cytochrome P450 reductase at carrying out a one-electron bioreduction of 
tirapazamine to the tirapazarnine radical which redox cycles and forms cytotoxic reactive oxygen 
species". However, although Khan and O'Brien (1995) briefly state that "tirapazamine was just 
as cytotoxic to hepatocytes under 1% oxygen as was previously observed under nitrogen", no 
evidence is provided to demonstrate the suggested one-electron reductive role of cyp450 2El 
under anoxia. 
Several difficulties complicate the interpretation of these data. Firstly, a specific inhibitor 
of cyp450 2El was not employed, it is not possible to unequivocally establish the participation of 
cyp450 2EI in TPZ metabolism. The use of reversible inhibitors is less effective, and in most 
cases the chemicals represent alternative substrates and/or ligands for other P450s as well. As the 
inhibition depends on the binding constant to cyp450 2El and to other forms of cyp450, some 
selectivity may be observed, but it is often difficult to interpret. Several compounds have been 
suggested to be specific mechanism-based inhibitors of cyp450 2E1 (Koop, 1990; Gannett et al' J 
1990). Secondly, the inclusion of 0.2% (v/v) DMSO (28 rnM) in the final incubations complicates 
the interpretation, since DMSO is an effective competitive inhibitor of cyp450 2E 1, with a K j = 
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0.39 mM (Yoo et al., 1987). DMSO is also a competitive inhibitor of imidazole-induced 
microsomal activity (Kaul and Novak, 1984). Thirdly, Riley et al. (1993) ruled out a role for 
murine cyp450 2El-dependent TPZ reduction through the use of an inhibitory monoclonal 
antibody (mAb 1-91-3), although 11% inhibition was seen in induced microsomes with the 
cyp450 2El substrate p-nitrophenol. However, DMSO was present in the [mal incubation 
questioning the apparent lack of effect. In tentative agreement, Lewis et al. (1996) failed to find 
any correlation between CYP450 2El expression and TPZ reduction in a panel of human liver 
microsomes (r = -0.40, P = 0.286). Fourthly, the lack of cytoprotection by metyrapone and SKF-
525A argues against the involvement of a one-electron reduction, since free radical formation of 
some other substrates by cyp450 has been shown to be inhibited by these agents (Harrelson and 
Mason, 1982; Masana et al.,1984; Iba and Lang, 1988; Yromans et al., 1990; Goeptar et al., 
1992, 1993). Finally the use of 1 % 02 in the cytotoxicty experiments markedly complicates 
interpretation, since molecular oxygen itself is an exellent substrate for reductive reactions. 
This oxidase activity of CYP450 2El is as important, if not more so, than the reduction of 
model substrates like CCI4• This isozyme is constitutively in its high-spin state (Koop et aZ., 
1982) and can readily accept electrons from P450 reductase in the absence of substrate. This not 
only confers the ability to efficiently reduce substrates such as CCI4, but it makes the enzyme 
especially effective in utilising dioxygen as an electron acceptor (Persson et al., 1990; Koop, 
1992). Consequently, purified CYP450 2El exhibits a higher rate of oxygen consumption and 
oxidase activity than other CYP450 forms (Gorsky et al., 1984). Such enhanced oxidase activity 
would operate efficiently at 1 % 02 (10.5 J.1M) (Persson et al., 1990) and would result in the 
increased production of both superoxide and hydrogen peroxide. This oxygen-dependent activity 
in the presence of chelated iron can produce reactive hydroxyl radicals (Dicker and Cederbaum, 
1987; Feierman et aZ., 1985), and is exemplified by the use of reconstituted systems in which 
cyp450 2El displays a unique ability to potentiate iron-catalysed Fenton chemistry. Of note, both 
DFX and Tiron have been shown to confer protection against TPZ aerobic, but not hypoxic 
cytotoxicity (Herscher et aZ., 1994). These oxidase-generated ROS would be indistinguishible 
from the ROS arrising from the postulated "redox cycling-mediated oxygen activation" if one 
speculated that TPZ could enhance the level of cyp450 oxidase activity or could itself donate 
mono-oxygen. Indeed some evidence exists for substrate-induced activation of oxygen through 
the uncoupling of cyp450 (van de Stratt et aZ., 1987). Two quinone imine substrates studied by 
van de Stratt et aZ. were themselves unable to redox cycle with oxygen, but in aerobic microsomal 
incubations they nevertheless produced marked increase in the formation of H20 2 and hydroxyl 
free radicals, thus appearing to stimulate the oxidase activity of cyp450. 
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Studies with liver microsomes and some purified cyp450s in vitro, indicate that a large 
fraction of the reducing equivalents of NADPH is used nonproductively, with the extent of 
uncoupling being dependent on the cyp450 form (Gorsky et al., 1984; Guengerich, 1991). 
However the in vivo significance of these nonproductive reactions is still uncertain. Thus the 
conjecture that the oxidase function of cyp450 2E 1 is involved in the hepatocyte cytotoxicity of 
TPZ observed by Khan and O'Brien is not deducible from the literature, with ambiguous evidence 
either way. However a comparative analysis of the inhibitors that prevented TPZ-dependent 
cytotoxicity in vitro (Khan and O'Brien, 1995), against independent studies (Persson et al., 1990; 
Bondy and Naderi, 1994) that evaluated their relative capacity to moderate cyp450 2El oxidase 
activity in a purified rat microsome system would tentatively suggest no such relationship. While 
ethanol and isoniazid were both capable of cytoprotection, only isoniazid produces significant 
inhibitory effects (70%) on cyp450 2El oxidase function in a reconstituted system. However, 
since the studies were conducted at different p02' and often differing inhibitor concentrations, it is 
difficult to draw any firm conclusions. Unfortunately no corroborative evidence regarding 
CYP450 2El mediated metabolism has been published. It would be of significant interest to 
expand these experiments in isoniazid-induced hepatocytes (Koop, 1990; Koop and Tierney, 
1990), in conjunction with mechanism-based CYP450 2El inhibitors and in the absence of both 
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Figure 19: Possible mechanisms of action of cytochrome P450 (CYP450) in the reduction of 
tirapazamine (TPZ) in the presence of molecular oxygen. (1) The single-electron reduction of TPZ 
by CYP450 with subsequent futile cycling of the nitroxide radical intermediate. (2) Oxidase 
activity of CYP450. (3) Dioxygen may compete for the transfer of electrons to TPZ, giving rise to 
an uncoupling of the CYP450 reaction cycle, with concomitant formation of reactive oxygen 
species (ROS). (4) ROS arising from TPZ-mediated activation of molecular oxygen or from a 
TPZ-dependent CYP450 uncoupling mechanism. (5) CYP450 may catalyse the concerted two-
electron reduction of TPZ, particularly if a second electron is readily available. 
There is good evidence that haemoproteins including CYP450 and haemoglobin can, in 
the absence of dioxygen, two-electron reduce N-oxides to their corresponding amines (Bickel, 
1969; Powis & McGraw, 1980, Burka et al., 1985). Indeed, TPZ has been shown to be 
reduced significantly to its mono-N-oxide (SR 4317) and zero-N-oxide (SR 4330) in hypoxic 
incubations containing mouse whole blood, but not plasma (Walton & Workman, 1993). 
Mechanistically N-oxides can be reduced by haem centres by a process requiring haem-N-oxide 
co-ordination to generate an [Fe-O-N] complex. A number of N-oxides have been shown to 
undergo type II spectral interactions with CYP450 in the absence of oxygen (Lindeke & 
Paulsen-Sorman, 1988). Such spectra are considered to be a result of direct coordination of the 
N-oxide (acting as a lone pair electron donor) with haem iron (Fe) of CYP450 to produce the 
[Fe-O-N] complex. 
Taken as a whole, no publication has yet to unambiguously assign a role for the CYP450 
system in the one-electron reductive bioactivation of TPZ, despite numerous demonstrations of 
the dominant role of murine cyp450 isoforms in mono-N-oxide formation. Thus, while evidence 
suggests human CYP450 may have some role in the overall metabolism of TPZ, it still remains 
unclear to what extent and in what context the CYP450 isozymes are important in the reductive 
activation and the subsequent cytotoxicity of TPZ. 
2.4.1.3 NADH: ferricytochrome bs reductase. 
No reports have been published to suggest a role for other recognised microsomal reductases such 
as NADH-cytochrome bs reductase and cytochrome bs in the metabolism of TPZ. Limited studies 
in our laboratory using the inhibitor p-hydroxymecuribenzoate (Barham et al .• 1996), have 
suggested a role for NADH-bs reductase in TPZ metabolism, for the panel of 15 human lung cell 
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lines (Chinje & Patterson, unpublished). Evidence for the involvement of cytochrome bs 
reductase in the reductive activation of a fused pyrazine mono-N-oxide (RB90740) has also been 
reported (Barham and Stratford, 1996). Further, the potential involvement of NADH-bs reductase 
and cytochrome bs in cytochrome P450-dependent one- or two-electron reductive metabolism of 
TPZ is undefined. 
2.4.2 Mitochondrial metabolism 
P450 reductase, CYP450 and DT -diaphorase are all present in the mitochondrial matrix, while bs 
reductase is found in the outer membrane of mammalian mitochondria (Prebble, 1981; Lind & 
Hojeberg, 1991; Waterman, 1982). Mitochondrial CYP450s receive their electrons from NADPH 
via the flavoprotein adrenodoxin reductase and the iron-sulphur protein adrenodoxin <waterman, 
1982). Spanswick et al. (1996) have recently identified a novel NADPH-dependent one-electron 
reductase capable of metabolising mitomycin C under anoxic conditions. Of the defined and 
uncharacterised mitochondrial reductases, limited evidence is available regarding their relevance to 
TPZ metabolism. Perhaps of significance, mitochondrial DNA has been identified as an important 
therapeutic target for mitomycin C-mediated damage (Pritsos et al., 1997), raising the possibility 
that the activity of these mitochondrial reductases might also be of importance in localised TPZ 
activation. 
Silva and O'Brien (1993) provided evidence that metabolites of TPZ can act as substrates 
for the mitochondrial respiratory chain. Incubation of TPZ (but not SR 4317 or SR 4330) with 
respiring rat liver mitochondria, induced NADH-dependent state 3 and 4 mitochondrial 
respiration, which was completely inhibited by cyanide and antimycin A but not rotenone. This 
implied a potential detoxification mechanism, in which the nitroxide radical could redox cycle via 
the mitochondrial electron transport chain without generating oxidative stress through oxygen 
activation. Cytotoxicity data supported this theory, since addition of a nontoxic concentration of 
KCN markedly narrowed the differential in TPZ sensitivity under oxic and hypoxic conditions. 
Interestingly, Ara et aZ. (1994) demonstrated that TPZ could itself behave as an uncoupler of 
oxidative phosphorylation, which could lead to a drop in the available ATP pool. Elwell et aZ. 
(1997) studied the changes associated with long term adaption to aerobic TPZ toxicity and found 
increased activities in manganese superoxide dismutase and gluathione reductase, both of 
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mitochondrial origin. This suggests that in aerobic cells, mitchondria may be a primary target for 
superoxide-mediated toxicity, as well as a potential site for TPZ radical detoxification. 
2.4.3 Cytosolic metabolism 
DT -diaphorase has been shown to contribute significantly to the NADPH supported reduction of 
TPZ (under N2) (Wang et aZ., 1993) in both murine sccvn (28%) and the human HT1080 
(41 %) sarcoma cell line in vitro. It has been suggested that TPZ may be directly reduced to its 2-
and 4-electron reduction products, SR4317 and SR4330 (detoxification) by obligate two-electron 
reductases such as DT -diaphorase. Its proposed detoxification role is consistent with the 
observation that NADPH-supported TPZ radical formation in rat liver micro somes (under N2) is 
unaffected by dicoumarol (100 J.lM) (Lloyd et al., 1991), a potent and relatively specific inhibitor 
of DT-diaphorase. Rat Walker tumour cell sonicates, a rich source of DT-diaphorase, readily 
reduce TPZ to both the 2 and 4-electron reduction products under air in the presence of NADH 
(Walton and Workman, 1990; Riley and Workman, 1992). This reduction is strongly inhibited by 
dicoumarol (100 j.lM). However Riley and colleagues (1993) subsequently showed that murine 
DT -diaphorase was not significantly involved in the anaerobic microsomal reduction of TPZ, 
implied not only by dicoumarol inhibition (10 j.lM), but also the marked oxygen sensitivity of 
reduction and the resultant metabolite profIle. 
This apparently limited role for murine DT -diaphorase was extended to human DT-
diaphorase when Patterson et aZ. (1994) failed to observe a relationship between DT-diaphorase 
activity and either aerobic or hypoxic TPZ sensitivity in a panel of 18 human lung and breast 
carcinoma cell lines. The apparent inability of the 5OO0-fold range in DT-diaphorase activity to 
influence the 12-fold range in TPZ sensitivity in vitro, together with the lack of NAD(P)H 
dependent SR4317 formation under aerobic conditions, strongly argued against a significant role 
for human DT -diaphorase in the cytoprotection from TPZ exposure. Similar findings were 
reported by Robertson et al. (1994). Further support comes from work on two human colon 
carcinoma cell lines; HT-29 with high DID activity and BE with undetectable DID due to a 
polymorphism in the NQOl gene (Traver et aZ., 1992). The cytotoxicity of TPZ was essentially 
identical, which strongly contrasted that seen for other known DID bioreductive drug substrates 
(Plumb & Workman, 1994). Utilising the human lung adenocarcinoma cell line A549, Elwell et 
al. (1997) demonstrated only a modest protection from aerobic (but not hypoxic) TPZ exposure 
by dicoumarol (2mM). This apparent "oxygen-dependence" for cytoprotection by DT-diaphorase 
is also suggested in studies with freshly isolated rat hepatocytes. Silva and O'Brien (1993) found 
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that dicoumarol (10 J!M) had no effect on the rate of TPZ metabolism by hypoxic «0.1 % O2) 
hepatocytes, which contrasted a later report showing significant protection by dicoumarol (25 
J.1M) against TPZ cytotoxicty under 1% O2 (Khan and O'Brien, 1995). However these 
observations may be artifacts, since dicoumarol can have multiple effects on cellular metabolism, 
including the inhibition of bs reductase and stimulation of xanthine oxidase and xanthine 
dehydrogenase activities (Ross et aZ., 1993; Hodnick & Sartorelli, 1993; Gustafson & Pritsos, 
1992). 
The cytosolic molybdoflavoproteins xanthine oxidase and aldehyde oxidase are also 
known to catalyse the reduction of N-oxides (Kitamura and Tatsumi, 1971; Bickel, 1969). 
Purified buttermilk xanthine oxidase, supported by its cofactor hypoxanthine has been shown to 
efficiently reduce TPZ to SR4317, and an allopurinol-inhibitable cytosolic reductase is seen in rat 
and mouse liver preparations (Walton et al., 1989; Walton and Workman, 1990). Further, 
xanthine oxidase can produce single strand breaks in plasmid DNA when co-incubated with TPZ 
under anoxia (Laderoute et aZ., 1988). Liver cytosol-dependent SR4317 fonnation displayed an 
equal dependence on NADH and NADPH, but was 40-fold slower than in equivalent microsomal 
preparations. Cytosolic aldehyde oxidase from mouse liver preparations has also been shown to 
reduce TPZ in a limited fashion (Walton and Workman, 1990), but no activity was seen in rat 
liver preparations (Walton et al., 1989). In agreement, Wang et aZ. (1993) reported that neither 
xanthine oxidase nor aldehyde oxidase supported significant reduction of TPZ in SCCVII and 
HTI080 cell line lysates (less than 10%). 
2.4.4 Nuclear metabolism 
A dominant role for nuclear xenobiotic-metabolising enzymes in the reductive activation of TPZ 
has been suggested, due to their proximity to cellular DNA (Cahill and White, 1990; Brown, 
1993). Since the endoplasmic reticulum and nuclear envelope are morphologically continuous, 
with each sharing certain biochemical similarities, it is not surprising that both are found to exhibit 
qualitative similarities in enzyme content. A number of drug-metabolising enzymes have been 
localised in liver nuclei or nuclear envelope preparations; these include cytochrome P450 
reductase, cytochrome P450, cytochrome bs reductase. cytochrome bs' DT -diaphorase, UDP 
glucuronyl transferase, epoxide hydrolase and flavin-containing monooxygenase (Franke et al., 
1970; Kasper, 1974; Bornstein et aZ., 1979; Thomas et al., 1979; Patton et al., 1980; Sum and 
Kasper, 1982). Quantitative comparison of whole nuclei, nuclear envelopes and liver microsomes 
has shown that considerable activity is associated with this sub-cellular compartment (Moody et 
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al., 1988). For example, utilising rat liver, Moody and colleagues found that 12% and 17% of 
total microsomal P450 reductase, and cyp450 activity respectively were detected in nuclear 
extracts. This was somewhat greater, but broadly in line with other reported values for 
comparative activity in whole nuclei vs. microsomal fractions, being 3.6 and 6.1 % for P450 
reductase and 2.7 and 3.3% for CYP450 (Jemstrom et al., 1976; Sagara et al., 1978). In support, 
Hishinuma et al. (1987) have immunohistochemically detected nuclear envelope-associated 
cyp450 components in cultured rat hepatocytes. Some cyp450 immunoreactivity has been 
identified within the nucleus itself (Bresnick et al., 1979), although others have found expression 
to be largely restricted to the nuclear envelope (Matsuura et al., 1978; Patton et al., 1980; 
Hishinuma et al., 1987). The potential importance of outer- versus inner- nuclear localisation of 
CYP450 in localised drug activation has not been defined. 
Cahill and White (1990) found that = 5% of total microsomal P450 reductase activity was 
detected in the nuclei of rat primary hepatocytes, which were able to reduce TPZ to SR4317 at = 
4% the rate for microsomes. Importantcorroborativeevidence has recently been reported by Evans 
et al. (1998), who showed that not only was:::: 20% of SR 4317 formation attributable to nuclear 
metabolism in the human lung adenocarcinoma cell line A549, but the addition of nuclear matrix 
extracts to naked plasmid DNA could produce single-strand breaks under anoxia, requiring the 
presence of both cofactor and TPZ. Furthermore, essentially all of the DNA damage induced by 
hypoxic TPZ exposure in intact A549 cells, could be produced in isolated nuclei. These results 
point to a dominant role for nuclear-matrix reductases, assuming the intra-nuclear concentrations 
of TPZ in intact cells and isolated nuclei are similar. Interestingly, very little P450 reductase 
activity was detected in these isolated nuclei. 
2.4.5 Enzyme profiles of the human tumour cell line xenografts. 
limited data exists on reductive enzyme profiles of human xenograft models. Studies in human 
colon and breast xenografts have identified CYP450 2A protein expression (not CYP450 2A6). 
Additionally in colon tumour xenografts very low levels of CYP450 2B and 2C8 were detected 
using the highly sensitive ECL detection method (Smith et al., 1993). Evaluation of CYP450, 
P450 reductase and DT -diaphorase activities both in vitro and in vivo xenograft models for the 
panel of human tumour cell lines showed that CYP450 IAI, lA2 and 2B activities were 
undetectable in all cases whereas CYP450 3A activity was elevated 2 - 10 fold in lung and breast 
tumour xenografts. Recent studies have suggested that elevated CYP450 3A4 and 3A5 expression 
is associated with increased cellular differentiation in vitro (Seree et ai., 1998). Increases in 
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reductive drug metabolism in xenograft models compared to in vitro culture have been reported 
(Hejmadi et al., 1996). In contrast to CYP450 3A, P450 reductase activity was reduced in vivo 
when compared to in vitro samples, while for DT -diaphorase apparently similar activities were 
recovered (Table 1). This contrasts studies conducted by Collard et ai. (1995), who showed that 
DT -diaphorase activities seen in xenografts were suppressed relative to parallel in vitro cultures in 
8 of 9 tumour cell lines. 
2.4.6 Rodent solid tumour models. 
Chemical induction of rodent hepatic neoplasia and its consequences upon cyp450 
expression is probably the most extensively studied model in vivo. With few exceptions, 
expression of cyp450 has been found to be reduced, or absent, in tumours compared to the 
surrounding normal tissues. Farber and colleagues generated four different rat models for liver 
carcinogenesis and compared the biochemical pattern in the hepatocyte nodules to the surrounding 
nonnal tissues (Farber, 1984, Roomi et ai, 1985). They showed a common pattern with an 
overall reduction of cyp450 and other phase I enzymes in the nodules. These levels were 
consistent with those published by other groups. Buchmann et al. (1985) immunohistochemically 
demonstrated that the level of four cyp450 forms varied widely in pre-neoplastic islets but were 
diminished in neoplastic nodules compared to the surrounding normal tissues. In the same model, 
P450 reductase was unchanged or low in islets but also reduced in neoplastic nodules. Both 
Buchmann and Farber suggested that these biochemical changes may contribute to the 
development of liver cancer. Comparable reductions in P450 reductase and cyp450 lAl 
expression have been observed in induced lung tumour models (Forkert et al., 1996). 
2.4.7 Relevence of CYP450 and P450 reductase to TPZ cytotoxicity in vivo. 
Some human P450 species have notably different catalytic activities towards various 
substrates, than that predicted by studies in animal systems. Consequently, extrapolation of 
metabolism data from rodent P450s to their human orthologues is hazardous. Large species-
specific differences in the enzymes involved in drug metabolism have been observed (Gonzalez, 
1992). In contrast, P450 reductase is more cleary implicated in the bioactivation of TPZ in both 
human and rodent tissues. Similarities might be anticipated from the close sequence homology 
between species (Nebert et al., 1991), and the fact that P450 reductase requires neither substrate 
binding nor conformational changes to facilitate the transfer of an electron to TPZ. Thus it would 
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be anticipated that the overall reduction reaction would be strongly dependent upon the redox 
potential of TPZ and the thermodynamics of the system, as opposed to reductive mechanism of 
the CYP450s, where active site constraints would contribute to specificity. 
An appreciation of which one-electron reductases are dominant in the activation of TPZ in 
human tumour tissues, would aid the clinical development of TPZ through the rational selection of 
tumour types. This might also allow the logical application of enzyme-profiling studies conducted 
on large panels of human cancer cell lines (Fitzsimmons et al., 1996), where patterns of reductive 
enzyme expression in particular tissue types can be examined in more detail in vivo. Further, it 
would also allow one to predict potential normal tissue toxicities, such as hepatotoxicity 
associated with ethanol-induced 2El, or the relatively high P450 reductase levels found in kidney 
medulla. Both these organs would be anticipated to have regions of low p02 . 
A good working knowledge of TPZ enzymology might also aid in the development of 
novel benzotriazene-di-N-oxide analogues with superior oxic/hypoxic differentials (Zeman et al., 
1989). Structure-activity relationships might ultimately be predicted from active site modelling of 
characterised CYP450 isozymes, or from variations in redox potential and the concurrent changes 
in rates of reduction by P450 reductase (Butler and Hoey, 1993b). The rational design and 
development of novel anologues through enzyme-directed techniques would be an attractive 
strategy. 
The observation that cyp450 2El may participate in TPZ cytotoxicity (Khan and O'Brien, 
1995) may have important implications for the acute liver toxicity that is seen in rat models (White 
et ai., 1992). TPZ-associated liver necrosis is confined to hepatocytes in the pericentral zone, a 
region that only experiences oxygen tensions of 2 - 4% (Lemasters et ai., 1981). Furthermore, it 
has been suggested that ethanol-induction of CYP450 2El in the centrilobular region of the liver 
may participate in the accentuation of the oxygen gradient between the perivenous and 
centrilobular regions of the liver (Lieber, 1984; 1990). The hypothesis that increased oxidase 
activity of CYP450 2El in the centrilobular region results in increased oxygen consumption while 
also increasing oxygen radical production, would account for the regioselective hepatotoxicity 
observed following ethanol treatment. While the importance of oxygen tension on TPZ-induced 
rat hepatocyte toxicity has been examined in vitro (Costa et al., 1989), the potential impact of 
ethanol consumption on TPZ related hepatotoxicty in humans is unknown. 
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2.4.8 Predicting clinical response. 
In view of the uncertainty surrounding the enzymology of TPZ, predictive assays such as 
the alkaline 'comet' single cell gel electrophoresis technique, which measures the level of DNA 
ssb in individual cells following TPZ treatment, may be the most appropriate way forward at 
present (Olive and Durand, 1992; Olive etal., 1993; Olive, 1995). Using the functional endpoint 
of DNA damage as a predictive marker, a measure of both the oxygen tension and the activity of 
single-electron reductases within individual cells is determined. This overcomes the difficulty in 
knowing how to interrelate independent measurements of enzyme activity with oxygen tension. 
Moreover, a knowledge of the possible influences of subcellular locatisation of key reductases at 
different oxygen tensions becomes unimportant. 
The utility of this approach has been demonstrated in vitro and in vivo (Olive et ai., 1996; 
Simm et al., 1996; 1997), and has confinned that DNA ssb correlate with cytotoxicity in both 
human and murine cell lines and xenograft models. Olive and collegues (1996) found the comet 
assay to be an adequate predictor of surviving fraction in xenograft models if samples were 
collected within 1 hour of TPZ administration. A similar relationship between DNA ssb at 60 
minutes and cell survival were reported by Simm and colleages (1996) in a murine cell line in 
vitro. These relationships were measureable at clinically relevent doses of TPZ, with the high 
levels of DNA ssb formation allowing accurate detection, yet with the background DNA damage 
being comparatively minimal. However variations in the cellular ability to repair DNA damage 
could complicate interpretation (Keohane et al., 1990; Beiderman et al., 1991), and the apparent 
inability of the technique to predict interactive toxicity with radiation may prove to be a limitation 
(Siim et al., 1997). 
Simm and colleagues (1997) demonstrated a relationship between tumour oxygenation, 
determined by the immunodetection of binding of the pentafluorinated etanidazole derivative EF5, 
and DNA 8sb induced by TPZ treatment. This relationship was consistent when tumour xenograft 
oxygenation was increased by carbogen (95% °2, 5% CO2) and nicotinamide administration or 
reduced by 10% oxygen breathing (r = 0.732; P<O.OOI). However only half of the variation in 
DNA damage could be accounted for by variations in tumour hypoxia as measured by binding of 
the hypoxic marker EF5, and it was suggested that the discrepancy may arise in part from the 
different oxygen tension dependencies for the reductive metabolism of nitroimidazoles and TPZ 
(Koch, 1993). However it must also be considered that the enzymology of reductive activation of 
these two class of compounds also differs significantly (Walton and Workman, 1987; Walton et 
al., 1989), making it difficult to differentiate between differences in oxygen dependence and 
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'enzyme profiles. Ultimately a clearer knowledge of the key reductive enzymes responsible for TPZ 
~-- .. ---
metabolism in humans could allow targeting of this drug to patients that have tumours with 
favourable enzyme profiles and p02 dependence. This together with non-invasive tumour imaging 
techniques (i.e. 19F MRI) may aid in predicting the response of individuals to TPZ ~ 
treatment. Such an approach, if viable, would have considerable advantages over the intrinsically 
invasive nature of tissue sampling necessary for comet assay measurements. 
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Chapter 3 
3. Overexpression of human NADPH:cytochrome P450 reductase 
in the breast adenocarcinoma cell line MDA-231 confers enhanced 
sensitivity to the bioreductive agent, tirapazamine in vitro. 
3.1 Introduction 
Following the observations in the panel of breast cell lines, a mammalian 
expression vector containing human P450 reductase (P450R) cDNA was transfected into 
the lowest endogenous P450R expressing cell line MDA-231. Since correlational studies 
do not imply causality, this provided a mechanistic approach to substantiate the 
relationship between P450R activity, SR4317 formation and tirapazamine (TPZ) 
sensitivity in the original panel of human breast cell lines. 
3.2 Methods 
Plasmid construction. The cDNA for human NADPH:cytochrome P450 reductase 
(P450R) was kindly provided by Professor C.R. Wolf (ICRF, University of Dundee, 
Scotland). Full length cDNA (2.4kb), originally isolated from human skin fibroblasts 
(Shephard et al., 1992), was subeloned into the pTZ19R bacterial vector. Restriction 
enzyme digest with BeoRI and Sal1 (Gibeo BRL) allowed the forced ligation into the 
multiple cloning region of the retroviral vector pBabelPuro (Morgenstern and Land, 
1990). The Moloney murine leukaemia virus LTR's promoter will drive transcription of 
the inserted gene, and has been demonstrated to be more efficient than most internal 
promoters in a number of cell types (Wilson et aZ., 1988; Osborne and Miller, 1988). The 
pac gene under the control of the SV40 early gene promoter confers resistance to the 
amionacyl nucleoside antibiotic, puromycin. The ATG gag sequences necessary for the 
high titre characteristics of the pBabe vector, when packaged into a retroviral system, does 
not influence expression of an inserted gene at the level of translation. 
Transfections and clonal selection of MDA 231 cells. Cells in exponential 
growth were harvested with a cell scraper, washed and resuspended in phosphate 
"cytomix" (Van den Hoff et aZ., 1992) to increase cell survival following electroporation. 
5x 106 cells were mixed with 10 J.lg linearised pBabelRed vector and electroporated. Cells 
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were plated at low density and 48h later were exposed to 3 J-lglml puromycin. Selection 
was maintained for at least 8 weeks. Individual colonies were isolated and samples of each 
were grown on glass coverslips for subsequent confocal microscopic examination. Cell 
monolayers were washed, fixed in 1:1 acetone:ethanol, blocked with 0.1% BSA, and 
incubated with anti-human P450R polyclonal antibody (1:100 dilution). Anti-rabbit IgG 
FITC-conjugated secondary antibody was used (1:1000 dilution) to visualise the 
uniformity and subcellular distribution of the primary antibody binding. The pre-screening 
of clonal lineage's on glass coverslips by immunohistochemistry avoided the unnecessary 
expansion of non-expressing clones for enzyme activity assays. Positive clones were 
further assessed for uniformity by similar anti-P450R antibody staining using flow 
cytometric single-cell analysis. Those populations of apparent single cell parentage were 
expanded for enzyme activity analysis and subsequent TPZ sensitivity work. A large 
number of colonies were screened in order to generate a set of clones exhibiting a range of 
elevated P450R expression. 
Cell lysate and primary breast biopsy sample preparation. Cell lysates were 
prepared in an identical manner to that previously described (Chapter 2). However the 
fractionation technique for the breast tumour biopsy samples was different to the standard 
5-9 lysate preparation. Tissue was cut up with surgical scissors under liquid N 2' 
homogenised in 10mM HEPES, ImM EDTA, O.5mM benzamide, 0.5mM PMSF, 1.0 
J.Lglml trypsin inhibitor (pH 7.4, 4°C) at a ratio of 1 gram tissue : 20ml buffer, and 
sonicated for 3 x 5 sec. (23kHz) as described previously. An initial 1600g spin (4°C) was 
used to remove excess cellular debris and the resulting supernatant was spun at lO5,000g 
for 45 mins., (2°C). Membrane pellets were dried and resuspended (with the aid of 
homogenisation) in Tris buffered saline (pH 7.4) containing 20% glycerol. In order 
directly to compare the P450R activities seen in the clinical tumour biopsy samples with 
the in vitro cell lines, identical membrane preparations were performed utilising a 
representative set of both the original panel of breast cell lines and the P450R-transfected 
MDA 231 clonal lines. 
Tirapazamine sensitivity. Dose-response curves were determined under aerobic and 
hypoxic conditions, and ICso values independently collated as described in chapter 2. Drug 
exposures were 3 h under hypoxic and 3 or 96 h under aerobic conditions. Total growth 
time before assay with MIT was 96 h. Experimental details differ from those described in 
chapter 2 (Patterson et al., 1995b), in that all hypoxic exposures were conducted under 
conditions of catalyst-induced anoxia « 1 p.p.m. 02)' All plastics and media were 
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preincubated in anoxia for 24 h before use to remove residual 02' The values of ICso in 
wild-type MDA 231 cells treated with TPZ under these extremely hypoxic conditions did 
not differ significantly from the earlier method of continual anoxic gas flow. Metabolism 
studies were conducted as described in chapter 2. Statistical analysis of the data was 
conducted as before. 
3.3 Results. 
Clonal characterisation. Six stable clones were selected, representing 6 to 53 -fold 
elevations in P450R activity above the parental cell line. These activities are thus within 
and beyond the range seen in the original panel of six breast cell lines. 
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Figure 1: Comparative NADPH:cytochrome P450 reductase (P450R) activitie in a panel 
of six human breast cancer cell lines, and a series of clonal lineages of the lowest P450R-
expressing cell line, MDA 231, into which human P450R has been stably transfected. 
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Confocal visualisation identified the presence of P450R protein which was found to 
localise to the endoplasmic reticulum (figure 2). Western blot experiments confirmed the 
expression of a single immunoreactive protein of identical gel mobility to that of the 
endogenous P450R protein (-78 kda) (data not shown). 
DT-diaphorase and NADH:ferricytochrome bs reductase activities. total 
glutathione, and cell doubling times determinations were also conducted on the six clonal 
lines. No statistically significant differences were seen for any of these parameters. The 
data is summarised in table 1. 
Table 1: MDA 231 P450 reductase transfected cell lines: determination of key 
characteristics for each clonal lineage. 
Cell line P450 reductase Bs reductase DT -diaphorase Intracellular Doubling 
± s.d. ± s.d. ± s.d. GSH ± s.d time ± s.d. 
nmol min-lmg"1 nmol min-Img-I nmol min-Img-I nmol 10-6 cells (h) 
Parental 4.5 ± 2.4 42.9 ± 5.2 36.6 ± 35.3 3.6 ± 3.0 23.0 ± 3.0 
Rd-06 25.3 ± 3.6 56.3 ± 6.2 7.8 ± 2.1 4.3 ± 1.5 22.7 ± 3.7 
Rd-09 40.6 ± 7.8 40.1 ± 2.4 37.8 ± 14.3 2.4 ± 1.9 24.0 ± 2.9 
Rd-16 71.2 ± 5.4 39.4 ± 2.4 9.5 ± 7.9 5.7 ± 1.6 22.2 ± 3.7 
Rd-22 100.1 ± 17.1 36.2 ± 8.6 6.3 ± 2.4 5.0 ± 2.2 23.3 ± 1.9 
Rd-42 189.6 ± 31.6 42.3 ± 4.7 12.1 ± 13.2 1.9 ± 0.4 24.6 ± 3.4 
Rd-53 239.0 ± 19.7 45.1 ± 5.4 36.3 ± 25.9 3.8 ± 1.3 23.9 ± 4.1 
Tirapazamine sensitivity. Analysis of the sensitivity of each of the derived clones to 
TPZ was conducted. and ICso values were determined as described (table 2). A 
representative dose-response curve is shown in figure 3. The data demonstrated a clear 
relationship between elevated P450R activity and increased sensitivity to tirapazamine 
under 3h hypoxic (slope = -1.83 ±o.26; P=0.0019) and 3h aerobic (slope = -1.52 ±O.30; 
P=0.0041). or 96h aerobic (slope= -1.38 ±o.26; P=0.0030) exposure conditions (Figures 
4 & 5 respectively). Furthermore. the rate of formation of the 2-electron reduction 
product, SR4317. using celllysates incubated with TPZ and NADPH under hypoxic 
conditions. supports the conclusion that P450R is responsible for the reductive 
metabolism of TPZ in this in vitro model (Figure 6). It can be seen from these data that 
there is a strong correlation (slope value = 3.31 ± 0.43; P = 0.0015) between P450R 
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activity and SR 4317 formation, with higher values of enzyme activity resulting in greater 
rates of metabolism. When similar experiments were carried out in air, no metabolism was 
detected. 
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Figure 3: Comparative dose-response curves for 3h aerobic (circular symbols) and 3h 
hypoxic (square symbols) TPZ exposures in the parental MDA 231 breast adenocarcinoma 
cell line (closed symbols), and a clonal line Rd-42 (open symbols), stably over-expressing 
human NADPH:cytochrome c (P450) reductase. Relative P450 reductase activities are 4.5 
and 190 nmol cyt c. reduced min-I mg-I protein respectively, representing a 42-fold 
elevation in whole-cell actvity. 
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Figures 4 & S: Dependence of Ie so values of the MDA 231 clones exposed to tirapazamine 
for 3h under aerobic (0) or hypoxic (e) conditions (fig.4), or for 96h under aerobic (0) 
conditions (fig.S), on P4S0 reductase activity. Bars indicate standard deviations. 
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Figure 6: Dependence of P450 reductase activity for the ability of membrane-preparations 
from the transfected MDA 231 clones to convert TPZ to SR 4317 under hypoxic 
conditions. Bars indicate standard deviations. 
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Table 2: MDA 231 :P540 reductase transfected breast cancer cell lines: response to TPZ 
under aerobic or hypoxic conditions. 
Cell line Tirapazamine Differential 
ICso O.lM) + s.d. toxicity 
96-h Aerobic 3-h Aerobic 3-h Hypoxic ICso ratio of 3-h 
exposure exposure exposure oxic/hypoxic 
Parental 34.2 ± 3.9 615 ± 104 22.6 ± 3.6 25.8 
Rd-06 18.6 ± 5.6 329 ±45 15.1 ± 4.6 21.8 
Rd-09 13.6 ± 1.8 258 ± 120 8.1 ± 1.0 31.9 
Rd-16 4.0 ± 1.3 72.6 ± 20.0 3.3 ± 0.8 22.0 
Rd-22 3.1 ± 1.3 84.4 ± 21.1 3.5 ± 0.8 24.1 
Rd-42 1.5 ± 0.4 40.7 ± 13.1 2.1 ± 0.6 19.4 
Rd-53 2.4 ± 0.8 50.6 ± 12.3 2.6 ± 1.0 19.5 
Comparative activity of P4S0 reductase In human breast cancer cell lines, 
the transfected clonal lines and clinical breast tumour biopsy samples. Five 
of the panel of original breast cancer cell lines and four of the isolated clonal lines (Rd-06, 
Rd-09, Rd-16 and Rd-42) were used to generate both whole-celllysates (S-9) and whole-
membrane fractions. As whole-membrane fractions are routinely prepared from all surgical 
breast biopsy samples for receptor analysis in other studies, membrane samples were 
prepared in an identical from the panel of breast cell lines and four of the P450R clonal 
lines. The activity of P450R for both preparator methods, in each clonal line, correlates 
well (P = 0.007), with membrane fractions showing an approximately two-fold higher 
level of activity (per mg of protein) than the whole-cell lysates. The membrane fraction 
P450R activities of each group of samples is plotted in figure 7. The activities found in the 
range of P450R clonal lines is within and beyond that seen for both the in vitro cell lines 
and the breast biopsies. A clear heterogeneity in functional P450R activity is seen in the 
breast biopsy samples, with an I8-fold range in membrane-associated activity. Indeed, 
within this limited group, 4 of 14 samples have activities greater than those found in the 
panel of unmodified breast cell lines. Further, immunohistochemical analysis of a range of 
sections taken from each tumour biopsy demonstrated unifonn immunoreactivity localised 
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to tumour epithelia. In some cases P450R-immunoreactivity appeared greater in peripheral 
normal epithelia than the adjacent neoplasia (Figure 8). 
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Figure 7: P450 reductase activity in human tumour cell lines. transfected MDA 231 clones 
and biopsy samples from primary human breast tumours. 
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Establishing the Rd·16 clonal cell line as a xenograft model in nude mice. 
During extended periods of selection-free in vitro growth, Rd-16 was found to express 
stable levels of P450R activity. This lineage was used to establish intraperitenial 
xenografts in the lower back of nude mice, in order to evaluate its potentat as an in vivo 
model of P450R overexpression. Four xenografts were initially established, from one of 
which, a tissue sample was serial passaged to create the next passage of xenografts and so 
forth for 4 passages. In vivo samples were harvested from each xenograft and the P450R 
activity was quantified. Initially activities were low, but by passage 3 a wide range in 
P450R activity was seen (figure 9), which was not obviously inversely related to the 
proportion of necrotic tissue in the tumour mass, as determined by immunohistochemical 
analysis (data not shown). Neither was enzyme activity related to the final tumour mass at 
the time of excision (Figure 10). More detailed histological analysis revealed the P450R 
immunoreactivity to be somewhat heterogeneous in the viable area of xenograft tissue 
sections (figure 11). This implied either a lack of clonal stability in vivo, or perhaps 
variations in the functioning of the MLV LTRs in vivo. Due to the lack of predicability in 
total P450R activity in this xenograft model, no further studies were conducted. 
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Figure 9: Individual P450 reductase determinations of Rd-16 xenografts serially passaged 
in nude mice in vivo. Mean in vitro activity ofRd-16 cell line = 71 ± 5 nmol/min/mg. 
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Figure 10: Relationship between P450 reductase activity and total tumour tissue mass in 
the Rd-16 xenograft model in vivo. 
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3.4 Discussion 
Evidence from enyzme-profiling studies (chapter 2) has implicated P450R as an 
important determinant of the hypoxic and aerobic toxicity of tirapazamine in breast cancer 
cells in vitro. 
In order to unequivocally confIrm the contribution of this enzyme by genetic 
means, the lowest of these P450 reductase-expressing breast cell lines, MDA 231, was 
transfected with the full length human P450R cDNA (Shepard et al., 1992), under the 
control of the Moloney murine leukaemia virus LTR (Osborne and Miller, 1988). Six 
stable clones were selected, representing 6 to 53 -fold elevations in P450R activity above 
that of the parental MDA 231. These activities were within and beyond the range seen in 
the original panel of six breast cell lines (Patterson et al., 1995). Confocal visualisation 
identified the presence of immunoreactive protein which apparently localised to the 
endoplasmic reticulum, while western immunoblots confmned the expression of a single 
immunoreactive protein of identical gel mobility to that of endogenous protein (78 kda). 
Analysis of the sensitivity of each of the derived clones to TPZ demonstrated a clear 
relationship between elevated P450R activity and increased sensitivity to TPZ under 3h 
hypoxic (~ II-fold; P=O.OOI9) and 3h aerobic (~ IS-fold; P=O.0041), or 96h aerobic (~ 
23-fold; P=O.003) exposure conditions. Further, the rate of formation of the 2-electron 
reduction product, SR4317, correlated with P450R activity, supporting the conclusion that 
P450R is responsible for the reductive metabolism of TPZ in this in vitro breast 
adenocarcinoma model. These observations support the conclusions of others, that 
P450R-dependent metabolism is proceeding via an oxygen-sensitive cytotoxic intermediate 
(Lloyd et at., 1991; Fitzsimmons et at., 1994). Statistical comparison of the inter-
relationships of enzyme activity and TPZ sensitivity from the original six breast cell lines 
(Patterson et al., 1995b) versus that of the MDA-231 clones provided no evidence to 
suggest that variations in the slopes for each exposure condition were other than random 
(3h hypoxia, P=0.19; 3h aerobic, P=O.90; 96h aerobic, P=0.54; Aspin-Welsh t-test). 
Thus, analysis of the data sets not only implicated the cDNA-expressed P450 reductase in 
the reductive metabolism of TPZ, but also indirectly substantiated the earlier conclusions 
(chapter 2) that the endogenous P450R activity measured in the six breast adenocarcinoma 
cell lines was correctly identified as the major determinant of TPZ sensitivity. 
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3.4.1 Relevanceof sub-cellular localisation for TPZ bioactivation. 
It has been proposed that only the nuclear metabolism of TPZ is responsible for the 
generation of the radical species which ultimately give rise to the lethal DNA damage 
(Brown, 1993). Yet, over-expression of full length human P450R cDNA in a breast 
cancer cell line conferredmarked sensitization to both hypoxic and aerobic TPZ exposure, 
despite an apparent reticular localisation. However, due to the intense immunoreactivity of 
the rough endoplasmic reticulum, and the absence of nuclear fraction activity assays or 
immunohistochemical analysis of isolated nuclei, it is difficult to accurately differentiate 
between reticular and nuclear envelope localisation. What is clear is that no detectable 
increase in intra-nuclear P450R immunoreactivity was observed, although since the 
P450R polypeptide contains putative lysine-rich nuclear-localisation signals, such a 
possibility can not be excluded. 
In the absence of oxygen the TPZ radical is thought to undergo an oxidising 
reaction with DNA (Laderoute et al., 1988; Baker et ai., 1988) yielding a DNA radical and 
SR4317. This may be the first step in a chain reaction between the DNA radical and TPZ, 
that could result in multiply damaged sites from a single reductive event. Laderoute et ai. 
(1988) demonstrated the existence of a short chain reaction during the radiolytic reduction 
of TPZ in a solution containing fonnate. Wardman et al. (1995) have suggested that the 
nitroxide anion mediated hydrogen abstraction from the sugar backbone of DNA will 
result in strand breakage and the formation of a sugar radical, and that this radical can 
subsequently reduce a further molecule of TPZ, establishing a highly localised chain 
reaction of TPZ activation, thereby 'amplifying' the initial DNA damage. It has been 
suggested that such multiply.' damaged sites in DNA (reminiscent of high-LET radiation 
damage) could be the critical lesions for TPZ -induced hypoxic cytotoxicity (Brown, 
1993) since they appear to be particularly difficult to repair (Wang et al., 1992). 
Wardman et al. (1996) subsequently argued, following theoretical considerations 
of the competition between diffusion of the second radical away from the site of generation 
at the initial sugar radical and its reaction close to the original site of DNA damage, that 
considerable doubt must exist as to whether damage initiated by a single drug radical could 
lead to the clustered damage that is proposed to occur (Wang et aI., 1992; Brown, 1993). 
This conclusion was based upon calculations suggesting the radical was predicted to live 
for = I to 10 msec, through which the mean diffusion distance of the radical in the cytosol 
was found to approximate to O.S - 2 Jlm. These estimates of radical stability under hypoxia 
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were consistent with earlier experimental estimates of 8 msec for the fIrst half-life of the 
radical under anoxia (pH 7.4, initial TPZ concn. = 4J.IM) by Laderoute et al. (1988), who 
concluded that "the <natural' lifetime of of the radical was sufficiently long that it could 
diffuse over significant distances within hypoxic cells and thus inflict oxidative damage on 
cellular targets ". By implication microsomal-generated TPZ radicals may have just as 
effective an access to DNA as any nuclear membrane-generated radicals under hypoxia. 
However, such a diffuse "halo" of microsomal radical generation around the nucleus 
would still leave the postulated formation of clustered DNA damage unexplained. One 
might suggest that if short chain reactions between DNA radicals and TPZ are unlikely to 
'amplify' damage, due to the significant radical stability and its inherent capacity to diffuse 
away from the site of generation, by the same logic, focal radical production by a nuclear 
reductase would be no more likely to generate the theoretical clustered DNA damage. 
Olive (1995) reported a ratio of 10: 1 for single vs. double strandbreaks (ssbs:dsbs) 
in anoxic V-79 spheroids treated with TPZ (lhr), compared with a ratio of 20:1 for X-
irradiation of aerobic V79 cells. This suggests that the incidence of dsbs, arising perhaps 
from the random proximity of two ssbs, is not remarkably dissimilar between the two 
agents. The complex nature of the TPZ-induced lesions that is suggested by the very slow 
half-life of single-strand break repair (= Ihr) compared to x-rays (= 3-5 min) (Olive, 
1995), together with the observation that TPZ-induced dsbs are protein associated (SUm et 
al., 1996), and the possibility that TPZ itself may modify the initial DNA damage (Jones 
and Weinfeld, 1996), might equally imply that certain lesions are intrinsically more 
difficult to detect I repair. The random proximity of several lesions, or possibly a diradical-
like mechanism, might suffice to produce the poorly repairable sites usually associated 
with the apparent "high-LET radiation-like" damage. 
In a theoretical consideration of the relevance of subcellular TPZ metabolism, it is 
clear is that both intracellular p02 and pH will profoundly influence the radical half-life 
(Laderoute et al., 1988; Wardman et al., 1995; 1996). These observations, taken together 
with the high reported ratios of microsomal to nuclear reductive activity (Moody et al., 
1988), suggests multiple microenviromental factors could influence the relative 
contributions of the nuclear and microsomal reductase(s), with respect to the generation of 
the TPZ radicals that ultimately give rise to the lethal DNA damage. In the presence of 
moderate hypoxia it might be argued that the limited nuclear reduction of TPZ will 
dominate (Cahill and White, 1990; Brown, 1993), while under more severe hypoxia, the 
large excess in microsomal activity, together with the relative stability of the radical and its 
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generation in close proximity to the nucleus, could also influence the extent of DNA 
damage. Moreover, one must also consider the effects of high levels of microsomal O2 
consumption, that result from the very rapid metabolism and subsequent futile-cycling of 
the radical, as well as that arising from microsomal and nuclear-associated cytochrome 
P450 oxidase activity, all of which could potentially create severe microregional p02 
gradients between the cytosolic and nuclear compartments. It has previously been 
suggested that increases in hypoxic toxicity could be achieved for drugs that rapidly redox 
cycle, and so deplete, cellular oxygen (Butler and Hoey, 1993a). O2 consumption has 
been noted as a consequence of TPZ metabolism (Lloyd et al., 1991), and significant 
cyanide-resistant respiration is seen in hepatocytes upon addition of TPZ (Silva and 
O'Brien, 1993). While small changes in the oxygen concentration would scarcely 
influence the cytotoxicity of TPZ towards aerobic cells, it would have a much greater 
impact on hypoxic cells. Such an effect, if it occurs at significant levels, would favourably 
influence the ability of microsomal-generated radicals to diffuse towards the nuclear 
compartment. 
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Chapter 4 
4. Evaluation of an alternative prodrug / enzyme system: 
Metabolic activation of 5'-deoxy-5-fluorouridine by human 
thymidine phosphorylase. 
4.1 Introduction 
An alternative approach to the development of hypoxia-specifc cytotoxins is to exploit the specific 
biochemical changes in hypoxic cells, or to utilise the properties of metabolic enzymes that are 
upregulated as a consequence of tissue hypoxia. An example of the former is the use of glucose 
analogues, such as 2'-deoxy-D-glucose and 5-thio-D-glucose. which exhibit selective toxicity 
towards hypoxic cells (Song et al., 1976; 1978; Tannock, 1983) due to their preferential uptake 
by malignant tissues (Weber et al., 1982), which is thought to arise, in part, through a 
dependence on high rates of anaerobic glycolysis. These glucose mimics can inhibit glucose 
uptake, and in their phosphorylated forms can competitively inhibit glucose utilisation (Chen and 
Wistler, 1957; Wick et al., 1957). An example of the latter approach is the angiogenic factor 
platelet-derived endothelial cell growth factor (PDECGF) which is significantly induced in 
response to hypoxia and acidosis (Griffiths et al., 1997; Takebayasbi et al., 1997). 
Recently it was realised that PDECGP is identical to thymidine phosphorylase 
(Moghaddam et al., 1995) being a product of the same gene. Thymidine phosphorylase 
(dThdPase) catalyses the reversible phosphorolytic cleavage of thymidine (dThd) and 
deoxyuridine to their respective bases and deoxyribose I-phosphate, but can also metabolise 
fluorinated analogues in a similar fashion (Dtzsch et al., 1985; Mahmoud et at., 1993). This may 
provide an opportunity to target prodrug metabolism to tumours, since evidence strongly 
implicated dThdPase in the metabolic activation of the prodrug 5'-deoxy-5-fluorouridine (5'-
dFUR) to the anti-neoplastic agent 5-fluorouracil (5-FU) (Fujimoto et at., 1985). However at the 
time of this work, no publication has definitively demonstrated that human dThdPase was the 
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principal enzyme responsible for catalysing the phosphorolytic cleavage of the glycosidic bond of 
the metabolically inactive thymidine analogue 5'-dFUR, to yield the mitotic poison 5-FU. 
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Figure 1: Reversible phosphorolytic cleavage of the fluorinated thymidine analogue, Furtulon (5'-
dFUR) to the anticancer agent, 5-fluorouracil (5-FU) and deoxyribose I-phosphate. 
5-FU is anabolic ally metabolised via the pyrimidine nucleoside and nucleotide pathways, 
mediating its toxic effects through DNA I RNA incorporation (Major et al., 1982; Kufe and 
Major, 1981) (Figure 2). Inhibition of thymidylate synthase (TS) activity, through the formation 
of a ternary complex with 5,lO-methyl-dihydrofolate and the 5-FU anabolite FdUMP. can also 
compromise de novo thymidine synthesis resulting in a potentially cytotoxic "thymidineless" state 
(Dananberg et al., 1974; Santi and McHenry. 1972). This is also the primary mechanism by 
which the pure TS inhibitor ZD1694 exerts its cytotoxic effects (Jackman et al. 1991a. 1991b). 
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Figure 2: Schematic representation of the de novo and salvage pathways of thymidine and its 
:fluorinat~d analogue and prodrug 5'-deoxy-5-fluorouridine (5'-dFUR). 
Expression of thymidine phosphorylase (dThdPase) is markedly elevated in many solid 
tumors including; breast, oesophageal, pancreas, lung, bladder, ovarian, gastric and colorectal 
cancers, but a wide range of activities have been reported (Zimmerman and Seidenberg, 1964; 
Yoshimura et at., 1990; Moghaddam et at., 1995; O'Brien et al., 1995; Takebayashi et al., 1996a, 
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1996b; Koukourakis et al., 1997; Reynolds et al., 1994). This heterogeneity was examined using 
dThdPase enzyme activity assays of a sample group of breast tumour cytosols prepared from 
primary excision biopsies. 
Utilising two stable clones of the human breast tumour cell line MCF-7 (TP-7 and TP-4), 
transfected with human dThdPase cDNA under the control of the CMV early gene promotor. the 
characterisation of enzyme activity with respect to dThd and 5'-dFUR metabolism and 
cytotoxicity was undertaken (Patterson et al., 1995a). 
4.2 Methods 
Cell lines. The human MCF-7 adenocarcinoma breast cell line (passage 60 to 80) and clones 
TP-4 and TP-7 were grown in DMEM media and supplemented as described previously. 
Transfection of dThdPase cDNA into MCF·7 cells. Transfection and isolation of 
dThdPase clones was carried out by Dr. H. Zhang at the Institute of Molecular Medicine, ICRF, 
Oxford. (Moghaddam et al., 1995). Briefly, pCDN-A3 ,vector containing full length dThdPase 
DNA was introduced into MCF-7 cells by electroporation. Stable transfectants were selected by 
long term incubation in 0.5 mglrnl Geneticin. 
Quantification of drug sensitivity. The MIT-proliferation assay was used to determine the 
dose response curves of the parental and clonal cell lines as described previously. IC,o values 
were determined relative to control wells containing no drug. All incubations were 7 day aerobic 
exposures. 
Preparation of cell Iysates. Cell lines were harvested, washed and sonicated using a MSE 
Soniprep 150 for 3 x 5 sec (nominal frequency of 23kHz and an oscillation amplitude of 5-10 
Jlm). Sonication was performed in 50rnM Tris-HCI, O.15M NaCI buffer, pH 7.4 at 4°C. 
Suspension was centrifuged at 10,OOOg for 15 minutes (4°C). Supernatants were stored in liquid 
N2 until required. 
Preparation of breast tissue cytosols. Breast tissue was removed during primary biopsy 
and stored in liquid N 2 until preparation. Samples were ground by pestle and mortar in the 
presence of liquid N2 prior to automated homogenisation in identical buffer at 4°C. Cell debris 
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was removed by spinning at 3000g for 10 minutes (4°C). The resulting supernatant was spun at 
100,OOOg for 40 minutes (4°C) and stored at -80°C. 
dThdPase activity determinations. Enzyme activity determinations were conducted for 
parental MCF-7 and cloned TP-4 and TP-7 lines in vitro, and also for 20 breast tissue samples, 
12 excision biopsies of primary neoplasia and 10 adjacent normal breast tissue samples. Lysates 
were incubated for 16h at 37°C in 10mM dThd or 5'-dFUR and lOmM K3P04, pH 7.4. The 
reaction was terminated by addition of 0.7ml of ice cold NaOH (500mM for dThd substrate, 
20mM for 5'-dFUR substrate) to 0.3ml of reaction mixture, to produce a final solution pH of 
13.3 and 12.0 respectively. Quenched samples were kept on ice, and the conversion of dThd to 
thymine and 5'-dFUR to 5-FU was measured spectrophotometric ally at 300nm and 305nm 
respectively (Schwartz, 1978; Choong and Lee, 1985). Optical densities were related to standard 
plots for known thymine and 5-FU concentrations. Breast tissue cytosols were only assayed with 
respect to dThd metabolism, due to limited sample availability. The protein concentrations of the 
cell lysates and breast tumour and normal tissue cytosols were determined using the Bio-Rad 
protein dye assay as described previously (Bradford, 1976). dThdPase activity is expressed as 
nmol substrate converted per mg total cytosolic protein per hour., and all samples were stored in 
liquid N2 until required « 6 weeks). 
Influence of ZD1694 exposure on [3H] dTbd uptake. Subconfluent monolayers of 
MCF-7 parental and TP-4 cells were incubated for 4hr with or without ZD1694 (10-100 nM) in 
serum free media. 0.3 J.lM [3H]dThd (20 f.LCi I mMol) was added for 30 min, after which the 
media was rapidly aspirated. Cells were washed 3 times in ice-cold calcium and magnesium free 
PBSA, harvested by tripsinisation and pelleted (4°C). The supernatant was discarded and 0.5 mI 
ice-cold 0.4 M PCA added to the pellet and mixed thoroughly. After standing on ice for 30 min, 
the acid insoluble material was pelleted at 1600g for 20 min (4°C). Supernatant, containing the 
acid soluble nucleotide pool, was spotted on silica gel 60 TLC plates, and dThd and thymine were 
separated in chloroform: acetone: methanol (17 : 3 : 1). The solvent front was run to the top of 
the TLC sheet, and spots corresponding to dThd and thymine were visualised under UV 
illumination (254 nm), recovered and dispensed into scintillation vials for counting. The acid 
insoluble pellet was washed twice with 0.2 M PCA and solubilised in 0.5 ml 0.3 M KOH prior to 
transfer to scintillation vials. 
Western immunoblot analysis. Analysis was performed as described previously, except that 
the primary antibody incubation was with specific anti-human dThdPase rabbit antibody (dilution 
1:500). 
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4.3 Results. 
dThdPase determinations. The parental MCF-7 cell line had some endogenous dThdPase 
activity, while celllysates ofTP-7 and TP-4 displayed a 5.6 and 67 -fold elevation, respectively. 
in their ability to catalyse the conversion of the prodrug 5'-dFUR to 5-FU. This unequivocally 
implicates dThdPase in the metabolism of the prodrug 5' -dFUR. The dataare,summarised in table 
1. 
Table 1: dThdPase activities of parental and clonal cell line lysates with respect to both dThd and 
5'-dFUR phosphorolytic cleavage. 
Cell line 
MCF-7 wt 
TP-4 
TP-7 
Thymidine Phosphorylase activity of celllysates ± s.e.m. @ 37°C 
nmol thymine releasedlmglh 
38.2 ± 5.9 
3383 ± 133 
269 ± 12.2 
nmol 5-FU releasedlmglh 
47± 1l.2 
3160±197 
264 ± 19.4 
dThdPase activity of normal and malignant breast tissue. Considerable heterogeneity 
was found in both the normal and tumour cytosol samples. although ·dThdPase activity was 
consistently elevated in the breast tumour cytosols (P< 0.0002). Values ranged from 46.5 to 929 
nmolJhr/mg (median 273 nmolJhr/mg) while nonna! tissue cytosols displayed a more modest 
variability. ranging from 1.6 to 47 nmollhr/mg (median 10.6 nmollhr/mg). However none of the 
breast tumour cytosols showed elevation in dThdPase activity in the order of that found for TP·4. 
whilst TP-7 represents the levels at the upper 113 of the tumour dThdPase range (figure 3). 
dThdPase activity did not correlate with ER or EGFR status in either the tumour or nonnal tissue 
samples. 
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Figure 3: Relative dThdPa e activity (nmol thymine relea ed h- I mg- l protein) f the parental 
MCF-7, TP-4 and TP-7 ly ate relative t 12 br a t tumour and ten n rmaJ brea t Ii su cyl I . 
dThdPa e activity was and protein conent were determined ind p ndently at least twic and mean 
value are shown. 
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Western immunoblot. Analysis of the protein content of the cell line conftrmed that the 
clones expressed elevated levels of a 45 kda protein that was detected by a polyc1onal anti-
dThdPase antibody (figure 4). Although enzyme activity could be detected, western blotting wa 
not as sensitive and could not demonstrate measurable dThdPase protein in the parental MCF-7 
cells unless excess SDS extract was used. 
recombinant 
dThdPase 
I 
MCF-7wt TP-7 TP-4 
Figure 4: Western immunoblot of recombinant dThdPa e , MCF-7 parental line TP-7, and TP-4 
with anti-dThdPase antibody. 30 Jlg of protein from a h cell line ample wa loaded per lane, 
re olved in 10% SDS, and detected u ing ECL chemilumine enc (Amer ham). 
In vitro drug sensitivity of the cell lines. D e re pon e curves were determined ~ r 5-
FU, 5'-dFUR, 5-fluoro-2'-deoxyuridine (5-FUdR). The ICso valu s ~ r 5-FU were not 
ignificantly different between the parental line and TP-7 and TP-4 (Figure 5). H wever the I 50 
values of the prodrug 5'-dFUR were markedly dif~ rent, TP-7 and TP-4 being 2.4 and 165 -f ld 
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more sensitive as determined by ICso ratios (figure 6). The differing sensitivities of the cell lines 
were reflected in their levels of dThdPase activity, with respect to the release of 5-FU from 51-
dFUR. Sensitivity to 5-F-2'dUR was not significantly different between the parental and clonal 
lines (table 2). The ICso dataaresummarised in table 2. 
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" ..... /j; ..... TP-7 
80 ·_·0·· TP-4 g 
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Figures 5 & 6: Representative in vitro dose-response curves of parental MCF-7 (0). TP-4 (0) 
and TP-7 (Ll) to 5-FU (fig.S) and to its prodrug SI-dPUR (fig.6). Per cent growth inhibition is 
relative to untreated controls. Error bars represent the s.d. of eight wells. 
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Table 2: ICSO values of three fluorinated pyrimidines for the parental and clonal MCF-7 cell lines. 
Drug sensitivity I ICso values ± s.e.m. 
Drug MCF-7 wt TP-4 TP-7 
5-FU (JlM) 1.03 ± 1.0 0.73 ± 0.48 1.44 ± 0.96 
5'-dPUR (J.lM) 17.3 ± 3.1 0.104 ± 0.032 7.1 ± 1.7 
5-FUdR (nM) 2.3 ± 0.42 2.6 ± 0.31 2.2 ± 0.7 
Sensitisation of neighbouring cells. Addition of a small fraction of TP-4 cells markedly 
sensitised neighbouring parental cells to the action of 5'-dFUR (figure 7). The ICso of a 
population containing 20 : 80 mixture of TP-4 and parental cells was reduced lO-fold. This 
represents a significant in vitro "bystander" killing effect at a concentration at which the parental 
line is refactory to the effects of 5'-dFUR. 
18 
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Figure 7: Plot of change in the mean ICso value of the parental MCF-7 cell line for 5'-deoxy-5-
fluorouridine with increasing proportions (%) of TP-4 cells, at a fmal cell density of 2x 103 Iwell. 
Cell-to-cell contact was negligi.ble. Individual wells were exposed to a range of 5'-dFUR 
concentrations for 7 days before being asseI¥ed for growth relative to an untreated control, in 
vitro. ICso values are the mean of at least three independent experiments ± s.e.m .. 
This suggests that the active anti-metabolite 5-FU, can diffuse from its site of formation 
and exert its effects upon neighbouring cells in vitro. It has been suggested that an important 
pathway for the bystander effect is via gap junctions (Freeman et al., 1993). This is certainly true 
for phosphorylated metabolites (Bi et al., 1993). However in the case of the MCF-7 cell line, 
micro-injection of the fluorescent dye Lucifer Yellow CH into single MCF-7 cells in confluent 
culture clea4' demonstrated the absence of functional gap junctions in this cell line, ruling out the 
involvement of metabolic co-operation in the facilitation of the bystander effect. Since 5-FU (but 
not its phosphorylated anabolites) can also diffuse via a facilitated transporter, the presence of 
gap junctions is not essential for the sensitisation of untransfected neighbouring cells. This 
phenomenon may be advantageous since gap junction communication could be down-regulated in 
some solid tumour in vivo (Pitts, 1994). However, it has been observed that only relatively low 
levels of cell-to-cell coupling is required to permit extensive metabolite exchange (Denning and 
Pitts, 1997). 
Since dThdPase may potentially be secreted (Kuchler, 1993), the relative contributions of 
intra- and extra-cellular dThdPase were assessed in two further experiments: 
i. Co-incubation experiments were repeated utilising individual well inserts to spatially sepcu-ate 
the parental and TP-4 cell lines. Anaphore membranes of 0.02, 0.2 amd 8.0 f..1m pore sizes were 
used to connect the two cell culture compartments in the media phase. Dose response curves 
following 5'-dFUR treatment demonstrated no difference in the ability of the TP-4 cells to 
sensitise the parental line to the prodrug for any of the pore sizes (data not shown). The stringent 
molecular cut-off impos, ed by the 0.02 f..1ID anapore membrane « 0.5 kda) , or the highly porous 
8.0 /lm membrane (>1000 kda) did not influence the observed bystander effect in this model, 
suggesting that secreted or lytically released dThdPase in the extracellular media was not 
detectably contributing to the sensitisation of the parental line. 
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ii. In a further experiment, the ability of MCF-7wt or TP-4 cell line "conditioned media" to 
sensitise the parental cells to 5'-dPUR was assessed. Media wereconditioned for 24h in the 
I 
presence or absence of the prodrug and was subsequently transferred on to parental cells in 
exponential growth phase. In the case of media conditioned in the absence of 5' -dFUR, the 
prodrug was added post-conditioning. The results (table 4) clearly demonstrate that the prodrug 
must be co-incubated with TP-4 cells to effect a cytotoxic response in the parental line. 
Table 4: Influence on media conditioning in the presence and absence of the 5'-dFUR. 
48 h CONDITIONING @ Ix 106 cells mI-) 
DRUG Media source ± Drug conditioning ICw values (flM) 
5-FU New none 2.73 
5-FU TP-4 conditioned none 2.25 
5-FU Wt conditioned none 2.47 
5'-dFUR New none 17.6 
5'-dFUR Wt conditioned none 21.2 
5'-dFUR Wt conditioned Wt conditioned 25.4 
5'-dFUR TP-4 conditioned none 21.0 
5'-dFUR TP-4 conditioned TP-4 conditioned 6.2 * 
5'-dFUR New TP-4 conditioned 6.0 * 
* indicates statistical significance COMpared to non-conditioned control (P < 0.05). ICso values 
are the mean of two independent experiments. 
Co-incubation of 5'-dFUR with the parental line did not result in a cytotoxic response. 
Furthermore, pre-conditioning of the media in the absence of 5'-dFUR, followed by its post-
addition, was not sufficient to elicit the subsequent metabolic release of the prodrug. Analysis of 
the relative proportions of dThdPase protein in the intra- and extracellular fractions following 24h 
media conditioning was conducted by western blotting (figure 8). Visualisation of total dThdPase 
protein in cell extracts, versus conditioned media concentrated tOO-fold by Macrostep centrifugal 
concentration (10 kda cut-of 0 , confirmed the presence of at least a WOO-fold excess of 
intracellular dThdPase protein. 
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Figure 8: Analysis of the relative proportions of dThdPase protein in the intra-and extra-cellular 
fractions following 24h media conditioning was conducted by western blotting of MCF-7 wt and 
TP-4 cell lysates along side conditioned media. dThdPase protein in conditioned media was 
concentrated up 100-fold by Macrostep centrifugal concentration (10 kda cut-off). Densitometric 
analysis confirmed the presence of at least a 5000-fold excess of intracellular dThdPase protein in 
the TP-4 cell line. 
Modulation of drug sensitivity by exogenous thymidine. Circulating dThd is present 
in the plasma of individuals at 0.1 - 0.2 ~ (Shaw et al., 1988a, 1988b). While the extent of 
vascularisation of a solid tumour largely dictates the bioavailability of such nutrients, dThd 
availability in the microenvironmentof a tumour may become elevated as a result of release from 
dying cells. Such increased bioavailability of dThd could modulate the efficacy of the prod rug 5 '_ 
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dFUR by competing for the phosphorolytic action of ThdPase. The cytotoxic effects of 5-FU are 
thought to be mediated, in part, by the inhibition of TS, through the anabolism of 5-FU to 5-
FdUMP (Dananberg et at., 1974; Santi and McHenry, 1972). Therefore the presence of 
salvageable dThd may also circumvent any toxicity associated with the inhibition of TS activity. 
Consequently, the capacity of physiologically relevant concentrations of dThd to modulate the 
toxicity of 5'-dFUR, 5-FU and 5-FUdR was determined in vitro. 
Co-addition of dThd during 5-FU exposure did not affect the sensitivity of either the 
parental or transfected cell lines, even at the maximum concentration (150 J.lM) that was nontoxic 
to the cells (data not shown). This suggests that TS inhibition is not an important determinant for 
5-FU toxicity in the MCF-7 cell line, since inhibition of de novo thymidine synthesis can be 
circumvented through the availability of an exogenous dThd source which can be salvaged via 
facilitated transport. 
1-10 JiM dThd had no effect on the response of the parental line to 5'-dFUR (figure 9). In 
contrast, physiologically relevant concentrations of dThd (1-10 J.lM) could partially reverse the 
inhibitory activity of 5'-dFUR on TP-4 and TP-7. Indeed, 1OJ.lM dThd shifted the ICso value of 
TP-4 for 5'-dFUR by 18-fold (figure 10). Nevertheless, TP-4 cells were still markedly sensitised 
to 5'-dFUR compared to controls, and sufficiently high prodrug concentrations (~1OJ.LM) could 
overcome the dThd-induced reversal of toxicity. Thus even levels of dThd 50-100 fold greater 
than those detectable in plasma could not fully reverse the cytotoxicity of 5'-dFUR in this breast 
cell line model in vitro. 
There was a marked capacity of exogenously added dThd (1-3 J.lM) to modulate the 
inhibitory effects of 5-F-2'dUR in the parental cell line, which was significantly reversed in the 
clone cells, particularly TP-4. This suggests that the phosphorolytic breakdown of dThd by 
dThdPase renders it metabolically unavailable to bypass the inhibition of thymidylate synthase, or 
to compete with 5FdUTP for incorporation into DNA (Nayak, 1992). Indeed, 1 J.lM dThd could 
increase the ICso value of 5-F-2'dUR for the parental line from 2.3 to - 2400 nM, some 1000-
fold (figure 11), while producing only a 3-fold reversal of toxicity in TP-4, from 2.6 to 8.0 nM 
(figure 12). 
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Figures 9 & 10: Representative in vitro dose-response curves of the parental MCF-7 cell line 
(fig.9) and the dThdPase transfected TP-4 cell line (fig.IO) to 5'-dFUR, in the absence (a) or 
presence of exogenously added thymidine, at a concentration of 1 JlM (0), 3 JlM (0) and 10 J.LM 
(0). 
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Figures 11 & 12: Representative in vitro dose-response curves of the parental MCF-7 cell line 
(fig.!l) and the dThdPase transfected TP-4 cell line (fig. 12) to 5F-2'-dUR, in the absence (~) or 
presence of exogenously added thymidine, at a concentration of 1 JiM (0) and 3 JiM (0). 
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In order to study the role of dThdPase in modulating the ability of the MCF-7 cells to 
salvage dThd following TS inhibition, ZD 1694 was utilised. ZD 1694 is a quinazoline antifolate 
thymidylate synthase inhibitor that is extensively polyglutamated by folylpolyglutamate synthase 
resulting in enhanced intracellular retention (Jackman et al., I99Ia, 1991b). Since ZD1694 
selectively inhibits TS activity upon polyglutamation, addition of exogenous dThd should be 
sufficient to prevent cytotoxicity. In the absence of salvagable extra-cellular dThd, a 
"thymidineless" state arises, and the concurrent perturbationsof the nucleotide triphosphatepools 
(Dananberg et al., 1974; Santi and McHenry, 1972) are considered the dominant mechanism by 
which ZD 1694 exerts its cytotoxic effects. dThdPase is the first catabolic enzyme in the dThd 
salvage pathway, and thus represents a potential mechanism by which dThd can be rendered 
unavailable for subsequent phosphorylation by thymidine kinase (TK). While the phosphorolytic 
cleavage of dThd and deoxyuridine to their respective bases and deoxyribose I-phosphate (Iltzsch 
et al., 1985; Mahmoud et aI., 1993) are reversible reactions, with an equilibrium constant close to 
one, the limited availability of deoxyribose donors favours the phosphorolytic over the transferase 
reaction. The utilisation of thymine in cells is generally less than 1 % of dThd incorporation; 
supporting the evidence that dThd catabolism dominates thymine anabolism (Gallo and Breitman, 
1968; Iltzsch et al., 1985; Schwartz et al., 1994). 
The addition of exogenous dThd (l-3J!M) for 96 h, during and following a 48 h drug 
exposure, could almost completely reverse the cytotoxicity resulting from TS inhibition in the 
parental cell line (figure 13). However, experiments conducted using TP-4 demonstrated that the 
presence of elevated dThdPase activity could very significantly modulate this "thymidine rescue" 
phenomenon (figure 14). Addition of 0.3J.LM dThd (96hr) resulted in a significant modulation of 
the dose-response curve for the parental line, such that an ICso value was no longer detenninable 
(fig.l3). In contrast 0.3J!M dThd rescue in the TP-4 cell line only shifted the ICso value from 3.5 
to 8.0 nm (fig. 14). Increasing concentrations of exogenous dThd (1.0 and 3.0 J-LM) were more 
effective at reversing the ZD 1694-dependent toxicity in both cell lines. However the rescue was 
far superior in the parental line. Indeed, no significant inhibition of growth could be achieved in 
the parental line at either 1.0 or 3.0 J.LM dThd, while ICso values for the TP-4line were 26 and 88 
nrn respectively. This represents a very significant modulation of rescue at physiologically 
relevent dThd concentrations and suggests that, within this in vitro model, elevated dThdPase 
activity need only be present during the initial period of TS inhibition inorder to compromise any 
dThd-dependent rescue phenomena. (Patterson et al., 1998). 
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Figures 13 & 14: Representative dose-response curves for parental MCF-7 (fig. 13) and TP-4 
(Fig. 14) cell lines to 48 h ZD1694 treatment. Exogenous thymidine was absent (~) or present 
during and for a further 48 h post-ZD1694 exposure, at concentrations of 0.3 J.lM (0), 1.0 J.1M 
(D) and 3.0 IJ.M (0). Cells were allowed to proliferate for a further 8 days following removal of 
dThd (total growth time = 12 days), Per cent growth inhibition was expressed relative to untreated 
control growth. 
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Uptake and metabolism of [3H]-thymidine in ZD1964 treated MCF-' cells. 
Following a 4h treatment at 3 or 30 nM ZD 1694, parental and TP-4 cells were pulsed with 30 
mins. O.3J.lM [3H] thymidine, prior to harvesting and acid extraction. Total uptake of [3H]-label 
was similar in both cell lines under comparable conditions. Consistent with the impact of 
exogenous dThd on the modulation of the dose-response curves of the parental, but not the TP-4 
cell line, a greater proportion of the initial thymidine up take was metabolised to thymine (figure 
15). At 30nM ZD1964 pre-treatment, 27% of the total salvaged dThd was rendered metabolically 
unavailable to relieve the acute TS inhibition in the TP-4 cells, combared to just 3.6% in the 
parental ceIl line. Therefore the presence of intracellular dThdPase activity could modify the extent 
to which dThd was available via the nucleotide salvage pathway. 
1 Parental MeF7 TP-4 MCF7 2.5 2.5 
j 
~ 2.0 2.0 
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Figure 15. Influence ofZD1694 exposure on [3H] dThd uptake in MCF-7 parental and TP-4 
cells. Cultures were incubated for 4hr with or without ZD 1694 (3 and 30 nM) in serum free 
media. 0.3 J.lM [3H] dThd (20 J.lCi I mMol) was added for 30 min, after which the media 
was rapidly aspirated. Cells were harvested (4°C) and [3H] dThd (open bars) and [3H] 
thymine (hatched bars) were separated by TLC and counted. 
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4.4 Discussion 
Introduction of the gene encoding human dThdPase, sensitised the human breast cancer 
cell line, MCF-7 to the prodrug 5'-dFUR. This provided a means of improving the 
chemotherapeutic selectivity of the fluorinated anti-metabolite 5-FU. Gene insertion into a small 
proportion of MCF-7 cells was sufficient to cross-sensitise neighbouring non-transfected cells in 
vitro, even though no functional-gap junctions could be found. Taken together, these data suggest 
that the targeting of a tumour mass with a tissue-specific promotor driven dThdPase sequence in 
vivo, may not require the transduction of the majority of tumour cells for effective killing of 
neighbouring cells to occur. Furthermore modulation of gap junction expression should not 
significantly compromise the efficacy of the bystander effect (Pitts, 1994; Denning and Pitts, 
1997). 
It is plausible that mechanistic advantages of the dThdPase I 5'-dFUR may result from the 
co-metabolism of endogenous dThd. In spite of being in direct substrate competition with 5'-
dFUR if present at 10 to 100 -fold excess of plasma concentrations (1-10 JlM), it might 
nevertheless enhance the cytotoxicity of 5-FU in a number of ways. Phosphorolytic cleavage of 
dThd by dThdPase would render it metabolically unavailable to bypass the inhibition of de novo 
dThd synthesis and to compete with FdUTP for incorporation into DNA (Major et al., 1982). The 
"thymidine-less" state, resulting from the inhibition of TS by FdUMP, would make tissues 
expressing dThdPase sensitive to the depletion of salvageable dThd, restricting any potential 
"rescue" from the thymidine-less induced stress and its associated cytotoxicity (Houghton et al., 
1993). Unfortunately the MCF-7 breast cell line appeared to be atypical. This was demonstrated 
by the inability of exogenous dThd to rescue from 5-FU cytotoxicty and suggests that TS 
inhibition by the 5-FU anabolite, FdUMP, did not contribute to cytotoxicity. This observation is 
in agreement with other published data indicating that the primary detenninant of 5-FU toxicity in 
the MCF-7 cell line is RNA inCOrpOration (Kufe and Major, 1981). However the underlying 
principle of such a role for dThdPase could be demonstrated in the MCF-7 cell line, through the 
use of the specific TS inhibitor ZD 1694. 
dThdPase can also catalyse the metabolism of 5-FU itself, facilitating the formation of 
FdUMP through the reversible addition of deoxyribose-I-phosphate. Thus it would be anticipated 
that this subsequent anabolism of the prodrug-released 5-FU by dThdPase, could result in 5-FU 
ultimately proceeding via the significantly more cytotoxic nucleotide pathway. This could lead to 
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increased DNA incorporation, particularly if synthetic ribose-I-phosphate donors were also 
present dwing 5-FU anabolism (Schwartz et ai., 1994). 
Depletion of the available dThd would also serve to increase local concentrations of 
thymine which would competitively inhibit the catabolism of 5-FU by dihydrouracil 
dehydrogenase, potentially extending its half-life within the tumour mass (Santelli and Valeriote, 
1980). Prolonging the duration and intensity of tumour tissue exposure to 5-FU, and its 
associated anabolites, has been shown to limit the occurrence of resistant clones associated with 
sub-optimal chronic exposures in vitro (Sobrero et ai., 1993). This may have implications in 
restricting the development of acquired resistance in vivo. Increasing the duration of 5-FU 
exposure has also beeen shown to significantly enhance the cytotoxicity of the bio-modulators 
leucovorin and interferon-a2A in vitro (Houghton et ai., 1993). 
It is possible that the generation of 5-FU through the dThdPase I 5'-dFUR system as 
opposed to CDase 15-FC might prove therapeutically superior, but the gain may not overcome the 
intrinsic problems associated with the treatment of hypoxic sub-populations within solid tumours. 
Nevertheless, poor cellular uptake of 5-FC has been demonstrated to be a limiting factor in the 
efficacy of the CDase I 5-FC system (Haberkorn et al., 1996), a ~phenornenonthat is not 
encountered by the thymidine analogue, 5'-dFUR, since active pyrimidine nucleotide salvage in 
tumour cells often exceed that of nonnal tissues (Kinsella et ai., 1997). If utilised in 
combinational chemotherapy using an enzyme-directed approach, the increased tumour specificity 
of prodrug activation in high dThdPase expressing neoplastic tissues, may provide 5' -dFUR with 
superior efficacy than that documented for 5-FU (Scheithauer and Raderer 1995). Alternatively, 
the mechanistic advantages of the dThdPase 15'-dFUR model could be applied in a GDEPT 
strategy in conjuction with a tissue-specific promoter, or in an antibody-directed approach, where 
a greater proportion of the cycling tumour mass could be targeted. Further, the capacity of 
dThdPase to compromise the ability of cells to salvage exogenous thymdine when present either 
intra- or extracellularly also makes it an attractive candidate for antibody-directed enzyme based 
therapeutic strategies in conjunction with TS inhibitors. However, the expression of dThdPase in 
many normal tissues may limit the tumour-specificity of this enzyme/prodrug paradigm (Fox et 
ai., 1995). 
-
The observation that ZD1694 toxicity is totally prevented by the presence of .s~lvageable. 
dThd. is consistent with the primary mode of action being TS inhibition, resulting in acute 
inhibition of de novo thymidine synthesis. Critically, nuc1eosides are present in human plasma at 
135 
Chapter 4 Thymidine Phosphorylase 
concentrations sufficient to fulfill a salvage function, and prefonned dThd is potentially 
bioavailable within a tumour mass, both from the vascular supply and that released by dying cells. 
The high levels of TK in tumour compared to nonnal tissues (Weber, 1983) implies that the 
salvage pathway is a preferred source of dThd for subsequent anabolism and DNA synthesis. 
Cellular uptake readily occurs via S-(p-nitrobenzyl)-6-thioinosine -sensitive and/or -insensitive 
cell-surface equilibrated nucleoside transporters (Belt, 1983; Belt et al., 1993), a Na+-associated 
concentrative transport process (Crawford et al., 1990; Griffith and Jarvis, 1993) or through non-
facilitated diffusion. It has been demonstrated that nucleoside transport (NT) activity can be 
upregulated 22 to 39 -fold "as a consequence of acute TS inhibition in the human bladder cancer 
cell line MGH-Ul (Pres sacco et al., 1995). Such elevations in NT function may be highly 
relevont where dThd availability is the potentially rate limiting step in the salvage pathway. Thus 
facilitated and non-facilitated uptake processes could provide an effective intracellular source of 
dThd for the salvage pathway, which could prove sufficient to circumvent the cytotoxic impact of 
ZD 1694-mediated TS inhibition. Taken together with evidence that the contribution of salvage 
flux is greater than that of de novo synthesis in neoplastic tissues, and further, inhibition of de 
novo synthesis leads to even higher salvage activity, any approach that modulates the availability 
of exogenous pyrimidine nucleotides should significantly enhance ZD 1694 toxicity. Consistent 
with this proposal, it was demonstrated that the presence of elevated dThdPase activity, the first 
enzyme in the thymidine salvage pathway, can markedly compromise the intracellular 
bioavailability of salvaged dThd. 
Approaches aimed at rational patient selection based upon "enzyme-profiling" of tumor 
tissues could target those individuals most likely to benefit from treatment with 5' -dFUR or 
ZD 1694. Several studies have indicated that high dThdPase expression is associated with poor 
prognosis (Takebayashi et al., 1996b; Koukourakis et al., 1997). However it has recently shown 
that patients treated with adjuvant cyclophosphamide, methotrexate and 5-FU for breast cancer, 
had a better prognosis if dThdPase was elevated in their tumors (Fox et al., 1997). Both 
methotrexate and 5-FU would be potentiated by preventing dThd-rescue and so provides in vivo 
clinical evidence of the potential for manipulation of the salvage pathway. Thus, perhaps therapies 
aimed at exploiting this clinically unfavourable tumor characteristic to advantage may prove to be 
of value. Alternatively, approaches aimed at inducing tumour dThdPase activity, such as 
interferon-a and -'Ytreatment (Schwartz et al., 1994), may enhance the response to 5'-dFUR and 
ZD 1694 treatment. 
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Chapter 5 
5. Evaluation of the hypoxia-responsive enhancer from the murine 
phosphoglycerate kinase-l gene in the transcriptional regulation of 
gene expression. 
5.1 Introduction 
A range of promoter/enhancer sequences have been characterised for application in 
gene therapy, potentially allowing the tightly regulated expression of therapeutic genes 
within neoplastic tissues. Targeted gene expression can be achieved using tissue- or 
disease-specific promoters (Reviews: Hart, 1996; Dachs et al., 1998), or alternatively 
through exploiting transcriptional elements that are responsive to physiological conditions 
unique to solid tumour microenviroments, including glucose-deprivation and hypoxia 
(Little et al., 1994; Gazit et al., 1995; Dachs et al., 1997). Gene expression could also be 
regulated by 'coupling' transcriptional activity to externally delivered stimuli, such as 
ionizing radiation (Weichselbaum et al., 1994; Seung et al., 1995; Hallahan et al., 1995). 
Attentions have also focused on the unique features of tumour physiology which 
arise as a consequence of inefficient blood supply, and how such differences might be 
exploited (Brown and Giaccia, 1994; Stratford et al., 1994; Dachs and Stratford, 1996). 
The most conspicuous of these features is tumour hypoxia. The recent observations that 
hypoxia responsive elements (HRBs), found within a number of genes (Firth et al., 1994), 
can specifically regulate transcription in response to biological hypoxia, has suggested that 
HRE-dependent expression of therapeutic enzymes might be one approach to exploiting a 
unique characteristic of tumour physiology. Such a HRE-drlven GDEPT strategy could be 
applied to a broad range of solid tumours of variable tissue origin and histology, and might 
fulfil an important therapeutic goal. 
5.1.1 The molecular basis of hypoxia responsive element dependent 
transcriptional regulation. 
Hypoxia enhancer regions have been found in a number of genes including erythropoietin 
(Epo) (Goldberg et al., 1987), vascular endothelial growth factor (Goldberg et al., 1994), 
and a number of proteins involved in glucose metabolism, including; phosphoglycerate 
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kinase-I, aldolase A, enolase 1, lactate dehydrogenase A, pyruvate kinase M, 
phosphofructokinase L and glucose transporter-l (Firth et al., 1994; Semenza et al., 1994; 
Ebert et at., 1995a, 1995b; Semenza et ai., 1996). Among the genes encoding glycolytic 
enzymes, regulation by hypoxia is isozyme specific in a way that correlates with their 
increased expression in malignant cells (Ebert et al., 1995). For example, lactate 
dehydrogenase (LDH) is a tetrameric enzyme with five isoforms which are composed of 
combinations of two subunits, A and B. The LDH-B subunit kinetically favours the 
conversion of lactate to pyruvate and is found at high levels in aerobic tissues such as the 
heart, while LDH-A converts pyruvate to lactate under nonequilibrium conditions. Only the 
LDH A subunit is selectively induced by hypoxia (Firth et al., 1995). 
The Epo gene HRE was the first enhancer to be characterised in detail. A minimal 
24 base pair (bp) sequence 3' of the coding region has been defined as sufficient for 
hypoxia response (S 1% 02) (Madan and Curtin, 1993). The EPO-derived hypoxia 
response element (HRE) was subsequently reported to confer 02-dependent transcription, 
independent of orientation, distance, homologous or heterologous promoter context and 
was universally functional in mammalian cells (Maxwell et ai., 1993). The nuclear 
transcription factor, Hypoxia Inducible Factor 1 (HIP-I), was shown to specifically 
interact with the HRE ofEpo (Wang and Semenza, 1993a). Mutations of the Epo enhancer 
that prevented HIP-I binding also eliminated the hypoxic induction of Epo reporter genes. 
Further studies demonstrated that hypoxia-mediated induction of transcription could be 
improved by reducing the distance between enhancer and promoter. and increased further 
by inserting multiple copies of the 24 bp sequence (Pugh et al., 1994). The finding that 
hypoxic ally inducible activity of the Epo HRE was widespread in mammalian cells implied 
that an oxygen sensing mechanism was present in non-Epo producing cells, and suggested 
that HIF-l was a universal transcription factor that served to regulate other oxygen-
dependent genes. 
5.1.2 Hypoxia Inducible Factor 1 
HIF-l is a 120 kda heterodimer found in both Epo-producing and non-producing 
mammalian cells (Beck et al., 1993), which is upregulated and has improved DNA binding 
capacity as a consequence of hypoxic stress. HIF-la/~ is a heterodimeric member of a 
subfamily of basic-helix-loop-helix (bHLH) transcription factors defined by a conserved 
PAS domain. The defining members of the PAS (fer-ARNT-Sim) groups of transcription 
factors were the period (Per) and single-minded (Sim) proteins of Drosophila 
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melanogaster, involved in circadian regulation of gene expression and neurogenesis, 
respectively (Review: Littlewood and Evan. 1995). Helix-loop-helix protein structures are 
a highly conserved motif employed by a family of transcription factors which typically 
bind as dimers and recognise an approximately symmetrical site. The two a-helicies 
govern interaction with DNA. one by binding in the major groove of B-fonn DNA and the 
other by contacting the DNA backbone. 
The 826 amino acid polypeptide HIP-l a subunit is unique to the HIF-l 
heterodimer (Wang et ai., 1995b), while HIF-l~ is identical to the aryl hydrocarbon 
receptor nuclear translocator (ARNT) protein, and exists as two alternately spliced 
isofonns of 774 and 789 amino acids (Hoffman et al., 1991). ARNT is also the 
heterodimeric partner for the aryl hydrocarbon receptor (AHR). which functions as a 
ligand-activated transcription factor that mediates the xenobiotic (polyaromatic hydrocarbon 
ego dioxin) response of a number of metabolic genes (Review: Hankinson, 1995). Thus, 
ARNT is an essential dimerisation partner in both AHR - and HIF-l a -mediated signalling 
pathways, and the fonnation of selective complexes allows the specific recognition of 
either xenobiotic responsive elements (XREs) or hypoxia responsive elements (HREs), 
respectively. Consistent with these observations, the hypoxia and dioxin signal 
transduction pathways have been demonstrated to functionally compete for recruitment of 
ARNT (Gradin et al .• 1996; Gassmann et al., 1997), and cells functionally deficient in the 
xenobiotic response. due to an ARNT mutation. are also defective in HIF-l mediated 
functions (Wood et al .• 1996). AHR and HIF-Ia share some apparent similarities, such as 
being associated with the molecular ch~rone. HSP-90, in the pre-activated state. which is 
probably a reflection of their common evolutionary past. 
A major control of HIF-l activity by oxygen tension is achieved through changes in 
the level of the HIF-l a subunit which complexes with the constitutively expressed HIF-
l~ARNT subunit, that is considered to be present in excess (Reviews: Poyton and Bunn. 
1996; Semenza. 1996; O'Rourke et al., 1997; Gassmann and Wenger. 1997). Dimerisation 
of HIF-l is essential, but not sufficient. to stimulate the trans-activation functions of HIF-
1. The induction of HIP-l and Epo mRNA is ablated by inhibitors of transcription 
(actinomycin D) or protein synthesis (cycloheximide) demonstrating that both de novo 
transcription and protein synthesis are required in the activation of the HIF-l dependent 
signal pathway (Wang and Semenza. 1993b; Wang et ai .• 1995d; Salceda et al., 1997). 
Hypoxic gene induction is also sensitive to protein kinase inhibitors. and evidence 
indicating that HIP-l is a phosphoprotein (Wang et al., 1995d) lend support for the 
participation of protein phosphorylation in HIP-l trans-activation. This suggests a possible 
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cascade of protein phosphorylation and dephosphorylation in transducing the hypoxic 
signal from sensor to HIF-l, and is thought to be mediated in part by protein tyrosine 
kinases. These include the proto-oncogenes c-Src and H-Ras (Jiang et al., 1997a; Mazure 
et al., 1996; Arbiser et at., 1997), although the relevance of c-Src has been questioned 
(Gleadle and Ratcliffe, 1995a). Signal transduction may involve the mitogen activated 
protein kinases, MEKI and MEK2, perhaps mediated via PKC (Salceda et al., 1997). The 
PKA pathway is also known to contribute to the amplitude of HRE-dependent 
transcription, although cAMP is not an essential component of the signal transduction 
pathway per se (Kvietikova et al., 1995; 1997). cAMP enhancer binding protein-l (CREB-
1) is implicated in the integration of the hypoxia and cAMP signalling pathways. The 
modulation of HIP-l activity by changes in cellular redox further suggests that signal 
transduction is integrated at multiple levels, and the participation of HAP-l and TDX 
suggest the presence of a specific redox signal cascade (Wang et aI., 1995c; Huang et al., 
1996). Perhaps analogous, another bHLH transcription factor, USF, is functionally 
regulated via two cysteine residues in the HLH dimer interface. These critical redox-
sensitive sites must be reduced to enable DNA binding and transcriptional activation 
(Pognonec et al., 1992). Some evidence also exists to suggest that HIP-! is involved in the 
cellular responsive to glucose deprivation (Maltepe et al., 1997), although recent evidence 
has implicated the involvement of an as yet unidentified transcription factor (Woods et al., 
1998). 
The HIF-la. subunit contains two minimal domains (amino acids 549-582, and 
775-826) each of which can act independently to convey a hypoxia-inducible 
transcriptional response (Pugh et al., 1997). Evidence suggests a dual mechanism of 
activation involving an inducible activation domain that is amplified by regulation of HIF-
la. abundance, probably via protein stabilisation (Wenger et al., 1997; Salceda and Caro, 
1997). Thus the regulation of HIF-la. levels is integrated with changes in DNA binding 
activity and post-translational enhancement of activation. This is reflected in the rapid 
kinetics of HIP-! association and dissociation with its DNA recognition sites, with a tIll for 
both of less than 1 minute, while the HIF-la subunit is readily degraded « 5 min.) upon 
reintroduction of cells to nonnoxia. The increases in HIP-l a protein levels may be partially 
independent of the process of transactivation (Pugh et al., 1997), although the relationship 
between these properties and hypoxia signal integration is not currently known. Functional 
trans-activation can also involve the recruitment of accessory co-activators. An interaction 
between the C-terminal portion of HIF-l a. and the co-activator p300 has been 
demonstrated, and over-expression of p300 could amplify the transcriptional response to 
hypoxia (Arany et al., 1996). P300, which is closely homologous to CREB protein, is a 
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general transcriptional co-activator that participates in multiple biological functions 
including induction of various tissue-specific enhancers, regulation of cell cycle, and 
stimulation of differentiation pathways. While p300 does not directly bind DNA, it plays a 
critical role in transducing the signal from the HIF-l enhancer complex to the transcription 
initiation complex. 
5.1. 3 Nature of the oxygen sensor 
Evidence indicates that the hypoxia response mechanism does not react to non-
specific cellular stresses but contains a specific oxygen sensor (Goldberg et al., 1988). The 
sensing mechanism(s) appear to be specific for hypoxic stress, since induction is not seen 
with hydrogen peroxide, heat shock, cyanide, 2-deoxyglucose, ionising irradiation or 
interferon-a (Goldberg et al., 1994). Hypoxia can be mimicked by carbon monoxide, by 
the iron chelator desferrioxamine as well as by inhibitors of heme synthesis. Induction can 
also be seen in response to colbalt, nickel and manganese, but not zinc, iron or cadmium. 
These results suggest that some component of the sensor mechanism involves a 
hemoprotein which changes confirmation according to its redox state; since carbon 
monoxide probably stimulates hypoxic induction by irreversibly substituting for oxygen 
and thereby preventing the porphyrin ring of the putative heme sensor from binding 
oxygen. The metals that mimic hypoxia are thought to displace iron in the porphyrin ring, 
and their low affinity for oxygen locks the heme protein in the constitutively-deoxy 
confirmation. Inhibitor studies also indicate that a redox-sensitive flavoprotein may operate 
upstream of the heme-containing sensor in this signalling cascade, since the signal 
generated by the formation of a putative colbalt-protoporphyrin complex is not inhibited by 
the flavoprotein inhibitor diphenylene iodonium (Gleadle et al., 1995a). This suggests the 
operation of a flavoprotein oxido-reductase that is redox-coupled to the heme-containing 
sensor, analogous to the relationship between cytochrome P450 reductase and the heme-
containing cytochrome P450s (Ratcliffe et ai., 1997), and raises the possibility of a 
CYP450 reduction product, perhaps a steroid molecule, provides a regulatory ligand for 
HIF-I. This would be analogous to the ligand-mediated activation of AHR by polyaromatic 
hydrocarbons. However recent evidence would argue against the involvement of a 
CYP450 monoxygenase-type oxygen sensor, in that HIF-Iex itself has been identified as a 
non-heme iron protein. It is postulated that destabilising redox reactions may occur directly 
in the iron centre of the HIF-1ex subunit under oxic conditions, and this Fenton-like 
chemistry may modify (oxidise) critical amino acids in the vicinity, targeting the 
transcription factor for proteosomal degrcdation. (Srinivas et al., 1998). 
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5.1.4 Analysis of a candidate hypoxia responsive element. 
Studies have focused on the minimal 18 bp sequence HRE isolated from the upstream 
promoter region (-309 to -290) of the phosphoglycerate I (pGK-I) gene (Firth et al. 
1994). It has close sequence homology to the 3' HRE of Epo, with 8 of 9 b.p. being 
identical. This 9-bp region in the core consensus overlaps with 7 of the 8 bp in the Epo 
enhancer sequence shown to bind HIF-I. Gel supershift assays have demonstrated that 
oligonucleotides of PGK-l and Epo HRE's cross-compete for hypoxia-induced nuclear 
factor binding, including HIF-l. 
GGGCCCTACGTGCTGCCTCGC&TQGC 
GGGCCCTACGTGCTGTCTCA~AGC 
ATTTGTCACGTCCTGCACGACGQQAG 
GCTGCAGACGTGCGTGTG 
CCAGCGGACGTGCGGGAACCCACGTG 
TCCACAGGCGTQCCGTCTGACACGCA 
AGTGCATACGTGGGCTTCCACAGQTC 
TCGCTTCACGTGCGGGGACCAGQGAC 
CTGGCGTACGTQCTGCAG 
EPO 
EPO 
PGK 1 
PGK 1 
LDH-A 
GLUT-l 
VEGF 
ALD-A 
PFK-l 
mouse 
human 
mouse 
human 
mouse 
mouse 
rat 
human 
mouse 
Figure 1: Comparative sequence homology of HIF-l binding sites in HREs from various 
hypoxia-inducible genes. 
In order to test the therapeutic potential of the HRE. ONA constructs which encode 
either cytosine deaminase (COase) or the cell surface protein C02. under the transcriptional 
control of three promoters containing a concatlmer of the PGK-l HRE. were introduced 
into the human fibrosarcoma cell line HTI080. Three stable clonal lineages were generated 
to study the potential of HRE-driven marker gene expression in response to changes in 
p02' glucose and cAMP modulation. 
The bacterial enzyme cytosine deaminase (COase) catalyses the deamination of 
cytosine to uracil, and can therefore convert the cytosine analogue S-FC into the anti-
metabolite 5-FU (Huber et at .• 1993). It has previously been tested in a therapeutic 
promoter (c-erbB2) context (Harris et al., 1994). Mammalian cells do not express 
detectable levels of COase. S-FU is still one of the most active single agents in the 
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treatment of neoplastic diseases of the colon and breast, and is commonly used in 
combinational chemotherapy (Scheithauer and Raderer, 1995). 
5.2 Methods. 
Transfection and clonal selection. Preparation of plasmid constructs and clonal 
selection of the HT1080 transfectants were conducted by Dr. J. D. Firth at the Institute of 
Molecular Medicine, ICRF, Oxford (Dachs et al. 1997). Briefly, a trimer of the PGK-l 
HRE sequence (18 or 24 bp) was placed in the context of its homologous promoter (M3 
cell line), a minimal (72 bp) thymidine kinase herpes simplex virus promoter (sTK5 cell 
line) or 1.8 Kba of the 9-27 gene promoter (9-3C cell line). A cell line, 2C4, which had 
been transfected with an identical 9-27 promoter/C02 reporter vector, except that it lacked 
the triplet p18 HRE insert was employed as a control. The vectors encoded either the 
therapeutic enzyme CDase or the marker gene C02. Co-transfection of both vectors was 
carried out for the M3 and 9-3C clonal lines, while sTK5 carried only the CD2 vector. 
Selection of stable clones was in 2 mglml Geneticin. Stable clones were tested for their 
response to oxygen deprivation. Multimerisation of the DNA sequence of the PGK P18+ 
trimer insert is shown in the context of the minimal TK promoter. 
Xb1Jl' X~I 
Xbal PGKP18R+ Ael PGKP18R+ ,....;;...Ae~I....-_ 
I I I I II I 
S'-TCTAGATG TCACGTCCTG CACGACACTA GATGTCACGT CCTGCACGAC ACTAGATGTC 
XblA" 
PGK P18R + jlfel 80x Mlul 
- ................ ---~--i,....;;..,;.-.-....,i iii i r-
ACGTCCTGCA CGACACTAGA CCACnCGCA TATTAAGGTG ACGCGTGTGG CCTCGAACAC 
HindI! 
i I 
CGAGCGACCC TGCAGCGACC CGcn AACAG CGTCAAC - 3' 
Figure 2: Short Herpes simplex thymidine kinase promoter containing three positively 
orientated copies of the murine PGK -1 gene hypoxia response element (p 18 HRE). 
Cell lines. HT1080 parental and clonal cell lines were maintained in modified minimal 
essential medium (DMEM). Media was supplemented as previously described. 
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Cytosine deaminase activity determinations. Cells of the 9-3C clonal line were 
exposed to 16h anoxia (palladium catalyst-induced) and reoxygenated for Sh prior to 
harvesting. Cells were washed in ice cold PBS, scrap ed, pelleted and resuspended in 20 
J.1llysis buffer (lOOrnM Tris-HCI, lrnM EOTA, 1M OTT, pH7.8). Samples were lysed by 
five rapid freeze-thaw cycles, spun at 1O,OOOg for 5 min and the S-9 fraction harvested. 
10 J.11 samples were added to 10 J.11 of l00rnM Tris, pH7.S, containing 5 mM 
cytosine-5-[14C] (specific activity O.S J.1CillO J.11). Samples were incubated at 37°C for 4h 
and quenched by addition of 20 J.11 of l00mM "cold" cytosine in 1M NaOH. 10 J.11 samples 
were loaded onto silica gel sheets and resolved in 86% I-butanol: 14% H20. After drying, 
bands corresponding to cytosine and uracil were visualised under short-wave UV 
illumination and cut out. 5m1 of scintillation fluid was added to each sample and total 
counts detennined on the scintillation spectrometer. Cytosine deaminase (COase) activity 
was expressed as pmol uracil produced I mg S-9 fraction I minute. 
Drug sensitivity determinations. The HTI0S0 parental, M3 and 9-3C cell lines were 
tested for their response to 24h 5-FC or 5-FU exposure following a 16h anoxic or aerobic 
pre-treatment. After drug exposure cells were allowed to grow for a further 4Sh. Dose 
response curves were determined using the MTT proliferation assay and values of ICso 
were determined from the individual survival curves of independent experiments. Mean 
ICso values were derived from at least 6 independent experiments conducted on different 
days. 
Induction of the CD2 cell surface marker. M3, sTKS and 9-3C transfectants were 
tested for their response to hypoxia (0.01% 02) and catalyst induced anoxia «0.001 % 02) 
and different levels of oxygen (0.1, 1, 2, 5 and 21 % 02)' The 9-3C and 2C4 cell lines 
were also assessed for their response to glucose deprivation, since nutrient deprivation 
might be expected to accompany hypoxia in vivo. Additionally, the modulation of PKA 
type IIII ratios by the therapeutic cAMP analogue, 8-CI-cAMP was studied, in order to 
assess it contribution and potential application in combination with HRE-directed gene 
transcription. Cell surface expression of transfected reporter-C02 was analysed using 
FITC-Iabelled anti-C02 monoclonal antibodies (Serotec). Labelled cells were assayed for 
CD2 expression on a fluorescence activated cell sorter (Beckton Dickinson). 
In vivo evaluation of drug sensitivity and CD2 expression. The 9-3C clonal 
line was inoculated into the hlndleg nu/nu mice. Xenografts were either treated with S-FC 
(375 mg/kg, 5 x week for 3 weeks) or saline, at a starting volume of 40mm3, or allowed to 
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grow to 300mm3 (-3 weeks) and removed for histological examination with a monoclonal 
anti-human CD2 antibody. 
5.3 Results 
In vitro CD2 expression. Cell surface presentation of the marker protein was 
monitored by labelling with mC-Iabelled anti-CD2 monoclonal antibody, followed by 
fluorescence activated cell sorting. The results are expressed as fold-induction (02:N2 ratio 
of median CD2 labelling) and summarised graphically in figure 3. The increase in CD2 
production depended on both the length and severity of hypoxia. Following acute hypoxia 
« 0.001 % 02)' CD2 expression in the transfected cell lines increased during subsequent 
reoxygenation, whereas, following less severe hypoxic conditions, CD2 expression 
peaked immediately after hypoxia. This would imply a role for both chronic (diffusion 
limited) and acute (perfusion limited) tumour hypoxia in the induction of gene expression. 
CD2 expression was not induced following exposure to 5% or 20% oxygen, suggesting 
that physiological oxygen tensions ( - 5% p02) would not result in gene induction. 
However, some constitutive expression of CD2 was seen in the M3 and 9-3C cell lines 
under aerobic conditions (- 4-fold above background auto-fluorescence). In contrast the 
minimal sTK promoter context (sTK5) was almost silent at 5% p02' 
Low glucose stress (0 - 300 J.1.M) induced CD2 expression by upto 2.2-fold in the 
9-3C cell line, but not in the 2C4 control cell line lacking the HRE trimer (figure 4). 
Induction was less than that seen in response to 16 h anoxia, but was of similar magnitude 
to that observed @ 1 % 02' The combination of low glucose and hypoxia could not be 
evaluated, since this treatment was highly cytotoxic, and resulted in extensive cell death in 
both cell lines « 5% survival after 16 h anoxia with 100 J.1.M glucose). 
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Figure 3: Increased production of CD2 by the three transfected cell line under various gas-
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determined by FACS analysis. No CD2 induction wa een in the 2C4 cell line under any 
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146 
Chapter 5 
-(1)::E 
c:E 
(1)LO 
0) • 
'-"-(1),.-
~(1) 
«SCI) 
E8 
C\J.2 
QO) 
(,)~ 
C:(1) 
.Q 0 ..... x 
0(1) 
::::So "'0_ c: .- (1) 
"'0 .~ ota LL-
~ -
3 -
. 
2 -
. 
1 
o 
3 
. 
2 -
" 
1 . 
o 
Hypoxia Response Elememnts 
9-3C 
",.. 
T 
. l. T I. 
! _'T 
"'" 
I I I I 
2C4 
T T T 
.,. .. J. -l. .. 
I I I I o 0.1 0.3 0.5 1 10 
GLUCOSE (mM) 
Figure 4: Increased production of C02 by the 9-3C and 2C4 transfected cell lines under 
various exogenous glucose concentrations. Incubations were for 24 h. The y-axis 
represents the ratio of C02 production relative to glucose-rich DMEM media (17.5 mM) as 
determined by FACS analysis. 
The cAMP analogue, 8-CI-cAMP, stimulated CD2 reporter gene expression in the 
9-3C cell line under both normoxic and anoxic conditions (Figure 5). CD2 expression was 
inducted 1.9-fold under normoxic conditions and 13-fold under severe hypoxia, but this 
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potentiation of transcriptional activation was not seen in the control 2C4 cell line. This 
supports the conclusions of Kvietikova and colleagues, that there is cAMP-dependent 
protein kinase A involvement in the HIF-l -mediated hypoxia signal transduction pathway. 
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Figure 5: Increased production of C02 by the 9-3C and 2C4 lran fected cell lines under 
various gas-phase oxygen tensions. Incubations were for 16 h plus 5 h reoxygenation in 
the absence (clear bars) or presence (shaded bar ) of 10 ~ 8-CI-cAMP. The y-axis 
represents the ratio of hypoxic to normoxic C02 production as determined by FACS 
analysis . 
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Hypoxic induction of cytosine deaminase activity in 9-3C. Cytosine 
deaminase activity determinations were conducted on the parental HTI080 and the 9-3C 
cell lines following either oxic or hypoxic « 1 ppm 02) pre-treatment (16h). Initially S-9 
fractions were prepared at various time points post-treatment, and the rate of uracil 
formation from [214C]cytosine was monitored for Ih at 37°C. Peak CDase activity was 
seen at approximately 4h post treatment and this time point was used in subsequent 
determinations. CDase activity had decreased to background levels by 28h post treatment 
(data not shown). No detectable CDase activity was seen in the parental cell line. The 
transfectant line 9-3C had detectable activity in normoxia (0.31 ± 0.04 pmoVminlmg) and 
showed a 6.8-fold increase in activity following 16 h hypoxia (2.10 ± 0.72 pmollminlmg) 
treatment. Results are expressed as pmol uracil formed I mg S-9 protein I minute ± S.D. 
Results are the mean of 3 independent determinations. 
The 1.8kb 9-27 promoter fragment containing a trimer of the PGK-l p18+ HRE 
oligonucleutide exhibited some constitutive activity, and further transcriptional induction 
could be achieved following hypoxic stress. 
5-FC and 5·FU drug sensitivity in vitro. Pre-incubation in hypoxia sensitised the 
9-3C cell line 5.4 -fold (ICso ratio) to 24h 5-FC exposure (figure 6). Significant sensitivity 
was not seen in the parental cell line. 5-FU toxicity was not significantly different for either 
of the cell lines following hypoxic or aerobic pre-treatment. ICso data is summarised in 
table 1. 
Table 1: Relative sensitivity of HT1080 parental and 9-3C cell lines to 5-FU & 5-FC 
following 16 h of aerobic or hypoxic pre-treatment. 
5-Fluorouracil 5-Fluorocytosine 
Oxic I 
ICso ± s.d. (mM) 
Oxic I 
ICso ± s.d. (J.1M) hypoxic hypoxic 
Post- Post- Fold Post- Post- Fold 
Aerobic Hypoxic sensitivity Aerobic Hypoxic sensitivity 
HT1080wt 4.3 ± 0.31 2.9 ± 0.37 1.5 32 ±4.3 23 ± 4.2 1.4 
9-3C 1.9 ± 0.24 2.1 ± 0.29 0.9 34 ± 3.9 6.3 ± 1.4 5.4 ** 
**P<O.OI 
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Figure 6: Representative dose-response curve of HTI080 and 9-3C cells to 5-FU and 5-
FC. Exposure of 9-3C transfectants, which contain the cytosine deaminase-encoding gene 
under the control of the PGK-l HRE, to anoxia before exposure to air induced sensitivity 
to 5-FC. Drug exposures in air for 24 h were preceded by 16 h growth in either nonnoxia 
or severe hypoxia (see legend), and sensitivity was assessed using the MIT test. 
Individual points are the mean of quadruplicate wells ± s.d .• 
In vivo S·FC sensitivity and CD2 expression. Both parental and 9-3C xenografts 
responded to 5-FU treatment but were not significantly sensitive to S-FC treatment (figure 
7). However, immunohistochemical analysis of serial xenograft sections revealed focal 
CD2 expressionin vivo. which localised in tissues adjacent to areas of necrosis (figure 8). 
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An adapted alkaline comet assay analysis (Olive et at., 1990) of in vivo xenograft cells 
demonstrated biologically relevant hypoxia in 10% of the tumour tissue. In vivo irradiation 
of the xenograft preferentially generated single-strand DNA breaks in cells that were 
normoxic at the time of treatment, while the bifunctional hypoxic cytotoxin RSU 1069 
produced DNA cross-links when metabolised under hypoxia. When individual cells are 
embedded in agarose, lysed and subjected to an electrical current, the mobility of DNA will 
be enhanced by single-strand breaks but retarded by cross-linking. This allows the accurate 
discrimination between individual hypoxic and non-hypoxic cells from a disagregated 
tumour mass. When C02 immunostaining was combined with the analysis of cellular 
hypoxia using the comet assay, two clearly distinct cell population were identified; short 
comet tails with big comet heads that were C02-positive. and long comet tails with small 
heads that did not stain with anti-CO2 antibody. Thus singie-cell electrophoresis of cells 
isolated from xenografts could be seporated into hypoxic and non-hypoxic populations by 
means of the adapted comet assay and the sub-population identified as hypoxic were also 
found to be positive for CD2. This clearly demonstrated that hypoxia-regulated gene 
expression could be induced in individual cells in vivo that were radiobiologically hypoxic 
at the time of treatment. 
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Figure 7: The parental HTI080 and 9-3C clonal line was inoculated into the hindleg nu/nu 
mice and allowed to establish to a starting volume of 40mm3• Xenografts were either 
treated with 5-FC (375 mglkg, 5 x week) or saline for a total of 7 days. Tumour growth 
was very rapid so only limited dosing could be achieved. While 5-FC treated 9-3C 
xenografts exhibited a modest tumour growth delay relative to saline controls, this was not 
statistically significant (P = 0.46). 
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Figure 8: Immunohistochemical analysis of C02 
expression in representative serial sections of 
HT1080 and 9-3C xenografts using a FITC 
conjugated anti-human C02 antibody 
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5.4 Discussion 
5.4.1 Properties of the PGK pI8 HRE regulated trimer 
A positively orientated trimer of the PGK-I minimal 18 bp HRE was sufficient to confer 
hypoxically-regulated expression of both a reporter and therapeutic cDNA. In the CD2 
reporter gene experiments the HRE trimer was found to be more active in a heterologous 
promoter context, perhaps suggesting that negative regulatory sequences are present in the 
homologous PGK-I promoter. Constitutive aerobic expression of C02 was very low in 
the minimal sTK promoter, which contrasted with the higher basal expression seen for the 
1.8 kb 9-27 promoter in vitro. The 9-27 promoter alone was utilised in the therapeutic 
context of COase expression. COase activity could be induced 7-fold by hypoxia, and this 
increase in enzyme activity resulted in a 5.4-fold enhancement in acute sensitivity to the 
prodrug 5-FC. However, this hypoxia-inducible prodrug sensitivity was not observed in 
vivo. 
C02 induction was induced much more strongly by severe hypoxia « 0.001% 02) 
than seen at 1.0 - 0.1 % 02' although it has been demonstrated that HIF-l binding is 
maximal at - 0.5 % 02 (Wang and Semenza, 1995b). This suggests that under severe 
hypoxia, additional signals are integrated into the hypoxic response that enhance the trans-
activation capacity of HIF-l, independent of its DNA-binding affinity. This most likely 
involves redox and/or phosphorylation dependent changes. Of note, utilising Src-deficient 
mutant cells, Gleadle and Ratcliffe (1995) reported a functional hypoxic response at 1% 
O2, while latter reports implicated a role for oncogenic v-Src in HIP-l activation (Jiang et 
al., 1997). It is possible that the tyrosine kinase activity of Src is only relevent to HIP-l 
trans-activation at < 0.01 % O2, since Src is also thought to partiCipate in NF-1(~ activation 
which only occurs at similarly low p02' 
5.4.2 HREs and the use of cytosine deaminase-directed prodrug activation 
Although the COase / 5-FC model appeared relatively ineffective in this therapeutic 
context, published experiments have shown it to be an adequate enzyme / prodrug 
combination in other expression systems in vivo (Mullen et al., 1994). However Mullen 
and colleagues reported that tumour cells escaped killing if either the levels of CDase gene 
expression were low or the dose or duration of 5-FC treatment was restricted. 
Furthermore, in vitro c1onogenic survival experiments with 5-FC "seemed to require 
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. continuous exposure to the drug for at least 5 days". This was despite the fact that the cells 
were sensitive to 5-FU (IC5o -1).1M) and the clonal line studied expressed CDase cDNA 
under the control of the powerful Moloney murine leukemia 5' LTR. The sharp contrast in 
CDase activities achievable in the hypoxia-inducible constructs relative to that of the 
reported MLV 5'LTR expression systems (maximal activity 1.88 vs. 1582 pmol uracil 
formed /106 cells / min respectively), probably explains why the 9-3C cell line did not 
respond in vivo. In support of this conclusion, the authors stated that "successful 
application of the system in vivo will require maximization of intracellular expression of the 
enzyme as well as effective prodrug delivery". This implies that the enzyme kinetics and 5-
FC pharmacodynamics of this enzme / prodrug paradigm were poor in vivo - even at 
optimised expression and delivery parameters. This supposition is consistent with studies 
on the uptake of radiolabelled 5-FC, where moderate and unsaturable amounts of the 
prodrug accumulated intracellularly, possibly by diffusion only (Haberkorn et al., 1996). 
This suggests that 5-FC uptake is the rate limiting factor in the treatment strategy. 
Since only 10% of 9-3C xenograft tissue demonstrated biological hypoxia (S 0.1 % 
02) in vivo, CDase activity would have been limited and focal. Although a bystander effect 
would be anticipated to occur, the relatively poor amplitude of therapeutic gene expression 
and thus prodrug metabolism, would preclude the possib ility of observing any measurable 
influence in tumour growth delay experiments. 
5-FU is considered an S-phase specific drug, since its anabolites are most cytotoxic 
when incorporated into replicating DNA (Pinedo and Peters, 1988). In vitro experiments 
demonstrated that hypoxic treatment resulted in cell-cycle arrest and the accumulation of 
cells in G1 and G2 / M phase. Therefore 5-FU is probably not an ideal product of such an 
enzyme-catalysed prodrug release within the hypoxic tumour enviroment. Therefore 
several factors would suggest that the 5-FC / CDase system is a relatively poor prodrug / 
enzyme model when used in this transiently-inducible context and targeted at a growth-
inhibited cell sub-population. Millimolar concentrations were required in vitro, and an 
aggressive treatment schedule was ineffective in vivo. Other more appropriate enzyme / 
prodrug paradigms may prove superior in this hypoxia-inducible GDEPT approach. 
5.4.3 Manipulating the hypoxic response for therapeutic gain 
The cAMP-dependent protein kinase A involvement in the HIF-! 'signal 
transduction pathway suggests a possible method to amplify the transcriptional response of 
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therapeutic HREs. The PKA~dependent signal transduction pathway is a cAMP-dependent 
process. The cAMP molecule binds to a regulatory subunit of PKA, releasing the 
regulatory subunit, and PKA is activated. In mammaliancells, PKA exists as two forms, 
type-I and type-II, which are distinguished by their different regulatory subunits R-I and 
R-II that interact with common catalytic subunits, Ca , Cp and Cr' Four isoforms of the R 
subunits, RIa' RIp, RlIa, and RIIp, have been identified. RI is found throughout the 
cytoplasm, whereas RU localises to nuclei, nucleoli, golgi, and to the microtubular-
organising centre. Ca and Cp are associated with both RI and RU, whereas Cr is localised 
with chromatin. The two PKA forms have different affinities for cAMP and different 
turnover rates, suggesting significant functional differences exist between them (Cadd et 
al., 1990). Upon activation of either PKA isoform, C translocates to the nucleus and 
appears to be essential for the induction of cAMP-regulated genes (Roesler et al., 1988). 
PKA stimulates the transcription of multiple genes containing CREs (Review: Lee and 
Masson, 1993) via phosphorylation of serine-133 on cAMP-responsive enhancer binding 
protein, CREB (Gonzalez and Montminy, 1989). CREB-l (Habener, 1990; Lee and 
Masson, 1993) is known to be a target of cAMP-inducible PKA-mediated 
phosphorylation, which is essential for its transcriptional activator functions (Yamamoto et 
al., 1988; Mednieks et al., 1989; Nichols et al., 1992). 
The cAMP analogue 8-CI-cAMP, a novel therapeutic agent currently in Phase I 
clinical trials, is known to modulate type IIII PKA activity ratios by substituting for 
endogenous cAMP, leading to differentiation and growth arrest in neoplastic tissues 
(Review: Cho-Chung, 1990). Its application as a hypoxia-selective co-stimuli for HRE-
driven gene therapy is an attractive strategy, since 8-CI-cAMP has growth inhibitory 
activity and differentation effects on a wide range of human cancer cell lines (Tagliaferri et 
al., 1988; Ally et al., 1988; Tortora et al., 1988). Furthermore, it has been shown to 
reduce the incidence of metastatic disease in animal models (Cho-Chung, 1990), and can 
biochemically reverse the multidrug phenotype (Rohlff and Glazer, 1995). This is thought 
to involve the restoration of lower type IIII ratios, and elevated type I levels are found in 
several MDR cell lines (Rohlff et al., 1993b). Additionally, significantly higher ratios of 
type IIII PKA have been found in primary breast carcinomas (Eppenberger et al., 1980), 
which is associated with poor prognosis and reduced disease-free survival (Miller et al., 
1993). 
8-CI-cAMP binds with high selectivity to site B of type II protein kinase, 
preserving PKA-II in the holoenzyme form and so preventing proteolysis, while efficiently 
down-regulating PKA-I by truncating RIa' This selectively modulates the R IIII unit ratio in 
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favour of RII (Ally et at., 1988). This is unlike other agents that non-specifically increase 
intracellular cAMP levels (eg. forskolin), resulting in the simultaneous activation of both 
type I and type IT isozymes maximally. 8-Cl-cAMP exhibits a 2.3-fold greater potency than 
cAMP towards PKA-I while showing 30% less potency than cAMP for type IT PKA (Ally 
et at., 1988). This contrasts 8-Br-cAMP, which not only exhibits a high-affinity for site B, 
but also induces potent activation of PKA-II (1.7-fold of cAMP), and is a less active 
growth inhibitor than 8-CI-cAMP. Two key properties of cAMP analogues appear to 
determine their efficacy in growth inhibition. high selectivity towards either site A or B of 
RH, but not towards RI. and low activation of the PKA-II holoenzyme (Cho-Chung. 
1990). 
Treatment of transformed cells with 8-Cl-cAMP increases total CRE-binding 
activity in vitro (Mednieks et at., 1989). Using a cAMP-unresponsive mutant PC12 cell 
line, it has been demonstrated that type II but not type I regulatory subunit of PKA is 
essential for cAMP-induced gene transcription, with RIIp being more efficient than RIIa 
(Tortora and Cho-Chung, 1990). Additionally, microinjection of purified C subunit has 
also been shown to activate CRE-containing genes (Riabowol et al., 1988), and co-
transfection of both C subunit and CREB genes into a cAMP-unresponsive F9 cell line 
induces dramatic responses with a CRE-containing reporter gene (Gonzalez and 
Montminy, 1989). 8-CI-cAMP treatment stimulates the transcription and nuclear 
translocation of RIIp and Ca (Rohlff et al., 1993a), events that are essential for the cAMP-
dependent and sequence specific binding of RIIp to cAMP-responsive elements (CREs) 
(WU and Wang, 1989). Following short 8-Cl-cAMP treatment, HL-60 cells exhibit a 10 
and 5-fold induction in the mRNA levels of RlIp and Ca respectively, suggesting an 
increased transcription rate of these genes (Rohiff et al., 1993a). Similarly large and 
selective increases in the rate of biosynthesis of RII have been observed in response to 8-
Br-cAMP (Schwartz and Rubin, 1985). Overexpression of RIIp results in increased PKA-
IIp holoenzyme with the concommitant down-regulation of PKA-I by sequestering the C 
subunit away from PKA-I. In agreement, exposure of HL-60 cells to antisense RIIp 
oligonucleotides resulted in decreased responsiveness to 8-Cl-cAMP-induced growth 
inhibition and differentiation, indicating a critical role for RIIp regulatory subunit in the 
cAMP-induced growth regulation (Tortora et at., 1990). 8-CI-cAMP also efficiently down-
regulates RIa by truncation of the 48 kDa RIa subunit to a 34 kDa form, possibly by 
provoking the action of a specific protease. Truncated RIa can still exist as the PKA-I 
holoenzyme. but truncation may facilitate rebinding of 8-Cl-cAMP, encouraging subunit 
dissociation and perpetuating down-regulation of PKA-I without producing accumulation 
of the free RIa subunit (Rohlff et al., 1993a). The rate of RI dissociation has been shown 
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to depend upon the relative occupancy of sites A and B by cAMP (Houge et at., 1990). 
Suppression of RIa by RIa anti-sense oligonucleotides brings about a compensatory 
increase in RIIJ3 (Tortora et al., 1991). indicating that the ratio of PKA-IIPKA-II is 
regulated by both RIa and RIll) availability, when RIIa remains constant. This might 
indicate that RIa. Rna' and RIll) sununits compete for a limited pool of the C subunit, and 
evidence suggests that RIIa forms the most favoured complex and serves as a reservoir of 
the inactive holoenzyme (RohIff et al., 1993a). 
Significantly, a CRE site overlaps the consensus HRE sequence, with the core 
CRE motif overlapping the core HIP-l motif ACGT (Kvietikova et al., 1995). ATF-
lICREB-l homodimers and heterodimers constitutively bind to the HIP-l recognition site, 
and suggest that PKA-dependent phosphorylation of CREB may enhance HRE function. 
CREB phosphorylation can exert different influences on its occupancy of of high and low 
affinity CRE sites. PKA-dependent changes in binding of CREB increases the occupancy 
of weak binding sites, while high affmity sites may have constitutive binding of 
transcriptionally active and inactive CREB. The weak CREB binding sites are characterised 
by asymmetry (CGTCA) whereas the second class containing symmetrical TGACGTCA 
sites show a much higher affinity for CREB (Nichols et al., 1992). Both human and 
mouse PGK HRE contain a variant of the weak asymmetrical CREB site, although the core 
ACGT motif is conserved between HRE and CRE. 
AGACGTGC 
TCACGTCC 
TGACGTCA 
human PGK-l 
mouse PGK-l 
consensus CRE 
The asymmetry of this weak CRE site within the HRE might suggest constitutive 
occupancy is not mediated by CREB alone. unless CREB is in an activated state. 
Methylation interference assays suggest HIP-I and the constitutive bound species (A TF-I 
and/or CREB-l) contact the same G residues (Wang and Semenza, 1993b), implying the 
possible exchange of factors upon hypoxic induction, rather than co-occupancy 
(Kvietikova et al., 1995). Consequently, the positive influence of 8-Cl-cAMP on HRE 
activity under hypoxia might reflect a cooperative effect between the consitiutively bound 
species and the affinity of HIP-I for the HRE site, although the direct influence of PKA on 
the phosphorylation status of HIP-l can not be excluded. 
Specific cooperativity between independent HRE and CRE sequences has also been 
demonstrated. The mouse LDH A gene is regulated by a tripartite enhancer element, 
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composed of a HIF-I consensus sequence, a middle section homologous to that of Epo 
enhancer, and a CRE, which is essential for a functional hypoxic-response (Firth et al., 
1995). This implies that cAMP-dependent PKA-mediated CREB transactivation is an 
important signal transduction pathway that is integrated into the hypoxia response in 
several distinct ways. However, it is unclear whether it is the influence of 8-CI-cAMP on 
the transcriptional upregulation of the C subunit, and/or the modulation of RIJRIIp ratios 
that contributes to the enhanced hypoxic response. Therefore, it is also uncertain as to 
whether the changes in type I/II PKA ratios contributes to this effect, which if true, could 
imply that PKA-II is more specifically involved in modulating the hypoxic response than 
PKA-1. 
Overall, these observations suggest a level of integration between the secondary 
messenger, cAMP, and the oxygen sensor via cooperative transcriptional activation. This is 
consistent with the patterns of regulation seen for the hypoxic induction of several other 
genes including Epo, tyrosine hydroxylase and Glut-I, which also appear to require the 
cooperative interaction of HIF-l with separate and distinct transcription factors binding at 
adjacent sites (Blanchard et al., 1992; Huang et al., 1997; Norris and Millhorn, 1995; 
Ebert et al., 1995). 
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Chapter 6 
6. Oxygen-sensitive GDEPT: 
Analysis of potential hypoxia-dependent diffusible prodrugs for 
activation by the flavoprotein NADPH:cytochrome P450 reductase. 
6.1 Introduction: Molecular chemotherapy. 
The clinical application of sytemically delivered chemotherapy largely owes its utility to a 
selective toxicity towards proliferating cells. Consequently most agents are not only toxic to 
cancerous cells, but also to nonnal tissues with high rates of cell turnover. In order to achieve 
major therapeutic improvements it is necessary to exploit properties of neoplastic cells which 
are tumour specific rather than proliferation specific (Anderson, 1984). Gene-directed 
enzyme-prodrug therapy (GDEPT) is one such approach, where the tumour-specific activation 
of phannacologically inert compounds (prodrugs), by either endogenous or specifically 
introduced exogenous "suicide" enzymes, brings tissue-selectivity to cancer chemotherapy. 
The utility of targeted chemotherapy relies upon the specificity of therapeutic gene delivery 
and/or appropriate neoplasia-specific gene expression. Additionally, the activated 
chemotherapeutic agent must elicit a tumour-localised cytotoxic effect, but equally must be 
capable of limited diffusion in order to target non-transfected neighbouring tumour cells. 
To date the literature contains six examples of prodrugs which have been described for 
GDEPT in combination with non-human enzymes: 
• 6-methoxy purine arabinonucleoside (ara-M) activated by varicella zoster virus 
thymidine kinase (VZV -TK) (Huber et al., 1991) 
• purine nucleosides; acyclovir (ACV), gancic10vir (OCV) and 1(2'-deoxy-2'-fluoro-~-D­
arabinofuranosyl)-5-iodouracyl (PIAU) -- activated by herpes simplex thymidine kinase 
(HSV-TK) (Moolten, 1986) 
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• 6-methylpurine-2'-deoxyribonucleotide (meP-dr) -- activated by Esherichia coli purine 
nucleotide phosphorylase (PNP) (Sorscher et al.,1994) 
• 5-fluorocytosine (5-FC) -- activated by Esherichia coli cytosine deaminase (CD) (Mullen 
et al., 1992; Huber et ai., 1993) 
• dinitrobenzamide mustard derivatives (CB 1954, SN 23862 & analogues) -- activated by 
Esherichia coli B nitroreductase (NR) (Bridgewater et al., 1995; Bailey et aI., 1996; 
Friedlos et al., 1997) 
• 5'-galactosylates of 1-~-D-arabinofuranosylcytosine (araC) and 1-~-D-deoxy­
ribofuranosylcytosine -- activated by Esherichia coli ~-galactosidase (lacZ) (Douglas et 
ai., 1991) 
Several other enzymelprodrug paradigms have been described for GDEPT, utilising 
human (or closely related mammalian) enzymes to activate prodrugs. The rationale for 
exploiting endogenous enzymes is based upon a knowledge of the rate limiting activation 
step(s) in prodrug activation together with the observations of limited or absent expression in 
neoplasic tissues. Additionally, the use of human proteins avoids the complications of 
acquired immunity to foreign drug metabolising enzymes, particularly following repeated 
administration or prolonged protein expression. 
• cyclophosphamide (CPA) and ifosphamide (IFA) -- activated by rat or human cytochrome 
P450 (CYP) 2B and 3A respectively (Wei et al., 1994; Chen and Waxman, 1995b; Chen 
et al., 1996) 
• dinitrobenzamide mustard derivatives (CB 1954, SN 23862 and related analogues) --
activated by human NADPH:cytochrome P450 reductase (P450R) (Walton et ai., 1989) 
• 1-~-D-arabinofuranosylcytosine (araC) -- activated by human deoxycytidine kinase (dCK) 
(Manome et al., 1996) 
• 5'-deoxy-5-fluorouridine (5dFUR) -- activated by human thymidine phosphorylase (TP) 
(Patterson et al., 1995) 
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6.1.1 Idealised enzyme/prodrug characteristics. 
The various catalytic mechanisms of prodrug activation have been extensively 
reviewed in the literature (Mullen, 1994; Moolten, 1994; Conners, 1995; Springer and 
Niculescu-Duvaz, 1996). Only aspects that relate specifically to therapeutic efficacy will be 
discussed here. An appreciation of the advantages and/or limitations of each enzyme/prodrug 
paradigm can be considered against an idealised set of characteristics for any GDEPT system. 
A number of specific properties are desirable in both enzyme and prodrug components, in 
order to achieve the maximum therapeutic potential: 
• therapeutic gene expression should be at high levels, but only in tumour cells (i.e. tumour-
specific delivery and/or expression required). 
• there should be low or absent background expression of any endogenous prodrug 
activating enzyme(s) in nonnal tissues. 
• activation of the prodrug substrate should be direct, since any dependence for further 
catalysis by other endogenous enzymes might result in incomplete conversion (Le. 
resistance). 
• the prodrug should be freely diffusible (i.e. neutral species, appropriate partition 
coefficent). 
• the cytotoxicity differential of the prodrug and its activated product should be as great as 
possible. 
• the activating enzyme should rapidly metabolise its substrate (high Kcal) and operate 
efficiently at low concentrations of prodrug (low ~). 
• released drug product should have an appropriate half-life, allowing the controlled 
diffusion to surrounding untransfected cells that are not expressing the enzyme 
("bystander effect"). while remaining sufficiently localised to prevent leakage back into the 
systemic circulation. 
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• the drug lesions should manifest their cytotoxic effects irrespective of cell cycle phase or 
proliferation status, so that all malignant cells will be effectively targeted. 
• The relationship between drug concentration and cytotoxicity should be constant over 
many logs of cell kill. 
6.1.2 Antimetabolite-generating systems. 
Most of the enzyme/prodrug systems listed do not fulfill these idealised criteria, not 
least because many release antimetabolites (Springer and Niculescu-Duvaz, 1996; Kinsella et 
al., 1997). Consequently not only do the activated antimetabolites require further metabolism 
by endogenous enzymes to manifest their cytotoxicity, but active DNA replication (S phase) at 
the time of exposure is also an essential requirement. This facilitates the incorporation of these 
activated nucleoside analogues into DNA, inhibiting DNA polymerase and inducing chain 
termination (Reid et ai., 1988). The dependence upon proliferation is a major limitation since 
the majority of neoplastic cells within a solid tumour mass will be non-cycling at anyone 
time, making protracted or repeated prodrug administration necessary. Further, the ultimate 
active agent generated by these antimetabolite strategies is a charged triphosphate, which can 
not freely diffuse, becoming dependent upon cell-ta-cell contact (gap-junction connections) to 
facilitate a bystander effect (Pitts, 1994; Fick et al., 1995; Mesnil et ai., 1996). These factors 
are thought to contribute towards the inability of HSV-TKlGCV-mediated prodrug therapy to 
produce curative results in some xenografted and spontaneous mammary tumor models 
(Sacco et al., 1995; 1996). Some of the antimetabolite prodrugs perhaps suffer from 
excessively long half-lives (e.g. 5-FU has a tissue half-life of several hours) (Pinedo and 
Peters, 1988; Kinsella et al., 1997), potentially allowing the unphosphorylated drug to diffuse 
back into systemic circulation. 
The impact of tumour hypoxia on chemotherapeutic response has been reviewed 
(Moulder and Rockwell, 1987; Hill, 1990; Teicher, 1994) and it is clear that the anti-
proliferative effects of oxygen and nutrient deprivation (Moulder and Rockwell, 1987) can 
also compromise the potency of antimetabolites against this predominantly cytostatic tumour 
population (Kinsella et al., 1997; Philips and Clayton, 1997). 
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6.1.3 Alkylating agent-generating systems. 
The alkylating agent prodrug systems, exemplified by P4502B lIep A and 
NRICB 1954, offer some significant advantages:- the DNA lesions are cytotoxic to both 
cycling and non-cycling cells, activation is much less dependent on other endogenous 
enzymes, and the cytotoxic products can diffuse across cell membranes without the need for 
metabolic cooperation (Douglas et al., 1991; Chen et al., 1996; Friedlos et al., 1997). This 
may be a significant therapeutic advantage since the down-regulation of gap-junction function 
is a common feature of the de-differentiated state seen in many tumour tissues (Pitts and 
Finbow, 1988; Pitts et al., 1988; Holder et al., 1993; Pitts, 1994). 
Other considerations include the in vitro and in vivo observations that alkylating agents 
kill cells in a log-linear manner with increasing dose of drug (~ 4 to 5 logs cell kill) whereas 
many antimetabolites plateau at only 1 to 2 logs (Frei et al., 1988). The relative inability of 
cancer cells to acquire high levels of alkylating agent resistance compared to that achieved 
against antimetabolites (Frei et al., 1988) may be clinically advantagous when applying 
GDEPT to heavily pretreated patients. Also, the versatility that E.coli NR offers by 
metabolising a range of nitro-prodrug substrates (Bailey et at., 1996; Friedlos et al., 1997) 
may have clinical relevance in view of the limited cross-resistance observed among alkylating 
agents (Frei et al., 1988). Furthermore, since many solid tumours contain areas of low 
oxygen tension (p02) (chapter 1), it is relevant that alkylating agents are generally equally 
toxic towards normally oxygenated and hypoxic cells in vitro (Teicher et ai., 1981). CPA has 
even been reported to demonstrate modest selectivity for hypoxic cells (Begg et al., 1985; 
Grau et al., 1990). However, the activation of CPA by CYP450-dependent hydroxylation 
does itself require molecular oxygen as a cofactor (Chang et at., 1993), and low tissue p02 
will inhibit this oxidative catalysis (Jones, 1981). The improvement of tumour tissue 
oxygenation (by carbogen adrninistraton) during CPA treatment appears significantly to 
enhance drug efficacy in vivo (Teicher, 1994), but this may be due, in part, to improved drug 
delivery to the tumour mass (Rodrigues et al., 1997). 
6.1.4 Utility of E. Coli Nitroreductase prodrugs. 
Most of the proposed E.coli NR "nitro-trigger" prodrugs were originally developed in 
their own right as hypoxia-specific cytotoxins (Denny and Wilson, 1993), relying on the 
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natural complement of reductive enzymes in tumours to activate these agents preferentially 
under low tissue p02' The recognition that the capacity of solid tumours for reductive 
metabolism may be limited in some individuals (Chapter 7), has prompted the parallel 
development of these prodrugs as substrates for E.coli NR in GDEPT based therapeutic 
strategies (Bailey et al., 1996; Friedlos et al., 1997; Siim et al., 1997). However E.coli NR-
dependent prodrug activation does not exploit the hypoxic compartment of solid tumours, 
since it is an oxygen-insensitive, obligate two-electron reductase (Anlezark et al., 1995). 
Consequently it reduces its nitro-prodrugs by a metabolic route that is not suppressed in 
oxygenated cells (see figure 1). 
Figure 1: Sequential reduction of nitro-compounds by one- or two electron steps. 
DT-DIAPHORASE 
Nitro Nitro radical anion 
Ie' • le- le' 
R-NO ~ R-NOH~ R-NHOH .. 
Nitroso Hydroxylamine 
radical 
Hydroxylamine 
R-NH2 
Amine 
Thus, although these prodrugs are selectively metabolised by endogenous tumour 
enzymes under low tissue p02' E.coli NR does not utilise this tumour-specific property. This 
can have clear advantages when little or no hypoxia is present within a tumour mass, but in 
some cases, the application of an oxygen-inhibitable nitroreductase could provide an 
additional level of tumour tissue-specific prodrug activation. Providing the activated prodrug 
is sufficiently stable to diffuse away from its site of generation (see section 6.1.6.), the 
requirement for an appropriate reductive enviroment for prodrug metabolism could contribute 
Significantly towards the therapeutic specificity of a GDEPT strategy. 
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6.1.5 Endogenous reductive enzymes as nitro-prodrug activators. 
A variety of human enzymes can act as one-electron nitroreductases and many have 
quite low substrate specificities. The major oxygen-inhibitable microsomal nitroreductases are 
the flavoprotein NADPH:cytochrome P450 reductase (P450R) (BC. 1.6.2.4) and the 
hemoproteins of the cytochrome P450 superfamily (FeUer et al., 1971; Walton and Workman, 
1987; Walton et al., 1989). These membrane-associated enzymes appear to be the most 
important metabolic systems responsible for the reduction of model nitro-compounds, such as 
the 2-nitroimidazole, benznidazole (Walton and Workman, 1987). P450R dominates in the 
initial reduction ofbenznidazole to its respective hydroxylamine (4e-), while cytochrome P450 
(CYP450) is involved in the terminal metabolic steps to the final amine reduction product (6e-) 
(Walton and Workman, 1987; Walton et ai., 1989). Benznidazole has also been implicated in 
the inhibition of murine cyp450 activity (Walton et al., 1986). The reduction of other nitro-
containing compounds has been shown to involve CYP450 (Anders and Englisch, 1985). 
The molybdoflavoproteins xanthine:oxygen oxidoreductase (xanthine oxidase, XO) 
and aldehyde oxidase are the two major cytosolic nitroreductases found in mammalian liver 
(Feller et al., 1971; Morita et al., 1971; Wolpert et al., 1973). Of these, aldehyde oxidase 
appears to dominate in the reduction of certain nitroimidazoles (Walton and Workman, 1987), 
although XO also has appreciable activity for many nitroarenes (Clarke et al., 1980; 1982). 
However, the nitroreductase activity of aldehyde oxidase is less sensitive to oxygen than 
either XO or the microsomal system (Wolpert et al., 1973). Xanthine:NAD+ oxidoreductase 
(xanthine dehydrogenase, XDH; EC 1.2.1.37), which can be converted to XO through 
reversible sultbydryl oxidation, irreversible proteolysis or tissue ischemia (Waud and 
Rajagopalan, 1976b; Clare et al., 1981; Anderson et al., 1989; Hasan et al., 1991; Poss et al., 
19?6), also has nitroreductase activity, yet like aldehyde oxidase, XDH is less sensitive to 
inhibition by oxygen than XO from the same source (Kutcher and McCalla, 1984). These 
enzymatic variations in oxygen sensitivity of nitroreduction are poorly defined, but may 
involve differences in oxygen competition at the substrate level, or could arise through 
variations in the steady-state form of the FAD prosthetic groups which can exist in eqUilibrium 
as either the flavin semiquinone (FADHO) or the flavin hydroquinone (FADH2) species. 
Nitro-compounds are generally poor substrates for the oxygen-insensitive concerted 
two-electron reductase DT-diaphorase (DTD) [NAD(P)H:quinone oxidoreductase; NQOl, EC 
1.6.99.2] which is better known in the context of quinone reduction (Lind et al., 1990; Ross 
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et ai., 1993; Beall et ai .• 1994). However DID does have limited nitroreductase activity. 
although turnover rates are lower with nitroaromatics than with most quinones. However. 
significant inter~species differences exist~ Rat DID is generally a far more efficient 
nitroreductase than than the human form, while murine DID has very poor nitroreductase 
capacity (Boland et aI., 1991; Beall et ai., 1995; Chen et aZ .• 1995c). Known substrates 
include CB 1954 (Knox et aZ., 1988; Boland et aZ., 1991; Beall et ai., 1994; Chen et aZ., 
1995c), 4-nitroquinoline N-oxide (De Flora et ai .• 1988) and 1,6-dinitropyrene (Hajos and 
Winston. 1991). It is this limited capacity for obligate two-electron reduction of nitroaromatics 
by human DID that allows the exploitation of efficient two-electron reductases such as E.coli 
NR as prodrug activators. 
Of the oxygen-inhibitable nitroreductases, P450R has the most appropriate one-
electron equivalent redox couples of -110. -270. -290 and ~365 mV, to facilitate the transfer of 
single electrons to artificial electron acceptors with a range of redox potentials (lyanagi et aZ., 
1974). Normally P450R shuttles electrons from NADPH via its FAD and FMN prosthetic 
groups to cytochrome P450, cytochrome bs or heme oxygenase (Peterson and Prough, 1986). 
The P450R polypeptide can be dissected into two structurally and functionally independent 
FAD and FMN-containing domains. each of which show striking homology to various flavin-
containing bacterial proteins. The N-terminus of P450R is homologous to the FMN-containig 
bacterial flavodoxins, while the C-terminus is related to the FAD-containing ferredoxin 
NADP+ reductases, strongly suggesting that P450R evolved as a fusion of two ancestral 
proteins. The FADINADPH domain is at least partly responsible for the one~lectron 
reduction of many compounds, including redox cycling drugs (Smith et aZ., 1994). 
The redox couples of P450R correspond to the one~lectron couples of the respective 
flavin prosthetic groups; FMNIFMNH·, FMNH·IFMNH2, FADIFADW and FADH·IFADH2 
(Vermillion and Coon. 1978a). Under aerobic conditions P450R exists exclusively as a stable 
semiquinone radical, probably FAD-FMNH· (Vermillion and Coon, 1978b; Yasukochi et ai., 
1979). The air-stable reduced state of the enzyme-radical allows it to donate single-electrons 
to any artificial substrate with an appropriate one-electron reduction potential, the value of 
which will strongly determine the rates of reduction by P450R (Butler and Hoey, 1993b). 
This dependence on substrate reduction potential implies that thermodynamic factors 
predominate, and implies the interactions between P450R and its substrates are simple 
electron transfers which do not involve any appreciable binding of the compound to the 
enzyme. This capacity of P450R to facilitate the one-electron reduction of many nitro. 
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quinone, aromatic N-oxide and transition metal containing compounds can therefore provide 
oxygen-inhibitable catalysis of many reductive prodrugs (Bachur et ai., 1979; Powis et al., 
1981; Walton et al., 1989; Wilson, 1992; Riley et ai., 1992). 
6.1.6 Bioreductive drugs as hypoxia-activated diffusible prodrugs. 
As an extension of the the original concept of bioreductive drugs as prodrugs activated 
under low tissue p02 to kill hypoxic cells, it has been proposed that these agents might ideally 
provide a bystander effect (Denny and Wilson, 1993). By releasing a diffusible cytotoxin 
upon reductive activation, these prodrugs could selectively utilise the small proportion of fully 
hypoxic cells present in most solid tumours. Of these four main redox-sensitive activation 
systems, only the nitro-triggered prodrugs have been extensively developed as hypoxia-
activated diffusible prodrugs capable of killing oxygenated bystander cells (Wilson, 1992; 
Denny and Wilson, 1993; Wilson and Pruijn, 1995; Denny et at., 1996). 
The development of hypoxia-selective prodrugs of diffusible cytotoxins arose from the 
concept of exploiting the physiological (rather than genetic) differences that exist between 
neoplastic and normal tissue organisation, the most conspicuous of which is an inefficent 
vascular system (Wilson, 1992; Denny and Wilson, 1993). The hypoxic microenviroments 
which result from this spatially and temporally disorganised blood supply are characteristic of 
solid tumours of diverse origin and histology (Vaupel et al., 1989), and represent an attractive 
approach to achieving tumour specificity through the exploitation of an oxygen-inhibitable 
prodrug activation. This relies on ulilising an oxygen sensitive prodrug "trigger", to allow the 
selective generation of diffusible products which can attack aerobic tumour cells surrounding 
hypoxic foci. Thus not all tumour cells need to be hypoxic if a long-range "effector" can 
produce a bystander effect in surrounding tissues (Wilson, 1992; Denny and Wilson. 1993). 
If applied in a GDEPT strategy, an additional level of specificity is introduced into the system, 
extending beyond that achieved by utilising promoter-specific expression or the targeting of 
DNA delivery. Thus in a case of aberrant (or endogenous) therapeutic enzyme expression in 
nonnal tissues, the nonnoxic (oxidative) tissue environment ensures that no unwanted 
prodrug activation occurs. Of the numerous nitro-prodrugs developed, none have yet been 
applied in a hypoxia-dependent GDEPT strategy. 
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6.1.7 Essential characteristics of the "bystander effect" 
The bystander effect can be defined as an amplification of the effects of a prodrug 
beyond the cell in which it was activated (Pitts, 1994). Since systemic or local delivery of 
therapeutic genes is unlikely to target greater than 10-20% of tumour cells in vivo, it is 
considered advantagous that a prodrug kills not only cells expressing the enzyme but also 
surrounding non-transfected cells. Thus less than 100% infection of tumour cells can still 
achieve total cell kill. However, active metabolite transfer can also protect the individual drug 
activating cells, the so-called "Good Samaritan" effect (Wygoda et al., 1997). Exploiting 
active metabolite transfer to induce a bystander effect might have disadvantages; it can 
concomitantly deliver the metabolite systemically, and there will be a large dilution effect. The 
half-life of activated drug is thus of considerable importance in achieving an efficient but 
localised bystander effect. If one considers that the diffusion range of oxygen in tumour tissue 
has an upper limit of - 200 Jlm, effective diffusion of a cytotoxin is unlikely to exceed this 
value (no matter how long-lived) since vascular clearence will interseed. Thus the diffusion 
range of 100-200 Jlm for a cytotoxin in tumour tissue would provide efficient localised cell 
killing with limited systemic leakage. Simplified calculations utilising Borg's equation suggest 
that a tissue half-live of - 1 minute for an activated cytotoxin would be adequate to provide an 
effective but localised bystander effect (assuming a diffusion coefficient in tissue of the order 
of 10,6_ 1O,S cm2 s'1) (Wilson, 1992; Denny and Wilson, 1993). 
Alkylating nitrogen mustard drugs generally have half-lives in the order of minutes, 
but agents such as the aziridin-l-yl CB 1954 are intrinsically reactive, although a bystander 
effect has been observed in the majority of studies in vitro (Bridgewater et al., 1995; Friedlos 
et al., 1997; Green et ai .• 1997; Friedlos et al., 1998), with a notable exception in vivo (Clark 
et al., 1997). Similarly, a bystander killing effect has been noted in vitro for the 2-
nitroimidazole, RSU 1069 (Hill et al., 1989). For both these agents, significant bystander cell 
killing in vitro is dependent on high cell density, suggesting the presence of a labile metabolite 
with relatively limited diffusion properties. This has promoted the design of reductively 
activated prodrugs with more stable toxic moieties (Friedlos et al., 1997), or, alternatively, 
prodrugs that can release an oxygen-insensitive diffusible cytotoxin following enzymatic 
reduction (Denny and Wilson, 1993). Examples of these nitro-compounds are discussed in 
the next sections (6.1.8.-6.1.12.) 
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6.1.8 The nitro group as a latent reactive centre. 
By far the largest class of bioreductive drugs are the nitro compounds, so it is 
pertinent to review the various mechanisms of bioreductive prodrug activation for this class of 
agents. Although nitro reduction products can themselves alkylate DNA, they are not 
sufficiently toxic to provide significant hypoxia-dependent cytotoxicity. Hypoxia-selective 
cytotoxicity requires that the products of net nitroreduction be more toxic than the superoxide 
(and resulting toxic species ego OH·) derived from the action of the one-electron futile cycle, 
and also more toxic than the diversion of reducing equivalents which the latter can cause 
(Wardman and Clarke, 1976; Biaglow et al., 1986). 
If agents are of "mixed-function" containing a secondmonofunctionalalkylating moiety 
such as an aziridine ring, then reduction of the nitro group serves to provide a second reactive 
centre. Thus under aerobic conditions aziridinyl-containing compounds will behave primarily 
as monofunctional alkylating agents, but the reduction of the nitro group (figure 1) will result 
in conversion of the molecule to a much more toxic bifunctional alkylating agent. DNA cross-
links generated by such bifunctional reactivity are intrinsically more cytotoxic than the adducts 
arising from either spontaneous mono-alkylation through the aziridine group alone, or the 
reactive oxygen species generated by futile cycling (Whitmore and Gulyas, 1986; Biaglow et 
al., 1986). Therein lies the biochemical basis for the hypoxia selective toxicity of agents such 
as the 2-nitroimidazole RSU1069 (Adams et al., 1984) and the aziridinyl dinitrobenzamide 
CB 1954 (Cobb et ai., 1969): 
Figure 2: Examples of "mixed function" agents. 
N 
~ 
RSU 1069 eB 1954 
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The actual reactive species of a sequentially reduced nitro group can vary with 
structural classes. With nitroimidazoles (e.g. RSU 1069) evidence suggests that the nitroso 
(2-e-) is the key reactive species responsible for DNA alkylation (Noss et al., 1989), with the 
nitro radical anion itself (I-e-) appearing to be insufficiently "reactive to be responsible for 
toxicity (Wardman, 1985; Boon et al., 1985). For the 2,4-dinitrobenzamide, CB 1954, 
reduction of the 4'-nitro group to the hydroxylamine (4-e-) appears to be the key metabolic 
step. In the case of CB 1954, the 4-hydroxylamine must also react further with cellular 
thioesters in order to generate the second reactive centre (Knox et al., 1991). CB 1954 is now 
well advanced as a prodrug in combination with E.coli NR (Anlezark et al., 1995; 
Bridgewater et al., 1995; Bailey et al., 1996; Green et al., 1997; Friedlos et aZ., 1998). 
6.1.9 Nitro-reduction as an oxygen-sensitive prodrug "trigger". 
Nitro group reduction is also a well-defined electronic switch that can be exploited to 
activate a latent alkylating function (Reviews: Denny and Wilson, 1993; Siim et al., 1997). 
Rather than relying on enhancement of cytotoxicity through a reactive product of the nitro 
group itself, reduction of a nitro group is utilised to redistribute profoundly the electron 
density in an aromatic bioreductive molecule. The nitro group is one of the most strongly 
electron-withdrawing substituents in aromatic systems, while its four- and six- electron 
reduction products (figure 1) are strongly electron donating (Simm et al., 1997). This 
dramatic shift in electronic ground state of aromatic molecules can be utilised to modify the 
reactivity of a second moiety. For example, the reactivity of nitrogen mustards are controlled 
almost exclusively by the electron density on the nitrogen, making it possible to prepare 
relatively non-toxic nitroaromatic prodrugs (Palmer et al., 1990). Thus, the electron-
withdrawing property of nitro substituents, when appropriately located in a ring position 
resonant to the mustard, ensure that the nitrogen mustard moiety is latent, but upon reduction 
the redistribution of electron density into the aromatic ring strongly activates the alkylating 
function of the mustard. This concept is exemplified by the nitrogen mustard analogue of CB 
1954, SN 23862 (Palmer et al., 1995) and the 2-nitrothiazole nitrogen mustard SN23727 
(Siim et al., 1997). 
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Figure 3: Examples of nitro-triggered reductively activated prodrugs. 
SN23862 SN 23727 
The 2,4-dinitrobenzamide nitrogen mustard, SN 23862, was designed as a less 
reactive analogue of CB 1954, with potentially superior diffusion capabilities following 
reduction (Palmer et al., 1995). This supposition has proved to be valid, and subsequent 
bromo- and iodo- derivatives have been developed which exhibit markedly improved 
bystander killing capabilities over that of SN 23682 itself in vitro (Friedlos et ai., 1997). 
SN 23862 requires two nitro groups on the aromatic ring in order to raise the 
reduction potential sufficiently to allow enzymatic nitroreduction. Generally a reduction 
potential in the range of -450 to -300 mV appears ideal (Denny et ai., 1996). Values much 
below -450 mV prevent significant enzymatic reduction, while agents above about -300 mV 
lack activity in vivo, probably reflecting excessively rapid rates of cellular metabolism and 
thus poor tissue penetration. Specific reduction of either the 2-nitro or the 4-nitro group has 
been shown to enhance cytotoxicity against AA8 cells by 160-fold and 9-fold respectively, 
while the complete chemical reduction of both nitro groups increases cytotoxicity by 1600-
fold (Palmer et al., 1995). However the enzymatic reduction of either one of the two nitro 
groups raises the reduction potential to -470 mY, limiting further cellular metabolism. Thus, 
enzymatic reduction of both nitro groups is not possible. Attempts to overcome this significant 
limitation of dinitro compounds has led to the design of mononitroheterocyclic mustards such 
as SN 23727 (Lee et ai., 1997). 
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6.1.10 Nitro reduction to trigger rearrangements and fragmentation. 
Intramolecular base-catalysed ~limination of latent mustard groups can also be 
controlled by nitro reduction, as illustrated by the nitroquinilone and nitrophenyl 
phosporamide mustards (Firestone et al., 1991; Mulcahy et al., 1994). 
Figure 4: Nitro reduction-dependent intramolecular base-catalysed elimination of the 
phosphoramide mustard from a nitroquinilone. 
6e' 
/ 
0'-..,/ 
Alternatively, molecular fragmentation can be used to eliminate nitrogen mustards. For 
the 4-nitroimidazole-5-methylquaternary mustard SN 25341, the one-electron reduction of the 
nitro group to the radical anion initiates an intramolecular electron transfer event, eliminating 
the halide ion and forming a benzyl radical (Neta and Behar, 1980; Denny et al., 1994). 
However, in the case of the 2-nitrobenzyl analogue SN 25246, fragmentation appears not to 
occur at the one-electron level (Siim et al., 1997). 
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Figure 5: Examples of compounds employing intramolecular fragmentation to release a 
diffusible quaternary mustard cytotoxin. 
SN 25341 SN25246 
While the mechanism of mustard release is unclear for SN 25246, it has hypoxia-selectivity 
up to 3000-fold in cell line culture models (Denny et ai., 1994; Tercel et al., 1996). 
6.1.11 Limitations of nitroaromatic compounds as oxygen-sensitive prodrug 
triggers. 
Certain intrinsic drawbacks are associated with the use of nitro functionalities as 
"triggers" for bioreductive prodrug activation. Of clinical importance, drug fonnulation is 
hampered by low solubility, and attempts to improve the hydrophilic properties have resulted 
in a loss of absolute potency, providing no net gain. Crucially, nitro-groups are kinetically 
sluggish in electron transfer reactions, with back-oxidation by molecular oxygen being too 
slow to generate very large hypoxia selectivity (Wardman et ai., 1995). A large differential in 
the rate of metabolic activation (i.e. high oxygen sensitivity of reduction) is a desirable 
property, and it has been suggested that this is probably the limiting factor for the activit}' of 
many nitroaromatics as bioreductive triggers (Wilson, 1992; Denny and Wilson, 1993). 
Cumulative evidence would suggest that the hypoxic selectivities of nitroaromatic deactivated 
mustards appear to be limited more by the degree of oxygen-inhibition of the activation step 
than the absolute differential cytotoxicity between the prOdrug and reduced forms. Thus. 
rather than increasing this differential potency, it is probably moreappropriateto enhance the 
oxygen-sensitivity of activation. Consistent with this concept, a good correlation has been 
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demonstrated between the one-electron reduction potentials of various nitroheterocyclic 
compounds at pH 7 [E'71 and cytotoxic potency in Chinese hamster cell line cultures under 
both aerobic and hypoxic conditions (Adams et al., 1980b). This suggests that nitroreduction 
is rate limiting for cell killing, and that mammalian nitroreductases are of sufficiently low 
specificity that E' is the primary detenninant of rates of reduction and toxicity. Thus 
quantitatively, the dependence on E' was consistent with a one-electron transfer process 
controlling this rate. However the requirement in some cases for up to six electrons for the total 
reduction of a nitro group to achieve optimal activation may also limit the apparent V max of 
prodrug metabolism. Furthermore, the terminal electron transfer events in nitro metabolism 
are suggested to be more dependent upon the slower reductive isozymes of cytochrome P450 
rather than P450 reductase (Walton and Workman, 1987; Walton et al., 1989). 
Another potential limitation in the design of nitro-deactivated aromatic mustards is that 
the nitro 'trigger' and the alky1ator 'effector' are electronically linked via the aromatic system, 
and yet have opposing electronic requirements. Efficient enzymatic reduction necessitates nitro 
reduction potentials above ca. -450 mY, which therefore requires a very electron-deficient 
aromatic ring. Yet aromatic mustards are relatively unreactive (Le. when compared with 
aliphatic mustards), and analogues with such electron-deficient rings may have very low 
absolute potencies, even upon reduction of the triggering nitro group. 
6.1.12 Other potential oxygen-sensitive bioreductive triggers. 
A number of other bioreductive agents make use of oxygen-sensitive 
biotransformation through functional groups other than nitro, including quinones, aromatic-
N-oxide, tertiary aliphatic-N-oxides and transition metal complexes (Denny et al., 1996). The 
mechanisms of reductive activation are generally similar, although significant differences in 
rate constants of reduction as well as reactivity with molecular oxygen (back-oxidation) can 
produce quite variable properties (Wardman et al., 1995). 
Five different redox centres have been used as reductive 'triggers' for these 
compounds, with the hypoxic selectivity of these agents relying upon the inactivation of a 
one-electron reduction intermediate through the reoxidation by molecular oxygen (Denny et 
al., 1996). Thus the "futile cycle" that occurs in the presence of oxygen inhibits the net 
reduction in aerobic cells. The tertiary amine N-oxides, including the analogue of 
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mitoxantrone, AQ4N, and nitracine N-oxide are notable exceptions to this mechanism since 
they require concerted two-electron reduction in order to become activated (Patterson, 1993; 
Patterson et al., 1994; Wilson et al., 1996). 
Figure 6: Examples of aliphatic N-oxide triggered prodrugs. 
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Nitracine N-oxide AQ4N 
The N-oxides of the anthraquinones, anthrapyrazoles and anthracenes are electrically 
neutral and consequently are poor DNA binders and topoisomerase inhibitors. However, once 
reductively metabolised to their respective amines, these cationic agents become persistent, 
oxygen-insensitive DNA binding agents. The major disadvantage of these intercalators is their 
strong dependence upon cellular proliferation for cytotoxicity. It has been demonstrated that 
plateau-phase cells are totally refractory to this class of activated prodrug (Wilson et al., 
1996). In contrast, plateau-phase cells are hypersensitive to other bioreductive agents such as 
RSU 1069, B09, mitomycin C and tirapazamine (Phillips and Clayton, 1997). 
Despite the absence of an oxygen-sensitive one-electron intermediate, their metabolic 
reduction is readily inhibited by oxygen. The mechanism of oxygen inhibition of the cellular 
reductases is not certain, but may involve competition between oxygen and the bioreductive 
drug for reducing species (Patterson et ai., 1994).The mechanism of oxygen sensitivity for 
the Co(ID) transition metal complexed-aliphatic mustard prodrugs is also thought to occur in a 
similar fashion (Ware et al., 1993; Anderson et al., 1996). 
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Figure 7: Example of a transition metal triggered prodrug. 
SN 24771 
To date, only the nitroaromatic and transition metal redox centres have been utilised as 
triggers to release deactivated effectors. Both these trigger designs have theoretical limitations, 
the most obvious of which is the limited oxygen-sensitivity of activation (Denny and Wilson, 
1993). In principle, a quinone-triggered diffusible cytotoxin might provide certain theoretical 
advantages, not least the fact that quinones radicals react with oxygen around two orders of 
magnitude more rapidly than nitro radicals (Wardman, 1985; Wardman et al., 1995). 
However quinones have not been studied in the context of oxygen-sensitive triggers to release 
diffusible cytotoxic effectors. 
6.1.13 Reductive enzymes as quinone-prodrug activators. 
Analagous to a nitroso radical, the distinction between a one- or two-electron reduction 
lies in the possibility for a single-electron reduced quinone, a semiquinone (Q. -), to redox 
cycle in the presence of oxygen. A concerted two-electron transfer leads to the formation of a 
more stable species, the hydroquinone (QH2). bypassing the semiquinone and the possiblity 
of redox cycling. Hydroquinones are stable under hypoxia, and depending upon the reduction 
potential of the couple E,(Q/QH2) are also relatively insensitive to autooxidation in the 
presence of oxygen. However a key difference between quinoids and nitro(hetro)arenes, is 
that the former are generally good substrates for direct two-electron reduction by the 
endogenous oxygen-insensitive reductase, DT-diaphorase (NQOl, DID) (EC. 1.6.99.2) 
(Ernster, 1967; Ernster 1987; Lind et al., 1990; Ross et al., 1993, 1994; Rockwell et al., 
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1993; Beall et al., 1994; Ross et al., 1996). Indeed, a large number of quinones as well as 
quinone imines, azo dyes and some nitrogen oxides can act as electron acceptors from DID 
(Lind et aI., 1990; Riley and Workman, 1992b), which is a reflection of its functional 
relevence in vivo. 
DID, or more accurately NQ01, is one of four diaphorases corresponding to four 
gene loci (Edwards etal., 1980), but interest has focused on NQOl because it appears to be 
the most important for activation of various bioreductive agents and it is markedly 
overexpressed in many tumours and tumour cell lines (Workman, 1994; Ross et al., 1994). 
However the enzyme is ubiquitously expressed in human tissues and often at high levels 
(Riley and Workman 1992b; Belinsky and Jaiswal, 1993). DID is a predominantly cytosolic 
flavoprotein that exists as a homodimer, containing one FAD molecule per subunit, and is 
unique in its ability to utilise both NADH and NADPH as reducing cofactors (Ernster, 1967). 
One of its physiological roles is the reduction of vitamin K3 (menadione), which is important 
for biosynthesis of prothrombin and related blood clotting factors (Ernster, 1987; Lind et al., 
1990). Its capacity to cataylse two and four electron reductions is also important in its role as a 
phase II detoxifying enzyme (Ernster, 1987; Lind et al., 1982). For example, the concerted 
two electron reduction of quinones to their respective hydroquinones allows them to be readily 
detoxified via conjugation with glucoronides, sulphates or glutathione, initiating elimination 
from the exposed cell (Lind et al., 1990). 
However, as implied above, the generation of hydroquinones by two-electron 
reduction can also bioactivate quinones to toxic species which can rearrange into potent DNA 
alkylating agents (Reviews: Riley and Workman, 1992b; Rockwell et al., 1993; Ross et al., 
1993) Yet, the structure-activity relationships between DTD and the various quinone-triggered 
bioreductive alkylating agents has proved complex and attempts to correlate rates of reduction 
to the two-electron reduction potentials have proved unsuccessful (Review: Cadenas, 1995). 
Active site constraints appear to contribute to the substrate preferences of DTD, and the 
absence of the x-ray crystal structure of human D1D has, so far, precluded the ability to 
rationally predict and design efficient quinone substrates for DID (Ross et al., 1996). 
Alternatively, it is arguably more rational to evolve quinone-prodrugs that are not substrates 
for DID if the intention is to specifically target tumour tissues through oxygen-sensitive 
bioreduction. Substrates that are bioactivated by a spectrum of one and two electron 
reductases, by their nature lack specificity in their application. This concept of "enzyme-
directed" drug development has been suggested as a more rational way forward in the design 
178 
Chapter 6 Bioreductive Gene Therapy 
of novel bioreductive prodrug strategies (Workman and Walton, 1990; Workman and 
Stratford, 1993; Workman, 1994). 
Quinones are also substrates for a variety of endogenous one-electron reductases since 
they will readily function as artificial single-electron acceptors (Martlus, 1963). However 
there are no specific quinone-binding sites on these enzymes and the quinones simply divert 
reducing equivalents away from normal cellular redox-couples (Butler and Hoey, 1993b). The 
single-electron reduction potential E,(Q/Q" -) of quinone substrates has been shown to be an 
important factor governing the rate of metabolism by flavoproteins that catalyse single-electron 
transfers (Powis and Appel, 1980; Powis et at., 1981; Svingen and Powis, 1981). The 
semiquinone radical generated by one-electron reduction is thought to be the dominant 
cytotoxic species (Keyes et al., 1984; Pan et at., 1984; Sartorelli 1986; Plumb et al., 1994b; 
Cummings et al., 1998). In agreement, the relative cytotoxicity of a series of diaziridinyl-
benzoquinones has been related to their ability to be reduced to the semiquinone form, E,(Q/Q· 
-), and the intensity of the intracellular semiquinone (EPR) signals could be related to E.,(Q/Qo 
-) (Dzielendziak et al., 1990). It was proposed that cytotoxicity resulted from the semiquinone 
radicals generated by the action of one-electron quinone-reductases. It has been suggested that 
under hypoxic conditions the free radical is sufficiently stable to enter the nucleus of a cell and 
interact directly with DNA (Bachur et al., 1979). 
The substituted 1,4-benzoquinones are the most well represented class of quinone-
based chemotherapeutic agents, and their one-electron reduction is a major biotransformation 
that can~~trongly inhibited by molecular oxygen (Reviews: Powis, 1987; Rockwell et al., 
1993; Ross et al., 1993). The stability of a semiquinone radical in the presence of oxygen will 
depend upon its reduction potential E,(Q/Q"1 relative to the oxygen couple itself, [E7(O/02°-) 
= -155 mY] (Wardman, 1977; 1989), although even quinones more electropositive than -155 
m V can transfer an electron to oxygen, probably because the rapid removal of the superoxide 
anion radical from the cell unbalances the eqUilibrium (Powis, 1987). Thus many 
semiquinone free radical forms can readily transfer their single electrons to molecular oxygen 
which generates superoxide and restores the original quinone (futile cycling). The superoxide 
radical anion is not a particularly reactive species but in the presence of catalytic amounts of 
transition metal ions it can give rise to secondry oxidising species, particularly the hydroxyl 
radical (OHO) (Halliwell and Gutteridge, 1984). The production of OHo is more efficient under 
hypoxic conditions due to the direct reduction of the metal by QO - (Gutteridge et al., 1984; 
Butler et al., 1985). The OHo radical is strongly oxidising, [E7(OHo,H+/H20) = + 2,180 mV] 
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(Koppenol and Butler, 1985), and can undergo -H abstraction or -OH addition with all 
biological components. However inactivation of these reactive intennediates is facilitated by 
various protective enzyme systems, including superoxide dismutase, catalase and the 
glutathione redox cycle (Review: Kappus, 1986). 
Of several flavoproteins studied, NADPH:cytochrome P450 reductase (P540R) (Be. 
1.6.2.4) was found to support the highest rates of single-electron quinone reduction, and this 
was related to the ~(Q/Q· -) values of substrates (Powis and Appel, 1980; Powis et al., 
1981). The rate of single-electron reduction of simple quinones by purified P450R was found 
to start decreasing significantly for substrates with ~(Q/Q· -) values below := -250 mY, 
apparently tending towards background at = -390 mV (Iyanagi et al., 1974; Powis and Appel, 
1980; Powis et aZ., 1981). A range of therapeutically relevant quinones have been shown to 
function as single-electron acceptors for P450R-dependent electron transfer, yielding free 
radical intermediates (Bachur et al., 1979; Svingen and Powis, 1981; Pan et al., 1984; Keyes 
et al., 1984; Butler and Hoey, 1993b). These semiquinones are poor substrates for further 
enzymatic reduction by P450R, but can dismutate to yield their respective quinone and the 
hydroquinone (Powis and Appel, 1980). 
Figure 8: Schematic representation of the one-electron reduction of quinone substrates by 
cytochrome P450 reductase. 
NADPH oxidised 
NADPH:cytochrome 
P4S0 reductase 
reduced 
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Putative single-electron reductases, such as microsomal NADH: femcytochrome bs 
reductase (bsR) (Ee 1.6.2.2) (Iyanagi and Yamazaki, 1969), mitochondrial NAD(P)H: 
ubiquinone oxidoreductase (EC 1.6.5.3) and ferredoxin-NADP+ reductase (EC 1.6.7.1) 
(Iyanagi and Yamazaki, 1970) can also reduce various quinone substrates, although distinctly 
different patterns of quinone reduction are seen (Powis and Appel, 1980). For bsR. which 
only contains 1 mole of FAD per polypeptide chain. the mid-point potential for reduction is -
258 mV (Iyanagi, 1977). However NAD+ binds to reduced bsR, stabilising the semiquinone 
form of the enzyme, and causes a shift in the mid-point potential to -160 m V. This binding of 
NAD+ may explain the relatively high minimum potential for quinone reduction of:= -170 m V, 
with rates of reduction decreasing sharply below -100 mV (Powis et al., 1981; Miller et al., 
1986). NADP+ does not bind in this manner to reduced P450R (Iyanagi, 1977). The FMN 
and iron-sulphur centres of Ubiquinone oxidoreductase can be reduced by either NADH or 
NADPH, and the pattern of substrate affinity varies with cofactor usage. NADH is the 
preferred cofactor and provides a mid-point potential of:= -230 mY. However, the maximum 
rate of cofactor oxidation (when coupled to quinone reduction) is == 20-fold lower for 
NADH:ubiquinone oxidoreductase than P450R (Powis and Appel, 1980; Powis et al., 1981). 
This is supported by studies with rotenone and antimycin A, two inhibitors of mitochondrial 
oxidative phosphorylation, neither of which have an appreciable effect on quinone-stimulated 
superoxide formation in isolated hepatocytes or mitochondrial subfractions (Powis et ai., 
1981; Hodnick and Sartorelli, 1993). Ferredoxin-NADP+ reductase can also catalyse the one-
electron reduction of quinones (Iyanagi and Yamazaki, 1970), but its role in therapeutic 
quinoid reduction has not been studied in detail. 
Several reductases have been shown to simultaneously catalyse both one- and two-
electron reduction of quinones including; xanthine:oxygen oxidoreductase (xanthine oxidase, 
XO; BC 1.2.3.2) (Nakamura and Yamazaki, 1973), xanthine:NAD+ oxidoreductase (xanthine 
dehydrogenase, XDH; EC 1.2.1.37) (Yamazaki, 1977; Gustafson and Pritsos, 1992), 
carbonyl reductase (Wermuth, 1981; Forrest et ai., 1991) and NADH:lipomide 
oxidoreductase (EC 1.6.4.3) (Nakamura and Yamazaki. 1972). Studies with XO comparing 
the specificity of one vs. two electron reduction have demonstrated cofactor- and pH-
dependent mixed-capability for several model quinone substrates, although evidence suggests 
that XO preferentially catalyses the single-electron reduction of therapeutic quinone substrates 
(Pan et al., 1984; Pritsos and Sartorelli, 1986; Butler et al., 1987; Maliepaard et al., 1995), In 
contrast, XDH clearly has both one and two electron donating capabilities with respect to 
therapeutic quinone substrates (Gustafson and Pritsos, 1992, 1993). Evidence for the 
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involvement of cytochrome P450 (CYP450) in the reduction of quinones is contradictary, 
with data supporting either a dominant role or no direct involvement of CYP450 as a quinone-
reductase (Compare Keyes etaZ., 1984; Vromans etat., 1990). 
6.1.14 Quinones as oxygen-sensitive alkylating prodrugs. 
6.1.14.1 Mitomycins. 
The quinone-containing antitumour antibiotic, mitomycin C (MMC), was in clinical 
use as an anticancer agent well before the development of synthetic Quinones as bioreductive 
alkylating agents. It is the prototype for this class of agent since reduction to the semiquinone 
(leO) or hydroquinone (2eO) is necessary to activate its alkylating propeties (Kennedy et al., 
1980; 1982). However the poor hypoxic differential of MMC (Rauth et aZ., 1983; Marshall 
and Rauth, 1986; Stratford and Stephens, 1989) prompted the development of more selective 
analogues such as the N-methyl aziridine analogue, Porfiromycin (POR) , which displays 
superior hypoxia-selectivity by virtue of a lowered aerobic cytotoxicity. This has been shown 
to be related to the lower incidence of DNA cross-links generated by porfiromycin under 
aerobic conditions (Remers, 1979; Keyes et aZ., 1985a). 
Figure 9: Examples of indole quinone-triggered antibiotic prodrugs 
0 0 )-NH. )-NH. 
0 0 
~OCH3 , OCH3 
,I' o~ 
o' 
N N-CH3 
Mitomycin C Porfiromycin 
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The vast majority of therapeutic quinone metabolism in human tissues has been 
conducted on MMC, so it is pertinent to review our current understanding of the reductive 
enzymes involved, and the relative importance of one- vs. two-electron reductions. 
DT-diaphorase. (DTD). 
Considerable evidence for an association between DID activity and MMC sensitivity 
has been reported in both human cell lines (Siegel et at., 1990; Dulhanty and Whitmore, 1991; 
Marshall et al., 1991; Beall et ai., 1994, 1995; Fitzsimmons et al., 1996) and xenograft 
models (Malkinson et al., 1992). However, MMC is preferentially activated by DID at low 
pH (eg. pH 5.8) (Siegel et ai., 1992) owing to the pH-dependent inactivation of the enzyme 
by its substrate (Siegel et ai., 1993), and this might account for the lack of correlation between 
DID activity and MMC cytotoxicity in some cell line studies (Robertson et al., 1992, 1994). 
Recently mechanistic proof in support of the majority of these correlational studies has been 
provided by the overexpression of human DTD in Chinese hamster ovary (CHO) cells, which 
was demonstrated to confer aerobic sensitivity to MMC (Gustafson et al., 1996). 
However it has been noted in dicoumarol-inhibition studies that DID may protect 
against MMC-induced cytotoxicity under hypoxic conditions (Keyes et al., 1984, 1985b, 
1989), although dicoumarol can have multiple effects on cellular metabolism, including 
inhibition of bsR (Ross et al., 1993; Hodnick and Sartorelli, 1993). Other evidence in support 
of a protective role for DID in hypoxic cells is suggested from work on two human colon 
carcinoma cell lines; HT-29 with high DID activity and BE with undetectable DID due to a 
polymorphism in the NQO 1 gene (Traver et al.. 1992). While MMC was more cytotoxic to 
HT -29 cells in air, only the sensitivity of BE cells was enhanced under hypoxic exposure 
conditions (Beall et al., 1994; Plumb and Workman, 1994). Since other one-electron 
reductases are present at similar levels in both cell lines, it was suggested that the lack of 
hypoxic sensitization might imply a protective influence for DID metabolism under low 
oxygen (Plumb and Workman, 1994). 
P450 reductase. (P450R). 
P450R is generally considered the major one-electron reductase involved in MMC 
activation (Kennedy et al., 1985; Pan et al., 1984; Keyes et al., 1984; Belcourt et al., 1996). 
Early studies with rat liver homogenates demonstrated the strong dependence of MMC 
metabolism on both NADPH and anaerobic conditions, with the microsomal fraction being 
identified as the major site of NADPH-dependent metabolism (87%) (Schwartz, 1962). A 
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specific role for P450R in MMC metabolism was first suggested when MMC was shown to 
disappear from anaerobic incubations of purified P450R and NADPH (Komiyama et al., 
1979). Komiyama et al. subsequently demonstrated that hydroxyl radicals were generated as a 
consequence of MMC reduction by purified P450R (Komiyama et al., 1982). Later it was 
confirmed that there was anaerobic metabolism of MMC by purified P450R to three major 
products. identified using HPLC followed by mass spectrometry (Pan et al., 1984). Further, 
the formation of an ESR signal during enzymatic reduction of MMC was seen under anaerobic 
conditions. This provide the first direct evidence that MMC could function as a reductively 
activated alkylating agent (Pan et al., 1984). Soon after the importance of P450R-dependent 
metabolism was reaffirmed, and it was concluded that under aerobic conditions enzymatic 
reduction ofMMC to the semiquinone radical led to redox cycling and formation of ROS, but 
under anaerobic conditions there was formation of an alkylating species (Keyes et ai., 1984). 
In the presence of NADPH as the electron donor. EMT6. V79 and CHO cell sonicates 
metabolised MMC to a product(s) capable of alkylating the model nucleophile p-
nitrobenzylpyridine (P-NBP), and this' reaction was strongly inhibited by oxygen. No 
alkylation of p-NBP was observed under aerobic conditions, which was consistent with 
observations using a reconstituted P450R system, where only 4% alkylation was observed in 
air (Kennedy et al., 1982). These metabolism studies were consistent with the observations 
that P450R exists as an air-stable semiquinone radical, probably FAD-FMNHe, and thus it 
will exclusively catalyse the single-electron addition to an appropriate artificial electron 
acceptor (Vermillion and Coon, 1978b). Kinetic measurements demonstrated that no 
saturation of P450R activity occured, even at MMC concentrations of 5 mM (Pan et ai., 1984; 
Keyes et at., 1984), consistent with the idea that there is no specific quinone-binding site on 
this enzyme, but rather, electron transfer is mediated by a proximity event (Butler et ai., 1987; 
Butler and Hoey, 1993b). 
Surprisingly, P450R was later implicated in the activation of MMC under aerobic, but 
not hypoxic conditions in a CHO cell line made resistant to MMC by chronic exposure, 
despite a 3-4 fold lowering of P450R activity being associated with a 2-3 fold suppression of 
anaerobic-dependent MMC metabolism (Hoban et ai., 1990; Bligh et ai., 1990). However 
subsequent experiments utilising the stable expression of human P450R in CHO cells directly 
verified the role of this enzyme in both the aerobic and hypoxic activation of MMC and POR 
(Belcourt et ai., 1996). This pattern of both aerobic and hypoxic co-sensitisation for MMC 
and POR by overexpression of human P450R was later confirmed in a human mammary 
carcinoma line (see section 6.3.) (Patterson et al., 1997). 
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Cytochrome P450. (CYP450). 
Prior to Pan et al. (1984) conclusively identifying P450R as the major microsomal 
reductase responsible for catalysing the one-electron activation of MMC to alkylating species, 
it had been reported that sonicates of Sarcoma 180 and EMT6 mammary carcinoma cell lines 
required the presence of NADPH and anaerobic conditions to metabolise MMC. but the 
reduction was completely inhibited by carbon monoxide (CO) (Kennedy et al.. 1980). This 
suggested a dominant role for CYP450. and was supported by further lines of evidence in 
studies with reconstituted systems and isolated nuclei. It was reported that neither P450R 
alone. nor in combination with phospholipid, or substitution of CYP450 with cytochrome c, 
could result in activation of MMC (Kennedy et ai .• 1982). However, due to a technical error, 
the involvement of CYP450 was later established as an indirect stimulation of P450R 
metabolism, with the reaction being increased upto 100% by the presence of CYP450 in a 1:1 
ratio with P450R (Keyes et al., 1984). Thus it appeared that CYP450 was not directly 
involved in the bioactivation of MMC, but under certain conditions in vitro. CYP450 could 
facilitate the P450R-dependent metabolism of MMC. This was in agreement with earlier work 
with a series of model quinone compounds, where no direct role for cyp450 was suggested 
(Powis et al., 1981). 
Yet, in later studies with rat liver microsome preparations, it was concluded that the 
dominant pathway in the one-electron reduction of MMC is via cyp450 (Vromans et ai .• 
1990). Under anaerobic conditions the initial rates of reduction of MMC by P450R was only 
45% of that seen for a complete microsomal system with identical total P450R activity. 
Assuming first-order kinetics, the relative initial rates of reduction of MMC by P450R was 
0.002 S·l, but this was 100-fold lower than that of a complete microsomal system (0.20 S·l). 
Liver microsomal H20 2 production was shown to be dependent on NADPH, 02 and MMC, 
and could be effectively inhibited by SKF-525A and metyrapone. This inhibition was seen to 
be specific for cyp4S0, and was not thought to be caused by MMC-stimulated oxidase activity 
i.e. uncoupling of the cyp450 system, since reduction rates under aerobic conditions were 
only 10% of that under anaerobic conditions (see discussion in chapter 2). Moreover the 
reduction of MMC, catalysed by phenobarbitol-induced microsomal preparations under 
anoxia. was strongly inhibited by SKF-525A (75%) and CO (61%). although metyrapone 
was somewhat less effective (17%). The observation that under anaerobic conditions, the 
MMC-dependent alkylation of p-NBP was also strong inhibited by SKF-525A (70%). 
metyrapone (55%) and imidazole (65%). supported the conclusion that in the intact 
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microsomal system cyp450 was the major tenninal electron recipient and donor to MMC 
(Vromans et al., 1990). Consistent with these observations, the SKF-525A-inhibitable one-
electron reductive bioactivation of 2,3,5,6-tetramethylbenzoquinone by cyp450 has also been 
shown (Goeptar et ai., 1992), and doxorubicin has been reported to be reduced to its 
semiquinone form by cyp2b1 (Goeptar et al., 1993). However, in the absence of direct 
evidence for CYP450-mediated bioactivation leading to anti-tumour quinoid cytotoxicity, it is 
difficult to draw any clear conclusions regarding the contradictory evidence in the literature. 
Bs reductase. (bsR) 
Considering the low mid-point potential of NAD+ bound bsR (-170 m V), and the 
the observations that rates of quinone reduction decrease sharply below -100m V (Powis et 
al., 1981; Miller et al., 1986), the relatively high one-electron reduction potential of MMC 
(E/ = -310 mY) (Wardman, 1989), might suggest that MMC would not be a poor artificial 
single-electron acceptor for this flavoenzyme. In agreement, data has shown that rat liver 
microsomal preparations are inefficient at supporting the NADH-dependent reduction of MMC 
(Schwartz, 1962). However, perhaps suprisingly, purified rabbit erythrocyte bsR has been 
demonstrated to catalyse the pH-dependent, NADH-supported metabolism of MMC to 
reactive species (Hodnick and Sartorelli, 1993). However, unlike P450R, bsR cataIysed the 
MMC-dependent alkylation of p-NPB under both aerobic and hypoxic conditions, with 
alkylation being - 1.5-fold greater under hypoxic conditions. The generation of alkylation 
products in air indicated that an oxygen-insensitive metabolite(s) was generated, and thus 
suggested bsR catalysed a two-electron reduction of MMC, analogous to that of DTD. 
However bsR also catalysed the NADH-dependent, MMC-induced consumption of °2, 
indicating simultaneous one- and two-electron reductions were occuring. In further contrast to 
P450R, the reduction of MMC by bsR was saturable, with an apparent ~ of 23 J.1M (pH 
6.6). 
Xanthine dehydrogenase. (XDH). 
XDH is widely distributed in human tissue, and catalyses a rate-limiting step in nucleic 
acid degradation. MMC acts as an alternative electron acceptor, generating both oxygen 
radicals and the stable MMC metabolite under aerobic conditions (Gustafson and Pritsos, 
1992). This is consistent with XDH being capable of bioactivating MMC by either a one- or a 
two- electron reduction event. Under hypoxia, rate of formation of2,7-diaminomitosene (2,7-
DM), the major metabolite of MMC, was increased 60% when xanthine was used as reducing 
equivalents (Gustafson and Pritsos, 1993), as compared to 120%, when NADH was the only 
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source of electrons (Gustafson and Pritsos, 1992). This suggested that the one-electron 
reduction of .Ml\1C by XDH is not as great when xanthine is used as an electron donor as 
opposed to NADH. Analysis of the NADH-reduced flavin in XDH has shown that the FAD 
existed as both the flavin semiquinone (FADH·) and the hydroquinone (FADH2), with the 
(FADH·) predominating (Schopfer et al., 1988) In contrast, xanthine-reduction favours 
FADH2 formation. If FADH2 is responsible for the two-electron reduction of MMC, and 
F ADW is responsible for the one-electron reduction, the cofactor-dependence of reduced 
flavin products, could account for differences in the increased rates of 2,7-DM formation 
under hypoxia. In agreement, aerobic 2,7-DM formation was greater for xanthine- than 
NADH-supported MMC metabolism, implying a greater proportion of xanthine-dependent 
reduction is proceeding via a direct two-electron transfer (Gustafson and Pritsos, 1993). The 
kinetics of hypoxic and aerobic MMC metabolism by XDH appear to differ significantly. 
Under hypoxia, 2,7-DM formation is linear and non-saturable, similar to that seen for P450R 
(Keyes et al., 1984). Yet, like DID and BsR reduction, XDH metabolism is saturable under 
aerobic conditions, indicated by the hyperbolic relationship between initial MMC 
concentration and 2,7-DM formation (apparent ~ = 299 J.1M; pH7.4). Of note, the rate of 
reduction of MMC by XDH increased as pH was decreased, and similar dependences have 
been noted for DID and BsR (Siegal et al., 1990; Hodnick and Sartorelli, 1993), while the 
reduction of MMC by P450R is markedly decreased as pH is lowered (Kennedy et al., 1985). 
The combination of xanthine and NADH increases the V max of XDH for a variety of 
substrates compared to each cofactor alone (Rajagopalan and Handler, 1967; Waud and 
Rajagopalan, 1976b). Thus it is suggested that the two electron donor sites are distinct, with 
the electron inlets for NADH and xanthine being the flavin (FAD) and molybdenum moieties 
respectively (Rajagopalan and Handler, 1967; Kanda et al., 1972; Schopfer et al., 1988). 
Evidence suggests that MMC is reduced at the flavin site within XDH, since xanthine does not 
compete with MMC at the xanthine site, but it can decrease the formation of NADH that 
accompanies the oxidation of xanthine to uric acid. This inhibition is competitive, suggesting 
MMC acts as a alternative electron acceptor to NAD+, facilitating the removal of electrons from 
the enzyme (Gustafson and Pritsos, 1993). 
XDH has been shown to be the precursor form of XO, which can be generated via the 
proteolytic cleavage of XDH. This XDH-to-XO interconversion is regulated through a 
hypoxia-dependent mechanism in tumour and normal tissues (Anderson et al., 1989), Chinese 
hamster V79 cells (Hasan et al., 1991) and hepatocytes (Wiezorek et al., 1994). The 
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physiological role of this interconversion is poorly understood. A hypoxia-dependent rise in 
XOIXDH mRNA transcript levels has also been shown in endothelial cells, accompanied by 
increasing XO enzyme activities (Partridge et al., 1992; Terada et al., 1992; Hassoun et al., 
1994 ). Yet, it has also been found that ischemia-dependent increases in XO activity in 
endothelial cells can occur in the absence of conversion of XDH to XO, and without changes 
in mRNA expression (Poss et al., 1996). 
Xanthine oxidase. (XO). 
Identification of the role of NADH-dependent reduction of MMC by the 
molyboflavoenzyme XO paralleled that of P450R. MMC was shown to disappear from 
anaerobic incubations of purified XO and xanthine (Komiyama et al., 1979). Along with 
P450R, it was later confrrmed that anaerobic metabolism of MMC by purified XO and NADH 
produced three major metabolites, and an oxygen-sensitive ESR signal could be generated 
(Pan et al., 1984). As with P450R and XDH, under hypoxia the rate of MMC reduction by 
XO could not be saturated. The generation of ROS by XO-mediated aerobic metabolism of 
MMC has also been reported (Pritsos and Sartorelli, 1986), and together, these observations 
provided good evidence for the single-electron reduction of MMC by XO. In agreement XO-
mediated reduction has been shown to be more effectively inhibited by oxygen than XDH 
from the same source (Kutcher and McCalla, 1984). 
Earlier studies have indicated that xanthine oxidase, like XDH, catalyses simultaneous 
one- and two-electron reductions of several model quinone substrates (Nakamura & 
Yamazaki, 1973; Gustafson & Pritsos, 1992, 1993). The proportion of one-electron flux 
depended not only upon the source of reducing equivalents but also on the acceptor molecule 
itself. NADH and xanthine donate electrons at separate sites on the enzyme, the flavin and 
molybdenum moieties respectively, and together with the two iron-st.4Jhur centres, this 
complex redox enzyme has the potential to retain upto six electrons at anyone time. When 
NADH is the only electron donor, the % of one-electron reduction varies greatly with pH but 
not substrate availability, while for xanthine-supported metabolism, the % of one-electron flux 
is strongly dependent on acceptor substrate concentration, not pH. Since either cofactor is 
sufficient for activity, and the rates of xanthine- and NADH-driven reductase reactions are 
additive in the presence of both donors, it implies that XO has two distinct routes of intra-
molecular electron transfer, although this does not necessarily imply the existence .of two 
distinct outlets of electrons in the enzyme (Nakamura and Yamazaki, 1973). Rather, like 
XDH, the bifunctional reductive ability of XO more likely represents the fact that the FAD 
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exists in equilibrium as both the flavin semiquinone (F ADH') and the flavin hydroquinone 
(F ADH2) species. It would appear that no study has demonstrated that metabolism of :MMC is 
1 truly oxygen-sensitive when xanthine is the only source of reducing equivalent. 
Mitochondrial reductases. 
MMC does not readily accept reducing equivalents from the mitochondrial electron 
transport chain (Powis et aZ., 1981; Hodnick and Sartorelli, 1993). Recent studies have 
identified a NADPH-dependent mitochondrial one-electron reductase that contributes 
significantly to metabolism of MMC, along with the minor involvement of a NADH-
dependent oxygen-inhibitable mitochondrial reductase (Spanswick et aZ., 1996). These 
mitochondrial reductases appear to be more efficient than urn at metabolising MMC 
(Cummings et aZ., 1995). Importantly mitochondria have been identified as a critical target for 
MMC toxicity, suggesting that the activity of these reductases may be of considerable 
therapeutic relevcmce (Pritsos et aZ., 1997). 
Nuclear reductases. 
Isolated nuclei have been identified as important sites for MMC metabolism (Kennedy 
et al., 1982; Bachur et al., 1982; Keyes et al., 1984; Kennedy et al., 1985). Despite earlier 
contradictions in the literature (Kennedy et al., 1982; Pan et al., 1984), it was apparently 
clarified that P450R was the dominant nuclear reductase that metabolises MMC (Keyes et al., 
1984; Kennedy et aZ., 1985). Yet the earlier suspected involvement of cyp450 in nuclear 
reduction of MMC (Kennedy et al., 1982), coupled with later reports of the dominant role of 
phenobarbitol-inducible cyp450s in MMC anaerobic bioactivation (Vromans et al., 1990) 
must leave the potential role of nuclear-localised cyp450 (Moody et al., 1988), at best, 
uncertain. 
6.1.14.2 Comparative role of one vs. two electron reduction in the initiation 
of MMC cytotoxicity. 
It is not clear whether the one-electron or two-electron reduced forms of quinones, or 
both, are responsible for cytotoxicity. and mechanisms have been proposed for either the 
semiquinone or hydroquinone as the toxic species. The mechanism is further complicated by 
the potential involvement of both species with 0z-driven autooxidation. and by the possibility 
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of both disproportionation and comproportionation reactions between the quinones and their 
reduced forms (Review: Powis, 1987). 
It has been suggested that the biologically active form of MMC is the two-electron 
reduced hydroquinone intermediate, where spontaneous elimination of methanol followed by 
aziridine ring opening generates a quinone methide. Nucleophilic attack by the methide 
initiates displacement of carbamate, providing bifunctional alkylating activity to give mitosene 
hydroquinone adducts (Moore and Czerniak, 1981). Yet the MMC hydroquinone has a very 
short half-life (= 0.07 sec) and rapidly and irreversibly breaksdown to a further reducible 
species (Rao et ai., 1977; Remers, 1979). 
202 -~ 
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It is also proposed that single-electron reduction will serve to activate MMe. In this 
mechanism, semiquinone formation allows spontaneous loss of the methoxy group, forming a 
semiquinone radical that undergoes nucleophilic attack to give a monoadduct (Pan et ai., 1984; 
Sartorelli, 1986). Subsequent reoxidation or dismutation back to the quinone then allows 
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secondary radical activation to generate a bifunctional adduct (Pan et al., 1986). Under 
anaerobic conditions the chemically generated semiquinone radical of MMC has an average 
lifetime of 10 seconds (Nagata and Matsuyarna, 1970), although it can undergo 
disproportionation to the hydroquinone, so it can not be ruled out that alkylation might 
proceed via the two-electron pathway. 
Overall, evidence favours an enzyme-mediated one-electron activation pathway since 
only electrochemical reduction of MMC by a single-electron gives a product profile similar to 
that seen for enzymatic reduction. Two-electron electrochemical reduction generates products 
of the 10-decarbamoyl-mitosene type that are not seen using enzyme preparations (Andrews et 
al., 1986). Furthermore, when MMC quinone and hydroquinone are mixed together, a MMC 
semiquinone radical is formed by comproportionation, and it is only this semiquinone radical 
that can evict the methoxy leaving group (Danishefsky and Egbertson, 1986). 
6.1.14.3 Indoloquinones: E09 and its analogues. 
A synthetic analogue of MMe, the aziridinylindoloquinone, Eoo (Oostveen and 
Speckamp 1987), was found to have a much superior hypoxia selectivity than MMC in vitro 
and in vivo (Robertson et at. 1992, 1994; Adams 1992; Hendriks et al. 1993). BOO has 
significant structural changes over MMC, of which the aziridinyl moiety at the 5-position of 
the quinoid ring is the most important in terms of cytotoxicity (Bailey et al., 1992; Phillips 
1996; Jaffar et at. 1998A). 
Figure 10: The indoloquinone E09: [3-hydroxy-5-aziridinyl-l-methyl-2(1H-indole-4,7-
dione )-prop-~-en-a-01]. 
OH 
E09 
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E09, like MMe, is subject to both one- and two- electron reductive metabolism to the 
semi- and hydroquinone respectively, although details of the relative contributions of cellular 
reductases, and their respective contributions to aerobic vs. hypoxic cytotoxicity, have only 
recently begun to emerge. 
Figure 11: Proposed differential oxygen-sensitivity of indoloquinone metabolism by one- or 
two- electron reduction pathways. 
o· 
R 
OH 
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Early studies identified DID as an imporant enzyme for the metabolism of E09, and 
bioactivation of EOO by purified DID resulted in DNA single-strand breaks (Walton et al., 
1991). The suggestion of a role for DTD in EOO cytotoxicity was confirmed by Robertson et 
al. (1992), when a good correlation was demonstrated between the sensitivity of a panel of 
human cell lines to aerobic E09 exposure with intracellular DT -diaphorase activity in vitro. A 
number of studies have since reafflffiled this relationship (Walton et al., 1992b, 1992c; 
Robertson et al., 1994; Smitskamp-Wilms et al., 1994; Plumb et al., 1994a; Collard et al., 
1995; Fitzsimmons et al., 1996), as well as confirming EOO to be a relatively good substrate 
for human DTD (Beall et al., 1994, 1995; Chen et al., 1995c; Phillips et al., 1996; Bailey et 
al., 1997). Reduction ofE09 by purified DTD has been shown to result in either DNA single-
strand breaks (Walton et al., 1991; Phillip 1996), or DNA alkylation and cross-linking (Bailey 
et al. 1994a; Maliepaard et al. 1995; Bailey et al., 1997) and as such there is disagreement in 
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the literature as to the nature of the cytotoxic lesions generated under aerobic conditions 
(Butler et ai., 1996; Cummings et ai., 1998). Butler et ai. (1996) demonstrated that the 
hydroquinone was rapidly backoxidised to EOO under aerobic conditions (t~ =1.5 sec) with 
the concomit ant production of H20 2, suggesting ROS fonnation (particularly OH
e
) would be 
the dominant cause of DNA damage. This must question the ability of the hydroquinone, 
formed directly by DID-dependent metabolism, to generate significant crosslinking in intact 
cells, and suggests in studies where correlations were observed between the cytotoxicity of 
E09 in air and DID expression, the effect was mediated via ROS. Yet, Walton et al. (1991) 
observed that superoxide dismutase did not prevent the fonnation of single strand breaks, 
implying that alkylation was initiating the DNA damaging effect. Whatever the mechanism, 
direct evidence that human DID is relev(ll1t to EOO toxicity in whole cells has recently been 
provided by transfection of human NQOl cDNA into CHO cells. Clones expressing high 
levels of enzyme were modestly more sensitive (3-fold) to aerobic EOO exposure (Gustafson 
et at., 1996). 
Robertson et at. (1994) also demonstrated that in cells with high DT -diaphorase, 
treatment with E09 under hypoxic conditions did not provide significant additional 
cytotoxicity, whereas cells with low DT -diaphorase were markedly sensitized to E09 in 
hypoxia. This is consistent with a dominant oxygen-insensitive role for DT -diaphorase in the 
metabolism of EOO (Walton et at., 1991; Bailey et al., 1994b), but in the absence of 
significant direct two-electron reduction, alternative oxygen-sensitive one-electron processes 
will contribute to cytotoxicity, but only under low oxygen tensions. In agreement, it has been 
demonstrated that an inverse correlation exists between the HCR of EOO and DT -diaphorase 
activity in two independent panels of human cell lines (Plumb et al., 1994a; Robertson et al., 
1994). However, like MMe, increasing D1D levels were also shown to actually confer 
protection from EOO cytotoxicity under hypoxia, and this correlation was lost in the presence 
of dicumarol (Plumb et al., 1994b). Plumb et al. (1994a) suggested that back-oxidation of the 
hydroquinone to the significantly more toxic semiquinone radical is prevented by the absence 
of oxygen, and this possibility, together with supporting evidence that the semiquinone is the 
proximate toxin, implied that direct two-electron metabolism of EOO by DID under hypoxic 
conditions is essentially a detoxifying process. If these hydroquinone reactions are not directly 
damaging, then this process will be in competition with the major cytotoxic single-electron 
reduction pathway. 
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The importance of one-electron reductases in the bioactivation of E09 was exemplified 
using the HT-29 and BE cell line pair (Plumb and Workman, 1994; Plumb et al., 1994b). 
Under hypoxia, the DID-rich HT -29 cells demonstrated only a 2.9-fold increase in 
cytotoxicity, while the DID-deficient BE cellUne became 1000 to 3000 -fold more sensitive to 
EOO exposure. The relationship between aerobic potency of Eoo has subsequently been 
correlated to DNA damage in these cell lines (Bailey et al., 1997). BE cells showed a dramatic 
30-fold increase in the extent of crosslinks formed under hypoxic conditions, supporting the 
relevance of one-electron reduction in E09 cytotoxicity under low oxygen tension. 
Perhaps more importantly, in vivo studies have also demonstrated that E09 functions 
as a hypoxia-selective cytotoxin (Adams et al., 1992). While Eoo was inactive against the 
KHT sarcoma in mice as a single agent, it could strongly potentiate the action of lOGy X-
irradiation. This effect was much larger for E09 than MMC, and appeared to be related to the 
superior hypoxic cytotoxicity ratio of Eoo against KHT cells in vitro. It was concluded that 
since lOGy was sufficient to eradicate the aerobic fraction of the xenograft, this implied that 
Eoo was functioning as a hypoxic cytotoxin. In support, a greater than additive effect was 
seen in four types of rat tumours when Eoo was administered postirradiation (Kal et al., 
1994, 1995). Two in vivo studies have attempted to correlate tumour response to E09 with 
reductive enzyme profile, but no relationship has been found for either DID (Collard et al., 
1995; Cummings et ai., 1998), P450R or bsR activities (Cummings et al., 1998). However in 
the latter study, tumour sensitivity in vivo was shown to be related to the overall ability of 
tumour homogenates to catabolise E09 (Cummings et al., 1998) under hypoxic conditions (r2 
= 0.86; P = 0.07), but not so clearly under aerobic conditions (r2 = 0.82; P = 0.17). 
However, since the severity and extent of hypoxia within these xenograft models was not 
determined, interpretation of the data is difficult. 
The specific role of P450R in the hypoxia-dependent bioactivation of E09 has been 
confirmed in cell free studies (Bailey et al. 1994a). ESR spectroscopy experiments using 
purified P450R detected Eoo and O2 radical species, while incubation of P450R, NADPH 
and E09 with marker DNA lead to the generation of DNA interstrand crosslinks, but only 
under anaerobic conditions. To date, the relevc.\l1ce of P450R has not been demonstrated in 
intact cells. 
" 
Purified XO has also been shown to activate Eoo to yield DNA interstrand crosslinks 
(Maliepaard et al. 1995). Incubations were only conducted under anaerobic conditions using 
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NADH as the source of reducing equivalents. Conversion of BOO was increased with 
lowering pH, but less DNA cross-linking resulted. XO-activated BOO was shown to be a 
more potent cross-linker than activated MMC under identical experimental conditions. 
However, no evidence was reported to confirm that XO does not metabolise Eoo to a cross-
linking species in aerobic conditions, and neither was xanthine employed as an alternative 
electron donor. Thus it is not possible to conclude whether XO-mediated activation of EOO is, 
like MMC, apparently an exclusive single-electron reduction event. 
6.1.15 Quinones as oxygen-sensitive triggers. 
While quinones and nitro groups appear to follow similar overall kinetics, being 
strongly dependent upon the substrate reduction potentials (Dzielendziak et al., 1990; Butler 
and Hoey, 1993b), the energetics controlling the rate of reaction of the two types of drug 
radicals with oxygen are significantly different. Quinones have low mid-point potentials (Elm) 
for the one-electron couples, and the rate constants are not much lower than the diffusion-
controlled limit. In contrast, for similar energetics, nitro radicals react with oxygen around 
two orders of magnitude more slowly than quinone radicals (Adams et al., 1980b; Wardman, 
1985; Wardman et al., 1995). Since the reaction of the radical with oxygen will also be in 
competition with radical disproportionation, a pathway which leads to toxicity, the rate of 
change of radical concentration with time will be, in simplest terms, an opposing balance of 
these two factors. For similar energetics, quinone radicals disproportionate up to four orders 
of magnitude faster than nitro radicals, but the oxygen sensitivity of this process is dependent 
upon the square of this rate constant (Wardman et al., 1995). However, since this difference 
is offset by the =100-fold greater rate constants for reaction of quinone radicals with oxygen 
compared with nitro radicals, the overall kinetic basis for the use of either nitro or quinone 
based agents as bioreductive drugs have evident parallels. Yet the absolute rate constants for 
their individual reactions differ by orders of magnitude. 
6.1.16 Implications for the oxygen concentration dependence of bioreductive 
drug metabolism. 
The marked sensitivity of quinone substrates to back-oxidation is reflected in their 'K· 
curves' or oxygen dependence of cell killing. Generally the half value {'K-value'} for most 
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nitroimidazoles is ~ 0.5 - 0.1 % 02 (Koch, 1990; Mulcahy, 1984; Brown, 1993; Koch, 
1993), while for quinone bioreductive drugs such as mitomycin C or diaziquone the K-value 
is in the order of 0.01 % 02 or less (Marshall and Rauth, 1986; O'Brien et al., 1990). 
The need for severe hypoxia to achieve significant reductive metabolism of Quinones 
when compared to nitrocompounds has obvious clinical disadvantages when considering their 
application as bioreductive drugs. Since the K-value for radiation sensitization by oxygen is ~ 
0.3% (Hall, 1994), the use of bioreductive drugs that require significantly more stringent 
hypoxia for maximal efficacy will leave cells at intermediate oxygen concentrations resistant to 
both the bioreductive agent and the radiation treatment (Brown, 1993). However, this acute 
hypoxia-dependence might also represent an advantage when considering the tissue specificity 
of quinone reduction, since the low oxygen concentrations required are unique to tumour 
tissues. Intermediate oxygen tensions are a common physiological property of several normal 
tissues, and have been associated with the severe side-effects of bioreductive drug therapy. 
For example, TPZ induces acute liver toxicity in rat models (White et al., 1992), and the 
resulting liver necrosis is confined to hepatocytes in the pericentral zone, a region that only 
experiences oxygen tensions of 2 - 4% (Lemasters et al., 1981). A second example of normal 
tissue involvement has been documented with the R-enantiomer of RB 6145, a less emetic 
bromo-ethylamino precursor of RSU 1069 (Adams and Stratford, 1994). Irreversible retinal 
degeneration (retinopathy) was reported in murine studies in vivo, and consequently the 
preclinical development of this compound was halted (Parker et al., 1996). Hypoxia is a 
distinctive feature of retinal tissue that is particularly prominent during low-light vision or the 
resting state. Thus when considering Quinones - not as a bioreductive agents (Le. quinone 
methide precursors), but as "trigger" units for the release of diffusible cytotoxins, their 
dependence on severe hypoxia for appreciable reductive metabolism might, in principle, prove 
to be an advantageous biochemical property. 
6.1.17 Theoretical considerations in the design of quinone-triggered hypoxia-
selective prodrugs of diffusible cytotoxins. 
To date, the indoloquinone nucleus has not been described as a trigger mechanism for 
the selective release of a covalently attached, but independent, cytotoxic unit. In order to 
usefully apply quinones as hypoxia-dependent triggers, the compounds by definition must not 
be significant substrates for oxygen-insensitive reductases, in particular DTD. The rational 
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design of the trigger-linker-effector based structures must also allow the reduction of the 
quinone ("trigger") moiety to facilitate a favourable redistribution of the intramolecular 
electron density ("linker"), promoting the kinetically efficient activation or release of a latent 
cytotoxin ("effector"). Additionally, the released "effector" must readily diffuse across cell 
membrane barriers, be insensitive to oxygen, and (perhaps) more potent than the reduced 
quinone "trigger" itself. 
The indoloquinone structure of E09 will behave as a trigger molecule, since one-
electron reduction will initiate a movement of electrons to evict a leaving group, and in doing 
so will generate a drug-radical which can alkylate DNA (Oostveen and Speckamp, 1987). 
E09 has three distinct functional groups:- the aziridinyl at the C-5 position of the indole ring, 
a hydroxypropenyl at the 2-position and a C-3 position hydroxymethyl functionality. 
Figure 12: Two closely related analogues ofE09lacking either the C-2 or C-3 functionality. 
E09 
OH 
Analogue 2 Analogue 3 
In order to establish the relative importance of the C-2 and C-3 positions in facilitating le'-
dependent Michael-type elimination processes, the P450R overexpressing MDA 231 clones 
were utilised to evaluate the oxic and hypoxic cytotoxicity of two E09 analogues 2 & 3. 
These analogues lacked either the C-2 or C-3 arm, respectively. allowing the relative 
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contributions of these groups to both aerobic and hypoxic toxicity to be assessed with respect 
to one-electron activation. 
Although the C-5 aziridinyl group contributes significantly to the aerobic potency of 
E09, its activity may be enhanced following quinone reduction. As the predicted pK of the 
aziridine on the semiquinone would be considerably higher than that of the parent quinone, at 
physiological pH the semiquinone should be more reactive (Butler et al., 1996). This 
mechanism is exemplified by studies of the reductive activation of the bis-
aziridinylbenzoquinones, DZQ and AQZ, where reduction of the quinone function activates 
attached aziridine groups by initiating electron release and subsequent protonation of the 
aziridine ring. This allows ring opening, facilitating the subsequent alkylation of nuc1eophiles 
(Ross et al., 1990; Ally et al., 1994). Alternatively, under acidic conditions protonation can 
directly yield an aziridinium ion, which encourages ring opening, releasing the strain energy 
of the aziridine ring to form a carbonium ion intermediate (Mossoba et ai., 1985). 
Figure 13: Examples ofbis-aziridinylbenzoquinones. 
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In order to assess this possibility with respect to E09, two further analogues with 
modifications at the C-5 position were evaluated. Either the reactivity of the aziridine was 
moderated by addition of an electron-donating 2'-methyl group (E08), or it was replaced with 
a non-alkylating methoxy group (E07) (Bailey et at., 1992; Naylor et al., 1997; Jaffar et al., 
1998a). The relative potency and hypoxic/oxic differential of E08 and E07 were tested 
against the Rd-42 clone. 
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Figure 14: Two analogues ofE09 with modified C-5 funtional groups. 
Haeo 
E08 E07 
6.1.18 Summary. 
This chapter describes the testing of the nitro-triggered prodrugs RSU 1069, CB 1954 
and SN 23862, as oxygen·sensitive substrates for the microsomal enzyme P450R. The 
potency of the bystander effect is also assessed in co-culture experiments in vitro. A series of 
analogues of the indoioquinone E09 are also evaluated with respect to P450R bioactivation in 
vitro, in order to further the understanding of the design of indoloquinones as potential trigger 
mechanisms for novel prodrug development. This may allow the rational enzyme-directed 
design of novel indoloquinone-triggered prodrugs linked to diffusible cytotoxic effectors. 
6.2 Methods. 
Materials. RSU 1069, CB 1954, SN 23862, E09 and its four analogues were synthesized 
in house according to published methods (Adams et al., 1984; Cobb et al., 1969: Palmer et 
al., 1995; Naylor et ai., 1997; Jaffar et ai., 1998a). MMC was purchased from Sigma. 
Porfiromycin was a gift from Dr. Rockwell. All other materials were of tissue culture grade 
and the highest purity commercially available. 
Prodrug sensitivities. Dose-response curves were determined under both aerobic and 
hypoxic conditions, and ICso values independently collated as previously described (chapter 
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2). All exposures were 3hr unless otherwise stated. Hypoxic cytotoxicity ratios (HCRs) were 
calculated as the ratio of drug concentration required to reduce cell growth by 50% under oxic 
vs. hypoxic conditions. Drug sensitivities were assessed in the parental MDA 231 and P450R 
overexpressing clonal cell lines as described in chapter 3. 
Evaluation of "bystander" effects. The P450 reductase overexpressing clone (Rd-42) 
was co-cultured with the parental MDA-231 cells in 96-well format @ 5x103 cells/well, in 
increasing proportions (10-50%) to assess the potential for a distal "bystander" killing effect. 
Modulation of ICso was examined. 
Additionally, parental cells were mixed with either 10%, 25% or 50% of Rd-42 cells 
and seeded at a final density of 5xIOs cells/weU (Le. confluent monolayers), allowed to settle 
overnight, and then exposed to a concentration range of the test prodrug for 24hr under 
hypoxic conditions. Cells were washed free of drug and 200 Jll of Ix trypsinlEDTA (Gibeo 
BRL) was added for 10 min. Plates were agitated vigorously to ensure a single cell 
suspension, and the plates were poured out and blotted on a pad of sterile tissue. This 
removed all but a thin film of liquid containing residual cells, so that only I>:S 1 0% of the 
original cell population remained behind. Plates were refed with fresh media and cells were 
allowed to proliferate for a further 96hr. This re-spreadingassay allowed the ICso profiles to 
reflect only the growth of the target (low-P450R) cells. Modulation of ICso was examined at 
the different ratios of target and activator cells, and when pooled, allowed the relationship 
between drug sensitivity and target/activator cell proportions to be interrelated. lFrom this, a 
value of the efficiency of bystander cell killing could be interpolated. 
In a further experiment, parental MDA-231 "marker" cells were seeded @ lxl04 
cells/well (24 well plates), and either 2xl06 Rd-42 cells (activator cells) or 2x106 parental cells 
(control cells) were seeded into a porous membrane co-culture insert (0.2 J..Lm pores). 0.5 ml 
of complete media was added to connect the two cell culture compartments in the media phase. 
Prodrug (100 J..LI) was added to the insert well, at the =- ICso concentration for the Rd-42 cell 
line, and incubated for 3hr under hypoxia. Following exposure, "marker" cells were washed 
free of drug and allowed to proliferate for 96hr. 
All exposures were carried out in a catalyst-induced anoxic chamber, and all plastic 
and media was equilibrated with the anoxic enviroment for> 24hr prior to experimentation. 
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6.3 Results. 
Sensitivity of P4S0R overexpressing cell lines to RSU 1069 under aerobic 
and hypoxic conditions in vitro. Analysis of the sensitivity of four of the P450R-
transfected MDA 231 clones to RSU 1069 was conducted, and ICso values were determined 
as previously described. As summarised in table 1, the data demonstrated a clear relationship 
between elevated P450 reductase activity and increased sensitivity to RSU 1069 under 3h 
hypoxic (slope = -1.61 ±O.22; P=0.018). However no relationship was apparent for the 3h 
aerobic (slope = -14.8 ±9.2; P=0.11) exposure conditions (Figure 15). The line of best fit for 
each relationship clearly demonstrated that elevations in P450R expression conferred hypoxia-
specific modulation ofRSU 1069 prodrug sensitivity. 
Table 1: Relationship of acute aerobic and hypoxic RSU 1069 toxicity with increasing P450 
reductase activity in the human breast adenocarcinoma cell line MDA 231. 
Clonal 
cell line 
Parental 
Rd-06 
Rd-16 
Rd-22 
Rd-42 
wtJRd42 fold-
sensitization 
RSU 1069 
(lCso JlM ± s.d.) 
Aerobic Hypoxic 
280±62 176 ± 39 
289 ±47 239 ±44 
269±66 38.8 ± 10.8 
258 ± 111 19.0 ± 5.3 
196 ±47 20.3 ± 7.0 
1.4 9.3 
Hypoxic 
cytotoxicity 
ratios 
(HeRs) 
1.6 
1.2 
6.9 
13.5 
9.7 
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Figure 15: Relationship between acute (3h) oxic and hypoxic sensitivity to the 2-
nitroirnidazole RSU 1069 and intracellular NADPH:cytochrome P450 reductase (P450R) 
activity in the parental MDA-231 breast cell line and four P450R-overexpressing clonallineso 
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Hypoxic and aerobic sensitivity of Clone Rd·42 to CD 1954 and SN 23862 in 
vitro. Due to limited material availability, CB 1954 and its nitrogen mustard analogue SN 
23862 were screened against two cell lines; the parental MDA 231 and clone Rd-42. ICso 
values were determined, from which HCRs were calculated, as before. 
Table 2: Relative sensitivity of MDA 231 wt and Rd-42 cell lines to the 2,4-dinitrobenzamide, 
CB 1954, and its nitrogen mustard analogue SN 23862 under oxic and hypoxic conditions. 
N02 0 
NH2 
02N 
ClfN\cl 
Cell CB 1954 SN 23862 
line (IC~IlI:!M ± s.d.) ~IC~IlI:!M ± s.d.) 
Aerobic HX]2oxic HCRs Aerobic H~Eoxic HCRs 
Parental 780 ±45 90±11 8.7 730 ±61 780 ±88 0.93 
Rd-42 350 ±38 9 to.6 39 630 ±58 80±1O 8.2 
1.1 9.8 
wtJRd42 fold-
2.2 10.0 
sensitization 
Although it is not possible to compare directly the relative stoichiometry of the 
relationships between increasing P450R activity and prodrug sensitivities (ICso)' with respect 
to RSU 1069 (Le. the slope of the line of best fit), it is clear that a similar oxic/hypoxic 
asymmetry emerges. Very limited aerobic sensitization occurs as a consequence of elevated 
P450R activity, with enhanced prodrug sensitivity being strongly dependent upon the hypoxic 
environment. The pattern of sensitivity between the two dinitrobenzamide analogues is 
significantly different. For the parental cell line, potency is equivalent under aerobic exposure 
conditions, but only CB 1954 produces any differential sensitivity under hypoxia (figure 16). 
This is unusual, since the majority of cell lines exhibit superior HCRs for SN 23862 when 
compared to CB 1954 (Palmer et ai., 1992). However the hypoxia-dependent sensitization 
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observed in the Rd-42 cell line is broadly similar, with a 42-fold increase in P450R activity 
producing a similar ... to-fold decrease in ICso value for both prodrugs. 
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Figure 16: Representative dose response curves for acute (3h) hypoxic and aerobic exposure 
to the aziridinyl 2,4-dinitrobenzamide CB 1954 and its nitrogen mustard analogue SN 23862 
in the parental MDA-231 and its P450R over-expressing Rd-42 clonal cell line. 
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Since SN 23862 sensitivity is not significantly influenced by P450R under aerobic 
conditions, its activation is more specific for oxygen-inhibitable reduction by P450R than CB 
1954, i.e. the HCRs for CB 1954 and SN 23862 were enhanced 4.5- and 8.8-fold by the 
presence of elevated P450R activity, respectively. This specificity, coupled with the fact that 
SN 23862 is not a substrate for human DT -diaphorase (Palmer et al., 1992), suggests that this 
agent (or a more soluble analogue) might be an,appropriateprodrug to employ in an 02 -
sensitive GDEPT strategy. In contrast, CB 1954 is a (poor) substrate for DT-diaphorase 
(Boland et al., 1991; Knox et al., 1993; Beall et ai., 1994; Chen et al., 1995c), and 
consequently the oxygen-inhibited reduction of CB 1954 might be superseded by direct two-
electron metabolism. This difference in substrate specificity is of little relevance in the MDA 
231 cell line model, since cytosolic DT-diaphorase activity is barely detectable (chapter 2). 
Confirmation of the role of P450R in the bioactivation of mitomycin C and 
Porfiromycin under aerobic and hypoxic conditions. Due to limited material 
availability, mitomycin C (MMC) and its methyl-aziridine analogue, porftromycin (POR), 
were screened against two cell lines; the parental MDA 231 and clone Rd-53. ICso values were 
determined, from which HCRs were calculated. 
Table 3: Relative sensitivity of MDA 231 wt and Rd-53 cell lines to mitomycin C (MMC) and 
its methyl-aziridine analogue, porfiromycin (POR), under oxic and hypoxic conditions. 
o 
)'-NH2 
o 
N N-CHa 
Cell MitomycinC Porfiromycin 
line (IC~1l J.1M ± s.d.~ ~IC~Q f:!M ± s.d.~ 
Aerobic Hypoxic HeRs Aerobic H~Eoxic HCRs 
Parental 10.6 3.7 2.8 1100 70 15.7 
Rd-53 2.5 0.7 3.6 180 9.3 19.4 
wtIRd53 fold-
4.2 5.3 6.1 7.5 
sensitization 
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In contrast to the nitro-prodrugs, elevated P450R activity conferred nearly equal 
sensitization to MMC and POR under both aerobic and hypoxic exposure conditions. Some 
selectivity was apparent, since the HCR values in the Rd-53 cell line were modestly increased 
for both MMC and POR. This difference in oxygen-sensitivity of activation by P450R when 
compared to the nitro-containing agents is unlikely to represent any fundamental distinction in 
the mechanism of reduction by FMN semiquinone of P450R, since the lack of a distinct 
substrate binding site precludes the possibility of any specific structure-activity relationships. 
Rather it most likely represents a distinction in the chemistry of the reduced prodrugs and their 
equilibria with molecular oxygen and their hydroquinone forms. It is possible that eviction of 
the C-9 methoxy group which preceeds intramolecular rearrangement, is sufficiently rapid to 
compete with the backoxidation of the semiquinone radical species. 
Alternatively, the rate of disproportionation of the Q" radicals to the oxidation-
insensitive QH2 may be sufficiently rapid in the localised enzyme enviroment, that oxygen-
selective activation is lost. This would result in the expression of cytotoxicity irrespective of 
the oxygen status of the activating cells. Less likely, changes in the rate of ROS generation by 
futile cycling might be nearly as cytotoxic as that derived from the enhanced activation of the 
indole quinones themselves under anaerobic conditions, particularly if redox metal ion 
availaility was good within close proximity to DNA. The observation that the differential 
toxicity of POR is significantly greater than that of MMC might also suggest that the intrinsic 
reactivity of the aziridine group is, in part, responsible for the P450R-dependent prodrug 
sensitisation in both the presence and absence of molecular oxygen. However, the relatively 
poor oxygen-sensitivity of mitomycin prodrug one-electron bioactivation, and the complex 
nature of structural rearrangement that occurs upon reduction, when coupled with the limited 
synthetic chemistry design options for novel analogue derivatives does not make this 
particular type of bioreductive prodrug an attractive model for the design of oxygen-sensitive 
trigger mechanisms. 
Hypoxic and aerobic sensitivity of P4S0R overexpresslng cell lines to E09 
and two closely related analogues lacking functionality In the C-Z and C-3 
positions in vitro. Analysis of the sensitivity of four of the P450R-transfected MDA 231 
clones to EOO was conducted, and 1C.so values were determined. In contrast to RSU 1069, 
there was a clear relationship between P450 reductase activity and increased sensitivity to BOO 
under h2th 3h hypoxic (slope = -1.87 ±O.28; P<IO-6) and 3h aerobic (slope = -7.10 ±3.0; 
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P=0.022) exposure conditions (Figure 17), although, unlike the mitomycin antibiotics, the 
aerobic sensitization was very modest. Table 4 summarises the data set. 
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Figure 17: Relationship between acute (3h) oxic and hypoxic sensitivity to the indoloquinone 
E09 and intracellular NADPH:cytochrome P450 reductase (P450R) activity in the parental 
MDA-231 breast cell line and four P450R-overexpressing clonal lines. 
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Table 4: Relationship of acute aerobic and hypoxic EOO toxicity with increasing P450 
reductase activity in the human breast adenocarcinoma cell line MDA 231. 
~N 
o 
0 
Clonal E09 Hypoxic 
cell line (ICso ~ ± s.d.) 
cytotoxicity 
ratios 
Aerobic Hypoxic HCRs 
Parental 1.34 ± 0.92 0.338 ± 0.15 4.0 
Rd-06 1.05 ± 0.29 0.449 ±O.29 2.3 
Rd-16 1.25 ± 0.43 0.136 ± 0.08 9.2 
Rd-22 0.75 ± 0.35 0.079 ± 0.05 9.5 
Rd-42 0.61 ± 0.06 0.036 ± 0.02 16.9 
wtlRd42 fold- 2.17 9.39 
sensitization 
The requirement for hypoxia in the P450R-mediated enhancement ofE09 toxicity was 
clearly apparent. The extent of this phenomenOlwas comparable to that observed with the nitro 
prodrugs. This is seen in the increasing HCR values with increasing P450R activity. 
However, while these differential toxicities for E09 were broadly similar to those of the nitro-
prodrugs, the absolute (molar) potency of EOO was approximately 500 to 1500 -fold greater 
under these exposure conditions. This potency may, in part, be a reflection of the rapid rates 
of indoloquinone disproportionation (relative to nitroarenes), but might also arise through 
fundamental differences in the nature of the DNA-drug lesions, such as the capacity for 
hydrogen bonding between the DNA bases which can, in some instances, favour the 
formation of crosslinks as opposed to single alkylations (Hartley et ai., 1991; Mayalarp et ai., 
1996). 
For the two closely related analogues of E09, lacking either the C-2 or C-3 
functionality, the tight relationship between P450R activity and hypoxic and aerobic 
cytotoxicity was still clearly apparent (table 5). However, compared to E09, both analogues 
had 5 to 20 -fold lower ICso values, indicating that both these functional leaving groups 
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contribute, in part, to the potency of E09. Yet the pattern of cytotoxicity differed from that of 
E09, with respect to the relationship with P450R activity and its relative influence on either 
the oxic or hypoxic sensitization (figures 18 and 19). 
Table 5: Relationship of acute aerobic and hypoxic toxicity for analogue 2 and 3, with 
increasing P450 reductase activity in the human breast adenocarcinoma cell line MDA 231. 
OH L::N 
OH 
0 
Cell Analogue 2 Analogue 3 
line (IC~1l ~ ± s.d.) (lC~1l J.1M ± s.d.) 
Aerobic H~Eoxic HeRs Aerobic Hypoxic HCRs 
Parental 26.5 ±3.0 3.54 ±o.90 7.5 28.7 ±9.1 8.16 ±o.lS 3.S 
Rd-06 15.1 ±S.2 2.10 ±o.5S 7.2 IO.S ±4.2 4.01 ±o.29 2.6 
Rd-16 9.9 ±2,4 O.SI ±o,41 19.4 8,4 ±l.8 1.18 ±o.08 7.1 
Rd-22 8.5 ±2.6 0.28 ±o.20 30.4 6.6 ±l.l 1.24 ±o.OS 5.3 
Rd-42 5.6 ±1.1 0.18 ±o.08 31.1 4.7 ±1.6 0.46 ±o.02 10.1 
wt/Rd42 fold- 4.7 19.7 6.2 17.7 
sensitization 
For analogue 2, lacking the C-2 hydroxypropenyl arm, the relationship between 
hypoxic ICso and P450R activity was significantly tighter (slope = -1.15 ± 0.15; P< 10.6) than 
seen for E09 (slope = -1.87), but, unlike E09, this was also accompanied by a rise in the 
aerobic sensitization by P450R (slope = -2.54 ± 0.30; P< 10.6) (figure 18). Similarly 
analogue 3, lacking the hYdroxymetbyl at the 3-position, showed a closer relationship with 
P4S0R under hypoxia (slope = -1.36 ± 0.21; P= 0.008) than E09, and again this was 
paralleled by a rise in aerobic cytotoxicity (slope = -2.23 ± 0.25; P< 10.6) (figure 19). While 
both analogues were of equivalent potency in the presence of oxygen, analogue 2 was more 
cytotoxic than analogue 3 under hypoxic conditions. suggesting that the contribution of the 
hydroxymethyl group at C-3 was greater than that of the leaving group at C-2 under these 
conditions. This perhaps reflects a difference in the energetic requirements for the movement 
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of electrons necessary to evict the respective C-2 or C-3 leaving groups and generate the 
activated alkylating species. 
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Figures 18 & 19: Comparative cytotoxicity (ICso) of the EOO analogues 2 and 3, lacking 
functionality in either the C-3 or C-2 positions of the indole ring, respectively: relationship to 
P450R activity in the MDA 231 cell line under aerobic and hypoxic conditions in vitro. 
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Hypoxic and aerobic sensitivity of Clone Rd·42 to C-5 aziridinyl.modffied 
E09 analogues; E08 and E07. Moderation of the C-5 ariridine reactivity by 
introduction of methyl group at the 2-position of the aziridinyl-ring, to produce the analogue 
E08, resulted in the lowering of the aerobic toxicity for both cell lines, without loss of 
hypoxic potency. Consequently the differential toxicity (HCR) of E08 is superior to that of 
E09 in both the parental and Rd-42 cell lines (table 6). Overexpression of P450R resulted in 
the hypoxia-selective enhancement of E08 cytotoxicity, suggesting that reduction of the 
quinone initiates a redistribution of electron density that activates the methyl-aziridinyl 
functionality. This activation of the C-S position upon one-electron reduction was more 
pronounced than for E09, where the more reactive aziridinyl moiety was not as oxygen-
inhibitable. This difference is unlikely to arise as a consequence of a change in the substrate 
specificty of E08 for the two-electron reductase DT -diaphorase since endogenous activity is 
negligible in this cell line model. The importance of the C-S aziridinyl group is further 
demonstrated with the C-S methoxy analogue E07, where a 100 to ISO-fold loss in potency, 
relative to E09, was found under both aerobic and hypoxic exposure conditions. 
Furthermore, the differential toxicity for E07 was narrowed in both cell lines, primarily 
through a loss of the oxygen-inhibitable activation by P4S0R. This agrees with the analysis of 
E08, indicating that the latent reactivity of the C-S methyl-aziridinyl group contributes to the 
hypoxia-selectivity of the indoloquinone analogues. 
Table 6: Relative sensitivity of MDA 231 wt and Rd-42 cell lines to the C-S 2-methylaziridin-
l-yl analogue, E08, and its C-5 methoxy analogue, E07, under oxic and hypoxic conditions. 
H~O 
Cell E08 E07 
line ~ICSQ JJM ± s.d.~ ~ICSQ l:!;M ± s.d·l 
Aerobic H~Eoxic HCRs Aerobic H~poxic HCRs 
Parental 4.6 ±1.0 0.40 to.08 11.S 190 ±29 S1.1 ±IS 3.7 
Rd-42 3.8 ±1.6 0.07 to.02 S4.3 2S.3 ± 21 6.1 ±O.5 4.1 
wtlRd42 fold- 1.2 S.7 7.S 8.4 
sensitization 
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Taken togetherthesedata suggests that the aziridinyl group in the C-5 position of the 
indole ring is the single most important detenninant of the absolute potency of E09, but its 
reactivity is not strongly influenced by reduction of the quinone. However, modification of 
this aziridine by addition of a methyl group lowers the intrinsic reactivity of the moiety, and in 
doing so appears to make it more responsive to the oxygen-sensitive reduction of the quinone. 
In agreement removal of the C-5 functionality (E07) lowers the HeR values and results in a 
major loss of cytotoxic specificity for oxygen-inhibitable one-electron reduction. 
Consequently P450R was almost as efficient at activating E07 under aerobic conditions as it 
was under hypoxia. 
Dependence of the hypoxia-dependent "bystander" cell kUling effect on 
cellular density in vitro. The dose-response curves generated from 100% parental 
(target), or 100% Rd-42 (activator) cells allow a measure of cytotoxicity (ICso) to be 
detennined for the three nitro-prodrugs. The ratio between the IC50 of these cell lines under 
hypoxia is the dose modification factor accompanying the elevated activation of the prodrugs. 
When activator and target cells are mixed, intermediate curves were generated, the pOSitions of 
which relative to the two extremes, is characteristic of a cross-sensitization phenomenon.The 
bystander effect of the prodrugs is a composite of the ability of the activated product to diffuse 
between cells, either through intimate cell-to-cell contact (confluent monolayers) or via the 
media phase (sparse single-cell culture), and is related to the proportion of activator cells 
present. For each defined proportion of activator cells a single ICso value is derived. This can 
then be expressed relative to the two extreme ICso detenninations to derive a value for the % 
of activator cells required to make the target cells experience 50% of their toxicity. Thus the 
proportion (%) of Rd-42 activator cells required to reduce the parental ICso value for the 
prodrug to halfway between the ICso for 100% Rd-42 cells and 100% parental cells is termed 
the "50% transmission efficiency" (TEso)' The relative TEso values thus provide a single 
comparative unit of the bystander killing efficiency for each prodrug. Application of this 
technique has been described recently in the context of E. coli NR-activated CB 1954 
bystander quantification (Friedlos et at., 1998). 
In the low density co-culture experiments in vitro only SN 23862 demonstrated any 
measurable bystander effect although this was modest (figure 20). RSU 1069 and CB 1954 
were both apparently unable to measurably cross-sensitize parental "target" cells under 
hypoxic conditions. The TEso values calculated were 50, 48 and 39 for RSU 1069, CB 1954 
and SN 23862, respectively. Thus in the case of RSU 1069, (TEso = 50), a 50:50 mix of 
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parental and Rd-42 cells was necessary to shift the ICso value by 50%, indicating the absence 
of any bystander phenomena. 
Figure 20: Comparative bystander effects of three nitro-prodrugs in sparse (5x103 ceUslweU) 
mixed populations of "marker" parental MDA 231 cells and hypoxia-dependent "activator" 
Rd-42 cells overexpressing human P450 reductase in vitro. (Broken line indicates predicted 
plot if no co-sensitization effect occurs). 
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The ability of SN 23862 to remain sufficiently stable in the media phase following reductive 
activation, was confmned in the subsequent Costar™ porous well-insert experiments. Even 
when the P450R-overexpressing cells were physically separated from the parental "marker" 
cells, the connection via the media phase was sufficient to allow transfer of prodrug sensitivity 
(Table 7). Indeed, the excess of Rd-42 activating cells (2xl06) in the porous insert inhibited 
the growth of the parental cell line slightly more than the Rd-42 cells were inhibited in the 
absense of any co-culture. Co-incubation with parental cells could not mimic this 
phenomenon. 
Table 7: Evaluation of the hypoxia-dependent "bystander" effect: Qualitative assessment of 
metabolite toxic transfer from the P450R-overexpressing cellline Rd-42 to the low expressing 
parental cell line. 
Marker cell line: Parental Rd-42 Parental Parental 
Co-culture insert cell line: Parental Rd-42 
Concn. Drug % growth of untreated control 
30 J.1M RSU 1069 85 47 87 89 
1OJ.1M CB 1954 88 49 84 78 
100 J1M SN 23862 87 46 81 37 '" 
0.1 J.1M E08 83 48 83 87 
'" Significantly different from "marker" cells alone (n= 2; P< 0.01). 
In a further experiment TE.so values were calculated using the confluent monolayer 
model (2x 1 06 cells/well) in order to identify the presence of any labile toxic metabolites that 
might confer a highly localized sensitization of neighbouring cells. In this two-dimensional 
monolayer model all three nitro-prodrugs were found to produce a hypoxia dependent 
bystander effect. TEso values of 12.7, 2.2 and 4.9 were extrapolated for RSU 1069, CB 1954 
and SN 23862, respectively (figure 21). 
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Figure 21: Comparative bystander effects of three nitro-prodrugs in confluent (2xl06 
cells/well) mixed populations of "marker" parental MDA 231 cells and hypoxia-dependent 
"activator" Rd-42 cells overexpressing human P450 reductase in vitro. (Broken line indicates 
predicted plot if no co-sensitization effect occurs). 
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Thus, in this particular in vitro model CB 1954 provided a superior bystander effect to 
that of SN 23862, despite the earlier observations that only SN 23862 could facilitate cross-
sensitization in the non-contact experiments. This suggests that the reduction product(s) of SN 
23862 are sufficiently stable to diffuse large distances in an aqueous enviroment, but by 
inference is too non-reactive to retain the effect locally in a two-dimensional bystander model. 
Consequently much of the activated drug is dissipating into the third-dimension, the large 
volume of media above the cells, limiting the potency of the cross-sensitization effect. CB 
1954, in contrast, is significantly more reactive, such that the drug exerts its effects in a more 
localised fashion. As a result the mono-layer model suggests the presence of a superior 
"transmission efficiency", which is not strictly true. In a three-dimensional tumour mass, the 
capacity to diffuse beyond the localised activation site may be an advantage, if the intention is 
to exploit the foci of acute hypoxia that occur as a consequence of vascular occlusion, 
although excessive diffusion would be undesirable. Thus the use of a three-dimensional in 
vitro model, such as spheroids, or multi-cellular co-culturing techniques (Cowan et al., 
1996), would probably provide a more accurate representation of the utility of these prodrugs 
as hypoxia-activated diffu~le cytotoxins. 
6.4 Discussion. 
6.4.1 Comparative sensitivity of the MDA 231 cell line to chemotherapeutic 
agents. 
The MDA 231 cell line was anomalous in its poor response to RSU 1069 under 
hypoxic exposure conditions. This is reflected in the very low HeR value of 1.6, which is the 
lowest value reported for any cell line evaluated with RSU 1069 (Patterson et al., 1997). This 
appeared to manifest in the limited differentials to all the other hypoxic cytotoxins evaluated in 
this study. For example, the differential toxicity for EOS was 11.5-fold in the parental cell 
line, but identical experiments in the rodent V79 cell line, revealed a HeR value in excess of 
5000-fold (Jaffar et al., 1998a). This is the highest value (by a factor of 100) for differential 
toxicity ever reported for any bioreductive indoloquinone (for comparison with other HCRs 
for indoloquinones in V79 cells see:- Moody et ai., 1994; Cotterill et al., 1994), and is in fact 
the largest published value for the oxic/hypoxic differential of any bioreductive drug to date. 
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This impressive differential is also seen, to a lesser degree, in human cell lines, where values 
upto 500-fold are seen (unpublished data). 
A possible explanation for the underlying mechanism of tolerance to these alkylating 
bioreductives can be found in the pattern of atypical resistance displays towards unrelated 
chemical cross linking agents such as cis-Platin and chloroambucil (Houlbrook et al., 1994). 
This suggests that the MDA 231 cell line is relatively competent at recognising and repairing 
DNA-DNA crosslink adducts, and this resistance is independent of the enzymology of the 
cells. However the low reductive enzyme status of the parental cell line (chapter 2) will also 
contribute to the lack of hypoxic sensitivity to bioreductive alkylating agents, as indicated by 
the trend of increasing HCRs for all agents with increasing P450R expression. 
6.4.2 Comparative utility of the nitro-prodrugs. 
All three nitro-prodrugs were oxygen-inhibited substrates for P450R, indicating they 
can act as anaerobic electron acceptors from the semiquinone flavin. The fold-sensitization 
under hypoxia was approximately equivalent for each agent in the Rd-42 cell line. Only CB 
1954 cytotoxitiy was significantly modulated by elevated P450R activity under aerobic 
conditions (2.2-fold). CB 1954 was also unique in its capacity to produce a significant HCR 
in the parental cell line. The result might imply that CB 1954 is a substrate for another 
endogenous one-electron reductase(s), while SN 23862 and RSU 1069 are not. The 
comparable sensitization of Rd-42 to the three nitro-triggered prodrugs is consistent with their 
similar one-electron reduction potentials ( -398, -385 and -371 mV for RSU 1069, CB 1954 
and SN 23862, respectively), which has been demonstrated to be the primary determinant of 
the rate of metabolism by P450R (Butler and Hoey, 1993b). However, one further possibility 
that can not be ruled out, is that the nature of the DNA-DNA crosslinks differs between these 
compounds in a complex and yet undefined manner. 
The differing patterns of sensitivity between the two 2,4-dinitrobenzamide analogues, 
SN 23862 and CB 1954, may be related to the stoichiometry of 2- vs. 4-nitro reduction by 
P450R, and its influence on DNA damage. For CB 1954, the 4-hydroxylamine reduction 
product is the potent cytotoxic agent capable of producing DNA-DNA interstrand crosslinks in 
cells, while the 2-hydroxylamine species is much less cytotoxic, and only strand breaks have 
been observed (Knox et al., 1988). Under hypoxia, P450R preferentially reduces the 4-nitro 
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group of CB 1954, with the stoichiometry of 4- to 2-amine metabolite formation being = 8: 1 
(Walton et ai., 1989). This probably reflects the fact that the 4-nitro group is the most 
electron-affinic site, and is consistent with evidence that radiolytic reduction of CB 1954 
produces clean conversion to one major product, the 4-hydroxylamine (palmer et ai., 1995). 
Experiments in hypoxic mammalian cells have also demonstrated that the major reductive 
metabolite is the 4-amine (Cliffe et ai., 1992; Simm et ai., 1997). 
Figure 22: CB 1954 - differential 2- and 4- nitro reduction by human P450R and E.coli NR 
NHOH NHa 
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Like CB 1954, the major SN 23862 metabolite formed by mammalian cells under 
hypoxic conditions appears to be the 4-hydroxylamine. although it is not known whether the 
reduction products of the 2-nitro group are recovered efficiently by HPLC (Cliffe et al .• 1992; 
Simm et ai .• 1997). However. reduction of the 2-nitro group generates the dominant cytotoxic 
species since the 4-hydroxylamine spontaneously cyclizes via intramolecular alkylation to 
generate a stable ring-closed 6-nitroquinoxaline. This represents an inactivation mechanism 
and might explain the greater potency of the 2- vs. 4-amine chemical reduction products 
(Palmer et al. 1995). 
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Figure 23: SN 23862 - differential 2- and 4- nitro reduction 
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Radiolytic reduction of SN 23862 has indentified the 4-nitro group as the most 
electron affinic site (Palmer et al. 1995), suggesting, as with CB 1954, that P450R may 
preferentially reduce SN 23862 to the 4-hydroxylamine. However, the cytotoxicity of a 2-
nitro analogue with a non-reducible (but equally electron-withdrawing) 4-methylsulfonyl 
substituent was found to be enhanced under hypoxic conditions, suggesting that endogenous 
oxygen-sensitive reductases can also reduce the 2-nitro group of SN 23862 (Atwell et al., 
1996). The comparable shift in sensitivity of the Rd-42 cell line to SN 23862 and CB 1954 
under hypoxia (9.8- and to-fold respectively), may be consistent with this proposal, and 
suggests that the putative 4-nitro reduction of SN 23862 by P450R is not a significant 
limitation. In agreement, the 4-amine metabolite was found to have a t~ = 60 min. in culture 
media (pH 7), implying that the loss of compound via internal cyclisation will not significantly 
compromise cytotoxicity. Further, since efficient cell killing within a diffusion range of 
200J.1M only requires a t~ "" 1 min, 4-nitro activation will still allow extensive tissue diffusion 
(Denny and Wilson, 1993). 
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Both CB 1954 and SN 23862 are good substrates for E.coli NR and are lead candidate 
prodrugs for both NR-based gene and antibody directed prodrug activation therapies (Knox et 
al., 1993; Anlezark et ai., 1995). Significant differences in metabolite profiJes are observed 
with the NR activating system compared to that of P450R. E.coli NR reduces either nitro 
group of CB 1954 to its corresponding hydroxylamine with equal efficiency, such that only 
50% of metabolism is therapeutically relevant. In contrast the only detectable NR-metabolite 
of SN 23862 is the cytotoxic 2-hydroxylamine product (Anlezark et al., 1995; Friedlos et al., 
1997). Thus SN 23862 is currently being developed as a superior candidate E.coli NR-based 
GDEPT prodrug, although its clinical application is hampered by poor aqueous solubility. The 
addition of various hydrophilic side chains to SN 23862 has provided improved aqueous 
solubility (Palmer et ai., 1994), but analogues either retained hypoxic selectivity yet were no 
longer substrates for E.coli NR, or were highly activated by the enzyme but became poor 
hypoxic cytotoxins (Anlezark et al., 1995). 
6.4.3 Comparative efficiency of E. Coli Nitroreductase and human P450 
reductase as nitro-prodrug activators. 
Considering the contrasting metabolic preferences between P450R and NR with 
respect to both CB 1954 and SN 23862, it is perhaps relevQI1t to compare their experimental 
utility as nitro-prodrug activators. Three publications, to date, have employed ICso ratios in 
NR-expressing and non-expressing cells to provide a composite measure of the degree of 
reductive metabolism due to the enzyme and the relative cytotoxicities of the prodrug and its 
activated form (Green et ai., 1997; Friedlos et al., 1997; 1998). Although variations occur in 
the cell line usage, the type of strong viral promoter driving transcription of the NR cDNA (in 
all cases CMV early immediate gene promoter) and the duration of prodrug exposure (24 or 
72hr), broad comparisons are possible if several loose assumptions are made. Firstly we must 
ignore intrinsic differences in sensitivity between the various cell lines, although the published 
ranges of NR ICso ratios provide some measure of the variation. Additionally, the comparison 
must assume the strength of the CMV (NR) and ML V L TR (P450R) promoters are roughly 
equal and both therapeutic proteins are expressed at equimolar levels. Since the background 
NR activity is nil in the parental cell lines, this is comparable with the ICso values for parental 
MDA 231 cells following a 24h prodrug exposure under aerobic conditions (i.e. P450R· 
dependent activation is negligible), while the Rd-42 dose-response experiments were 
performed under 24h hypoxia. The absolute ICso ratios for oxic parental vs. hypoxic Rd-42 
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were 221 and 39-fold for 24h CB 1954 and SN 23862 exposures, respectively. This 
corresponds to ICso values of 288 !JM vs. 1.3 !JM for CB 1954, and 446 JlM vs. 11.6 JlM for 
SN 23862 (results not shown). Freidlos et al. (1997) found ICso ratios for 24h exposure in 
V79 cells of 177 and 63-fold for CB 1954 and SN 23862, respectively. Similar ICso 
comparisons in WiDr and SKOV-3 (human colon carcinoma and ovarian carcinoma cell lines) 
gave values of 52 and 225-fold for CB 1954 (Frieldos et al., 1998). In a series of 72h 
exposure experiments, Green et al. (1997) recorded ICso ratios for 72 h exposures in NR-
positive and negative paired cell lines ranging from 17 to 517-fold (4 cell lines). No measure 
of catalytic activity was performed on these NR-expressing cell lines and the Kca, for these 
substrates has not been determined for P450R, so a more direct comparison is not possible. 
Nevertheless, this simplified approximation of the relative modulations in cytotoxicity 
conferred by. therapeutic gene transfection and stable intracellular expression serves to illustrate 
the similar utility of the two enzymes as nitro-prodrug activators. The TE.50 values calculated 
for P450R under hypoxia were also broadly similar to those seen for aerobic NR-dependent 
activation (Freidlos et al., 1997; 1998), further iIl/lstrating the comparisons between the two 
prodrug-activation strategies. 
6.4.4 Indole quinones as prodrug triggers. 
All the indolequinone analogues were oxygen-inhibitable substrates for P450R, 
indicating they are efficient single-electron acceptors from P450R. The hypoxia-dependent 
. sensitization in the Rd-42 cell line was variable among the five analogues; ranging from 5.7-
fold for E08 to 19.7-fold for analogue 2. However, elevations in P450R activity (eg. Wt vs. 
Rd-42) also influenced the aerobic cytotoxicty of the indolequinone-prodrugs, although this 
was less pronounced than seen under hypoxia, and varied from 1.3-fold for E08 to 6.2-fold 
for analogue 3. Importantly, the modifications that remove anyone of the three functional 
groups will reduce the number of reactive sites on the molecule, but may also change the 
reactivity towards DNA, and the fmal profile of cytotoxic lesions. However, it must also be 
considered that these differences may, in part, reflect changes in the rate at which the radical 
species of these indolequinone analogues disproportionate in relation to their oxygen 
sensitivity. 
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Under hypoxia, after one or two electron reduction. the hydroquinone and 
semiquinone forms of EOO exist in equilibrium. with the equilibrium greatly favouring the 
hydroquinone (~ > 4000. pH 7.4) (Butler et al .• 1996): 
The rate constant is independent of the radical concentration in the range 1.0 - 5.2 J.1M and 
quinone concentrations upto 2.0 mM. However. this eqUilibrium would not be anticipated to 
be of significance in cellular systems under hypoxic conditions. Although it is possible that 
two semiquinones could react together and form a hydroquinone and a regenerated parent 
quinone, it is unlikely to be important at the very low nanomolar concentrations of drug 
required to kill cells (Butler et al., 1996). The semiquinone radical. E09", decays in the 
absence of oxygen over a period of milliseconds, in a dose dependent manner. In the presence 
of oxygen, E09-- is unstable and is rapidly oxidised: 
where K,,4E09 = 1.3 ± 0.15 x 108 M-I S-I 
These two rate constants are relatively similar, suggesting that spontaneous QH2 formation by 
radical disproportionation might compete with backoxidation, thus rendering the one-electron 
reduction of the parent quinone potentially oxygen-insensitive. However, the vast molar 
excess of molecular oxygen over Q" in aerobic tissues ensures that backoxidation effectively 
out competes the possibility of radical disproportionation. 
6.4.5 Comparative electrochemistry of the C-2 and C-3 positions or the 
indolequinone nucleus 
A significant result was the fact that removing of the C-2 group (analogue 2) to 
generate a bi-functional agent. enhanced the hypoxia-dependent relationship between P4S0R 
activation and cytotoxicity. when compared to the tri-functional parent compound BOO (19.7 
and 9.4-fold respectively). This was reflected in the improved HCR values for analogue 2, 
which were amplified with increasing P450R expression. Taken together with the observation 
that analogue 2 was more potent than analogue 3 under hypoxia, the data suggests that the 
contribution of the hydroxymethyl group at C-3 was greater than the leaving group at C-2 
under these conditions. Since both analogues are hi-functional, this difference may reflect the 
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ease by which a Michael-type elimination can initiate from the activated nitrogen in analogue 2 
(figure 24). rather than the more dramatic movement of electrons from the semiquinone radical 
intermediate that is necessary to evict the leaving group (i.e. water) from the of 
hydroxypropenyl group of analogue 3 (figure 25). 
DNA will behave as a nucleophile and attack the methide electrophile on the C-3 arm. 
Consequently the radical will alkylate DNA (Moody et al., 1994.) If an aziridinyl group is 
present in the C-5 position it will rapidly react with the DNA to generate a DNA-DNA 
crosslink, believed to be the dominant cytotoxic lesion (Bailey et al., 1994; Maliepaard et al., 
1995). 
Figure 24: Proposed elimination of water from the C-3 hydroxymethyl group following the 
one-electron activation of analogue 2. 
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Figure 25: One-electron activation of analogue 3: Initiation of the elimination process from the 
semiquinone radical in order to evict water from the hydroxypropenyl C-2 group. 
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Interestingly, pulse radiolysis studies have suggested that the loss of the leaving group 
from a bioreductive quinone occurs only upon two-electron reduction to the hydroquinone and 
not at the level of the semiquinone radical (Wilson et al., 1986). Yet a dichotomy is apparent 
between the chemical literature, where conditions favouring two-electron reduction are studied 
and alkylation mechanisms involving the hydroquinone have generally been proposed, and the 
biological literature, where most enzymes responsible for quinoid reduction transfer only a 
single-electron and mechanisms involving semiquinone formation leading to alkylation have 
been proposed. Since a quinone activated by an initial single-electron reduction will be in 
rapid equilibrium with its hydroquinone form, the difference may be more apparent than real. 
Recent evidence has suggested that the hydroquinone form of E09 is unstable in air (t~ = 1.5 
sec), resulting in the formation of the parent compound and H20 2 (Butler et al., 1996): 
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Radiolytic reduction studies of a number of 5-methoxy analogues have conflrmed that 
a range of leaving groups located in the C-3 position undergo efficient Michael-like 
elimination, while the C-2 position fails to function as a site for elimination (Jaffar et al., 
unpublished observations). Furthermore, the efficiency of elimination from the C-3 position 
can be related to the pKa value of the leaving group. 
These results taken together with the in vitro cytotoxicity data, suggest a model by 
which a diffusible cytotoxin can be linked to the indolequinone nucleus, so as to remain latent 
until the compound is reduced under anoxia to the semiquinone radical form. Utilisation of a 
cytotoxic leaving group with both a desirable pKa value, and an inherent latency as a 
consequence of electron withdrawal (eg. an aliphatic nitrogen mustard), will ensure that futile 
cycling of the indolequinone in the presence of oxygen does not result in the inappropriate 
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release of the "effector". The very rapid kinetics of backoxidation of semiquinones ensures the 
hypoxia specificity of this process (Wardman et al., 1995; Bulter et al., 1996). 
Figure 26: Proposed model for exploiting the indolequinone nucleus as an oxygen-inhibited 
"trigger" to release an oxygen-insensitive diffusible cytotoxin. 
o 
6.4.6 Avoiding aerobic bioactivation 
An important aspect of this model is to develop indolequinone prodrugs that will not 
be substrates for the two-electron reductase, Dr -diaphorase. Critically, metabolism by this 
enzyme will diminish the specificity for hypoxia cytotoxicity, and as discussed earlier, may 
actually confer protection from EOO cytotoxicity under hypoxia (Plumb et al., 1994b). The 
observations of increased expression of OID following acute hypoxia (Yao et al., 1994) 
suggest a potential conflict could arise in hypoxic tissues if the hypoxia-targeted prodrug is 
significantly metabolised by OTO. Moreover, the high basal levels of DID activity found in 
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normal human tissues such as the kidney, stomach, breast and colon (Schlager and Powis, 
1990; Riley and Workman, 1992; Belinsky and Jaiswal, 1993; Smitskamp-Wilms et al., 
1995, 1996), clearly constitutes a major problem when attempting to selectively target 
bioreductive drug metabolism to tumour tissues. The intrinsically high DTD levels in the 
human kidney may account for the nephrotoxicity observed in Phase I trials of E09, with 
proteinuria being the dose-limiting toxicity (Schellens et al., 1994). Similarly, the very high 
DTD activity in stomach and colon tissues of the mouse (Schlager and Powis, 1990) might be 
related to the dose-limiting gastrointestinal toxicity observed with E09 in murine studies 
(Hendriks et at., 1993). Additionally, DID (and other phase I and/or phase II enzymes) is 
strongly induced (upto 300-fold) by a wide variety of chemical agents and dietjy constituents 
including dioxin, polyaromatic hydrocarbons, azo dyes, flavonoids. diphenols, 
isothiocyanates, dithiolthiones and thiocarbamates (Prochaska et al., 1985: Prochaska and 
Talalay, 1988). It is thought that the induction of DID is regulated, in part, by promoter 
elements including the antioxidant response element (ARE) (Li and Jaiswal, 1992a; Belinsky 
and Jaiswal, 1993). 
The problem of tissue selectivity is perhaps illustrated by the clinical history of the 
aminoquinone antibiotic, streptonigrin, which is an exellent substrate for human DT-
diaphorase (Beall et al., 1994; Ross et ai., 1996) and was shown to have the best correlation 
between DT -diaphorase activity and cytotoxicity of over 31,000 compounds tested in the NCI 
human tumour cell line panel (Fitzsimmons et al., 1996). Streptonigrin given either 
intravenously or orally was evaluated against a wide range of human tumours and at the 
maximum tolerated dose produced objective responses only in patients with lymphoid 
. malignancies (Review: Kremer and Laszlo, 1975). However the high degree of toxicity, in 
the form of severe nausea and vomiting and life-threatening delayed bone marrow 
suppression, led to its abandonment for clinical trial (Humphrey and Blank, 1961). 
The design of indoloquinone prodrugs that are not metabolised by DT -diaphorase has 
already been partially achieved through modification of the aziridine at the C-5 position (Rs)' 
Both B08 and E07 are poor substrates for DT -diaphorase, and are reduced 7.6 and 13.1-fold 
less efficiently than E09, respectively (table 7) (Jaffar et ai., 1998a). These changes in D1D 
substrate specificity (and aerobic cytotoxicity) might in part reflect changes in the two-electron 
reduction potentials of these compounds, but more likely suggest the introduction of marked 
sterle hinderence effects at the active site of DTD. 
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Table 7: E09 and four related analogues: Substrate specificity for human DT-diaphorase and 
one-electron reduction potentials at pH 8.5. 
Indoloquinone Specific activity Es.s(l) 
analogue (J.lM I min I mg) (mV) 
E09 19.90 + 0.50 - 265 
Analogue 2 52.78 ± 0.93 - 277 
Analogue 3 41.59 ± 1.08 - 276 
E08 1.52 ± 0.14 - 284 
E07 2.62 ± 0.93 - 309 
More recent work has also identified the C-2 position of the indoloquinone backbone 
(R2) as an important detenninant of DID substrate specificity (data not shown), and several 
analogues have been identified that are either exellent or poor substrates for this enzyme 
(Specific activity DID 127 - 0.3 J.lMIminlmg). In general terms, introduction of a bulky 
chemical moiety, such as a phenyl group can markedly increase DID specificity. These 
modifications can also incorporate increased aqueous solubility into the structural design, and, 
importantly, can improve the pharmacokinetic stability of the parent molecule in murine 
studies (chapter 7). 
6.4.7 Role of the C-5 position in determining potency and enzyme specificity 
Since the C-5 aziridinyl is the major contributor to the potency of the indoloquinone 
analogues (Bailey et al., 1992; Phillips 1996; Naylor et al., 1997; Jaffar et al., 1998a, 
1998b), it may be desirable to remove this reactive group when designing a non-toxic trigger 
molecule for the release of a cytotoxic effector. In this respect it is fortuitous that the 
displacement of the aziridinyl for a methoxy group not only renders the compound a poor 
substrate for DT -diaphorase, but also favourably raises its one-electron reduction potential. In 
the case of the C-5 methoxy, E07, potential alkylating functionality is still retained at both the 
C-2 and C-3 positions, and this is necessary to achieve any appreciable hypoxia-specific 
cytotoxicity. Since modification of the C-2 group (or replacement with a non-alkylating 
group) will prevent the molecule from crosslinking DNA, it effectively lowers the HCR of the 
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indolequinone nucleus (Jaffar et al., 1998a). Thus the cytotoxicity arising as a consequence of 
futile cycling of the semiquinone I hydroquinone in the presence of oxygen becomes as 
significant as that resulting from monoalkylation by the indoloquinone itself. 
Table 9: Sensitivity ofV-79 cells to E07 and its mono-substituted regioisomers in the C-2 and 
C-3 positions. (From: Jaffar et al., 1998a). 
E07 
Regioisomers Oxic Hypoxic HeR 
H3CO OH 851 30 27.8 
~ 
0 
OH 
0 
H3CO 
~ 
500 30 16.7 
0 
OH 
0 
H3CO~OH 220 240 0.9 I I ' N 
o \ 
0 
H3C0V;{ OH 633 430 1.5 I I ,--' 
o ~ 
o ~OH 
H3CO~ -I I ~ 360 260 1.4 
N 
o \ 
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The low potency of the 5-methoxy analogue ofE09 enables the linkage of an effector, 
such as a mustard, which is == 500-fold more cytotoxic than the trigger. For example the acute 
(3h) aerobic ICso value for E07 in the V -79 cell line is 850 J..lM, while the ICso for acute (3h) 
hypoxic ICso is 30 ~ (i.e. HCR= 27.8), (Jaffar et al., 1998a). This compares to the ICso 
value (3h) for a proposed phosphoramide dichloro-mustard leaving group of 1.7 J1M, in this 
cell line. Alternatively, bromo- and iodo-mustard effectors could be utilised, since they are 50 
to 75-fold more potent than their corresponding chloro-mustards and can transmit their 
toxicity to neighbouring cells with much greater efficiency in vitro (Friedlos et al., 1997). It 
might be argued that if the trigger itself is highly potent but non-diffusible, it will 
preferentially kill the transfected cells that are overexpressing the reductive enzyme in vivo, 
compromising the production and distribution of the diffusible effector, and perhaps limiting 
the therapeutic window of prodrug administration. Modification of the C-5 position with other 
inactive moieties is currently being studied since it appears to be an important determinent of 
both DID substrate-specificity and by implication, the aerobic (normal tissue) cytotoxicity. 
In agreement with these observations, the importance of the C-5 position for 
determining both DID substrate specificity and aerobic cytotoxicity has recently been 
confirmed (Phillips, 1996) and is in broad agreement with earlier findings (Bailey et al., 
1992). Structure-activity studies (Phillips, 1996) demonstrated than relatively minor changes 
at C-5 can have a major effect on both DID substrate specificity and aerobic potency. Of six 
E09 analogues evaluated, only two retained specificity for human DID. Of particular 
relevOtlce, replacing the aziridine ring of E09 with a phenyl-amino group (-NHC6Hs) lead to 
the total inability of purified human DID to metabolise the analogue and complete loss of 
aerobic cytotoxicity. In contrast, replacing the hydroxyl group in the C-2 position ofE09 with 
the phenyl-amino group had little effect on DID substrate specificity and did not influence 
aerobic potency. The potential contribution of one-electron reductases to metabolism and the 
HCR values of these analogues were not reported. 
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6.4.8 Chemical and biological factors relevent to the design of appropiate 
quinone-triggered diffusible prodrugs 
It may be advantagous to retain the potency of the bioreductive trigger in the design of 
a hypoxia-activated diffusible cytotoxin. The utility, for example, of the methyl-aziridinyl 
group (EOS) in lowering the substrate specificity for DT-diaphorase while retaining specificity 
for activation by one-electron reduction might be, in principle, a desirable property. An 
analogue of E08 supporting a latent diffusible cytotoxin in the C-3 position, would function 
both as a conventional quinone methide precursor and as a hypoxia-activated trigger for a 
diffusible cytotoxic effector. This would allow the trigger-effector combination to target both 
the hypoxic and aerobic compartments of a tumour mass, and might have significant utility 
when combined with ionising irradiation. Thus a bioreductive trigger can have a dual role; the 
potent trigger ensures that the radio-resistant acute hypoxic subpopulation of a solid tumour is 
targeted, while its oxygen-sensitive electrochemistry colaterally exploits the unique 
physiology of the tumour to release a diffusible cytotoxin. Lethal exposure of the hypoxic 
cells to the trigger unit, while eventually manifesting itself as a loss of clonogenicity, should 
not compromise the short term metabolic functions of cells. The ability to maintain metabolic 
integrity and successfully divide several times following lethal free radical damage is a well 
documented property of neoplastic cells (Hall, 1994). 
The key requirements of a novel co-therapeutic trigger-effector design is that the 
effector unit must be significantly more potent than that of the trigger under aerobic 
conditions, and ideally the trigger should have a large HeR value. This is necessary to allow 
the administration of therapeutically relevant doses of the compound, with respect to the 
released effector function. In the case of E08, this is made possible by adapting the linker arm 
that inactivates the effector, in order to limit the aerobic potency of the quinone but retain 
toxicity following eviction of the leaving group. This is readily achieved by manipulating the 
energetics of electron redistribution through the linker, coupled with an appropriate electron-
affinity for the effector i.e. its willingness to leave (pKa). The design principle of the linker is 
exemplified in the loss of aerobic potency for both of the hydroxypropenyl substituted EOS 
regioisomers in the rodent V-79A cell line (Jaffar et ai., 1998a). Thus it should, in principle, 
be possible to design novel analogues of E08 that retain the impressive HeR, while reducing 
the aerobic potency of the molecule. 
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Table 9: Sensitivity of V -79 cells to EOS and its mono-substituted regioisomers in the C-2 and 
C-3 positions. (From: Jaffar et al., 1998a). 
E08 IC~g H!M~ 
Regioisomers Oxic Hypoxic HCR 
~N OH 57.7 0.011 5245 
~ 
0 OH 
~N 
0 
153 5.6 27.2 
N ~ 
0 \ OH 
~N&.OH 4.4 0.18 24.4 I I ' N 
o \ 
~N~-YH 54 1.8 30.0 
o \ 
~ 0 r-0H 276 13.1 21.1 NV,'> -
o \ 
The C-5 methyl-aziridine, although considerably less active than the aziridine 
functionality of E09 under aerobic conditions, still dominates in determining the potency of 
EOS under both aerobic and hypoxic conditions. Therefore other modifications have been 
considered to improve the aerobic latency of the 5-position, including utilising alternative 
chemistry to provide inactivation of the aziridinyl group. One example is the use of a mono-
functional nitrogen mustard. These aspects of trigger design are currently being studied, and a 
schematic representation of the one-electron activation pathway is shown in figure 27. 
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Figure 27: Schematic representation of an indoloquinone based, dual-function hypoxic 
cytotoxin and hypoxia-activated diffusible cytotoxin. 
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In this example R3 could be a phosphoramide or aliphatic nitrogen mustard, while R2 
can be a hydrophilic side chain which does not function as a leaving group, but importantly, 
contributes to both substrate specificity and pharmacokinetic stability. One significant 
limitation in the rational design of indolequinone based hypoxic cytotoxins with additional 
diffusible leaving groups. is the lack of predictability regarding the structural requirements 
essential in the generation of exclusive one-electron reductase substrates. This has been 
exemplified for a series of E09 analogues, where relatively minor structural changes have 
resulted in major changes in substrate specificity for human DT -diaphorase, which were 
strongly interrelated with similarly dramatic modifications of aerobic cytotoxic potency 
(Phillips, 1996). Consistent with the lack of predictability, no correlation was found between 
reduction potential and rates of reduction by DT-diaphorase for a series of naptboquinones 
(Buffington et al., 1989) or a series of aziridinylbenzoquinones (Gibson et al., 1992). 
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Resolution of the X-ray crystalbgraphic structure of human DT-diaphorase will aid in the 
design of indoloquinone analogues that do not conform with the catalytic requirements of this 
enzyme's active site. So far the crystal structure of rat liver DT -diaphorase has been 
determined to 2.1A resolution and is published in preliminary form (Li et al., 1995). 
Despite the lack of predictability, early DID structure-activity studies have provided 
insight into the importance of the C-3 position (leaving group) chemistry. Any increases in 
bulkiness of R3 renders the indolequinone a poorer substrate for human DID. This is a 
desirable property in view of the large effector groups that would be desirable in this position. 
Table 10: Influence of R3 on DT -diaphorase specificity of 5-methoxy-[1H-indole-4,7-dione). 
HsCO 
OH 
CI 
OCOAr 
OCOAr' 
OCOAr" 
OAr 
Ultimately, the application of this knowledge in rational prodrug design, when coupled with 
the minimal design constraints necessary to for these agents to be oxygen-sensitive electron 
acceptors, will guide the enzyme-directed prodrug synthesis programme and may yet prove 
fruitful. 
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Chapter 7 
7. Discussion. 
7.1 The potential clinical role of gene therapy in local disease control. 
The need for local control in the cure of cancer remains a matter of crucial importance. At 
diagnosis approximately 70% of patients have no detectable distant metastasis and over half are 
cured by loco-regional treatment only (Brady et al., 1990). Since '/3 of patients die as a 
consequence of failure to control loco-regional disease (Suit, 1982), therapeutic strategies 
aimed at this patient sub-population are a source of potential progress. 
Importantly, securing local control is related to the reduction in the incidence of 
metastatic spread, since local residual disease may constitute a nidus for distant dissemination. 
This has been observed for several types of cancer including; breast (Tubiana et al., 1986), 
cervix (Anderson and Dishe, 1980), prostate (Fuks et al., 1991) and head and neck (Leibel et 
al., 1991). For example, in breast cancer the probability of distant dissemination increases 
from 15% to 75% when the diameter of the tumour increases from 1.5 cm to 5.5 em 
(Koscielny et al., 1985). Thus clinical evidence suggests that local recurrence is a step on the 
path to metastatic spread, and therapeutic progress will come from the introduction of more 
effective local control. 
In western Europe and the USA (DeVita, 1983), of the patient sub-population that 
present with localised disease, approximately 22% are cured by surgery, 18% by radiotherapy, 
but only 5% by chemotherapy. This is despite the development and clinical exploitation of a 
wealth of novel chemotherapeutic agents in the last 20 years. These disappointing figures, 
result in part, from the fact that surgery and radiotherapy are localised regimens, whereas 
chemotherapy is a systemic treatment and its toxicity, particularly against bone marrow, limits 
the tolerated doses of drug that can be administered. This inevitably leads to sub-optimal 
concentrations, particulary in tumour cell sub-populations with acquired or intrinsic resistance. 
Such resistance is multi-factorial (chapter 1), and a recognised component of these 
mechanisms is the presence of areas of low oxygen tension within the solid tumour mass 
(Gatenby et al., 1988; Hockel et al., 1991; Vaupel, 1991). Tissues within this micro-
enviroment can frequently remain viable, contributing significantly to both radio- and chemo-
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resistance (Gatenby et al., 1988; Hockel et al., 1993; Okunieff et al., 1993; Teicher, 1994). 
As a result, cells within this aberrant enviroment may ultimately become active clonogens, 
which repopulate the tumour and facilitate the relapse of a multidrug-resistant cancer phenotype 
(Review: Kallinowski, 1996). 
Therefore, therapeutic strategies aimed at delivering acute localised concentrations of 
cytotoxic agents to these clinically resistant solid tumour sub-populations, without concurrent 
systemic complications, could represent a fundamental clinical gain, improving not only the 
efficacy of chemotherapy treatments but overall patient quality of life. "Targeted" 
chemotherapy is possible through an understanding of the role of potential therapeutic 
enzymes and the inert prodrugs that they can metabolise (Senter et al., 1993). If such 
knowledge is complemented by tissue-specific expression stategies, to localise production of a 
therapeutic protein only within a defined tissue enviroment, such selectivity can be achieved. 
In addition, the successful application of molecular chemotherapy in cancer will require high 
level gene expression in a tumour-specific manner, ideally combined with highly selective 
therapeutic gene delivery (Anderson, 1984; Spooner et al., 1995; Anderson, 1998). The 
efficient delivery of therapeutic DNA is becoming a realistic possibility through advances in 
the efficiency of gene delivery to tissues, utilising techniques such as "gene-gun" inoculation 
(Cheng et al., 1993), lipofection (FeIgner et al., 1987), virus-mediated delivery systems (Vile 
and Russell, 1994), receptor-mediated endocytosis (Cristiano et al., 1993) and replication-
incompetent adenovirus co-internalisation (Cotten et al., 1992). Some of these delivery 
strategies have resulted in favourable increases in the amplitude of tumour-specific gene 
delivery and subsequent expression, a factor that has clear implications for any therapeutic 
enzyme based prodrug treatment. 
7.2 The potential to target metastatic disease. 
Several lines of evidence suggests that micrometastasis can potentially contain regions of 
hypoxia that can stimulate neovascularisation and initiate the capillary networks necessary to 
provide an adequate nutrient supply (Craft and Harris, 1994; Weinsat-Saslow and Steeg, 
1994; Folkman, 1995). However a major limitation in the application of oxygen-sensitive 
GDEPT to disseminated disease is the ability to efficiently deliver therapeutic DNA. Yet in 
some cases it may prove possible to deliver therapeutic genes through cell surface receptors, 
such as the epidermal growth factor receptor (EGFR), which can be upregulated by low tissue 
p02 (Laderoute et al., 1992a; 1992b). DNA delivery via EGFR-mediated endocytosis 
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(Cristiano and Roth, 1996; Michael and Curiel, 1994), or through ligand-directed retroviral 
targeting (Chu et aZ., 1994; Han et aZ., 1995; Cosset and Russell, 1996) might then target 
metastatic disease that is susceptible to periods of transient hypoxia. Alternatively, anaerobic 
spore-forming bacteria such as the CZostridium genus could be employed to provide hypoxia-
specific therapeutic gene delivery (Minton et aZ., 1995; Fox et az', 1996b). 
These hypoxia-responsive gene delivery approaches could be complemented with the 
utilisation of alternative splicing, such as observed for CD44 isoforms (Reviews: East and 
Hart, 1993; Zoller, 1995). The CD44 variant isoforms (CD44v) can promote the metastatic 
behaviour of cancer cells, and strategies that incorporate the alternative splice control elements 
into therapeutic gene constructs can target preferential pre-mRNA processing of therapeutic 
gene/CD44 chimeras to metastatic cells (Asman et ai., 1995; Cooper et ai., 1996). 
7.3 Cytochrome P450 reductase as an oxygen-sensitive prodrug activator. 
Among the potential oxygen-sensitive mammalian reductases, P450R is the most 
clearly characterised with respect to the biochemical specificity of one-electron transfer, and 
this is reflected in the wealth of publications identifying its role in the hypoxia-specific 
activation of a wide range of bioreductive prodrug substrates. The unique chemistry conferred 
by the presence of two cooperative flavin prosthetic groups (Vermilion and Coon, 1978a), 
provides a distinction between P450R and other flavoenzymes such as aldehyde oxidase, XC, 
XDH and BsR. These latter reductases contain only a single FAD unit as the proximal redox 
centre (Rajagopalan and Handler, 1967; Iyanagi, 1977), and appear to utilise this prosthetic 
group as both the electron inlet and outlet site when reducing artificial electron acceptors 
(prodrugs). Since the reaction of NADH with FAD is an obligatory two-electron reduction, 
FADH2 is, by implication, the immediate product (Kanda et aZ., 1972; Powell and Bruice, 
1983a, 1983b). The subsequent outcome of a one- vs. a two-electron reduction of a 
bioreductive prodrug will then depend upon the redox enviroment of the flavin within its 
polypeptide microenviroment, the resulting equilibrium between the flavin semiquinone and 
hydroquinone forms and their stability with respect to autooxidation. The implication must also 
be that cofactor and drug substrate will be in direct competition for the same redox site in the 
enzyme. In contrast, P450R accepts two-electrons from NADPH at the FAD prosthetiC group, 
whereas FMN transfers electrons to the acceptor, through the stable FMNHe semiquinone 
form (Vermillion and Coon, 1978b; Yasukochi et aZ., 1979). The necessity for intramolecular 
electron transfer in order to facilitate single-electron availability is suggested by the fact that 
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FMN-depleted P450R, while readily reducible by NADPH, is unable to transfer an electron to 
quinone acceptors (Vennillion and Coon, 1978b). This is in agreement with kinetic studies on 
the individually encoded and expressed domains of P450R, where the truncated FAD-
containing domain of P450R is rapidly reduced by NADPH, but can not in turn reduce model 
quinone substrates such as menadione (Smith et al., 1994). The unique redox chemistry of 
P450R, coupled with an inherent flexibility in prodrug metabolism provided by its capacity to 
donate an electron to any artificial acceptor with an appropriate reduction potential, makes 
P450R a promising candidate for oxygen-sensitive GDEPT. 
The potential for therapeutic gain following the introduction of a P450R-expressing 
therapeutic construct will depend in part upon the backgroundlevels of endogenous P450R, as 
well as the presence of tissue hypoxia. Tumour hypoxia, and the ability to manipulate it, has 
been discussed in chapter 1. The contribution of other reductive enzymes, such as CYP450 
and DTD, may also playa role in detennining tissue specificity, but this may depend upon the 
choice of prodrug substrate. However, currently only limited information regarding reductive 
enzyme expression in human solid tumours is published. 
P450R appears to be widely distributed in human tissues. This has been documented 
immunohistochemically in the liver acinus, enterocytes of the small intestine and colonic 
epithelial cells, pancreatic ductal cells and a number of cellular types in the lung and kidneys. 
This distribution was similar to that found in laboratory animals but the reductase localisation 
in the kidney was more extensive in humans than that seen in the rat, guineapig and rabbit 
(Hall et al., 1989). In the presence of sufficient oxygen, the broad normal tissue expression of 
P450R should be of little therapeutic relevence with respect to the specificity of targeted 
prodrug activation. 
Rampling and colleagues (1994) conducted reductive enzyme profiling for P450R, b.sR 
and DID in human malignant gliomas, revealing a broad spectrum of activities. with values 
ranging by 8, 11 and 18 fold respectively. A similar heterogeneity in functional P4S0R activity 
was documented in the primary breast biopsies. Immunohistochemically, the staining for 
P450R appeared to be greater in the peritumoural normal tissues, suggesting down-regulation 
in some samples (chapter 3). However P450R activities of paired normal tissues was not 
conducted. Interestingly, the reduction in P450R expression has also been documented in a 
chemically-induced lung tumour model, with reductions in expression being associated with 
advancing stage and progression of the lung neoplasia (Forkert et ai., 1996). Reduced 
expression of P450 reductase relative to the adjacent normal tissues has been reported in 
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human primary and secondary liver tumours (Philip et al., 1994). Thus, the available data 
would suggest that significant scope may exist for the re-introduction of high P450R activity 
into hypoxic tumours for therapeutic gain. 
The CYP450 system exhibits a more limited and tissue-specific expression pattern. A 
distinctive pattern of CYP450 down-regulation has been reported in human primary and 
secondary liver tumours, showing reduced expression of CYP450 isozymes lAl, 2A6, 2B6, 
2C8/9, 3A4, and 4A, relative to the adjacent normal tissue (Philip et al., 1994). Similarly, de 
Waziers et at. (1991) found significant decreases in CYP450 3A4 in human colonic tumours 
compared to adjacent nonnal tissues, with CYP450 IAI, IA2, 2C8/10 and 2EI being 
undetectable by western blotting in either tumour or nonnal tissue pairs. Further evidence for 
the low level of CYP450 in human tumours has been found by Forrester et al. (1990). They 
compared the expression of CYP450 in 41 breast cancer samples relative to the surrounding 
nonnal tissues. Only CYP450 2C was detected by Western blot analysis, with no CYP450 
lA2, 2A6, 2B6, 2D6 and 3A immunoreactivity being apparent. In contrast to western blotting 
results, staining of tumour sections revealed significant CYP450 3A immunoreactivity. 
In some cases, CYP450 has been shown to be expressed in human tumours without 
any expression in the adjacent nonnal tissues. Murray et al. (1993) immunohistochemically 
detected CYP450 in a series of tumour samples without revealing any staining of the matched 
normal tissue samples. In breast cancer, 39% were found to be positive for CYP450 lA and 
22% for CYP450 3A, whereas 70 and 78% were found to stain positively for CYP450 lA and 
3A respectively in soft tissue sarcomas (Murray et al., 1993a; 1993b). Recently this group also 
showed neoplasia-specific staining for CYP450 1 B 1 in a wide range of human tumour 
samples, again without any detectable immunoreactivity in adjacent normal tissues (Murray et 
al., 1997). 
In general DTD activity is higher in tumours than the surrounding nonnal tissues (Ross 
et al., 1993; 1996). Schlager and Powis (1990) showed that elevated levels of this enzyme 
have be found in primary colonic, breast and lung carcinoma as well as human hepatoma, 
whilst renal cell and gastric adenocarcinomas had low DTD activities compared to adjacent 
normal tissues (Schlager and Powis, 1990). De Waziers et al (1991) showed that DT-
diaphorase levels were unchanged in colorectal adenocarcinoma compared to the surrounding 
nonnal colonic tissue. However cumulative in vitro evidence would suggest that differing 
levels of tumour DTD expression will have little influence upon the efficacy of TPZ treatment. 
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Thus, with the notable exception of DID activity, reductive enzyme profiles are often 
down-regulated in the neoplastic state, suggesting that the re-introduction of high levels of 
expression of specific single-electron reductases, such as P450R, preferably in a 
compementarY oxygen-sensitive gene expression strategy, couId provide a valid approach to 
targeting bioreductive prodrug activation to hypoxic tumour tissues. 
7.4 Choice of P450 reductase prodrugs 
The nitro-prodrugs are now well advanced as GDEPT substrates in combination with 
E.coli NR. Their well defined mode of activation, their proven mechanism of cytotoxicity as 
well as their high specificity for NR-mediated catalysis, will probably ensure rapid 
development towards clinical trials. In partiCUlar, the limited metabolism by normoxic tissues 
(particularly the mustard derivatives) should contribute towards the selectivity of these agents 
in both GDEPT and ADEPT strategies. If the efficacy of P450R-dependent GDEPT in 
combination with these prodrugs can also be demonstrated in vivo, particularly in combination 
with anti-vascular strategies, this could extend the potential role of these hypoxia-activated 
diffusible cytotoxins in GDEPT of solid tumours. 
While the principle of exploiting indolequinones as hypoxia-activated trigger units has 
been demonstrated, much work is required to define the prodrug characteristics that are suited 
to an oxygen-sensitive GDEPT strategy. In particular, a very low or absent DID substrate 
specificity is essential, and the pharrnacokinetic properties of any such prodrug analogues 
must be a primary consideration. Nevertheless, the theoretical advantages that a 
indolequinone-triggered prodrug might offer, must make the search for such analogues a valid 
drug development strategy. 
7.5 Role of quinone-triggered bioreductive prodrugs and their potential in 
oxygen-sensitive GDEPT 
Delivering therapeutic genes to hypoxic cells within a solid tumour mass is a 
fundamental hurdle to any oxygen-sensitive GDEPT strategy. Systemic targeting of the 
diffusion-limited hypoxic tumour tissues is by its nature impeded by the distance of such 
tissues from the functional vasculature. It is thus technically more desirable to target the 
dynamically fluctuating "acute" hypoxic tumour cell population. As reviewed in chapter one, 
interruptions in blood flow generate transient foci of acute hypoxia in tumour tissues normally 
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proximal to well established microvascular networks (Reinhold et al., 1977; Brown, 1979). 
Studies in human tumour xenograft models indicate that perfusion-limited hypoxia is a 
common phenomeIlOl\(Chaplin and Trotter, 1990), and clinical analysis of a variety of tumours 
of different histologies, have confirmed these experimental observations (Hill et al., 1996). 
Critically, the observation that radiobiologically hypoxic cells can result from dynamic 
perfusion changes (Chaplin et at., 1987) lends support to the inference that acute hypoxia can 
arise from changes in vascular flux, and targeting cells that are proximal to the vascular supply 
is a valid hypoxia-directed GDEPT strategy. 
While experimental data suggest these transient periods of acute oxygen deprivation 
can give rise to severe radiobiological hypoxia (i.e. anoxia; < 10 ppm. 02)' the duration of this 
deprivation can be limited. Therefore upon establishment of this acute hypoxic 
: microenvironment, 1t is clearly advantageous if an applied prodrug substrate is very rapidly 
metabolised. Consequently, the fact that quinone radicals disproportionate up to four orders of 
magnitude faster than nitro radicals has obvious theoretical advantages when considering the 
design of oxygen-sensitive prodrug triggers as delivery vehicles for diffusible cytotoxins. 
However the design constraints il'lposed by the use of the indolequinone nucleus are greater 
than that of the nitro-aromatic compounds, and suffer from the necessity to design out any 
DID substrate-specificity as well as ensuring good pharmacokinetic properties in vivo. 
Nevertheless, the permutations of prodrug design are potentially broad enough to allow the 
rational development of sub-classes of quinone analogues that conform to these desired 
properties. 
7.6 Pharmacokinetic considerations in rational indolequinone prodrug design 
A major factor in the efficacy of chemotherapeutic agents is appropriate 
pharmacokinetic stability in vivo. This property is particularly relevant to indole quinones. 
Pharmacokinetic metabolism depends, for the most part, upon the nature of the functional 
groups surrounding the quinoid nucleus. This is exemplified by an analogue of the 
antbracycline doxorubicin (Adriamycin). 4'-epidoxorubicin (Epirubicin), where a small 
change in the stereochemistry of the daunosamine sugar results in a large difference in the 
levels of glucuronide conjugate formation. This lack of glucuronide formation by doxorubicin 
compared to 4'-epidoxorubicin arises through the axial C-4'-hydroxyl of doxorubicin being 
sterically hindered by an adjacent cis equatorial 3'-amino group, which does not occur in 4 '. 
epidoxorubicin since the C-4'-hydroxyl is in an equatorial orientation (Cassinelli et al., 1984; 
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Arcamone et al., 1984). 4'-Epidoxorubicin glucuronide is the major metabolite found in 
plasma of patients receiving this drug (Robert et al., 1985; Vrignaund et al., 1985). and this 
glucoronidation is believed to underlie the enhanced rates of elimination of 4'-epidoxorubicin 
compared with doxorubicin (Weenen et ai., 1984). Dextoxification of quinones by 
conjugation to glucuronic acid is facilitated by their two-electron reduction (Lind et al., 1990). 
In considering the EOO analogues, improvements in the plasma half-life might be 
achieved through modelling structural changes to the quinoid nucleus based upon observations 
of the superior plasma stability of MMC. In humans, the plasma pharmacokinetics of MMC 
elimination has a t~ = 50 minutes (Verwey et al., 1987). while t~ value for E09 was 7.8 ± 5.6 
minutes (range 0.8-19 min) (Schellens et al., 1994). Similarly, a very short plasma half-life 
was seen for EOO in murine studies (t~ =1.9 minutes) while the t~ for MMC was 8-fold 
longer (Workman et ai., 1992b) The poor pharmacokinetics of EOO is thought to account, in 
part, for the poor performance of this agent in phase II clinical trials (Wanders et al., 1995; 
Pavlidis et al., 1996; Dirix et al., 1996), and has raised doubts as to whether the initial clinical 
scheduling is optimal (5 minute infusions or bolus injections) (Pavlidis et al., 1996; 
Smitskamp-Wilms et ai., 1996). Alterations to the quinoid nucleus of E09 which mimic the 
structural details of MMC, such as the methylation of the C-6 position. could provide agents 
with superior' pharmacokinetic properties. It must also be considered that the clinical efficacy 
of MMC might also be a consequence of the relatively slow rate of pharmacodynamic 
metabolism of MMC by various flavoproteins (E, 1 = -310m V), which will contribute towards 
effective tissue penetration. Modification of EOO at the C-5 position (i.e EOS & E07) lowers 
the El of these agents to similar values reported for MMC, and may thus improve tissue 
penetration properties. 
7.7 Future prospects of hypoxia-activated cytotoxins 
The utility of hypoxia-specific cytotoxins has not been conclusively demonstrated in 
the clinic, with neither ClIO 1 0 nor EOO having so far lived upto expectations. The 
randomised phase III clinical trials evaluating the impact of TPZ in combination with 
conventional anti-tumour therapies are eagerly awaited. TPZ would not be normally 
considered as an appropriate prodrug to utilise in combination with an oxygen-sensitive 
GDEPT approach, since its active metabolite is too labile to produce any direct bystander 
effects. Yet, one might envision that replacing the membrane anchor of P450R with a trans-
cellular targeting sequence could ensure export from a transduced cell and import into 
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neighbouring cells. Thus rather than relying on activated metabolite distribution, novel 
approaches aimed at distributing the enzyme throughout the target tissue would increase the 
bystander effect with clinically well advanced agents such as TPZ. Such export/import 
targeting signals might be obtained from a diverse array of biological systems including; basic 
fibroblast growth factor (Sosnowski et at., 1996), the Drosophila antennapoedia protein 
(Derossi et al., 1994), the VP22 protein from herpes simplex virus (Phelan et al., 1998), 
truncated Pseudomonas aeruginosa exotoxin A encoding the translocating domain (Chen et 
at., 1997) or simple membrane-translocating carrier peptides (Rojas et al., 1998). These 
protein fusions could be further refmed by including nuclear localisation sequences to target 
TPZ activation to the nuclear compartment (Nigg, 1997). This approach has proved sucessful 
with nuclear-localised P450R in combination with MMC (Belcourt et al., 1998). These 
concepts are the subject of ongoing studies. 
7.8 Amplifying transcriptional output in response to hypoxia. 
A desirable property in any GDEPT strategy is a large output of therapeutic gene 
message and protein product in response to an appropriate cellular environment. Many 
mechanisms can influence the expression of a gene, including chromatin structure, 
transcription, transcription termination, RNA processing, and mRNA stability. Of these, 
transcription is perhaps the primary mechanism by which oxygen regulated gene expression is 
modulated in response to hypoxia. An important characteristc of transcription factors is that 
they are modular, such that one module can make sequence specific contacts with DNA, while 
other modules are required to interact with the basal transcriptional machinery, with 
intermediary co-activator proteins or with other adjac ent bound transcription factors (Pabo and 
Sauer, 1992). Genes respond in a unique fashion to enviromental and cell-specific signals, 
and regulation is governed, in part, by the specific array of transcription factor binding sites. 
HIF-l binding sites are no exception, with sequence conservation existing not only at 
HIF-l binding sites, but also at precisely distanced adjacent sites shown to be of functional 
releVQJ1ce, suggesting that the factors which bind at these adjacent sites are important for both 
the operation of HIF-l, and the cooperative induction of gene expression in response to low 
oxygen tension. Adjacent transcription factors bound to promoters and enhancers probably 
form stereospecific nucleoprotein complexes which are capabJe of inte grating responses from 
mUltiple signal transduction pathways (Tjian and Maniatis, 1994). For example, in the LDH-A 
promoter, the HIF-l site interacts with a cAMP-response element (eRE) located 14 bp. away, 
and both elements are essential for enhancer activity, and the LDH-A HIF-l element is not 
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capable of independent function (Firth et al., 1995). Similarly, the Epo 3' enhancer is 
functionally dependent on a putative steroid response element which interacts with various 
orphan nuclear receptors (Blanchard et aZ., 1992; Galson et al., 1995). A synergistic 
interaction has been observed between the serum-response element (SRE) and the HIF-l site 
in the murine GLUT-l 5' enhancer which is located at -3.3 to -2.7 kb from the transcription 
start site (Ebert et al., 1995a). Also, the co-activators p300/CBP have been demonstrated to 
interact with the C-tenninus ofHIF-la (Arany et ai., 1996), the potential role of which is to 
serve as a mediator of 'cross-coupling' between HIF-l ex and other transcription factors, 
perhaps forming an activation scaffold (Chakravarti et al., 1996). P300 andlor CBP also co-
activate the cAMP-responsive binding protein (CREB), and may mediate the cooperative 
interaction between the CRE and HRE in the LDH-A enhancer. 
Further HIF-l ~ (when dimerised with AhR) has been shown to interact directly with 
the zinc finger domain of the proximal promoter factor SP 1 via its bHLH and PAS domains. 
The binding of either transcription factor to its cognate DNA element facilitated the binding of 
the second factor, inducing a synergistic effect on CYPIAI gene promoter activity (Kobayashi 
et al., 1996). This observation likely extends to HIF-l aJ~ heterodimers, and it is of note that 
HRE and GC box elements have been found in proximity in several hypoxia-responsive gene 
promoters, including VEGF and GLUT-I (Levy et al., 1995; Ebert et al., 1995a). This 
suggests a mechanism by which HIP-l cxI~ may directly interact with the basal transcriptional 
apparatus assembled in proximal promoter regions. and might even play a role in the 
transcriptional synergy that is seen between distally and proximally bound SPI (Courey et al., 
1989). These observations imply a possible mechanism by which long distance interactions 
may be encouraged between HIP-lISPl bound enhancers and their proximal promoter 
regions. Interestingly. the VEGF minimal promoter, which lacks its HIF-l binding site(s) but 
contains 3 SP} sites, retains some hypoxia-inducible properties (Levy et al., 1995). which 
may reflect the redox-sensitivity of SPI via its zinc finger sulphydryl groups (Wu et al .• 1996; 
Ammendola et al., 1994; Knoepfel et al., 1994). The rational design of HRE-driven 
therapeutic DNA constructs to incorporate the potential for cooperative interactions between 
HIF-l with other constitutive or inducible transcription factors, represents one method by 
which large transcriptional outputs might be achieved in response to hypoxia. 
The marked synergy observed between hypoxia and phorbol 12-myristate 13-acetate 
(PMA) in the GLUT-l 5' enhancer, is an example of cooperativity between distinct elements. 
The exploitation of GLUT -1 regulatory sequences is attractive in view of its well documented 
upregulation in many neoplasias (Younes et al., 1996; Mellanen et al., 1994; Glick et al., 
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1993; Minn et ai., 1991; Yamamoto et al., 1990). Deletion analysis has demonstrated that both 
functional HIP-! and SRElfRE binding sites are essential to produce an augmented response 
(Ebert et al., 1995a). Phorbol esters can substitute for diacylglycerol (DAG) in the activation 
of the serine/threonine kinase PKC, but unlike DAG they are not rapidly metabolised and are 
therefore useful for in vitro analysis of PKC-dependent signal transduction. PKC in mammals 
is comprised of at least 12 distinct polypeptides or isoforms that orchestrate multiple cellular 
functions including differentiation, growth and transcription (Review: Dekker and Parker, 
1994). PKC-mediated signal transduction through the activation of mitogen-activated protein 
kinases (MAP kinases) stimulates several transcription factors that interact with and activate 
the SRE (Treisman, 1992). SRE activity is also stimulated by activated forms of membrane-
associated tyrosine kinases such as Src, and by activated forms of c-Raf and Ras, signal 
pathways that also stimulate HIP-I. The serum response factor (SRF) binds directly to the 
SRE and forms a complex with a ternary complex factor (p621fCF), which can be composed 
of any member of the Ets domain proteins, incuding SAP-I, SAP-2, Elk-! and NET. SRF is 
directly implicated in the regulation of SRE activity, and at least one of its accessory proteins, 
Elk-I, appears to be a direct target for phosphorylation by MAPIERK kinases. Other 
transcription factors including NF-IL6 and APlIATF can also bind the core SRE. The PKC-
dependent MAP kinase cascade also stimulates the gene products of the proto-oncogenes Fos 
and Iun which specifically bind to AP-l (TRE) sites. It is therefore of note that the GLUT-l 
SRE has adjacent to AP-lffRE binding sites, which are juxtaposed to the core SRE motif. 
(Ebert et al., 1995a). The SRE is induced by a variety of factors, including serum, mitogens, 
H20 2, UV-A radiation, cAMP and mitochondrial inhibitors (Treisman, 1994; Ebert et al., 
1995a). 
Since mitogens such as PMA are tumour promoters, other pharmagological agents 
must be considered as co-stimuli to induce the transcriptional synergy observed in the GLUT-
1 enhancer in vivo. It may be~~~tUltageo~~f potential agents have independent anti-neoplastic 
properties. Candidates might include the PKC partial agonist, bryostatin-l (Zhang et al., 
1996), the mitochondrial inhibitor, MKT-077 (Koya et al., 1996), the PKA modulator, 8-CI-
cAMP (and 8-Br-cAMP) (Cho-Chung, 1990), or perhaps 'Y-irradiation. The macrocyclic 
lactone bryostatin-l modulates PKC activity by binding and activating the enzyme, but in the 
presence of activating ligands it will behave primarily as an antagonist. It has currently 
completed three phase I clinical trials and some antitumour activity has been reported. The 
positively charged rhodacyanine dye, MKT -077, selectively accumulates in the mitochondria 
of neoplastic cells due to the elevated negative transmembrane potentials that are characteristic 
of the transformed state. This might allow the targeted inhibition of mitochondrial function in 
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tumour tissues, possibly providing an additional level of specificity in the regulation of the 
induction of the GLUT-l enhancer-regulated therapeutic construct. Alternatively, induction of 
cAMP-dependent PKA type II activity with the cAMP analogues, 8-CI-cAMP and 8-Br-
cAMP, may stimulate the SRE and AP-lIfRE sites in a similar fashion to that seen with PKC-
dependent activation. This is suggested by evidence implicating PKA in the nuclear 
localisation of the transcription factor NF-IL6, which binds to the SRE in the c-fos promoter 
in response to cAMP stimulation by forskolin (Metz and Ziff, 1991). This re-distribution of 
NF-IL6 from the cytoplasm to the nuclear compartment correlates with increased 
phosphorylation ofNF-IL6 suggesting its involvement in SRE regulation by cAMP. Further, 
PKA activation promotes the nuclear entry of SRF, although this appears not to be directly 
dependent 0'" SRF phosphorylation, since a putative PKA phosphorylation site on SRF 
(serine-103) is not essential for nuclear localisation. Nevertheless, 8-Br-cAMP or 
microinjection of the C subunit of PKA initiates the redistribution of SRF to the nuclear 
compartment. Nuclear localisation could be specifically inhibited by microinjection of a 
specific inhibitory peptide against PKA (Gauthier-Rouviere et al., 1995). Also of potential 
relevClllce, PKA-mediated phosphorylation is suggested to be invol ved in the nuclear 
translocation of c-fos (Roux et al., 1990), and the AP-l enhancer element can be regulated by 
PKA activation (Merino et ai., 1989). Fos and Jun can also form heterodimers with CREB to 
activate genes with either the AP-l/TRE or CRE elements (Hai and Curran, 1991), both of 
which are present in the GLUT-l 5'-enhancer. 
Although PKA and PKC are independent signal transduction pathways, there is 
evidence that "cross-talk" occurs between the two pathways, implying that if one pathway is 
induced or repressed, the other may be affected. For example PKC, but not PKA, stimulates 
the formation of transcriptionally active CREB dimers in PCl2 cells, a process that is 
dependent upon CREB phosphorylation (Yamamoto et al., 1988). PKA stimulates CRE-
dependent transcription without influencing dimerisation. suggesting dual regulation of CREB 
binding activity and transcriptional efficacy. Also cAMP has been shown to stimulate the 
translocation of PKC to the nuclei of B lymphocytes (Cambier et al., 1987). 
In addition to the therapeutic co-stimuli, several other agents were employed in the 
initial assessment to determine which cellular stimuli were relevent to the augmentation of 
GLUT-l enhancer activity. These included the PKC inhibitor, calphostin C, and two 
inhibitors of the mitochondrial electron transport chain, rotenone and azide. 
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These potential signal transduction pathways and their possible sites of action on the 
multiple transcription factors that bind and activate the GLUT -1 enhancer are illustrated in 
figure 1. Signal integration might also involve co-activators such as p300/CBP, also known 
targets of the action of cAMP-dependent protein kinase A. 
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Preliminary experiments have been conducted, utilising the transient transfection of the 
short 1-326 bp. GLUT-l enhancer fragment in order to identify which clinically relevont co-
stimuli might mimic the synergistic effects of phorbol esters on GLUT-l 5'-enhancer 
activation when combined with hypoxia. Ebert et al. (1995a) identified the shortened pG( 1-
326) GLUT -I sequence as sufficient to confer an augmented response to both PMA and 
hypoxia. This enhancer fragment lacks the 3' eRE and Sp 1 sites. but was found to be 
modestly more responsive to hypoxia compared to the complete pG(l-61O) sequence (6 vs. 4-
fold). pG(l-326) also exhibited lower constitutive activity under normoxia (63% of full 
enhancer). A single copy of the truncated 1-326 bp. enhancer sequences, in the context of the 
short aI-globin promoter, was employed to regulate ai-globin mRNA. Transcriptional 
activity of these reporter constructs was monitored by RNase protection assay as described by 
Ebert et at. (l995a) and standardised against an internal transfection control reporter construct 
(ferritin promoter-driven human growth hormone (hGH». The human breast adenocarcinoma 
cell line, MDA 468 was used to examine the influence of 16-h hypoxia (1 % 02) ± co-stimuli, 
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following transfection of the reporter plasmids. Following RNA extraction, mRNA levels for 
both (XI-globin and hGH were detennined by cross-hybridization of appropriate 32P-Iabelled 
riboprobes, followed by quantification of the corresponding protected mRNA bands using a 
flat-bed scintillation counter. The exact details of reporter plasmids, mRNA extraction, 
riboprobes and experimental techniques have been described by Ebert et al. (1995). 
Transient transfections are non-physiological in several respects, including the 
abnormal copy number of reporter genes per cell, unchromatinised templates, and the time-
course of expression of , transiently transfected plasmids. Probably of most significance, 
chromatin serves important roles in regulating gene expression, by controlling access to the 
DNA template and bringing regulatory sequences which are widely separated into close 
contact, enabling the interaction of trans-acting factors bound to dispersed cis-acting 
sequences (Wolffe, 1994). The patterns of nucleosome binding are dynamic, changing with 
alterations in gene expression (Lewin, 1994). Nevertheless, tr~siently transfection reporter 
gene-readout experiments represent a valuble experimental tool for studying enhancer 
functions and the potential interactions of transcription factors, even though they may not 
accurately describe the response of the native sequences. The therapeutic relevQllce of these 
differences will depend upon the method of gene delivery employed to transduce the target 
tissues. 
The results of this preliminary analysis were quite striking. Transcriptional synergy 
induced by hypoxia (1 % O~ and PMA co-treatment was seen, with similar values (= 18-fold) 
to that reported by Ebert et al. (1995a). The type II PKA upregulators 8-CI-cAMP and 8-Br-
cAMP markedly synergised with hypoxia in the activation of the pG[I-326](X. reporter 
plasmid, generating upto 47-fold induction of (X.-globin mRNA. The superior effects of these 
cAMP analogues relative to PMA may be a reflection of their multiple influences on HIF-l, 
SRF, CREB, NF-IL6 and AP-l, any combination of which might facilitate the observed 
transcriptional interactions. Modest stimulation of the reporter plasmid by the cAMP analogues 
was also apparent under aerobic conditions (= 5-fold), which was approximately similar to the 
effect of 1 % O2 treatment alone. In addition, both cAMP analogues modestly stimulated the 
constitutive ferritin promoter-regulated control plasmid, suggesting that modulation of PKA II 
can have multiple effects on gene expression. 
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Figure 2: Regulation of the truncated GLUT- l enhancer, pG[l -326]up by various PKC, 
PKA and SRF stimuli, with or without co-treatment under hypoxia (1 % 0 2) in the human 
breast adenocarcinoma cell line MDA 468, 
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The mitochondrial inhibitors rotenone and azide could not mimic the augmented 
response of the GLUT -1 enhancer to the phorbol ester and cAMP analogues, despite their 
known stimulatory influence on the activity of the SRE (Ebert et al., 1995a). Azide stimulated 
GLUT -1 dependent reporter gene activity under norroxic conditions, but co-stimulation with 
hypoxia was apparently not additive. This is in contrast to a recent report, where similar co-
stimulation was reported to be additive with respect to GLUT -1 protein expression (Behrooz 
and Ismail-Beigi, 1997). Both rotenone and MKT-077 strongly inhibited ai-globin mRNA 
expression which could be overcome by hypoxic stimulation. This perhaps suggests some 
level of inteference in the energy requirements for transcription and/or mRNA processing. 
Fl tLorescence microscopy of MKT -077 treated cells revealed a strong accumulation of the dye 
",,1)4 
in both mitochondria and nucleosomal bodies, which contrasted"the mitochondrial-specific 
uptake of rhodamine 123 (data not shown). In the case of MKT-077, the observation of 
highly localised intra-nuclear accumulation might explain the observed inhibition of mRNA 
expression, and perhaps suggests a novel mechanism of action for this agent. 
The PKC inhibitor calphostin C partially inhibited the hypoxic response in the MDA 
468 cell line, which is consistent with published reports in other transformed cell lines 
(Salceda et al., 1997). However the PKC partial agonist bryostatin-l only modestly 
stimulated the GLUT -1 enhancer at a concentraton of 100 nM, the effects of which were only 
additive in the presence of hypoxia. However, at higher concentrations (1 J.lM) bryostatin-l 
was inhibitory, which is consistent with its mixed agonist and antagonistic effects on PKC 
activation. Ionising irradiation (10 Gy) could also stimulate pG[1-326]a., reporter plasmid 
activity, and co-treatment with hypoxia was apparently additive. 
In an attempt to localise the influence of these stimuli to the independent subsequences 
found within the GLUT-l 5'-enhancer, a series of further transient transfection reporter gene 
experiments were performed, utilising oligonucleotides corresponding to the GLUT-l HRE, 
the c-fos SRE or a consensus AP-l site. Each element was concatemerised as a triplet and 
cloned 10 bp 5'. to the TAT A box in a minimal thymidine kinase promoter linked to a human 
growth hormone (hGH) readout (Ebert et at., 1995a). The MDA 468 cell line was transfected 
with these reporter constructs as before. and pooled transfections were divided and cells were 
exposed to the individual stimuli. In this experiment, reporter gene readout was by means of a 
radioimmunoassay for hGH protein secreted into the media over a period of 96-h (hGH assay 
performed by Dr. Gillian Campling, Wameford hospital. Oxford). The levels of hGH 
secretion (mUlL) were expressed relative to a untreated control for each reporter plasmid. 
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Figure 3: Relative induction of pTKGH reporter pJasmids under the transcriptional control of 
either GLUT -1 HRE, c-fos SRE or consensus AP-l triplet sites. Cells were expo ed to 
stimuli for 16-h (except x-rays), washed free of the agent, and conditioned media was 
harvested after 96-h. Data are the mean of two independent experiments. 
4 
pG7(Glut-1 HIF)+++ 
(5 3 ... -c 0 u 2 "0 
Q) -<IS Q) ... 
C 
::l 
B 0 
Q) 
> 
~ 
Qi ... 
pG7(consensus AP-1 )+++ c 
0 4 :;:; 
Q) ... 
u 
Q) 3 (/) 
c 
'iii - 2 0 ... a. 
Q) 
c 
0 
E ... 
0 0 .s:;; 
.s:;; 
~ 
0 ... 
Ol 
c pG7(c-Fos SRE)+++ 
<IS 4 E 
::l .s:;; 
'0 3 
c 
0 ·u 2 
::l 
"0 
C 
-c 
(5 
u.. 
0 
c CJ) j:: Q) Q) c a... Q) >- -0 c -.;:; ~ 0> co 0 ~ 
0 co 
>- .... , c - <{ , ~ CJ) x X Q) 0 cr 0 ~ ->- ~ 0 ~ () 
~ (!J :::t. a: co , 0 
~ co ,.... 0 0 E ~ ,.... ::i M :::t. ~ ('t) 0> :::t. 
0 :::t. ,.... 0 0 ...-,.... 
0 
25 1 
Chapter 7 Discussion 
GLUT -1 HIF-1 activation was stimulated by 1 % 02 and 10 J.LM 8-CI-cAMP. A very 
modest stimulation was seen for 100 nM bryostatin-1. but this was not apparent at other 
concentrations. No other agents were stimulatory, although MKT-077 strongly inhibited hGH 
production. The consensus AP-I triplet was induced by y-irradiation (to Gy). and modestly 
by 8-Cl-cAMP. The mitochondrial inhibitors azide and rotenone were ineffective. although 
like the HIF-l reporter, MKT-077 was strongly inhibitory. The c-fos SRE driven reporter 
plasmid was reproducibly induced by azide. rotenone, 8-CI-cAMP. and 'Y-irradiation. The 
suppression of hGH by MKT -077 was not seen. suggesting that perhaps SRE stimulation 
was compensating for the interference with hGH production. Together. these results imply 
that the GLUT -1 5' enhancer conveys transcriptional responses to hypoxia, mitochondrial 
inhibitors, 'Y-irradiation and PKA modulators through individual elements. The increased 
activation of the GLUT-I enhancer by PMA or 8-CI-cAMP in combination with hypoxia 
resulted from a positive integration of distinct inducible responses. which exert influence on 
different cis-acting sequences. The cooperative behaviour of these elements could be 
harnessed in the design of future therapeutic constructs aimed at exploiting tumour hypoxia in 
a GDEPT strategy. 
Many other mechanisms besides transcriptional initiation can potentially influence the 
level of gene expression in specific cell types under precise enviromental conditions. For 
'exampl~:, both transcriptional elongation and termination are possible sites of regulation 
(Greenblatt et al .• 1993), and mRNA must undergo many stages of processing including 5' 
capping and 3' polyadenylation before it can be translocated to the cytoplasm (Rosbash and 
Singer. 1993). In principle. any of these steps could be rate limiting for the production of a 
therapeutic mRNA. A gr'eater understanding of each of these individual processes and their 
interacting influences will facilitate the design of optimal therapeutic gene constructs that are 
efficiently expressed in the desired target tissues. 
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